Introducing PHARMAC 2

December 2013

Volume 20 Number 3

Editors: Kaye Wilson,

Donna Jennings & Sarah Le Leu email: schedule@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, 40 Mercer Street PO Box 10 254 Wellington

Freephone Information Line 0800 66 00 50 (9am – 5pm weekdays)

Circulation

Published each April, August and December. Changes to the contents are published in monthly updates.

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website www.pharmac.govt.nz

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website www.schedule.co.nz.

Production

Typeset automatically from XML and T_EX. XML version of the Schedule available from www.pharmac.govt.nz/schedule/archive/

Programmers

Anrik Drenth & John Geering email: texschedule@pharmac.govt.nz

© Pharmaceutical Management Agency



ISSN 1179-3686 pdf ISSN 1172-9376 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Section /	4
-----------	---

Section B

General Rules 10

n B	Alimentary Tract & Metabolism	24
	Blood & Blood Forming Organs	44

- Cardiovascular System 52
- Dermatologicals 65
- Genito Urinary System 76
- Hormone Preparations Systemic 82
- Infections Agents For Systemic Use 90
 - Musculoskeletal System 114
 - Nervous System 122
- Oncology Agents & Immunosuppressants 151
 - Respiratory System & Allergies 181
 - Sensory Organs 188

Various 192

Section C Extemporaneous Compounds (ECPs) 193

Section DSpecial Foods 200Section EPractitioner's Supply Orders 220
Rural Areas 224Section FDispensing Period Exemptions 225

Section G

Section I National Immunisation Schedule 230

Index 232

Safety Cap Medicines 227

Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to six members appointed by the Minister of Health. All decisions relating to PHARMAC's operation are made by or under the authority of the Board. The functions of PHARMAC are to perform, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals within their hospitals, as applicable, and in accordance with it annual plan and any directions given by the Minister (Section 103 of the Crown Entities Act).

Members of the PHARMAC Board

Stuart McLauchlan Jens Mueller David Kerr

Decisions taken by the PHARMAC Board members, or made under the authority of the Board, incorporate a balanced view of the needs of prescribers and patients. The aim is to achieve long-term gains and efficient ways of making pharmaceuticals available to the community and for DHB Hospitals to purchase them.

The following attend PHARMAC's Board meetings as observers

- Murray Georgel, CE MidCentral DHB
- Kate Russell, Chair Consumer Advisory Committee
- Sisira Jayathissa, Chair Pharmacology and Therapeutics Advisory Committee (PTAC)

Kura Denness

Jan White

The functions of PHARMAC are to perform the following, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals in their hospitals, as applicable, and in accordance with its annual plan and any directions given by the Minister (Section 103 of the Crown Entities Act):

- a) to maintain and manage a pharmaceutical schedule that applies consistently throughout New Zealand, including determining eligibility and criteria for the provision of subsidies;
- b) to manage incidental matters arising out of (a), including in exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the pharmaceutical schedule;
- c) to engage as it sees fit, but within its operational budget, in research to meet its objectives as set out in Section 47(a) of the Act;
- d) to promote the responsible use of pharmaceuticals;
- e) to manage the purchasing of any or all pharmaceuticals, whether used either in a hospital or outside it, on behalf of DHBs;

f) any other functions given to PHARMAC by or under any enactment or authorised by the Minister.

The policies and criteria set out in the Pharmaceutical Schedule and PHARMAC's Operating Policies and Procedures arise out of, and are designed to help PHARMAC achieve and perform, PHARMAC's objective and functions under the Act.

However PHARMAC may, having regard to its public law obligations, depart from the strict application of those policies and criteria in certain exceptional cases where it considers this necessary or appropriate in the proper exercise of its statutory discretion and to give effect to its objective and functions, particularly with respect to:

- Determining eligibility and criteria for the provision of subsidies; and
- In exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the Pharmaceutical Schedule.

Decision Criteria

PHARMAC updates the Pharmaceutical Schedule at regular intervals to notify prescribers, pharmacists, hospital managers and patients of changes to Community Pharmaceutical subsidies and the prices for Hospital Pharmaceuticals. In making decisions about amendments to the Pharmaceutical Schedule, PHARMAC is guided by its Operating Policies and Procedures, as amended or supplemented from time to time. PHARMAC takes into account the following criteria when making decisions about Community Pharmaceuticals:

- the health needs of all eligible people within New Zealand (eligible defined by the Government's then current rules of eligibility);
- the particular health needs of Māori and Pacific peoples;
- the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
- the clinical benefits and risks of pharmaceuticals;
- the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
- the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Pharmaceutical Schedule;
- the direct cost to health service users;

- the Government's priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC's Funding Agreement, or elsewhere; and
- such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such "other criteria" into account.

The Operating Policies and Procedures, including any supplements, also describe the way in which PHARMAC determines the level of subsidy or purchase price payable for each Community Pharmaceutical or Hospital Pharmaceutical, respectively.

The decision criteria for Hospital Pharmaceuticals are set out in the hospital supplement to the Operating Policies and Procedures and in the introductory part of Section H of the Pharmaceutical Schedule.

Copies of PHARMAC's Operating Policies and Procedures and of any applicable supplements are available on the PHARMAC website (www.pharmac.govt.nz), or on request.

PHARMAC's clinical advisors

Pharmacology and Therapeutics Advisory Committee (PTAC)

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals.

The committee members are all senior, practising clinicians. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

PTAC helps decide which community pharmaceuticals are to be subsidised from public monies by making recommendations to PHARMAC. Part of the role of PTAC is to review whether Community Pharmaceuticals already listed on the Schedule should continue to receive Government funds. The resources freed up can be used to subsidise other community pharmaceuticals with a greater therapeutic worth.

PHARMAC may obtain clinical advice from PTAC in relation to national purchasing strategies for Hospital Pharmaceuticals. There may be additional specialist hospital representatives on PTAC subcommittees, or additional PTAC subcommittees, where PHARMAC considers this necessary.

PTAC members are:

Sisira Jayathissa	MMBS, MMedSc (Clin Epi), MD, FRCP (Lon, Edin), FRACP, FAFPHM, FNZCPHM, Dip Clin Epi, Dip OHP, DipHSM, MBS, Chair
Melissa Copland	PhD, BPharm(Hons), RegPharmNZ, FNZCP
Stuart Dalziel	MBChB, PhD, FRACP
Ian Hosford	MBChB, FRANZCP, psychiatrist
George Laking	PhD, MD, FRACP
Graham Mills	MBChB, MTropHlth, MD, FRACP, infectious disease specialist and general physician
Marius Rademaker	BM (Soton), FRCP (Edn), FRACP DM
Jane Thomas	MBChB, FANZGL
Mark Weatherall	BA, MBChB, MApplStats, FRACP
Sean Hanna	MB ChB, FRNZCGP, FRACGP, PGDipGP, PGCertClinEd

Contact PTAC C/- PTAC Secretary, Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON, Email: PTAC @pharmac.govt.n:

PHARMAC's consumer advisors

Consumer Advisory Committee (CAC)

The Consumer Advisory Committee is an advisory committee to the PHARMAC Board. It provides written reports to the Board, and its Chair attends Board meetings as an observer to report on the activities and findings of the Committee, and to comment on consumer issues. While accountable to the Board, the Committee's general working relationship is with the staff of PHARMAC. The Committee is made up of people from a range of backgrounds and interests including the health of Māori people, Pacific peoples, older people, women and mental health.

For current membership of the Consumer Advisory Committee, visit our website. The Consumer Advisory Committee can be contacted by email: CAC@pharmac.govt.nz, or you can write to the Consumer Advisory Committee at PHARMAC's postal address.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price (if it differs from the Subsidy) and any access conditions that may apply; and
- some Hospital Pharmaceuticals that are purchased and used by DHB Hospitals, including those for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, on any logistics arrangements put in place by individual DHB Hospitals.

Finding Information in the Pharmaceutical Schedule

Community Pharmaceuticals

For Community Pharmaceuticals, the Schedule is organised in a way to help the reader find Community Pharmaceuticals, which may be used to treat similar conditions. To do this, Community Pharmaceuticals are first classified anatomically, originally based on the Anatomical Therapeutic Chemical (ATC) system, and then further classified under section headings structured for the New Zealand medical system.

- Section A lists the General Rules in relation to Community Pharmaceuticals and related products.
- Section **B** lists Community Pharmaceuticals and related products by anatomical classification, which are further divided into one or more therapeutic headings. Community Pharmaceuticals used to treat similar conditions are grouped together.
- Section C lists the rules in relation to Extemporaneously Compounded Products (ECPs) and Community Pharmaceuticals that will be subsidised when extemporaneously compounded.
- Section D lists the rules in relation to Special Foods and the Special Foods that are subsidised.
- Section E Part I lists the Community Pharmaceuticals that are subsidised on a Practitioner's Supply Order (PSO).
- Section E Part II lists rural areas for the purpose of PSOs.
- Section F lists the Community Pharmaceuticals dispensing period exemptions.
- Section G lists the Community Pharmaceuticals eligible for reimbursement of safety cap and related rules.
- Section I lists the National Immunisation Schedule.

The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification level.

The therapeutic headings in the Pharmaceutical Schedule do not necessarily correspond to the therapeutic groups and therapeutic subgroups, which PHARMAC establishes for the separate purpose of determining the level of subsidy to be paid for each Community Pharmaceutical.

The index located at the back of the book in which Sections A-G and I of the Pharmaceutical Schedule are published can be used to find page numbers for generic chemical entities, or product brand names.

Hospital Pharmaceuticals

Section H lists Pharmaceuticals that can be used in DHB Hospitals, and is split into the following parts:

- Part I lists the rules in relation to use of Pharmaceuticals by DHB Hospitals.
- Part II lists Hospital Pharmaceuticals that are funded for use in DHB Hospitals. These are classified based on the Anatomical Therapeutic Chemical (ATC) system used for Community Pharmaceuticals. It also provides information on any national contracts that exist, and an indication of which products have Hospital Supply Status (HSS).
- Part III lists Optional Pharmaceuticals for which national contracts exist, and DHB Hospitals may choose to fund. These
 are listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if
 applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance Limit
 (DV Limit).

The index located at the back of the Section H can be used to find page numbers for generic chemical entities, or product brand names, for Hospital Pharmaceuticals.


The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classificationlevel.

Community Pharmaceuticals are listed in a separate publication with Sections A to I (excluding Section H).

Explaining drug entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the amount of that subsidy paid to contractors, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gramq	miaragram	millimala mmal
gram	microgrammcg	millimolemmol
kilogramkg	milligrammg	unitu
international unitiu	millilitreml	

Abbreviations

Ampoule	Amp	Granules	Gran	Suppository	Supp
Capsule	Сар	Infusion	Inf	Tablet	Tab
Cream	Crm	Injection	Inj	Tincture	Tinc
Device	Dev	Linctus	Linc	Trans Dermal Delivery	
Dispersible	Disp	Liquid	Liq	System	TDDS
Effervescent	Eff	Long Acting	LA		
Emulsion	Emul	Ointment	Oint		
Enteric Coated	EC	Sachet	Sach		
Gelatinous	Gel	Solution	Soln		

BSO Bulk Supply Order.

CBS Cost Brand Source. There is no set manufacturer's price, and the Government subsidises the product at the price it is obtained by the pharmacy.

- CE Compounded Extemporaneously.
- CPD Cost Per Dose. The Funder (as defined in Part I of the General Rules) cost of a standard dose, without mark-ups or fees and excluding GST.
- ECP Extemporaneously Compounded Preparation.
- HSS Hospital Supply Status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.
- OP Original Pack subsidy is rounded up to a multiple at whole packs.
- PSO Practitioner's Supply Order.

Sole Subsidised

Supplier Only brand of this medicine subsidised.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

- ▲ Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner or pharmacist.
- * Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless the medicine meets the Dispensing Frequency Rule criteria.
- [‡] Safety cap required for oral liquid formulations, including extemporaneously compounded preparations.
- Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a
 manufacturer's surcharge.
- S29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should:
 - a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretions, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.

Note: Where medicines supplied under Section 29 that are used for emergency situations, patient details required under Section 29 of the Medicines Act may be retrospectively provided to the supplier.

	Definitions					
Abbrev.	Pharmacy Services Agreement	All other Pharmacy Agreements				
[HP3]	Subsidised when dispensed from pharmacies that have a Special Foods Service appended to their Phar- macy Services Agreement by their DHB.	Available from selected pharmacies that have an ex- clusive contract to dispense Special Foods.				
[HP4]	Subsidised when dispensed from pharmacies that have the Monitored Therapy Variation (for Clozapine Services)	Avaliable from selected pharmacies that have an ex- clusive contract to dispense 'Hospital Pharmacy' [HP4] pharmaceuticals.				

Patient costs

Community Pharmaceutical costs met by the Government

Most of the cost of a subsidised prescription Community Pharmaceutical is met by the Government through the Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to Contractors, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to Contractors does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a \checkmark in the product's Schedule listing.

SALBUTAMOL		
Aerosol inhaler 100 mcg per dose	3.80	 Fully subsidised brand
	(6.00)	Higher priced brand

Pharmaceutical Co-Payments

Some Community Pharmaceutical costs are met by the patient. Generally a patient pays a prescription charge. In addition a patient will sometimes pay a manufacturer's surcharge, after hours service fee and any special packaging fee. PRESCRIPTION CHARGE

From 1 January 2013, everyone who is eligible for publicly funded health and disability services should in most circumstances pay only \$5 for subsidised medicines.

All prescriptions from a public hospital, a midwife and a Family Planning Clinic are covered for \$5 co-payments.

Prescriptions from the following providers are approved for \$5 co-payments on subsidised medicines if they meet the specified criteria:

- After Hours Accident and Medical Services with a DHB or a PHO contract.
- Youth Health Clinics with a DHB or a PHO contract.
- Dentists who write a prescription that relates to a service being provided under a DHB contract.
- Private specialists (for example, ophthalmologists and orthopaedics) who write a prescription for a patient receiving a publicly funded service contracted by the DHB.
- General practitioners who write a prescription during normal business hours to a person who is not enrolled in the general practice provided the person is eligible for publicly funded health and disability services and the general practice is part of a PHO.
- Hospices that have a contract with a DHB.

Patients can check whether they are eligible for publicly funded health and disability services by referring to the Eligibility Direction on the Ministry of Health's website.

To check if a medicine is fully subsidised, refer to the Pharmaceutical Schedule on PHARMAC's website or ask your pharmacist or general practitioner.

DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not specifically listed by a DHB as an approved provider/prescriber should be regarded as not approved.

NOTE: Information sourced from Ministry of Health Website, for more information please visit www.moh.govt.nz

MANUFACTURER'S SURCHARGE

Not all Community Pharmaceuticals are fully subsidised. Although PHARMAC endeavours to fully subsidise at least one Community Pharmaceutical in each therapeutic group, and has contracts with some suppliers to maintain the price of a particular product, manufacturers are able to set their own price to pharmacies. When these prices exceed the subsidy, the pharmacist may recoup the difference from the patient.

To estimate the amount a patient will pay on top of the prescription charge, take the difference between the manufacturer's price and the subsidy, and multiply this by 1.86. The 1.86 factor represents the pharmacy mark-up on the surcharge plus other costs such as GST. Pharmacies charge different mark-ups so this may vary.

Manufacturer's surcharge to patient = (price - subsidy) $\times 1.86$

For example, a Community Pharmaceutical with a supplier (ex-manufacturer) cost of \$11.00 per pack with a \$10.00 subsidy will cost the patient a surcharge of \$1.86 on top of the prescription charge. The most a patient should pay is therefore \$16.86 - being \$15.00 maximum prescription charge, plus \$1.86.

Hospital Pharmaceutical and Pharmaceutical Cancer Treatment Costs

The cost of purchasing Hospital Pharmaceuticals (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) is met by the relevant DHB hospital Funder from its own budget. Pharmaceutical Cancer Treatments (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) are funded through the Combined Pharmaceutical Budget. As required by section 23(7) of the Act, in performing any of their functions in relation to the supply of Pharmaceuticals including Pharmaceutical Cancer Treatments, DHBs must not act inconsistently with the Pharmaceutical Schedule.

PHARMAC web site

PHARMAC has set up an interactive Schedule on the Internet.

Other information about PHARMAC is also available on our website. This includes copies of the Annual Review, Annual Report and Annual Plan, as well as information such as the Pharmaceutical Schedule, Pharmaceutical Schedule Updates, National Hospital Pharmaceutical Strategy, other publications and recent press releases.

Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person. Applications must be submitted to the Ministry of Health by the prescriber for the request to be processed.

Subsidy

Once approved, the presciber will be provided a Special Authority number which must appear on the prescription. Specialists who make an application must communicate the valid authority number to the prescriber who will be writing the prescriptions.

The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical.

Some approvals are dependent on the availability of funding from the Pharmaceutical Budget.

Criteria

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website.

For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised. Criteria for each Special Authority Community Pharmaceutical are updated regularly, based on the decision criteria of PHARMAC. The appropriateness of the listing of a Community Pharmaceutical in the Special Authority category will also be regularly reviewed. Applications for inclusion of further Community Pharmaceuticals in the Special Authority category will generally be made by a pharmaceutical supplier.

Special Authority Applications

Application forms can be found at www.pharmac.govt.nz. Requests for fax copies should be made to PHARMAC, phone 04 460 4990. Applications are processed by the Ministry of Health, and should be sent to:

Ministry of Health Sector Services, Fax: (06) 349 1983 or free fax 0800 100 131

Private Bag 3015, WANGANUI 4540

For enquiries, phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666

Note: The Ministry of Health can only provide information on Special Authority applications to prescribers and pharmacists.

Each application must:

- Include the patients name, date of birth and NHI number (codes for AIDS patients' applications)
- Include the practitioner's name, address and registration number
- Clearly indicate that the relevant criteria, have been met.
- Be signed by the practitioner.

Named Patient Pharmaceutical Assessment policy

The Named Patient Pharmaceutical Assessment (NPPA) Policy is PHARMAC's process for considering applications about named patients seeking funding for treatments not listed on the Schedule, either at all or for the named patient's clinical circumstances. For PHARMAC to perform its legislative function of maintaining and managing a Schedule that applies consistently throughout New Zealand, the NPPA Policy will, and must, operate in a way that does not undermine the Schedule decision making process. Together, the Schedule process and the NPPA Policy, ensure there is a pathway for consideration of an individual's clinical circumstances. If an individual has a set of clinical circumstances not covered by the NPPA Policy, the Schedule decision making process is available.

It is not the purpose of the NPPA Policy to provide access to every treatment not listed on the Schedule. There are two main pathways by which named patients can be considered for funding under the NPPA Policy. PHARMAC will exercise its discretion to determine the most appropriate pathway for an application under the NPPA Policy based on the information that is provided.

Information concerning NPPA in hospital use can be forund at http://www.pharmac.health.nz/tools-resources/forms/named-patientpharmaceutical-assessment-nppa-forms.

PHARMAC will assess applications that meet the prerequisites described below according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions. For more information on NPPA, or to apply, visit the PHARMAC website at http://www.pharmac.govt.nz/nppa, or call the Panel Coordinators at 0800 60 00 50 option 3.

Unusual Clinical Circumstance (UCC)

The purpose of the Unusual Clinical Circumstances (UCC) pathway is to provide a process for consideration for funding for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule. The prerequisite requirements for UCC consideration are:

- The patient has reasonably tried and failed all alternative funded treatments (or alternative treatments have been contraindicated, or there are no other treatments available), or the patient has experienced such serious side effects with all other relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and
- The patient is experiencing an indication or set of clinical circumstances that are so unusual that PHARMAC is unlikely to consider listing treatments for these on the Schedule; and
- Generally, PHARMAC has not already considered/is not considering, through the Schedule decision making process, the treatment for the patient's clinical circumstances, or has not considered the treatment at all.

Urgent Assessment (UA)

The purpose of the Urgent Assessment (UA) pathway is to provide a process for PHARMAC to consider funding treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient's clinical circumstances justify urgent assessment, prior to a decision on Schedule listing. The prerequisite requirements for UA are:

- The patient has reasonably tried and failed all alternative funded treatments (or alternative treatments have been contraindicated, or there are no other treatments available), or the patient has experienced such serious side effects with all other relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and
- The patient is experiencing an indication or set of clinical circumstances that may be experienced by a population group (either currently or over time); and
- The patient has serious clinical circumstances and not receiving the treatment within six to 12 months would lead to either a significant deterioration in a serious clinical condition or the patient would miss the opportunity for significant improvement in clinical outcome (length or quality of life); and
- The treatment has either not been prioritised by PHARMAC, or if it has, PHARMAC has funded the treatment under the NPPA Policy for the same clinical circumstances prior to prioritisation.
- PHARMAC has not declined to list, on the Schedule, this treatment for these clinical circumstances.

INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 December 2013 and is to be referred to as the Pharmaceutical Schedule Volume 20 Number 3, 2013. Distribution will be from 20 December 2013. This Schedule comes into force on 1 December 2013.

PART I INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

"90 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

"**180 Day Lot**" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

"Access Exemption Criteria" means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

a) have limited physical mobility;

b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;

- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.

"Act" means the New Zealand Public Health and Disability Act 2000.

"Advisory Committee" means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

"Alternate Subsidy" means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

"Annotation" means written annotation of a prescription by a dispensing pharmacist in the pharmacist's own handwriting following confirmation from the Prescriber if required, and "Annotated" has a corresponding meaning. The Annotation must include the details specified in the Schedule, including the date the prescriber was contacted (if applicable) and be initialled by the dispensing pharmacist.

"Authority to Substitute" means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

"Bulk Supply Order" means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

"Class B Controlled Drug" means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975.

"Community Pharmaceutical" means a Pharmaceutical listed in Sections A to G and Section I of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

"Contractor" means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

"Controlled Drug" means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

"Cost, Brand, Source of Supply" means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor's annotated purchase price, brand, and source of supply. Alternatively a copy of the invoice for the purchase of the Pharmaceutical may be attached to the prescription, in the place of an annotation, in order to be eligible for Subsidy.

"Dentist" means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

"Diabetes Nurse Prescriber" means a registered nurse practising in diabetes health who has authority to prescribe specified diabetes medicines in accordance with regulations made under the Medicines Act 1981, and who is practicing in an approved DHB demonstration site.

"Dietitian" means a person registered as a dietitian with the Dietitians Board, and who holds a current annual practicing certificate under the HPCA Act 2003.

"DHB" means an organisation established as a District Health Board by or under Section 19 of the Act.

"DHB Hospital" means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

"Dispensing Frequency Rule" means the rule in Part IV, Section A of the Pharmaceutical Schedule that defines patient groups or medicines eligible for more frequent dispensing periods.

"Doctor" means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

"DV Limit" means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit. "DV Pharmaceutical" means a discretionary variance Pharmaceutical, that does not have HSS and which:

- a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or
- b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

"Endorsements" - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as "certified condition", or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes "certified condition" as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

"Funder" means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

"GST" means goods and services tax under the Goods and Services Tax Act 1985.

"Hospital Care Operator" means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

"Hospital Pharmaceuticals" means the list of pharmaceuticals set out in Section H part II of the Schedule which includes some National Contract Pharmaceuticals.

"Hospital Pharmacy" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner.

"Hospital Pharmacy-Specialist" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either:

- a) on a Prescription signed by a Specialist, or
- b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either:
 - i) endorsed with the words "recommended by [name of specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol",

iii) annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and date of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as either:

a)

- i) follows a substantive consultation with an appropriate Specialist;
- ii) the consultation to relate to the Patient for whom the Prescription is written;
- iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
- iv) except in emergencies consultation to precede annotation of the Prescription; and
- v) both the specialist and the General Practitioner must keep a written record of the consultation; or
- b) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital. "Hospital Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is not eligible for Subsidy unless

"Hospital Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"HSS" means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

"In Combination" means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

"Individual DV Limit" means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"Licensed Hospital" means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

"Lot" means a quantity of a Community Pharmaceutical supplied in one dispensing.

"Manufacturer's Price" means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

"Maternity hospital" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

"Midwife" means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

"Month" means a period of 30 consecutive days.

"Monthly Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 30 consecutive days' treatment;

"Named Patient Pharmaceutical Assessment Advisory Panel" means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising, within its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and Exceptional Circumstances renewal applications submitted after 1 March 2012 (EC renewal application form located at http://www.pharmac.govt.nz/healthpros/EC/ECForms)

"National Contract Pharmaceutical" means a Hospital Pharmaceutical for which PHARMAC has negotiated a national contract and the Price.

"National DV Limit" means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"National Immunisation Schedule" means Section I of the Pharmaceutical Schedule, which is a schedule administered by PHARMAC, being a schedule specifying a programme of vaccinations to promote immunity against the diseases specified in the schedule.

"Not In Combination" means that no Subsidy is available for any Prescription containing the Community Pharmaceutical

in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

"Nurse Precriber" means a nurse registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003 and who is approved by the Nursing Council to prescribe specified prescription medicines relating to his/her scope of practice including, for the avoidance of doubt, a Diabetes Nurse Prescriber.

"Optional Pharmaceuticals" means the list of National Contract Pharmaceuticals set out in Section H Part II of the Schedule

"Optometrist" means a person registered as an optometrist with the Optometrists and Dispensing Opticians Board, who holds a current annual practising certificate under the HPCA Act 2003, and who is authorised by regulations under the Medicines Act 1981 and approved by the Optometrists and Dispensing Opticians Board to prescribe specified medicines.

"Outpatient", in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person's home.

"PCT" means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

"PCT only" means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.

"Penal Institution" means a penal institution, as that term is defined in The Penal Institutions Act 1954;

"PHARMAC" means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC).

"Pharmaceutical" means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

"Pharmaceutical Benefits" means the right of:

- a) a person; and
- b) any member under 16 years of age of that person's family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

"Pharmaceutical Budget" means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

"Pharmaceutical Cancer Treatment" means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a "PCT" or "PCT only" Pharmaceutical that DHBs must provide access to, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

"Pharmacist Prescriber" means a person registered with the Pharmacy Council of New Zealand, who holds a current annual practising certificate under the HPCA Act 2003, and is approved by the Pharmacy Council of New Zealand to prescribe specified prescription medicines relating to his/her scope of practice.

"Pharmacist" means a person registered with the Pharmacy Council of New Zealand and who holds a current annual practicing certificate under the HPCA Act 2003.

"Practitioner" means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber, an Optometrist, or a Pharmacist Prescriber as those terms are defined in the Pharmaceutical Schedule.

"Practitioner's Supply Order" means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

"Prescription" means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

"Prescription Medicine" means any Pharmaceutical listed in Part I of Schedule 1 of the Medicines Regulations 1984.

"Private Hospital" means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

"Residential Disability Care Institution" means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

"Rest Home" means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

"Restricted Medicine" means any Pharmaceutical listed in Part II of Schedule 1 of the Medicines Regulations 1984.

"Retail Pharmacy-Specialist" means that the Community Pharmaceutical is only eligible for Subsidy if it is either:

- a) supplied on a Prescription or Practitioner's Supply Order signed by a Specialist, or,
- b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner's Supply Order and either:
 - i) endorsed with the words "recommended by [name of Specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol", or
 - iii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and year of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.
- "As recommended by a Specialist" to be interpreted as either:

a)

- i) follows a substantive consultation with an appropriate Specialist;
- ii) the consultation to relate to the Patient for whom the Prescription is written;
- iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
- iv) except in emergencies consultation to precede annotation of the Prescription; and
- v) both the Specialist and the General Practitioner must keep a written record of consultation; or
- b) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

"Retail Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner's Supply Order, signed by a Specialist. For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"Schedule" means this Pharmaceutical Schedule and all its sections and appendices.

"Special Authority" means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

"Specialist", in relation to a Prescription, means a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) below:

- a) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; or
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that prescription in the course of practising in that area of competency; or
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine; or
- d) the doctor writes the prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

"Subsidy" means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

"Supply Order" means a Bulk Supply Order or a Practitioner's Supply Order.

"**Unapproved Indication**" means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 5.5. "Unlisted Pharmaceutical" means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical but is not listed in Section H part II

"Unusual Clinical Circumstances (UCC)" means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule.

"Urgent Assessment (UA)" means the pathway under the Named Patient P harmaceutical Assessment policy for funding consideration for treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient's clinical circumstances justify urgent assessment, prior to a decision on Schedule listing.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
 - a) the singular includes the plural; and
 - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

PART II COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G and I of the Schedule subject to:
 - 2.1.1 clauses 2.2 of the Schedule; and
 - 2.1.2 clauses 3.1 to 5.4 of the Schedule; and
 - 2.1.3 the conditions (if any) specified in Sections B to G and I of the Schedule;
- 2.2 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless the Community Pharmaceuticals so supplied:
 - 2.2.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or
 - 2.2.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
 - 2.2.3 in the absence of the standards prescribed in clauses 2.3.1 and 2.3.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
 - 2.2.4 in the absence of the standards prescribed in clauses 2.3.1, 2.3.2 and 2.3.3, are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

PART III PERIOD AND QUANTITY OF SUPPLY

3.1 Doctors', Dentists', Dietitians', Midwives', Nurse Prescribers', Optometrists and Pharmacist Prescribers' Prescriptions (other than oral contraceptives)

The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dentist, Dietitian, Midwife, Nurse Prescriber, an Optometrist, or a Pharmacist Prescriber unless specifically excluded:

- 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity sufficient to provide treatment for a period not exceeding three Months will be subsidised.
- 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate (except for Dentist prescriptions), only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
- 3.1.3 For a Class B Controlled Drug:
 - a) other than Dentist prescriptions and methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity:
 - i) sufficient to provide treatment for a period not exceeding 10 days; and
 - ii) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
 - b) for a Dentist prescription only such quantity as is necessary to provide treatment for a period not exceeding five days will be subsidised.
- 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dentist, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for

an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:

- a) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
- b) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
 - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
 - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
 - A) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
 - B) both:
 - the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
 - every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
- 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
 - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
 - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
- 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
 - a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
 - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.
- 3.1.7 If a Community Pharmaceutical:
 - a) is stable for a limited period only, and the Practitioner has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that may be dispensed at any one time; or
 - b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
 - c) is under the Dispensing Frequency Rule,

The actual quantity dispensed will be subsidised in accordance with any such specification.

3.2 Oral Contraceptives

The following provisions apply to all Prescriptions written by a Doctor, Midwife, Nurse Prescriber or a Pharmacist Prescriber for an oral contraceptive:

- 3.2.1 The prescribing Doctor, Midwife, Nurse Prescriber or a Pharmacist Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed six Months.
- 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:
 - a) in Lots as specified in the Prescription if the Community Pharmaceutical is under the Dispensing Frequency Rule; or
 - b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.
- 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.
- 3.2.4 Where a Community Pharmaceutical on a Prescription is under the Dispensing Frequency Rule and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.

3.3 Original Packs, Certain Antibiotics and Unapproved Medicines

- 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference:
 - a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
 - b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
- 3.3.2 If a Community Pharmaceutical is either:
 - a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or
 - b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981, but excluding any medicine listed as Cost, Brand, Source of Supply, or
 - c) any other pharmaceutical that PHARMAC determines, from time to time and notes in the Pharmaceutical Schedule

and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:

- a) the difference between the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and
- b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

3.4 Pharmacist Prescribers' Prescriptions

- The following apply to every prescription written by a Pharmacist Prescriber
- 3.4.1 Prescriptions written by a Pharmacist Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) a Community Pharmaceutical classified as a Prescription Medicine and which a Pharmacist Prescriber is permitted under regulations to prescribe; or
 - b) any other Community Pharmaceutical that is a Restricted Medicine (Pharmacist Only Medicine), a Pharmacy Only Medicine or a General Sales Medicine.
- 3.4.2 Any Pharmacist Prescribers' prescriptions for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

3.5 Dietitians' Prescriptions

The following provisions apply to every Prescription written by a Dietitian:

- 3.5.1 Prescriptions written by a Dietitian for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) special foods, as listed in Section D; or
 - b) any other Pharmaceutical that has been identified in Section D of the Pharmaceutical Schedule as being able to be prescribed by a Dietitian,
 - providing that the products being prescribed are not classified as Prescription Medicines or Restricted Medicines.
- 3.5.2 For the purposes of Dietitians prescribing pursuant to this clause 3.5, the prescribing and dispensing of these products is required to be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.

3.6 Diabetes Nurse Prescribers' Prescriptions

The following provisions apply to every Prescription written by a Diabetes Nurse Prescriber:

3.6.1 Prescriptions written by a Diabetes Nurse Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:

- a) a Community Pharmaceutical classified as a Prescription Medicine or a Restricted Medicine and which a Diabetes Nurse Prescribers is permitted under regulations to prescribe; or
- b) any other Community Pharmaceutical listed below:

aspirin, blood glucose diagnostic test meter, blood glucose diagnostic test strip, blood ketone diagnostic test meter, glucagon hydrochloride inj 1 mg syringe kit, insulin pen needles, insulin syringes disposable with attached needle, insulin pump accessories, insulin pump infusion set, insulin pump reservoir, ketone blood beta-ketone electrodes test strip, nicotine, sodium nitroprusside test strip,

3.6.2 Any Diabetes Nurse Prescribers' prescription for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

Note: A list of Diabetes Nurse Prescribers will be published periodically in the Update of the Pharmaceutical Schedule for the duration of an initial pilot scheme. After this period there will be no approved DHB demonstration sites and hence no Diabetes Nurse Prescribers.

PART IV DISPENSING FREQUENCY RULE

The Pharmaceutical Schedule specifies, for community patients, a default period of supply for each Community Pharmaceutical (a Monthly Lot, 90 Day Lot or for oral contraceptives 180 Day Lot). This Dispensing Frequency rule defines patient groups or medicines eligible for more frequent dispensing periods; and the conditions that must be met to enable any claim for payment of handling fees for the additional dispensings made. "Frequent Dispensing" means:

- for a Community Pharmaceutical referred to in Section F Part I, dispensing in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot); or
- for any other Community Pharmaceutical, where any of 4.1, 4.2 or 4.3 of Part IV apply, dispensing in quantities less than a Monthly Lot

NOTE patients who have had more frequent dispensings due to being "intellectually impaired, frail, infirm or unable to manage their medicines" will continue to receive the same frequency of dispensings until they are assessed to see if they are eligible for additional support under the Long-Term Condition (LTC) service. The structure of the remainder fee payment provides funding for pharmacy to continue to provide more frequent dispensings for patients until they are assessed.

4.1 Frequent Dispensings for persons in residential care

4.1.1 Pharmaceuticals can be dispensed in quantities of not less than 28 days to:

- any person whose placement in a Residential Disability Care Institution is funded by the Ministry of Health or a DHB; or
- a person assessed as requiring long term residential care services and residing in an age related residential care facility;

on the request of the person, their agent or caregiver or community residential service provider, provided the following conditions are met:

- a) the quantity or period of supply to be dispensed at any one time is not less than 28 days' supply (except under conditions outlined in 4.2.2 below); and
- b) the prescribing Practitioner or dispensing pharmacist has
 - i) included the name of the patient's residential placement or facility on the Prescription; and
 - ii) included the patient's NHI number on the Prescription; and
 - iii) specified the maximum quantity or period of supply to be dispensed at any one time.
- 4.1.2 Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changed is able to have their medicine dispensed in accordance with 4.2.2 below.

4.2 Frequent Dispensings for trial periods or safety medicines

- 4.2.1 If a Pharmacist considers more frequent dispensing is required, this can occur as follows:
 - For Long Term Condition (LTC) patients dispensing frequency can occur as often as the dispensing pharmacist deems appropriate to meet the patients compliance and adherence needs;
 - For non-LTC patients the dispensing frequency should be no more often than monthly. If Frequent Dispensing more often than monthly is necessary for non-LTC patients, prescriber approval is required. Verbal approval is acceptable, provided that it is annotated by the pharmacist on the Prescription and

dated.

NOTE this rule does not override alternative dispensing frequencies as expressly stated in the Medicines Act, Medicines Regulations, Pharmacy Services Agreement, Pharmaceutical Schedule or under rule 4.2.2 Trial Periods or rule 4.2.3 safety and co-prescribed medicines below.

Pharmacy would claim handling fees only on repeats under the above scenarios.

Prescribers can request, and pharmacists may dispense a higher frequency of dispensing in the following circumstances:

4.2.2 Trial Periods

The Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient's first changed Prescription only);

and the prescribing Practitioner has:

- endorsed each Community Pharmaceutical on the Prescription clearly with the words "Trial Period", or "Trial"; and
- specified the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time.

Patients who reside in Penal Institutions are not eligible for Trial Periods.

- 4.2.3 Safety and co-prescribed medicines
 - a) The Community Pharmaceutical is any of the following:
 - i) a tri-cyclic antidepressant; or
 - ii) an antipsychotic; or
 - iii) a benzodiazepine; or
 - iv) a Class B Controlled Drug; or
 - v) codeine (includes combination products)
 - vi) buprenorphine with naloxone

All of the following conditions must be met:

The Community Pharmaceutical has been prescribed for a patient who is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.1 above. The prescribing Practitioner has:

- Assessed clinical risk and determined the patient requires Frequent Dispensing; and
- Specified the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time.
- b) The Community Pharmaceutical is co-prescribed with one of the Community Pharmaceuticals listed in 4.2.3(a) above and has been prescribed for a patient who is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.1 above. The dispensing pharmacist has:
 - Assessed clinical risk and determined the patient requires Frequent Dispensing;
 - Annotated the Prescription with the amended dispensing quantity and frequency.

4.3 Frequent Dispensing for Pharmaceutical Supply Management

- 4.3.1 Frequent Dispensing may be required from time to time to manage stock supply issues or emergency situations. Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met:
 - a) PHARMAC has approved and notified pharmacists to annotate Prescriptions for a specified Community Pharmaceutical(s) "out of stock" without prescriber endorsement for a specified time; and
 - b) the dispensing pharmacist has:
 - i) clearly annotated each of the approved Community Pharmaceuticals that appear on the Prescription with the words "out of stock" or "OOS"; and
 - ii) initialled the annotation in their own handwriting; and
 - iii) has complied with maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

Note – no claim shall be made to any DHB for subsidised dispensing where dispensing occurs more frequently than specified by PHARMAC to manage the supply management issue.

PART V MISCELLANEOUS PROVISIONS

5.1 Bulk Supply Orders

- The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:
- 5.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
- 5.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
- 5.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
- 5.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 and:
 - a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
 - b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
- 5.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.
- 5.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.

5.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

- 5.2.1 Subject to clause 5.2.3 and 5.2.6, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.
- 5.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:
 - a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.
 - b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)
- 5.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:
 - a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which:
 - i) is personally signed and dated by the Practitioner; and
 - ii) sets out the Practitioner's address; and
 - iii) sets out the Community Pharmaceuticals and quantities, and;
 - b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.
- 5.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.

- 5.2.6 A Practitioner working in the Rheumatic Fever Prevention Programme (RFPP) may order under a Practitioner's Supply Order such Community Pharmaceuticals (identified below) as he or she requires to ensure medical supplies are available for patients with suspected or confirmed Group A Streptococcal throat infections for the purposes of the RFPP in the following circumstances:
 - a) the RFPP provider name is written on the Practitioner's Supply Order; and
 - b) the total quantity ordered does not exceed a multiple of:
 - i) ten times the Practitioner's Supply Order current maximum listed in Section E Part I for amoxycillin grans for oral liq 250 mg per 5 ml, amoxycillin cap 250 mg and amoxycillin cap 500 mg; or
 - ii) two times the Practitioner's Supply Order current maximum listed in Section E Part I for phenoxymethyl penicillin grans for oral liquid 250 mg per 5 ml, phenoxymethyl penicillin cap 500 mg, erythromycin ethyl succinate grans for oral liq 200 mg per 5 ml and erythromycin ethyl succinate tab 400 mg; and
 - c) the practitioner must specify the order quantity in course-specific amounts on the Practitioner's Supply Order (e.g. 10 x 300 ml amoxycillin grans for oral liq 250 mg per 5 ml). This will enable the pharmacy to dispense each course separately and claim multiple service fees as per the Community Pharmacy Services Agreement.

5.3 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

5.3.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

5.3.2 Expiry

The recommendation expires at the end of two years and can be renewed by a further consultation.

- 5.3.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 5.3.1 and 5.3.2, for the individual Patient.
- 5.3.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.
- 5.3.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the Ministry of Health's routine auditing procedures.

5.4 Pharmaceutical Cancer Treatments

- 5.4.1 DHBs must provide access to Pharmaceutical Cancer Treatments for the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.
- 5.4.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:
 - a) has Named Patient Pharmaceutical Assessment (NPPA) approval;
 - b) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
 - c) is being used and funded as part of a paediatric oncology service; or
 - d) was being used to treat the patient in question prior to 1 July 2005.
- 5.4.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatements with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:
 - a) Part 1;
 - b) clauses 2.1 to 2.3;
 - c) clauses 3.1 to 3.4; and
 - d) clause 5.4,
 - of Section A of the Schedule
- 5.4.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer

Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.

- 5.4.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 decision by the Minister of Health as to pharmaceuticals and indications for which DHBs must provide access. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:
 - a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.
- 5.4.6 Applications to add pharmaceuticals, and add or amend indications for Pharmaceutical Cancer Treatments, may be made in writing by pharmaceutical suppliers and/or clinicians to PHARMAC. Applications should follow the Guidelines for Funding Applications to PHARMAC 2010 and Recommended methods to derive clinical inputs for proposals to PHARMAC, copies of which are available from PHARMAC or PHARMAC's website.

5.5 Practitioners prescribing unapproved Pharmaceuticals

Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

- a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or
- b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;

Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

5.6 Substitution

Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, unless either or both of the following circumstances apply:

a) there is a clinical reason why substitution should not occur; or

b) the prescriber has marked the prescription with a statement such as 'no brand substitution permitted' Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and sign the prescription and inform the patient of the brand change.

5.7 Alteration to Presentation of Pharmaceutical Dispensed

A Contractor, when dispensing a subsidised Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed to another subsidised presentation but may not alter the dose, frequency and/or total daily dose. This may only occur when it is not practicable for the contractor to dispense the requested presentation. If the change will result in additional cost to the DHBs, then annotation of the prescription by the dispensing pharmacist must occur stating the reason for the change, and the Contractor must initial the change for the purposes of Audit.

5.8 Conflict in Provisions

If any rules in Sections B-G and Section I of this Schedule conflict with the rules in Section A, the rules in Sections B-G and Section I apply.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Pric \$	e) (Per	Subsidised Ge	nd or neric nufacturer
Antacids and Antiflatulants				
Antacids and Reflux Barrier Agents				
ALGINIC ACID Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet	•	30	🖌 Gavis	con Infant
SIMETHICONE * Oral liq aluminium hydroxide 200 mg with magnesium hydrox- ide 200 mg and activated simethicone 20 mg per 5 ml		500 ml	Mylan	ta P
SODIUM ALGINATE * Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour	1	60	Gaviso	con Double
* Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml		500 ml	Stre Acide»	ngth
Phosphate Binding Agents				
ALUMINIUM HYDROXIDE * Tab 600 mg CALCIUM CARBONATE Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement Only when prescribed for children under 12 years of age endorsed accordingly.	- 	100 500 ml osphate b	 Alu-Ta Roxar inding agent a 	ie
Antidiarrhoeals				
Agents Which Reduce Motility				
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPH * Tab 2.5 mg with atropine sulphate 25 mcg (Diastop Tab 2.5 mg with atropine sulphate 25 mcg to be delisted LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a	3.90 1 February 2014)	100	🗸 Diasto	р
* Tab 2 mg	8.95	400 400	🖌 Nodia 🖌 Diami	
Rectal and Colonic Anti-inflammatories				
BUDESONIDE				
Cap 3 mg – Special Authority see SA1155 on the next page – Retail pharmacy		90	🖌 Entoc	ort CIR

Subsidy (Manufacturer's Price)	Su	Fully bsidised	Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1155 Special Authority for Subsidy

Initial application — (Crohn's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:
 - 2.1 Diabetes; or
 - 2.2 Cushingoid habitus; or
 - 2.3 Osteoporosis where there is significant risk of fracture; or
 - 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an Unapproved Indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications)	25.30	21.1 g OP	✓ Colifoam
MESALAZINE			
Tab 400 mg		100	Asacol
Tab EC 500 mg		100	Asamax
Tab long-acting 500 mg		100	Pentasa
Modified release granules, 1 g		120 OP	Pentasa
Enema 1 g per 100 ml		7	Pentasa
Suppos 500 mg		20	✓ Asacol
Suppos 1 g		28	Pentasa
	54.60	30	Pentasa
OLSALAZINE			
Tab 500 mg		100	Dipentum
Cap 250 mg		100	 Dipentum
SODIUM CROMOGLYCATE			
Cap 100 mg		100	 Nalcrom
SULPHASALAZINE			
* Tab 500 mg – For sulphasalazine oral liquid formulation re	efer,		
page 194		100	Salazopyrin
* Tab EC 500 mg	12.89	100	Salazopyrin EN

	Subsidy (Manufacturer's Pric \$	e) Sub Per	Fully Brand sidised Gene Manu	
Local preparations for Anal and Rectal Disorders	S			
Antihaemorrhoidal Preparations				
FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVA Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cin-	LATE AND CINCH	OCAINE		
chocaine hydrochloride 5 mg per g Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and		30 g OP	 Ultrapro 	
cinchocaine hydrochloride 1 mg HYDROCORTISONE WITH CINCHOCAINE		12	✓ Ultrapro	
Oint 5 mg with cinchocaine hydrochloride 5 mg per g Suppos 5 mg with cinchocaine hydrochloride 5 mg per g		30 g OP 12	 Proctos Proctos 	
Management of Anal Fissures				
GLYCERYL TRINITRATE – Special Authority see SA1329 below * Oint 0.2%		30 g OP	✔ Rectog	esic
⇒SA1329 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid chronic anal fissure that has persisted for longer than three weeks		newal unles	s notified whe	re the patient has a
Antispasmodics and Other Agents Altering Gut	Motility			
HYOSCINE N-BUTYLBROMIDE * Tab 10 mg * Inj 20 mg, 1 ml – Up to 5 inj available on a PSO		20 5	✓ <u>Gastros</u> ✓ <u>Buscop</u>	
MEBEVERINE HYDROCHLORIDE * Tab 135 mg		90	✓ Colofac	
Antiulcerants				
Antisecretory and Cytoprotective				
MISOPROSTOL * Tab 200 mcg	52.70	120	🗸 Cytoted	:
Helicobacter Pylori Eradication				
CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement a) Maximum of 14 tab per prescription	10.95	14	✓ <u>Apo-Cla</u>	arithromycin
b) Subsidised only if prescribed for helicobacter pylori erad Note: the prescription is considered endorsed if clarithromycin is amoxycillin or metronidazole.				
H2 Antagonists				
CIMETIDINE – Only on a prescription * Tab 200 mg	5.00	100		
* Tab 400 mg	(7.50)	100	Apo-Cin	netidine
-	(12.00)		Apo-Cin	netidine

	Subsidy		Fully	/ Brand or
	(Manufacturer's Pr	rian)	Subsidised	
		Per	Subsidised	
	\$	Per	~ ~	Manufacturer
RANITIDINE HYDROCHLORIDE – Only on a prescription				
* Tab 150 mg	6 7 9	250	~	Arrow-Ranitidine
* Tab 300 mg	9.34	250		Arrow-Ranitidine
* Oral lig 150 mg per 10 ml		300 ml	~	Peptisoothe
		5		Zantac
* Inj 25 mg per ml, 2 ml	0.75	5	v	Zaniac
Proton Pump Inhibitors				
LANSOPRAZOLE				
	0.00	00		Color
* Cap 15 mg	2.00	28		Solox
* Cap 30 mg	2.32	28	~	Solox
1 0				
OMEPRAZOLE				
For omeprazole suspension refer, page 197				
		~~		
* Cap 10 mg	2.91	90	V	Omezol Relief
* Cap 20 mg	3 78	90	~	Omezol Relief
* Cap 40 mg		90		Omezol Relief
* Powder – Only in combination		5 g	~	Midwest
Only in extemporaneously compounded omeprazole sus		- 5		
		_		
* Inj 40 mg		5	~	Dr Reddy's
, ,				Omeprazole
				Omephazole
PANTOPRAZOLE				
	1.00	00		
* Tab 20 mg	1.23	28	V	Dr Reddy's
				Pantoprazole
Nr. Tab 40 mm	4 5 4	00		•
* Tab 40 mg	1.54	28	V	Dr Reddy's
				Pantoprazole
Site Protective Agents				
BISMUTH TRIOXIDE				
Tab 100 mg	20 E0	112		De Nol S29
Tab 120 mg		112	v	De NOI 329
SUCRALFATE				
Tab 1 g	35.50	120		
•	(48.28)			Carafate
	(10.20)			ouraidio
Diabetes				
Blaberes				
Hyperglycaemic Agents				
DIAZOXIDE – Special Authority see SA1320 below – Retail pha	armacy			
	•			
Cap 25 mg – For diazoxide oral liquid formulation refer, pag	je			
194	110.00	100	~	Proglicem S29
				•
Cap 100 mg		100	~	Proglicem S29
The CA1000 Creatial Authority for Cubaidy				
SA1320 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals va	lid for 12 months w	here used	for the tr	eatment of confirmed hypo
glycaemia caused by hyperinsulinism.				, , , , , , , , , , , , , , , , , , ,
Renewal from any relevant practitioner. Approvals valid without	further renewal unle	ess notified	d where th	ne treatment remains appro
priate and the patient is benefiting from treatment.				
onato and the patient is benchang norm treatment.				
GLUCAGON HYDROCHLORIDE				
	22.00	4		Glussen Hynakit
Inj 1 mg syringe kit – Up to 5 kit available on a PSO		1	V	Glucagen Hypokit

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or sidised Generic ✔ Manufacturer
Insulin - Short-acting Preparations			
NSULIN NEUTRAL ▲ Inj human 100 u per ml	25.26	10 ml OP	 ✓ Actrapid ✓ Humulin R
▲ Inj human 100 u per ml, 3 ml	42.66	5	 Actrapid Penfill Humulin R
Insulin - Intermediate-acting Preparations			
NSULIN ASPART WITH INSULIN ASPART PROTAMINE ▲ Inj 100 iu per ml, 3 ml prefilled pen		5	NovoMix 30 FlexPen
NSULIN ISOPHANE ▲ Inj human 100 u per ml	17.68	10 ml OP	 Humulin NPH Protaphane
▲ Inj human 100 u per ml, 3 ml	29.86	5	 Humulin NPH Protaphane Penfill
NSULIN ISOPHANE WITH INSULIN NEUTRAL ▲ Inj human with neutral insulin 100 u per ml	25.26	10 ml OP	 ✓ Humulin 30/70 ✓ Mixtard 30
▲ Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	 Humulin 30/70 PenMix 30 PenMix 40 PenMix 50
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE ▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml		5	✔ Humalog Mix 25
 Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml 	,	5	 Humalog Mix 23 Humalog Mix 50
Insulin - Long-acting Preparations			
NSULIN GLARGINE			
 Inj 100 u per ml, 10 ml Inj 100 u per ml, 3 ml Inj 100 u per ml, 3 ml disposable pen 	94.50	1 5 5	 ✓ Lantus ✓ Lantus ✓ Lantus SoloStar
Insulin - Rapid Acting Preparations			
NSULIN ASPART ▲ Inj 100 u per ml, 3 ml ▲ Inj 100 u per ml, 10 ml		5 1	 ✓ NovoRapid Penfill ✓ NovoRapid
NSULIN GLULISINE Inj 100 u per ml, 10 ml Inj 100 u per ml, 3 ml Inj 100 u per ml, 3 ml disposable pen Inj 100 u per ml, 3 ml disposable pen	46.07	1 5 5	 ✓ Apidra ✓ Apidra ✓ Apidra SoloStar
 Inj 100 u per mi, 3 mi usposable pen INSULIN LISPRO ▲ Inj 100 u per mi, 10 ml ▲ Inj 100 u per mi, 3 ml 		10 ml OP 5	 Humalog Humalog

	Subsidy (Manufacturer's Pric \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Alpha Glucosidase Inhibitors	Ŷ	Fei		Manulacturer
ACABBOSE				
* Tab 50 mg	9.82	90	V <u>A</u>	Accarb
* Tab 100 mg	15.83	90	<u> </u>	Accarb
Oral Hypoglycaemic Agents				
GLIBENCLAMIDE				
* Tab 5 mg	5.00	100	~ [Daonil
GLICLAZIDE				
* Tab 80 mg	17.60	500	VA	Apo-Gliclazide
GLIPIZIDE * Tab 5 mg	2.00	100	~	<i>l</i> inidiab
METFORMIN HYDROCHLORIDE		100	• •	
* Tab immediate-release 500 mg		1.000	VA	Apotex
* Tab immediate-release 850 mg		500		potex
PIOGLITAZONE				
* Tab 15 mg		28		Pizaccord
* Tab 30 mg * Tab 45 mg		28 28		Pizaccord Pizaccord
Diabetes Management		20	• 1	1200010
Diabetes Management				
Ketone Testing				
BLOOD KETONE DIAGNOSTIC TEST METER – Up to 1 meter Meter funded for the purposes of blood ketone diagnostics at risk of future episodes. Only one meter per patient will be Meter	only. Patient has had subsidised every 5	d one or		odes of ketoacidosis and is
KETONE BLOOD BETA-KETONE ELECTRODES	40.00	I	• 1	reestyle optium
a) Maximum of 20 strip per prescription				
b) Up to 10 strip available on a PSO				
Test strip – Not on a BSO	15.50 1	0 strip C)p 🖌 F	reestyle Optium Ketone
SODIUM NITROPRUSSIDE - Maximum of 50 strip per prescrip				
* Test strip – Not on a BSO	6.00 5	0 strip C	DP VA	Accu-Chek Ketur-Test
	14.14		🗸 K	Ketostix

	Subsidy (Manufacturer's Pric \$	e) Su Per	Fully bsidised	Brand or Generic Manufacturer
Blood Glucose Testing				
 BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by a) Up to 1 pack available on a PSO b) Maximum of 1 pack per prescription c) A diagnostic blood glucose test meter is subsidised for a p 1) is receiving insulin or sulphonylurea therapy; or 2) is pregnant with diabetes; or 3) is on home TPN at risk of hypoglycaemia or hyperg 4) has a genetic or an acquired disorder of glucose syndrome. 	patient who: glycaemia; or	ling type 1	or type	2 diabetes and metabol
Only one CareSens meter per patient. No further prescriptions w For the avoidance of doubt patients who have previously received meter. The prescription must be endorsed accordingly. Pharmac a record of prior dispensing of insulin or sulphonylureas.	d a funded meter, oth ists may annotate th	ner than Ca	reSens,	are eligible for a CareSer
Meter with 50 lancets, a lancing device and 10 diagnostic tes strips		1 OP	VC	<u>areSens II</u> areSens N areSens N POP
Note: Only 1 meter available per PSO			• •	
 BLOOD GLUCOSE DIAGNOSTIC TEST STRIP – Up to 50 test The number of test strips available on a prescription is restri- 1) Prescribed with insulin or a sulphonylurea but are on a dif 2) Prescribed on the same prescription as insulin or a sulpho or 3) Prescribed for a pregnant woman with diabetes and endo 4) Prescribed for a patient on home TPN at risk of hypoglyce 5) Prescribed for a patient with a genetic or an acquired dis and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirement 	cted to 50 unless: iferent prescription a onylurea in which ca rsed accordingly; or aemia or hyperglyca order of glucose hou s	se the pres emia and er neostasis e	cription i ndorsed excluding	s deemed to be endorsed accordingly; or g type 1 or type 2 diabete
below		50 test OP	✓ C	<u>areSens</u> areSens N ccu-Chek
				Performa
a) Accu-Chek Performa brand: Special Authority see SA1 b) Freestyle Optium brand: Special Authority see SA1291 c) Note: Accu-Chek Performa and Freestyle Optium are r ⇒SA1294 Special Authority for Subsidy	l below – Retail pha not available on a PS	rmacy 60		reestyle Optium
Notes: Application details may be obtained from PHARMAC's we PHARMAC PO Box 10 254 Facsimile: (04) 974 4788	ebsite http://www.pha	armac.govt.	.nz and o	can be sent to:
PO Box 10 254 Facsimile: (04) 974 4788 Wellington Email: bgstrips@pharmac.govt.nz				
►SA1291 Special Authority for Subsidy Notes: Application details may be obtained from PHARMAC's we PHARMAC	ebsite http://www.pha	armac.govt.	.nz and o	can be sent to:

PO Box 10 254 Facsimile: (04) 974 4788 Wellington Email: bgstrips@pharmac.govt.nz

		Subsidy (Manufacturer's P \$	rice) Su Per	Fully bsidised	Brand or Generic Manufacturer
ЗL	OOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)				
	The number of test strips available on a prescription is r	estricted to 50 unless:			
	1) Prescribed with insulin or a sulphonylurea but are on				
	2) Prescribed on the same prescription as insulin or a si	ulphonylurea in which o	case the pres	cription i	s deemed to be endorse
	or				
	3) Prescribed for a pregnant woman with diabetes and e				
	4) Prescribed for a patient on home TPN at risk of hypor				
	5) Prescribed for a patient with a genetic or an acquired	a alsoraer of glucose n	omeostasis	excluaing	type 1 or type 2 diabet
·~	and metabolic syndrome and endorsed accordingly. nsoCard blood glucose test strips are subsidised only if p	recorribed for a patient	who is sover	obuviouo	lly impaired and is using
	nsoCard Plus Talking Blood Glucose Monitor.	rescribed for a patient	WITO IS Sever	ely visua	iny impaired and is using
56	Blood glucose test strips	26.20	50 test OP	v s	ensoCard
	· ·		00100101		onooouru
Ir	sulin Syringes and Needles				
su	bsidy is available for disposable insulin syringes, needles	, and pen needles if p	rescribed on	the same	e form as the one used
	supply of insulin or when prescribed for an insulin patien				
N	SULIN PEN NEEDLES – Maximum of 100 dev per presci	ription			
	29 g $ imes$ 12.7 mm		30	🖌 В	-D Micro-Fine
	5	10.50	100	🖌 В	-D Micro-Fine
ŧ	31 g $ imes$ 5 mm	11.75	100	🖌 В	-D Micro-Fine
ŧ	$31 \text{ g} \times 6 \text{ mm}$	10.50	100	🖌 A	BM
		(26.00)		N	ovoFine
*	31 g \times 8 mm	3.15	30	🖌 В	-D Micro-Fine
		10.50	100		-D Micro-Fine
	aa b	10.50	100	V A	
*	$32 \text{ g} \times 4 \text{ mm}$	10.50	100	VB	-D Micro-Fine
	ovoFine 31 g $ imes$ 6 mm to be delisted 1 June 2014)				
N	SULIN SYRINGES, DISPOSABLE WITH ATTACHED NEE			rescriptic	n
*	Syringe 0.3 ml with 29 g \times 12.7 mm needle		10	-	
		(1.99)	400		-D Ultra Fine
		13.00	100	VB	-D Ultra Fine
ŧ	Syringe 0.3 ml with 31 g \times 8 mm needle $\hfill \hfill \$		10		D I III III III
		(1.99)	100		-D Ultra Fine II -D Ultra Fine II
	Syringe 0.5 ml with 29 g $ imes$ 12.7 mm needle	13.00	100	VD	
ĸ		(1.99)	10	в	-D Ultra Fine
¥		13.00	100		-D Ultra Fine
¥	Syringe 0.5 ml with 31 g \times 8 mm needle		100	• 5	Donarine
		(1.99)		В	-D Ultra Fine II
		13.00	100	🖌 В	-D Ultra Fine II
			100	🗸 A	
*	Syringe 1 ml with 29 g \times 12.7 mm needle		10		
*	Syringe 1 ml with 29 g \times 12.7 mm needle $\hfill \ldots$	1.30		В	-D Ultra Fine
*	Syringe 1 ml with 29 g \times 12.7 mm needle $\hfill \ldots$	1.30 (1.99)			D IIII Ela
*		(1.99) 13.00	100	🗸 В	-D Ultra Fine
* *	Syringe 1 ml with 29 g \times 12.7 mm needle Syringe 1 ml with 31 g \times 8 mm needle	(1.99) 13.00	100 100	✔ B ✔ A	
* * * *		(1.99) 13.00 13.00 1.30		✔ A	BM
* *		(1.99) 13.00 13.00	100	√ А В	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
Insulin Pumps				
INSULIN PUMP – Special Authority see SA1237 below – Retail (a) Maximum of 1 dev per prescription b) Only on a prescription c) Maximum of 1 insulin pump per patient each four year perior Min basal rate 0.025 U/h; black colour Min basal rate 0.025 U/h; blue colour	od. 4,500.00 4,500.00	1	~	Animas Vibe Animas Vibe
Min basal rate 0.025 U/h; green colour Min basal rate 0.025 U/h; pink colour Min basal rate 0.025 U/h; silver colour	4,500.00	1 1 1	~	Animas Vibe Animas Vibe Animas Vibe
Min basal rate 0.05 U/h; blue colour	4,400.00	1	~ I	Paradigm 522 Paradigm 722
Min basal rate 0.05 U/h; clear colour		1	~	Paradigm 522 Paradigm 722 Paradigm 500
Min basal rate 0.05 U/h; pink colour		1	~ I	Paradigm 522 Paradigm 722 Paradigm 522
Min basal rate 0.05 U/h; purple colour		1	~	Paradigm 722 Paradigm 722 Paradigm 522
WIII DASALTALE 0.05 0/1, SHIOKE COIDUL	4,400.00	I		Paradigm 722

SA1237 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The IPP Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 974 7806
PO Box 10 254	Email: ipp@pharmac.govt.nz
Wellington	

Insulin Pump Consumables

➡SA1240 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The IPP Co-ordinator	Phone: (04) 460 4990			
PHARMAC	Facsimile: (04) 974 7806			
PO Box 10 254	Email: ipp@pharmac.govt.nz			
Wellington				
INSULIN PUMP ACCESS	SORIES - Special Authority see SA1240) above – Retail pl	harmacy	
a) Maximum of 1 cap	per prescription			
b) Only on a prescrip	tion			
c) Maximum of 1 pres	scription per 180 days.			
Battery cap			1	🖌 Animas Battery Cap

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
 INSULIN PUMP INFUSION SET (STEEL CANNULA) – Special a) Maximum of 3 sets per prescription 	Authority see SA1240) on the	e previous	page – Retail pharm	nacy
b) Only on a prescription					
c) Maximum of 13 infusion sets will be funded per year.					
10 mm steel needle; 29 G; manual insertion; 60 cm tubing \times					
10 with 10 needles		1 OP	🖌 P	aradigm Sure-T MMT-884	
10 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$					
10 with 10 needles; luer lock	130.00	1 OP	🗸 S	ure-T MMT-883	
10 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$					
10 with 10 needles	130.00	1 OP	✔ P	aradigm Sure-T MMT-886	
10 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$					
10 with 10 needles; luer lock	130.00	1 OP	🗸 S	ure-T MMT-885	
6 mm steel cannula; straight insertion; 60 cm grey line \times 10					
with 10 needles		1 OP	V C	ontact-D	
6 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$					
10 with 10 needles		1 OP	V P	aradigm Sure-T	
		1 01	• •	MMT-864	
6 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$					
10 with 10 needles; luer lock		1 OP	./ 9	ure-T MMT-863	
		I UF	• 3		
6 mm steel needle; 29 G; manual insertion; 80 cm tubing ×		4 00			
10 with 10 needles		1 OP	V P	aradigm Sure-T	
				MMT-866	
6 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$					
10 with 10 needles; luer lock		1 OP	V S	ure-T MMT-865	
8 mm steel cannula; straight insertion; 110 cm grey line $ imes$ 10					
with 10 needles	130.00	1 OP	V C	ontact-D	
8 mm steel cannula; straight insertion; 60 cm grey line \times 10					
with 10 needles	130.00	1 OP	V C	ontact-D	
8 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$					
10 with 10 needles		1 OP	V P	aradigm Sure-T	
				MMT-874	
8 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$					
10 with 10 needles; luer lock		1 OP	V S	ure-T MMT-873	
8 mm steel needle; 29 G; manual insertion; 80 cm tubing \times		. 01	•••		
10 with 10 needles		1 OP	/ D	aradigm Sure-T	
			▼ F	MMT-876	
9 mm staal noodles 20 Cs manual incertions 20 are tables				WIWI 1-07 0	
8 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles; luer lock		1 OP		ure-T MMT-875	
			v 3		

	Subsidy (Manufacturer's \$	Price) Sut Per	Fully Brand or osidised Generic Manufacti	urer
SULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE IN	Ŧ			
A1240 on page 32 – Retail pharmacy a) Maximum of 3 sets per prescription				a numonty se
b) Only on a prescriptionc) Maximum of 13 infusion sets will be funded per year.				
13 mm teflon cannula; angle insertion; insertion device; 110 cm grey line \times 10 with 10 needles	140.00	1 OP	🖌 Inset 30	
13 mm teflon cannula; angle insertion; insertion device; 60 cm blue line × 10 with 10 needles	140.00	1 OP	Inset 30	
13 mm teflon cannula; angle insertion; insertion device; 60 cm grey line × 10 with 10 needles		1 OP	🖌 Inset 30	
13 mm teflon cannula; angle insertion; insertion device; 60 cm pink line × 10 with 10 needles		1 OP	🖌 Inset 30	
SULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE IN	ISERTION) - S	Special Authorit	y see SA1240 on	page 32 – Reta
armacy a) Maximum of 3 sets per prescription b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year. 13 mm teflon cannula; angel insertion; 60 cm grey line \times 5				
with 10 needles		1 OP	 Comfort Sh 	ort
10 needles	130.00	1 OP	Paradigm S MMT-382	Silhouette
13 mm teflon cannula; angle insertion; 45 cm line \times 10 with 10 needles		1 OP	✓ Paradigm S MMT-368	Silhouette
13 mm teflon cannula; angle insertion; 60 cm line \times 10 with 10 needles		1 OP	✓ Paradigm S MMT-381	Silhouette
13 mm teflon cannula; angle insertion; 80 cm line \times 10 with 10 needles		1 OP	✓ Paradigm S	likevette
		TOP	MMT-383	Sinouelle
17 mm teflon cannula; angle insertion; 110 cm grey line × 5 with 10 needles	120.00	1 OP	 Comfort 	
17 mm teflon cannula; angle insertion; 110 cm line \times 10 with 10 needles		1 OP	🗸 Paradigm S	Silhouette
17 mm teflon cannula; angle insertion; 110 cm line $ imes$ 10 with			MMT-377	
10 needles; luer lock	130.00	1 OP	 Silhouette 	MMT-371
with 10 needles	120.00	1 OP	 Comfort 	
17 mm teflon cannula; angle insertion; 60 cm line \times 10 with 10 needles		1 OP	✓ Paradigm S MMT-378	Silhouette
17 mm teflon cannula; angle insertion; 60 cm line \times 10 with 10 needles; luer lock		1 OP	✓ Silhouette	MMT-373
17 mm teflon cannula; angle insertion; 80 cm line \times 10 with 10 needles		1 OP	✓ Paradigm S	
			MMT-384	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGH see SA1240 on page 32 – Retail pharmacy a) Maximum of 3 sets per prescription b) Only on a prescription	T INSERTION WITH	INSE	RTION DE\	/ICE) – Special Authority
 c) Maximum of 13 infusion sets will be funded per year. 6 mm teflon cannula; straight insertion; insertion device; 110 				
cm grey line \times 10 with 10 needles	140.00	1 OP	🖌 In	set II
6 mm teflon cannula; straight insertion; insertion device; 45	100.00			
cm blue tubing \times 10 with 10 needles		1 OP		aradigm Mio MMT-941
6 mm teflon cannula; straight insertion; insertion device; 45				WW1-341
cm pink tubing \times 10 with 10 needles	130.00	1 OP		aradigm Mio MMT-921
6 mm teflon cannula; straight insertion; insertion device; 60	100.00		4.5	
cm blue tubing \times 10 with 10 needles		1 OP		aradigm Mio MMT-943
6 mm teflon cannula; straight insertion; insertion device; 60				WW 1-5-6
cm pink tubing \times 10 with 10 needles	130.00	1 OP		aradigm Mio MMT-923
6 mm teflon cannula; straight insertion; insertion device; 80 cm blue tubing \times 10 with 10 needles	130.00	1 OP		aradigm Mio
6 mm teflon cannula; straight insertion; insertion device; 80 cm clear tubing \times 10 with 10 needles	130.00	1 OP	🖌 Pa	MMT-945 aradigm Mio MMT-965
6 mm teflon cannula; straight insertion; insertion device; 80 cm pink tubing \times 10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Mio MMT-925
6 mm teflon cannula; straight insertionl insertion device; 60 cm blue line \times 10 with 10 needles	140.00	1 OP	🖌 In	set II
6 mm teflon cannula; straight insertionl insertion device; 60 cm grey line × 10 with 10 needles	140.00	1 OP	🗸 In	set II
 6 mm teflon cannula; straight insertionl insertion device; 60 cm pink line × 10 with 10 needles	140.00	1 OP	🗸 In	set II
cm blue line × 10 with 10 needles		1 OP	🗸 In	set II
cm grey line \times 10 with 10 needles		1 OP	🖌 In	set II
9 mm teflon cannula; straight insertion; insertion device; 60 cm pink line × 10 with 10 needles	140.00	1 OP	🖌 In	set II
9 mm teflon cannula; straight insertion; insertion device; 80 cm clear tubing × 10 with 10 needles	130.00	1 OP		aradigm Mio MMT-975
9 mm teflon cannula; straight insertionl insertion device; 110 cm grey line \times 10 with 10 needles \ldots	140.00	1 OP	🗸 In	set II

	Subsidy (Manufacturer's F	Price) Su	Fully Brand or ubsidised Generic
	\$	Per	 Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIG	GHT INSERTION)	 Special A 	uthority see SA1240 on page 32 -
Retail pharmacy a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
6 mm teflon cannula; straight insertion; 110 cm tubing \times 1			
with 10 needles		1 OP	 Paradigm Quick-Set MMT-398
6 mm teflon cannula; straight insertion; 110 cm tubing $ imes$ 1	0		
with 10 needles; luer lock		1 OP	✔ Quick-Set MMT-391
6 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 1			
with 10 needles	130.00	1 OP	 Paradigm Quick-Set MMT-399
6 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 1			
with 10 needles; luer lock		1 OP	✔ Quick-Set MMT-393
6 mm teflon cannula; straight insertion; 80 cm tubing \times 1			
with 10 needles		1 OP	Paradigm Quick-Set MMT-387
9 mm teflon cannula; straight insertion; 106 cm tubing $ imes$ 1	0		WWW 1-507
with 10 needles		1 OP	Paradigm Quick-Set
			MMT-396
9 mm teflon cannula; straight insertion; 110 cm tubing \times 1		4.05	
with 10 needles; luer lock		1 OP	Quick-Set MMT-390
9 mm teflon cannula; straight insertion; 60 cm tubing \times 1		1.00	A Devedierer Quick Set
with 10 needles		1 OP	Paradigm Quick-Set MMT-397
9 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 1	0		MM 1-007
with 10 needles; luer lock		1 OP	✔ Quick-Set MMT-392
9 mm teflon cannula; straight insertion; 80 cm tubing \times 1			
with 10 needles		1 OP	 Paradigm Quick-Set MMT-386
INSULIN PUMP RESERVOIR - Special Authority see SA1240	on page 32 - Ret	ail pharmacy	
a) Maximum of 3 sets per prescription	1 0		
 b) Only on a prescription 			
c) Maximum of 13 packs of reservoir sets will be funded per			
10 \times luer lock conversion cartridges 1.8 ml for Paradigi		1.00	
pumps		1 OP	ADR Cartridge 1.8
10 × luer lock conversion cartridges 3.0 ml for Paradigi pumps		1 OP	✓ ADR Cartridge 3.0
Cartridge 200 U, luer lock × 10		1 OP	 ADR Cartridge 3.0 Animas Cartridge
Cartridge for 5 and 7 series pump; 1.8 ml \times 10		1 OP	 Paradigm 1.8
			Reservoir
Cartridge for 7 series pump; 3.0 ml \times 10	50.00	1 OP	 Paradigm 3.0
			Reservoir
Syringe and cartridge for 50X pump, 3.0 ml \times 10		1 OP	✓ 50X 3.0 Reservoir

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Digestives Including Enzymes				
PANCREATIC ENZYME				
Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease		100	~ 0	Creon 10000
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease	94.38	100	~ 0	Creon Forte
Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease		100	🗸 P	Panzytrat
URSODEOXYCHOLIC ACID – Special Authority see SA1383 belo	ow – Retail pharmac	y		
Cap 250 mg – For ursodeoxycholic acid oral liquid formula- tion refer, page 194	71.50	100	✓ <u>u</u>	Irsosan

SA1383 Special Authority for Subsidy

Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Fither:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Cirrhosis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application — (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initial application — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
 - 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
 - 2 Liver function has not improved with modifying the TPN composition.

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.

Renewal — (Pregnancy/Cirrhosis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Pr	rice)	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 100 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription * Powder for oral soln	5.51	500 g OP	✓ Konsyl-D
MUCILAGINOUS LAXATIVES WITH STIMULANTS			
* Dry	2.41	200 g OP	
	(8.72)		Normacol Plus
	6.02	500 g OP	Newseed Dive
	(17.32)		Normacol Plus
Faecal Softeners			
DOCUSATE SODIUM – Only on a prescription			
* Cap 50 mg	2.57	100	Laxofast 50
* Cap 120 mg		100	Laxofast 120
* Enema conc 18%	5.40	100 ml OP	Coloxyl
DOCUSATE SODIUM WITH SENNOSIDES			
* Tab 50 mg with total sennosides 8 mg	6.38	200	Laxsol
POLOXAMER – Only on a prescription			
Not funded for use in the ear.			
* Oral drops 10%	3.78	30 ml OP	✓ Coloxyl
Osmotic Laxatives			
GLYCEROL			
* Suppos 3.6 g – Only on a prescription	6.50	20	✓ <u>PSM</u>
LACTULOSE – Only on a prescription			
* Oral liq 10 g per 15 ml		500 ml	Laevolac
	7.68	1,000 ml	✓ Laevolac
MACROGOL 3350 - Special Authority see SA0891 below - Retail	pharmacy		
Powder 13.125 g, sachets - Maximum of 60 sach per pre-	. ,		
scription	10.00	30	Lax-Sachets

►SA0891 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated.

Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gain benefit from treatment.

				_
	Subsidy		Fully Brand or	
	(Manufacturer's Pi \$	rice) Sul Per	osidised Generic Manufacturer	
	÷			
SODIUM ACID PHOSPHATE – Only on a prescription				
Enema 16% with sodium phosphate 8%	2.50	1	 Fleet Phosphate Enema 	
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACE		cription		
Enema 90 mg with sodium lauryl sulphoacetate 9 mg	per ml,			
5 ml		50	✓ <u>Micolette</u>	
Stimulant Laxatives				
BISACODYL - Only on a prescription				
* Tab 5 mg	4.99	200	🖌 Lax-Tab	
* Suppos 5 mg	3.00	6	Dulcolax	
* Suppos 10 mg	3.00	6	Dulcolax	
DANTHRON WITH POLOXAMER - Only on a prescriptio	n			
Note: Only for the prevention or treatment of constipat				
Oral lig 25 mg with poloxamer 200 mg per 5 ml	•	300 ml	Pinorax	
Oral liq 75 mg with poloxamer 1 g per 5 ml		300 ml	Pinorax Forte	
SENNA – Only on a prescription				
 Tab, standardised 	0.43	20		
	(1.72)	20	Senokot	
	2.17	100	OCHOROL	
	(6.16)	100	Senokot	
	()			
Metabolic Disorder Agents				
Gaucher's Disease				
MIGLUCERASE – Special Authority see SA0473 below -	- Retail pharmacy			
Inj 40 iu per ml, 200 iu vial		1	 Cerezyme 	
Inj 40 iu per ml, 400 iu vial		1	Cerezyme	
►SA0473 Special Authority for Subsidy				
Special Authority approved by the Gaucher's Treatment Pa	anel			
Notes: Subject to a budgetary cap. Applications will be con	nsidered and approved s		ling availability.	
Application details may be obtained from PHARMAC's wel	bsite http://www.pharma	c.govt.nz or:		
	: (04) 460 4990			
	nile: (04) 916 7571			
Wellington Email:	gaucherpanel@pharma	ac.govt.nz		
Mouth and Throat				
Agents Used in Mouth Ulceration				
•				
BENZYDAMINE HYDROCHLORIDE				
Soln 0.15%		200 ml	2.11	
	(8.50)		Difflam	
	9.00	500 ml	5.///	
	(17.01)		Difflam	
CHLORHEXIDINE GLUCONATE				
Mouthwash 0.2%	2.68	200 ml OP	✓ healthE	

	Subsidy (Manufacturer's P \$	rice) Sub Per	Fully Brand or Isidised Generic ✔ Manufacturer
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE			
* Adhesive gel 8.7% with cetalkonium chloride 0.01%		15 g OP	
	(5.62)		Bonjela
SODIUM CARBOXYMETHYLCELLULOSE			
With pectin and gelatin paste		56 g OP	 Stomahesive
	1.52	5 g OP	
	(3.60)		Orabase
	4.55	15 g OP	
Mith mostin and melatic name	(7.90)	00 - 00	Orabase
With pectin and gelatin powder		28 g OP	Stomahesive
	(10.95)		Stomanesive
TRIAMCINOLONE ACETONIDE			
0.1% in Dental Paste USP	4.34	5 g OP	✓ Oracort
Oropharyngeal Anti-infectives			
AMPHOTERICIN B			
Lozenges 10 mg	5.86	20	🖌 Fungilin
MICONAZOLE			-
Oral gel 20 mg per g	4 95	40 g OP	✓ Decozol
		40 9 01	• <u>BCCCECI</u>
NYSTATIN Oral list 100,000 u por ml	2.10	24 ml OP	A Nilotot
Oral liq 100,000 u per ml	3.19	24 MI OP	✓ <u>Nilstat</u>
Other Oral Agents			
For folinic mouthwash, pilocarpine oral liquid or saliva substitute	formula refer, pag	e 197	
HYDROGEN PEROXIDE			
* Soln 10 vol - Maximum of 200 ml per prescription	1.28	100 ml	🗸 PSM
THYMOL GLYCERIN			
* Compound, BPC	9.15	500 ml	✔ PSM
•		000 111	• • •
Vitamins			
Alpha tocopheryl acetate is available fully subsidised for specific	patients at the M	edical Director	r of PHARMAC's discretion. Rel
to PHARMAC website www.pharmac.govt.nz for the "Alpha tocor			

Vitamin A

VITAMIN A WITH VITAMINS D AND C * Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops4.50	10 ml OP	✓ Vitadol C
Vitamin B		
HYDROXOCOBALAMIN * Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO5.10	3	✓ <u>ABM</u> Hydroxocobalamin
PYRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription		
* Tab 25 mg – No patient co-payment payable	90 500	 <u>PyridoxADE</u> <u>Apo-Pyridoxine</u>

_					
		Subsidy (Manufacturer's Pric \$	ce) S Per	Fully Subsidised	Brand or Generic Manufacturer
тн	AMINE HYDROCHLORIDE – Only on a prescription				
*	Tab 50 mg	5.62	100	~	Apo-Thiamine
	v			• •	
	AMIN B COMPLEX	4.20	500		3-PlexADE
ጥ	Tab, strong, BPC	4.30	500		Splex Splex
(B-	PlexADE Tab, strong, BPC to be delisted 1 January 2014)			•	phex
۷	itamin C				
AS	CORBIC ACID				
	a) No more than 100 mg per dose				
	b) Only on a prescription				
*	Tab 100 mg	7.00	500	v (Cvite
	-			•	/itala-C
(Vi	tala-C Tab 100 mg to be delisted 1 January 2014)				
۷	itamin D				
AL	FACALCIDOL				
*		26.32	100	~	One-Alpha
	Cap 1 mcg		100		Dne-Alpha
	Oral drops 2 mcg per ml		20 ml OP		Dne-Alpha
	1 01				
	LCITRIOL	2.02	30		Airflow
*	Cap 0.25 mcg	10.10	100		Calcitriol-AFT
*	Cap 0.5 mcg		30		Airflow
ጥ	Cap 0.5 mcg	18.73	100		Calcitriol-AFT
*	Oral liq 1 mcg per ml		10 ml OP		Rocaltrol solution
-	ocaltrol solution Oral liq 1 mcg per ml to be delisted 1 February			• 1	
СН	OLECALCIFEROL				
*	Tab 1.25 mg (50,000 iu) - Maximum of 12 tab per prescription	on7.76	12	v (Cal-d-Forte
Μ	ultivitamin Preparations				
М	ILTIVITAMINS – Special Authority see SA1036 below – Retail	nharmacy			
	Powder		200 g OP		Paediatric Seravit
_			200 9 01	• •	
	SA1036 Special Authority for Subsidy ial application from any relevant practitioner. Approvals vali	id without further i	concural u	nlago noti	fied where the notiont has
	orn errors of metabolism.		enewai u	mess nou	med where the patient has
	newal from any relevant practitioner. Approvals valid without f	further renewal up	occ notifi	ad whore	nationt has had a provinue
	proval for multivitamins.	untier reflewal Uff	C22 101110	eu wriere	pauent nas nau a previous
	AMINS	7.00	4 000		
*	Tab (BPC cap strength)	7.60	1,000		AultiADE
					Ivite
*	Cap (fat soluble vitamins A, D, E, K) – Special Authority see		~~		//
	SA1002 on the next page – Retail pharmacy		60		/itabdeck
(M	ultiADE Tab (BPC cap strength) to be delisted 1 January 2014)				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	
SA1002 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid the following criteria:	d without further renev	val unless notif	ied for applications meeting

Either:

- 1 Patient has cystic fibrosis with pancreatic insufficiency; or
- 2 Patient is an infant or child with liver disease or short gut syndrome.

Minerals

Minerals			
Calcium			
CALCIUM CARBONATE * Tab eff 1.75 g (1 g elemental) * Tab 1.25 g (500 mg elemental) CALCIUM GLUCONATE		30 250	✓ <u>Calsource</u> ✓ <u>Arrow-Calcium</u>
* Inj 10%, 10 ml	21.40	10	✓ Hospira
Fluoride			
SODIUM FLUORIDE * Tab 1.1 mg (0.5 mg elemental)	5.00	100	✔ PSM
lodine			
POTASSIUM IODATE * Tab 256 mcg (150 mcg elemental iodine)	6.53	90	✓ NeuroKare
Iron			
FERROUS FUMARATE * Tab 200 mg (65 mg elemental)	4.35	100	✓ Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID * Tab 310 mg (100 mg elemental) with folic acid 350 mcg	4.75	60	✓ Ferro-F-Tabs
FERROUS SULPHATE * Tab long-acting 325 mg (105 mg elemental)	1.01	30	
	(4.26) 5.06	150	Ferrograd
*‡ Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)	(15.58) 10.30	500 ml	Ferrograd Ferodan
FERROUS SULPHATE WITH FOLIC ACID			
* Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg	1.80 (4.29)	30	Ferrograd F
IRON POLYMALTOSE # Inj 50 mg per ml, 2 ml		5	✓ <u>Ferrum H</u>
Magnesium			
For magnesium hydroxide mixture refer, page 197			
MAGNESIUM SULPHATE * Inj 2 mmol per ml, 5 ml		10	✓ Martindale✓ Hospira
	20.00		

	Subsidy (Manufacturer's Price) \$	Sul Per	Fully bsidised	Brand or Generic Manufacturer
Zinc				
ZINC SULPHATE * Cap 137.4 mg (50 mg elemental)	11.00	100	✓ <u>Zi</u>	ncaps

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Antianaemics

Hypoplastic and Haemolytic

SA0922 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Both:

- 1.1 patient in chronic renal failure; and
- 1.2 Haemoglobin \leq 100g/L; and
- 2 Any of the following:

2.1 Both:

- 2.1.1 patient is not diabetic; and
- 2.1.2 glomerular filtration rate \leq 30ml/min; or

2.2 Both:

- 2.2.1 patient is diabetic; and
- 2.2.2 glomerular filtration rate \leq 45ml/min; or
- 2.3 patient is on haemodialysis or peritoneal dialysis.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Notes: Erythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:

GFR (ml/min) (male) = (140 - age) × Ideal Body Weight (kg) / 814 × serum creatinine (mmol/l)

GFR (ml/min) (female) = Estimated GFR (male) $\times ~$ 0.85

ERYTHROPOIETIN ALPHA - Special Authority see SA0922 above - Retail pharmacy

Inj human recombinant 1,000 iu prefilled syringe		6	Eprex
Inj human recombinant 2,000 iu, prefilled syringe		6	Eprex
Inj human recombinant 3,000 iu, prefilled syringe		6	Eprex
Inj human recombinant 4,000 iu, prefilled syringe		6	Eprex
Inj human recombinant 5,000 iu, prefilled syringe	243.26	6	Eprex
Inj human recombinant 6,000 iu, prefilled syringe		6	Eprex
Inj human recombinant 10,000 iu, prefilled syringe		6	Eprex
ERYTHROPOIETIN BETA – Special Authority see SA0922 ab Inj 2,000 iu, prefilled syringe Inj 3,000 iu, prefilled syringe Inj 4,000 iu, prefilled syringe Inj 5,000 iu, prefilled syringe Inj 6,000 iu, prefilled syringe		cy 6 6 6 6 6	 NeoRecormon NeoRecormon NeoRecormon NeoRecormon NeoRecormon NeoRecormon NeoRecormon
Megaloblastic			
FOLIC ACID			
W Tob 0.0 mg	10.00	1 000	Ana Calia Aaid

*	Tab 0.8 mg19.80	1,000	Apo-Folic Acid
*	Tab 5 mg	500	Apo-Folic Acid
	Oral liq 50 mcg per ml24.00	25 ml OP	 Biomed

	Subsidy (Manufacturer's Pri \$	ce) S Per	Fully ubsidised	Brand or Generic Manufacturer
Antifibrinolytics, Haemostatics and Local	Sclerosants			
PTACOG ALFA [RECOMBINANT FACTOR VIIA] - Hos	spital pharmacy [Xpharm]			
For patients with haemophilia, whose treatment is ma		Treaters G	roup in co	njunction with the Nation
Haemophilia Management Group.				
Inj 1 mg syringe		1	V N	ovoSeven RT
Inj 2 mg syringe		1		ovoseven RT
Inj 5 mg syringe		1		ovoseven RT
Inj 8 mg syringe		1	✓ N	ovoseven RT
ACTOR EIGHT INHIBITORS BYPASSING AGENT – H				
For patients with haemophilia, whose treatment is ma	anaged by the Haemophilia	Treaters G	roup in co	njunction with the Nation
Haemophilia Management Group. Inj 500 U	1 640 00	1	🖌 Fl	-IRA
Inj 1,000 U		1	V FI	
•				
IOROCTOCOG ALFA [RECOMBINANT FACTOR VIII]				
For patients with haemophilia, whose treatment is ma	anaged by the Haemophilia	ireaters G	roup in co	njunction with the Nation
Haemophilia Management Group. Inj 250 iu vial	005.00	1	. / V.	untho
Inj 500 iu vial		1		yntha yntha
Inj 1.000 iu vial		1		/ntha
Inj 2,000 iu vial		1		/ntha
Inj 3,000 iu vial		1		/ntha
3 ·	*			
ONACOG ALFA [RECOMBINANT FACTOR IX] – Hosp				
		Trootoro C	roun in oo	niunation with the Nation
For patients with haemophilia, whose treatment is ma		Treaters G	roup in co	njunction with the Nation
For patients with haemophilia, whose treatment is ma Haemophilia Management Group.	anaged by the Haemophilia			
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial	anaged by the Haemophilia	1	✔ B	eneFIX
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial	anaged by the Haemophilia 		✓ Be	eneFIX eneFIX
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial	anaged by the Haemophilia 	1 1	✓ B ✓ B ✓ B	eneFIX
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial	anaged by the Haemophilia 	1 1 1	✓ B ✓ B ✓ B	eneFIX eneFIX eneFIX
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos	anaged by the Haemophilia 	1 1 1 1	✓ Bi ✓ Bi ✓ Bi	eneFIX eneFIX eneFIX eneFIX
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma	anaged by the Haemophilia 	1 1 1 1	✓ Bi ✓ Bi ✓ Bi	eneFIX eneFIX eneFIX eneFIX
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial ICTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group.	anaged by the Haemophilia 	1 1 1 1	✓ Bi ✓ Bi ✓ Bi ✓ Bi	eneFIX eneFIX eneFIX eneFIX njunction with the Nation
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma	anaged by the Haemophilia 	1 1 1 Treaters G	B B B B C B C C B C C C C C C C C C C C	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G	Ba Ba Ba roup in co Aa Ka	eneFIX eneFIX eneFIX eneFIX njunction with the Nation
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group.	anaged by the Haemophilia 	1 1 1 Treaters G 1	B B B B C B C B C C C C C C C C C C C C	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1	B B B C B C B C B C B C B C C C A C K C K	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1	Barroup in co Arrow Karrow K	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 500 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1	B B C B C	eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1 1	B B C B C	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate dvate dvate
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 2,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1 1 1 1	B B C B C	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1 1 1 1	B B C B C	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 2,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1 1 1 1	B B C B C	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 2,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1 1 1 1	B B C B C	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,000 iu vial Inj 2,000 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1 1 1 1	B B C B C	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,000 iu vial Inj 2,000 iu vial Inj 3,000 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1 1 1 1 1 1	B B C B C	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] – Hos For patients with haemophilia, whose treatment is ma Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,000 iu vial Inj 2,000 iu vial Inj 3,000 iu vial	anaged by the Haemophilia 	1 1 1 Treaters G 1 1 1 1 1 1	B B C B C	eneFIX eneFIX eneFIX eneFIX njunction with the Nation dvate ogenate FS dvate ogenate FS dvate dvate dvate dvate dvate fogenate FS dvate dvate fogenate FS dvate fogenate FS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
Vitamin K				
PHYTOMENADIONE Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO		5 5	-	Konakion MM Konakion MM
Antithrombotic Agents				
Antiplatelet Agents				
ASPIRIN * Tab 100 mg CLOPIDOGREL		990	V	Ethics Aspirin EC
Tab 75 mg – For clopidogrel oral liquid formulation refer, page 194		84 90	~	Arrow - Clopid
Apo-Clopidogrel Tab 75 mg to be delisted 1 March 2014)	(16.25)			Apo-Clopidogrel
Tab 25 mg – For dipyridamole oral liquid formulation refer, page 194	8.36	84	· · ·	Persantin
* Tab long-acting 150 mg		60	~	Pytazen SR
PRASUGREL – Special Authority see SA1201 below – Retail pha Tab 5 mg Tab 10 mg	108.00	28 28	-	Effient Effient
⇒SA1201 Special Authority for Subsidy nitial application — (coronary angioplasty and bare metal st where the patient has undergone coronary angioplasty in the prev nitial application — (drug eluting stent) from any relevant prace	vious 4 weeks and is o	clopid	ogrel-aller	gic*.

Initial application — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Initial application — (stent thromobosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Renewal — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrelallergic*.

Renewal — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Note: * Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

TICAGRELOR – Special Authority see SA1382 below – Retail pharmacy

*	Tab 90 mg	90.00	56	🖌 Brilinta
---	-----------	-------	----	------------

SA1382 Special Authority for Subsidy

Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

46

- 1 Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

continued...

Subsidy (Manufacturer's Price)	Su	Fully bsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Heparin and Antagonist Preparations

DALTEPARIN SODIUM - Special Authority see SA1270 below - Retail pharmacy

Inj 2,500 iu per 0.2 ml prefilled syringe		10	 Fragmin
Inj 5,000 iu per 0.2 ml prefilled syringe		10	Fragmin
Inj 7,500 iu per 0.75 ml graduated syringe		10	Fragmin
Inj 10,000 iu per 1 ml graduated syringe	77.55	10	 Fragmin
Inj 12,500 iu per 0.5 ml prefilled syringe		10	Fragmin
Inj 15,000 iu per 0.6 ml prefilled syringe		10	Fragmin
Inj 18,000 iu per 0.72 ml prefilled syringe	158.47	10	 Fragmin

➡SA1270 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Low molecular weight heparin treatment is required during a patient's pregnancy; or

2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Low molecular weight heparin treatment is required during a patient's pregnancy; or

2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, Acute Coronary Syndrome, cardioversion, or prior to oral anti-coagulation).

ENOXAPARIN SODIUM - Special Authority see SA1174 on the next page - Retail pharmacy

Inj 20 mg	19.69 74.91 99.86 25.06 55.40	10 10 10 10 10 10	 <u>Clexane</u> <u>Clexane</u> <u>Clexane</u> <u>Clexane</u> <u>Clexane</u> <u>Clexane</u> <u>Clexane</u> <u>Clexane</u>
Inj 150 mg		10	✓ <u>Clexane</u>

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	

►SA1174 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.
- **Initial application (Venous thromboembolism other than in pregnancy or malignancy)** from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:
- Any of the following:
 - 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
 - 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
 - 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
 - 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
 - 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu p	er ml, 5 ml		10	Hospira	
		66.80	50	Hospira	
		11.44	10	Pfizer	
		46.30	50	Pfizer	
Inj 1,000 iu p	er ml, 35 ml		1	Hospira	
	er ml, 1 ml		5	Hospira	
	ver ml, 5 ml		50	✓ Pfizer	
	per ml, 0.2 ml		5	✓ Hospira	
HEPARINISED S				•	
	==	20 50	50	Pfizer	
* Inj 10 iu per i	ml, 5 ml		50	V Filzer	
PROTAMINE SUI	∟PHATE				
* Inj 10 mg per	r ml, 5 ml	22.40	10		
		(101.61)		Artex S29	
Oral Anticoa	aculante				
	iguiants				
DABIGATRAN					
Cap 75 mg -	- No more than 2 cap per day		60	Pradaxa	
			60	Pradaxa	
			60	Pradaxa	
	 Special Authority see SA1066 on the ne 			A Manalka	
Tab 10 mg		153.00	15	Xarelto	

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sul	bsidised	Generic	
\$	Per	~	Manufacturer	

►SA1066 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 weeks for applications meeting the following criteria: Either:

- 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or
- 2 For the prophylaxis of venous thromboembolism following a total knee replacement.

Note: Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.

Renewal from any relevant practitioner. Approvals valid for 5 weeks where prophylaxis for venous thromboembolism is required for patients following a subsequent total hip or knee replacement.

WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

*	Tab 1 mg	50	Coumadin
	6.86	100	 Marevan
*	Tab 2 mg4.31	50	Coumadin
*	Tab 3 mg9.70	100	Marevan
*	Tab 5 mg5.93	50	Coumadin
	11.75	100	Marevan

Blood Colony-stimulating Factors

	فتسمطنه فالمتعمد		Datail shawsaa.
FILGRASTIN	- Special Authori	ty see SA1259 below -	- Retail pharmacy

Inj 300 mcg per 0.5 ml prefilled syringe	 5	✓ Zarzio
Inj 480 mcg per 0.5 ml prefilled syringe	 5	 Zarzio

➡SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk ≥ 20%*); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia (ANC < 0.5×10^9 /L); or
- 5 Treatment of drug-induced prolonged neutropenia (ANC < 0.5×10^9 /L).

Note: *Febrile neutropenia risk \geq 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM - Special Authority see SA1384 below - Retail pharmacy

Inj 6 mg per 0.6 ml syringe1,080.00

Neulastim

1

➡SA1384 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk $\geq 20\%^*$).

Note: *Febrile neutropenia risk $\geq 20\%$ after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Fluids and Electrolytes

Intravenous Administration

DEXTROSE

*	Inj 50%, 10 ml - Up to 5 inj available on a PSO	5	Biomed
*	Inj 50%, 90 ml - Up to 5 inj available on a PSO11.25	1	 Biomed

	Subsidy (Manufacturer's F	Price) Sub	Fully sidised	
	\$	Per	~	Manufacturer
POTASSIUM CHLORIDE				
Inj 75 mg per ml, 10 ml	55.00	50	~	AstraZeneca
SODIUM BICARBONATE				
lnj 8.4%, 50 ml	19.95	1	~	Biomed
a) Up to 5 inj available on a PSO				
b) Not in combination Inj 8.4%, 100 ml	20 50			Diamad
a) Up to 5 inj available on a PSO	20.50	1	V	Biomed
b) Not in combination				
SODIUM CHLORIDE				
Not funded for use as a nasal drop. Only funded for nebulise	r use when in co	niunction with a	an anti	biotic intended for nebulis
USE.				
Inf 0.9% – Up to 2000 ml available on a PSO	3.06	500 ml	~	Baxter
	4.06	1,000 ml		Baxter
Only if prescribed on a prescription for renal dialysis, mai	ernity or post-na	tal care in the	home	of the patient, or on a PS
for emergency use. (500 ml and 1,000 ml packs)		_		
Inj 23.4%, 20 ml		5	V	Biomed
For Sodium chloride oral liquid formulation refer Standard Inj 0.9%, 5 ml – Up to 5 inj available on a PSO		50	~	Multichem
	15.50	50		Pfizer
Inj 0.9%, 10 ml – Up to 5 inj available on a PSO		50		Multichem
	15.50			Pfizer
Inj 0.9%, 20 ml	4.72	6	~	Pharmacia
	11.79	30		Pharmacia
	8.41	20	~	Multichem
TOTAL PARENTERAL NUTRITION (TPN) – Retail pharmacy-Sp	ecialist			
Infusion	CBS	1 OP	~	TPN
NATER				
1) On a prescription or Practitioner's Supply Order only whe	en on the same f	orm as an inje	ction I	isted in the Pharmaceutic
Schedule requiring a solvent or diluent; or				
2) On a bulk supply order; or3) When used in the extemporaneous compounding of eye d	rono			
Purified for inj, 5 ml – Up to 5 inj available on a PSO		50	~	Multichem
Purified for inj, 10 ml – Up to 5 inj available on a PSO		50		Multichem
Purified for inj, 20 ml – Up to 5 inj available on a PSO		20		Multichem
Oral Administration				
CALCIUM POLYSTYRENE SULPHONATE	400.05	000 - 00		
Powder		300 g OP	V	Calcium Resonium
COMPOUND ELECTROLYTES		_		
Powder for oral soln – Up to 10 sach available on a PSO		5		Electral
	1.80	10	V	Enerlyte
DEXTROSE WITH ELECTROLYTES	~ 	4 000 1 00		Deallabet
Soln with electrolytes	6.55	1,000 ml OP	V	Pedialyte -
				<u>Bubblegum</u>
POTASSIUM BICARBONATE				
Tab eff 315 mg with sodium acid phosphate 1.937 g and		100		Dheenhate Canda-
sodium bicarbonate 350 mg		100	~	Phosphate-Sandoz

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
POTASSIUM CHLORIDE				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	5.26 (11.85)	60	C	Chlorvescent
* Tab long-acting 600 mg	7.42	200	✓ <u>s</u>	Span-K
SODIUM BICARBONATE Cap 840 mg	8.52	100	/ s	Sodibic
SODIUM POLYSTYRENE SULPHONATE Powder		50 g O	P 🖌 F	Resonium-A

	Subsidy		Fully	Brand or
	(Manufacturer's Pric \$	e) Per	Subsidised	Generic Manufacturer
Alpha Adrenoceptor Blockers				
00XAZOSIN ← Tab 2 mg	8 23	500	<u> </u>	Apo-Doxazosin
 Tab 2 mg € Tab 4 mg 		500	-	Apo-Doxazosin
		000	• •	ipo Bokazoom
	7.00	00		
 Cap 10 mg 		30		Dibenyline S29
	26.05	100	V	Dibenyline S29
RAZOSIN				
Tab 1 mg		100		Apo-Prazo
Tab 2 mg		100		Apo-Prazo
 Tab 5 mg 	11.70	100		Apo-Prazo
ERAZOSIN				
Tab 1 mg		28	-	Arrow
Tab 2 mg		28		Arrow
 Tab 5 mg 	0.68	28	v <u>i</u>	Arrow
Agents Affecting the Renin-Angiotensin System				
ACE Inhibitors				
APTOPRIL				
 Tab 12.5 mg 	2.00	100	🖌 🖌 I	n-Captopril
 Tab 25 mg 	2.40	100	/ 1	n-Captopril
 Tab 50 mg 		100		n-Captopril
€‡ Oral liq 5 mg per ml	94.99	95 ml OF		Capoten
Oral liquid restricted to children under 12 years of age.				
CILAZAPRIL				
 Tab 0.5 mg 		90	-	Zapril
Tab 2.5 mg		90	-	Zapril
← Tab 5 mg	6.98	90	V <u>1</u>	Zapril
NALAPRIL MALEATE				
 Tab 5 mg 	0.36	30	• •	Acetec
	5.94	500	· · ·	Acetec
	1.07	90		m-Enalapril
	1.19	100		Ethics Enalapril
 Tab 10 mg 		30		Acetec
	7.33 1.32	500		Acetec n Englanril
	1.32	90 100		n-Enalapril Ethics Enalapril
A Tab 20 mg Ear analapril malagta aral liquid formulation ra		100	•	Lunco Enalapín
 Tab 20 mg – For enalapril maleate oral liquid formulation re- fer, page 194 		30	1	Acetec
101, paye 134	0.57 1.72	30 90		n-Enalapril
	1.91	90 100		Ethics Enalapril
m-Enalapril Tab 5 mg to be delisted 1 May 2014)	1.01	100	•	
m-Enalapril Tab 10 mg to be delisted 1 May 2014)				
m-Enalapril Tab 20 mg to be delisted 1 May 2014)				

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
LISINOPRIL			
* Tab 5 mg		90	Arrow-Lisinopril
* Tab 10 mg	4.08	90	Arrow-Lisinopril
* Tab 20 mg	4.88	90	Arrow-Lisinopril
PERINDOPRIL			
* Tab 2 mg		30	Apo-Perindopril
,	(18.50)		Coversyl
* Tab 4 mg		30	Apo-Perindopril
, , , , , , , , , , , , , , , , , , ,	(25.00)		Coversyl
QUINAPRIL			
* Tab 5 mg	3.44	90	Arrow-Quinapril 5
* Tab 10 mg		90	Arrow-Quinapril 10
* Tab 20 mg	6.34	90	Arrow-Quinapril 20

TRANDOLAPRIL

Higher subsidy by endorsement is available for patients who were taking trandolapril for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". For the purposes of this endorsement, congestive heart failure includes patients post myocardial infarction with an ejection fraction of less than 40%. Patients who started on trandolapril after 1 June 1998 are not eligible for full subsidy by endorsement.

* Cap 1 mg – Higher subsidy of \$18.67 per 28 cap with En-			
dorsement		28	
	(18.67)		Gopten
W Can 0 mg Uigher subsidy of \$07.00 per 00 con with En	()		Copton
* Cap 2 mg - Higher subsidy of \$27.00 per 28 cap with En			
dorsement		28	_
	(27.00)		Gopten
ACE Inhibitors with Diuretics			
CILAZAPRIL WITH HYDROCHLOROTHIAZIDE			
* Tab 5 mg with hydrochlorothiazide 12.5 mg	5.36	28	Inhibace Plus
		20	
ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE			
* Tab 20 mg with hydrochlorothiazide 12.5 mg	3.32	30	
	(8.70)		Co-Renitec
QUINAPRIL WITH HYDROCHLOROTHIAZIDE			
	0.07	00	A Accumatic 10
* Tab 10 mg with hydrochlorothiazide 12.5 mg		30	✓ <u>Accuretic 10</u>
* Tab 20 mg with hydrochlorothiazide 12.5 mg	4.57	30	Accuretic 20
Angiotension II Antagonists			
Anglotension in Antagonists			
CANDESARTAN CILEXETIL - Special Authority see SA1223 on	the next page - Re	tail pharma	CV
* Tab 4 mg	1.0	90	✓ Candestar
* Tab 8 mg		90	✓ Candestar
100 C		90	
i ao i o ing			Candestar
* Tab 32 mg	17.66	90	Candestar

Subsidy (Manufacturer's Pric \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer	
---------------------------------------	-----------	---------------------	-------------------------------------	--

SA1223 Special Authority for Subsidy

Initial application — (ACE inhibitor intolerance) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Either:
 - Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or
 - 2 Patient has a history of angioedema.

Initial application — (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

LOSARTAN POTASSIUM

*	Tab 12.5 mg	2.88	90	Lostaar
	Tab 25 mg		90	Lostaar
*	Tab 50 mg	5.22	90	Lostaar
*	Tab 100 mg	8.68	90	✓ Lostaar

Angiotension II Antagonists with Diuretics

LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE	
Tab 50 mg with hydrochlorothiazide 12.5 mg4.89	30

V	Arrow-Losartan &	
	Hydrochlorothiazide	

Antiarrhythmics

For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesth	netics, Local, pa	ge 122	
AMIODARONE HYDROCHLORIDE			
▲ Tab 100 mg – Retail pharmacy-Specialist		30	 Aratac
▲ Tab 200 mg – Retail pharmacy-Specialist	30.52	30	 ✓ Cordarone-X ✓ Aratac ✓ Cordarone-X
Inj 50 mg per ml, 3 ml ampoule – Up to 6 inj available on a PSO	22.80	6	✓ <u>Cordarone-X</u>
ATROPINE SULPHATE			
* Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	71.00	50	✓ <u>AstraZeneca</u>
DIGOXIN			
* Tab 62.5 mcg – Up to 30 tab available on a PSO	6.67	240	🖌 Lanoxin PG
 * Tab 250 mcg – Up to 30 tab available on a PSO 		240	Lanoxin
*‡ Oral liq 50 mcg per ml	16.60	60 ml	Lanoxin
DISOPYRAMIDE PHOSPHATE			
▲ Cap 100 mg	15.00	100	
	(23.87)		Rythmodan
▲ Cap 150 mg	26.21	100	Rythmodan
FLECAINIDE ACETATE – Retail pharmacy-Specialist			
▲ Tab 50 mg	45.82	60	Tambocor
▲ Tab 100 mg – For flecainide acetate oral liquid formulation			
refer, page 194	80.92	60	Tambocor
▲ Cap long-acting 100 mg		30	Tambocor CR
▲ Cap long-acting 200 mg		30	Tambocor CR
Inj 10 mg per ml, 15 ml ampoule	52.45	5	Tambocor

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
MEXILETINE HYDROCHLORIDE				
▲ Cap 150 mg	65.00	100	•	Mexiletine Hydrochloride USP 529
▲ Cap 250 mg	102.00	100	~	Mexiletine Hydrochloride USP S29
PROPAFENONE HYDROCHLORIDE – Retail pharmacy-Specialis				
▲ Tab 150 mg		50	~	Rytmonorm
Antihypotensives				
MIDODRINE – Special Authority see SA0934 below – Retail phari	nacy			
Tab 2.5 mg		100	~	Gutron
Tab 5 mg	79.00	100	~	Gutron
►SA0934 Special Authority for Subsidy				

SA0934 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Disabling orthostatic hypotension not due to drugs; and
- 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and
- 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night.

Notes: Treatment should be started with small doses and titrated upwards as necessary.

Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta Adrenoceptor Blockers

ATENOLOL

* Tab 50 mg		500	Mylan Atenolol
* Tab 100 mg		500	Mylan Atenolol
 Oral liq 25 mg per 5 ml Restricted to children under 12 years of age. 	21.25	300 ml OP	Atenolol AFT \$29
BISOPROLOL			
Tab 2.5 mg		30	Bosvate
Tab 5 mg	4.74	30	Bosvate
Tab 10 mg		30	 Bosvate
CARVEDILOL			
* Tab 6.25 mg		30	Dilatrend
* Tab 12.5 mg		30	 Dilatrend
* Tab 25 mg – For carvedilol oral liquid formulation refe	r, page		
194		30	 Dilatrend
CELIPROLOL			
* Tab 200 mg		180	✓ Celol

Manufacturer's Price) \$8.2310.0617.5559.06 (88.60)0.961.412.424.66	Per 100 100 5 30 30 30	~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~	['] Manufacturer Hybloc Hybloc Trandate Metoprolol - AFT CR
10.06 17.55 59.06 (88.60) 0.96 1.41 2.42	100 100 5 30 30 30	~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~	Hybloc Hybloc Trandate Metoprolol - AFT CR
10.06 17.55 59.06 (88.60) 0.96 1.41 2.42	100 100 5 30 30 30	~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~	Hybloc Hybloc Trandate Metoprolol - AFT CR
17.55 59.06 (88.60) 0.96 1.41 2.42	100 5 30 30 30	~	Hýbloc Trandate Metoprolol - AFT CR
17.55 59.06 (88.60) 0.96 1.41 2.42	100 5 30 30 30	~	Hýbloc Trandate Metoprolol - AFT CR
59.06 (88.60) 0.96 1.41 2.42	5 30 30 30		Trandate Metoprolol - AFT CR
(88.60) 0.96 1.41 2.42	30 30 30	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Metoprolol - AFT CR
	30 30	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Metoprolol - AFT CR
1.41 2.42	30 30	~	
1.41 2.42	30 30	~	
2.42	30		Meternalel AFT OD
			Metoprolol - AFT CR
4.66	20	~	Metoprolol - AFT CR
	30	~	Metoprolol - AFT CR
16.00	100	~	Lopresor
21.00	60	~	Lopresor
18.00	28	~	Slow-Lopresor
24.00	5	V	Lopresor
15.57	100	~	Apo-Nadolol
23.74	100	~	Apo-Nadolol
			-
9.72	100	~	Apo-Pindolol
15.62	100		Apo-Pindolol
23.46	100	V	Apo-Pindolol
	100	~	Аро-
			Propranolol S29
			•
4.65	100	~	Аро-
			Propranolol S29
	100	~	Cardinol LA
		•	
CBS	500 ml	~	Roxane S29
	15.57 23.74 9.72 15.62 23.46 3.65 4.65 16.06	15.57 100 23.74 100 9.72 100 15.62 100 23.46 100 3.65 100	15.57 100 ✓ 23.74 100 ✓ 9.72 100 ✓ 15.62 100 ✓ 23.46 100 ✓ 3.65 100 ✓ 16.06 100 ✓

► SA1327 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or

2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or

2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
OTALOL				
 Tab 80 mg – For sotalol oral liquid formulation refer, page 1 	94 27.50	500	~	Mylan
 Tab 160 mg 		100		Mylan
 Inj 10 mg per ml, 4 ml ampoule 		5		Sotacor
MOLOE MALEATE € Tab 10 mg	10.55	100		Apo-Timol
	10.55	100		Аро-тіпіог
Calcium Channel Blockers				
Dihydropyridine Calcium Channel Blockers				
MLODIPINE				
✓ Tab 2.5 mg	2.45	100	~	Apo-Amlodipine
 Tab 5 mg – For amlodipine oral liquid formulation refer, page 	je			
194	2.65	100	~	Apo-Amlodipine
← Tab 10 mg	4.15	100	V	Apo-Amlodipine
ELODIPINE				
← Tab long-acting 2.5 mg	2 90	30	~	Plendil ER
 Tab long-acting 5 mg 		30		Plendil ER
← Tab long-acting 10 mg		30		Plendil ER
			•	
SRADIPINE	7.50	20		
Cap long-acting 2.5 mg		30		Dynacirc-SRO
 Cap long-acting 5 mg 		30	V	Dynacirc-SRO
IIFEDIPINE				
 Tab long-acting 10 mg 		60	-	Adalat 10
 Tab long-acting 20 mg 		100		Nyefax Retard
 Tab long-acting 30 mg 	8.56	30		Adefin XL
			~	Arrow-Nifedipine XR
	5.50			
t. Tab lang asting 00 mm	(19.90)	00		Adalat Oros
 Tab long-acting 60 mg 	12.28	30		Adefin XL
	0.00		~	Arrow-Nifedipine XR
	8.00			Adalat Orea
	(29.50)			Adalat Oros
Other Calcium Channel Blockers				
VILTIAZEM HYDROCHLORIDE				
 Tab 30 mg 		100	~	Dilzem
 Tab 60 mg – For diltiazem hydrochloride oral liquid formula 				
tion refer, page 194		100		Dilzem
 Cap long-acting 120 mg 		500		Apo-Diltiazem CD
 Cap long-acting 180 mg 		500		Apo-Diltiazem CD
 Cap long-acting 240 mg 	63.58	500	~	Apo-Diltiazem CD
		horm	ICV	
ERHEXILINE MALEATE – Special Authority see SA1260 on t	ne next page – Retail t	ланна	loy	

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once

CARDIOVASCULAR SYSTEM

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
SA1260 Special Authority for Subsidy				
nitial application only from a cardiologist or general physician.	Approvals valid for	2 years	for applicat	tions meeting the following
riteria: Both:				
1 Patient has refractory angina; and				
2 Patient is on the maximal tolerated dose of a beta-blocker,	, a calcium channel b	olocker	and a long a	acting nitrate.
Renewal only from a cardiologist or any relevant practitioner on			ardiologist.	Approvals valid for 2 year
where the treatment remains appropriate and the patient is benef	fiting from treatment			
ERAPAMIL HYDROCHLORIDE				
₭ Tab 40 mg		100	✓ <u>Is</u>	optin
Tab 80 mg – For verapamil hydrochloride oral liquid formula.		400		
tion refer, page 194 ≰ Tab long-acting 120 mg		100 250		<u>eoptin</u> erpamil SR
 K Tab long-acting 120 mg K Tab long-acting 240 mg 		250 250		erpamil SR
 Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on a 		200	• •	
PSO		5	🖌 İs	optin
Centrally-Acting Agents	-	-		
CLONIDINE	00.00	4		atomica TTC 1
 Patch 2.5 mg, 100 mcg per day – Only on a prescription Patch 5 mg, 200 mcg per day – Only on a prescription 		4 4		atapres-TTS-1 atapres-TTS-2
 Patch 5 mg, 200 mcg per day – Only on a prescription Patch 7.5 mg, 300 mcg per day – Only on a prescription 		4		atapres-TTS-3
CLONIDINE HYDROCHLORIDE				
k Tab 25 mcg	15.09	112	~ 0	Ionidine BNM
k Tab 150 mcg		100		atapres
k Inj 150 mcg per ml, 1 ml ampoule		5		atapres
/ETHYLDOPA				
₭ Tab 125 mg		100	🗸 Р	rodopa
🖌 Tab 250 mg		100	🖌 P	rodopa
₭ Tab 500 mg	23.15	100	🖌 Р	rodopa
Diuretics				
Lean Diverties				
Loop Diuretics				
BUMETANIDE	10.00	400		
k Tab 1 mgk − ml 4 ml viel		100 5	• -	urinex urinex
k Inj 500 mcg per ml, 4 ml vial		э	VD	urinex
UROSEMIDE [FRUSEMIDE]	10.05	1 000		iunin 40
Tab 40 mg – Up to 30 tab available on a PSO		1,000 50		<u>iurin 40</u> rex Forte
k Tab 500 mgk‡ Oral lig 10 mg per ml		50 30 ml O		
k Ini 10 mg per ml, 25 ml ampoule		5		
 Inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a 		-		
,		_	<i>.</i> -	
PSO	1.30	5	V F	rusemide-Claris

AMILORIDE HYDROCHLORIDE

*	Tab 5 mg17.50	100	Apo-Amiloride
‡	Oral liq 1 mg per ml	25 ml OP	Biomed

	Subsidy (Manufacturer's P \$	rice) Sub Per	Fully Brand or osidised Generic Manufacturer
METOLAZONE – Special Authority see SA1349 below – Retail ph	,		
Tab 5 mg		1 50	 Metolazone S29 Zaroxolyn S29
⇒SA1349 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid ment of patients with refractory heart failure who are intolerant or nation therapy.			
SPIRONOLACTONE			
* Tab 25 mg	3.65	100	 Spiractin Spirotone
* Tab 100 mg	11.80	100	 Spiractin Spirotone
Oral liq 5 mg per ml		25 ml OP	✓ Biomed
Potassium Sparing Combination Diuretics			
MILORIDE HYDROCHLORIDE WITH FUROSEMIDE * Tab 5 mg with furosemide 40 mg		28	🖌 Frumil
MILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIE Tab 5 mg with hydrochlorothiazide 50 mg		50	✓ Moduretic
Thiazide and Related Diuretics			
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]			
✤ Tab 2.5 mg – Up to 150 tab available on a PSO		500	✓ <u>Arrow-</u> <u>Bendrofluazide</u>
May be supplied on a PSO for reasons other than emerger		500	✓ <u>Arrow-</u>
			Bendrofluazide
CHLOROTHIAZIDE Oral liq 50 mg per ml	26.00	25 ml OP	✓ Biomed
CHLORTALIDONE [CHLORTHALIDONE]	20.00	20111101	• Biomed
★ Tab 25 mg		30	✓ Igroton S29
	8.00	50	✓ Hygroton
Igroton S29 Tab 25 mg to be delisted 1 January 2014)			
NDAPAMIDE			
₭ Tab 2.5 mg	2.25	90	✓ Dapa-Tabs
Lipid-Modifying Agents			
Fibrates			
BEZAFIBRATE			
₭ Tab 200 mg		90	✓ Bezalip
K Tab long-acting 400 mg	5.70	30	Bezalip Retard
GEMFIBROZIL		60	✓ Lipazil

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Other Lipid-Modifying Agents				
ACIPIMOX	/a 			
* Cap 250 mg		30	~	Olbetam
NICOTINIC ACID				
* Tab 50 mg		100		Apo-Nicotinic Acid
₭ Tab 500 mg		100	V	Apo-Nicotinic Acid
Resins				
HOLESTYRAMINE				
Powder for oral liq 4 g		50		
	(52.68)		(Questran-Lite
COLESTIPOL HYDROCHLORIDE				
Grans for oral liq 5 g		30	~ (Colestid
HMG CoA Reductase Inhibitors (Statins)				
TORVASTATIN – See prescribing guideline above ★ Tab 10 mg		90	-	Zarator
🖌 Tab 20 mg		90	~	Zarator
€ Tab 40 mg	7.32	90	-	Zarator
 Tab 80 mg 	16.23	90	V <u>2</u>	Zarator
RAVASTATIN – See prescribing guideline above				
 Tab 20 mg 		30	-	Cholvastin
at Tab 40 mg	9.28	30	<u> </u>	<u>Cholvastin</u>
IMVASTATIN – See prescribing guideline above				
Tab 10 mg		90	-	Arrow-Simva 10mg
k Tab 20 mg k Tab 40 mg		90	-	Arrow-Simva 20mg
₭ Tab 40 mg ₭ Tab 80 mg		90 90	-	Arrow-Simva 40mg Arrow-Simva 80mg
		30	• •	anow-Siniva boing
Selective Cholesterol Absorption Inhibitors				
ZETIMIBE – Special Authority see SA1045 below – Reta Tab 10 mg		30	~ 1	Ezetrol
→SA1045 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals NI of the following:			•	•
 Patient has a calculated absolute risk of cardiovascu Patient's LDL cholesterol is 2.0 mmol/litre or greater; Any of the following: 		over 5	5 years; an	d

- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
 - $3.2\ \mbox{The patient is intolerant to both simvastatin and atorvastatin; or }$
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

continued...

Subsidy		Fully Subsidised	Brand or Generic	
(Manufacturer's Pri \$	e) Per		Manufacturer	

continued...

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN - Special Authority see SA1046 below - Retail pharmacy

Tab 10 mg with simvastatin 10 mg		30	🖌 Vytorin
Tab 10 mg with simvastatin 20 mg		30	 Vytorin
Tab 10 mg with simvastatin 40 mg		30	 Vytorin
Tab 10 mg with simvastatin 80 mg	45.45	30	Vytorin

➡SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to ≤ 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

100 OP	Lycinate
250 dose OP	✓ <u>Glytrin</u>
30	Nitroderm TTS
30	Nitroderm TTS
100	🖌 Ismo 20
30	 Corangin
90	✓ Duride
5	Aspen Adrenaline
	✓ Hospira
	•
5	Hospira
10	Aspen Adrenaline
	250 dose OP 30 30 100 30 90 5 5

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise •	
SOPRENALINE				
 Inj 200 mcg per ml, 1 ml ampoule 		25		Isuprel
Vasodilators				
AMYL NITRITE				
 ✗ Liq 98% in 0.3 ml cap 	62.92 (73.40)	12		Baxter
HYDRALAZINE HYDROCHLORIDE				
* Tab 25 mg - Special Authority see SA1321 below - Retail				
pharmacy	CBS	1	~	Hydralazine
		56	~	Onelink S29
₭ Inj 20 mg ampoule	25.90	5		Apresoline Apresoline
 2 For the treatment of heart failure in combination with a nitra inhibitors and/or angiotensin receptor blockers. WINOXIDIL – Special Authority see SA1271 below – Retail pharm ▲ Tab 10 mg 	nacy	100		Loniten
⇒SA1271 Special Authority for Subsidy nitial application only from a relevant specialist. Approvals valid refractory hypertension which has failed to respond to extensive m		val ur	iless notifi	ed where patient has seve
NCORANDIL – Special Authority see SA1263 below – Retail pha	irmacy			
Tab 10 mg		60	-	Ikorel
Tab 20 mg		60	~	Ikorel
SA1263 Special Authority for Subsidy nitial application only from a cardiologist or general physician. riteria: Both:	Approvals valid for 2	years	for applic	ations meeting the followir
1 Patient has refractory angina; and				
2 Patient is on the maximal tolerated dose of a beta-blocker, a Renewal only from a cardiologist or any relevant practitioner on the where the treatment remains appropriate and the patient is benefit	ne recommendation of			
APAVERINE HYDROCHLORIDE				
Inj 12 mg per ml, 10 ml ampoule	73.12	5	~	Hospira
PENTOXIFYLLINE [OXPENTIFYLLINE]				
Tab 400 mg		50		
-	(40.00)			Transfel 400

Tab 400 mg		0
-	(42.26)	Trental 400

(Ma	Subsidy anufacturer's Price) \$	F Subsidi Per	ully Brand or sed Generic Manufacturer
Endothelin Receptor Antagonists			
→SA0967 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertension Pa Notes: Application details may be obtained from PHARMAC's website The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.govt.r	http://www.pharr	nac.govt.nz	or:
AMBRISENTAN – Special Authority see SA0967 above – Retail phar Tab 5 mg	,585.00		VolibrisVolibris
BOSENTAN – Special Authority see SA0967 above – Retail pharmac Tab 62.5 mg	у		✓ pms-Bosentan ✓ Tracleer
Tab 125 mg2	2,000.00		 pms-Bosentan Tracleer

►SA1293 Special Authority for Subsidy

Initial application — (Raynaud's Phenomenon* - for Pulmonary Arterial Hypertension see note below)) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has Raynaud's Phenomenon*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Notes: Sildenafil is also funded for patients with Pulmonary Arterial Hypertension who are approved by the Pulmonary Arterial Hypertension Panel (an application must be made using form <u>SA1293-PAH</u>).

Application details may be obtained from:

The Coordinator, PAH Panel

PHARMAC, PO Box 10 254, Wellington

Phone: (04) 916 7512 Facsimile: (04) 974 4858 Email: PAH@pharmac.govt.nz

Indications marked with * are Unapproved Indications.

SILDENAFIL - Special Authority see SA1293 above - Retail pharmacy

Tab 25 mg1.85	4	Silagra
Tab 50 mg 1.85	4	 Silagra
Tab 100 mg – For sildenafil oral liquid formulation refer, page		
194	4	Silagra

Prostacyclin Analogues

SA0969 Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz

	Subsidy (Manufacturer's Price) \$	S Per	Fully Subsidised	
ILOPROST – Special Authority see SA0969 on the previous page Nebuliser soln 10 mcg per ml, 2 ml		30	~	Ventavis

	Subsidy (Manufacturer's Price) \$) S Per	Fully Subsidised	Brand or Generic Manufacturer
Antiacne Preparations				
For systemic antibacterials, refer to INFECTIONS, Antibacterials,	page 90			
ADAPALENE				
a) Maximum of 30 g per prescription				
b) Only on a prescription				
Crm 0.1%		0 g OP	🖌 Di	ifferin
Gel 0.1%		0 g OP	🖌 Di	ifferin
ISOTRETINOIN - Special Authority see SA0955 below - Retail r	oharmacv			
Cap 10 mg	,	120	v 0	ratane
Cap 20 mg		120	✔ 0	ratane

➡SA0955 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN

Crm 0.5 mg per g – Maximum of 50 g per prescription 13.90 50 g OP 🖌 ReTrieve

	Subsidy (Manufacturer's \$	Price) Sul Per	Fully Brand or osidised Generic ✔ Manufacturer
Antibacterials Topical			
For systemic antibacterials, refer to INFECTIONS, Antibacterial	s, page 90		
FUSIDIC ACID			
Crm 2%	3.25	15 g OP	🖌 Foban
 a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination 			
Oint 2%	3.45	15 g OP	🖌 Foban
a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination			
HYDROGEN PEROXIDE			
₭ Crm 1%	8.56	15 g OP	 Crystaderm
<i>I</i> UPIROCIN			
Oint 2%		15 g OP	D
a) Only on a prescription	(9.26)		Bactroban
b) Not in combination			
	10.00	50 ~ OD	Flamazine
Crm 1% a) Up to 250 g available on a PSO b) Not in combination	12.30	50 g OP	
Antifungals Topical			
For systemic antifungals, refer to INFECTIONS, Antifungals, pa	ge 96		
AMOROLFINE			
a) Only on a prescription			
b) Not in combination Nail soln 5%	37.86	5 ml OP	
	(61.87)	51111 01	Loceryl
CICLOPIROX OLAMINE	()		
a) Only on a prescription			
b) Not in combination			
Nail-soln 8%	8.23	7 ml OP	✓ Apo-Ciclopirox
Soln 1%		20 ml OP	
	(11.54)		Batrafen
CLOTRIMAZOLE			
₭ Crm 1%	0.54	20 g OP	Clomazol
a) Only on a prescription			
b) Not in combination ₭ Soln 1%	1 26	20 ml OP	
	4.36 (7.55)	20 IIII OF	Canesten
a) Only on a prescription	(1.00)		Sunoton
b) Not in combination			

	Subsidy (Manufacturer's l \$	Price) Su Per	Fully Brand or bsidised Generic Manufacturer
ECONAZOLE NITRATE			
Crm 1%	1.00 (7.48)	20 g OP	Pevaryl
a) Only on a prescription	(110)		· · · · · · · · · · · · · · · · · · ·
b) Not in combination			
Foaming soln 1%, 10 ml sachets	9.89 (17.23)	3	Pevaryl
a) Only on a prescription			
b) Not in combination			
MICONAZOLE NITRATE			
* Crm 2%	0.46	15 g OP	✓ <u>Multichem</u>
a) Only on a prescription			
b) Not in combination	4.00	00 ml OD	
* Lotn 2%		30 ml OP	Doktorin
a) Only on a prescription	(10.03)		Daktarin
b) Not in combination			
* Tinct 2%	4.36	30 ml OP	
	(12.10)		Daktarin
a) Only on a prescription			
b) Not in combination			
NYSTATIN			
Crm 100,000 u per g	1.00	15 g OP	
	(7.90)		Mycostatin
a) Only on a prescription			
b) Not in combination			
Antipruritic Preparations			
CALAMINE			
 a) Only on a prescription 			
b) Not in combination			4 -1 -1 -1
Crm, aqueous, BP		100 g	Pharmacy Health
Lotn, BP	13.45	2,000 ml	✓ <u>PSM</u>
CROTAMITON			
a) Only on a prescription			
b) Not in combination Crm 10%	2.40	20 a OB	1 Itah Saatha
		20 g OP	✓ <u>Itch-Soothe</u>
MENTHOL – Only in combination Only in combination with aqueous cream, 10% urea creation with aqueous cream, 10% urea creation of the second	im, wool fat with mine	eral oil lotion. 1	% hydrocortisone with wool fat and
mineral oil lotion, and glycerol, paraffin and cetyl alcohol		, .	,
Crystals		25 g	🖌 PSM
	6.92	-	✓ MidWest
	29.60	100 g	✓ MidWest

\$	Per	 Manufacturer
RELATED AGEI	NTS, page 82	
2.96	15 g OP	✓ Diprosone
8.97	50 g OP	✓ Diprosone
4.33	30 g OP	 Diprosone OV
2.96	15 g OP	 Diprosone
8.97	50 g OP	 Diprosone
4.33	30 g OP	Diprosone OV
3.50	50 g OP	🖌 Beta Cream
3.50	50 g OP	 Beta Ointment
	50 ml OP	 Betnovate
3 68	30 a OP	V Dermol
	•	✓ Dermol
	00 g 01	• Donnor
E 00	20 ~ OD	
	30 g OP	Eumovate
· · ·	100 a OB	Eumovale
	TOU Y OF	Eumovate
(22.00)		Edinovale
0.07	50 × 00	
	50 g OP	Neviene
		Nerisone
	50 g OP	Nerisone
(15.60)		Nelisone
	105	(D) ((((((((((
	•	Pharmacy Health
		Pharmacy Health
		✓ <u>ABM</u>
cal Conicosteri	od – Plain) Witi	n or without other dermatologica
	30 g OP	Locoid Lipocream
6.85	100 g OP	Locoid Lipocream
	•	✓ <u>Locoid</u>
6.85	100 ml OP	Locoid Crelo
	250 ml	✓ DP Lotn HC
4.05	15 c OP	✓ Advantan
	•	✓ Advantan ✓ Advantan
		8.97 50 g OP 4.33 30 g OP 2.96 15 g OP 8.97 50 g OP 4.33 30 g OP 4.33 30 g OP 3.50 50 g OP 3.68 30 g OP 3.68 30 g OP (7.09) 16.13 16.13 100 g OP (15.86) 8.97 8.97 50 g OP (15.86) 3.75 3.75 100 g 14.00 500 g 2.30 30 g OP 6.85 100 mI OP

MOMETASONE FUROATE Crm 0.1% Oint 0.1% Lotn 0.1% TRIAMCINOLONE ACETONIDE Crm 0.02%	3.42 1.78 3.42 7.35	Price) Sub Per 15 g OP 45 g OP 15 g OP 45 g OP 30 ml OP	Fully Brand or psidised Generic ✓ Manufacturer ✓ <u>m-Mometasone</u> ✓ <u>m-Mometasone</u> ✓ <u>m-Mometasone</u> ✓ <u>m-Mometasone</u> ✓ <u>m-Mometasone</u> ✓ <u>Elocon</u>
Crm 0.1% Oint 0.1% Lotn 0.1% TRIAMCINOLONE ACETONIDE Crm 0.02%		15 g OP 45 g OP 15 g OP 45 g OP	✓ <u>m-Mometasone</u> ✓ <u>m-Mometasone</u> ✓ <u>m-Mometasone</u> ✓ <u>m-Mometasone</u>
Crm 0.1% Oint 0.1% Lotn 0.1% TRIAMCINOLONE ACETONIDE Crm 0.02%	3.42 1.78 3.42 7.35	45 g OP 15 g OP 45 g OP	 ✓ m-Mometasone ✓ m-Mometasone ✓ m-Mometasone
Oint 0.1% Lotn 0.1% IRIAMCINOLONE ACETONIDE Crm 0.02%	3.42 1.78 3.42 7.35	45 g OP 15 g OP 45 g OP	 ✓ m-Mometasone ✓ m-Mometasone ✓ m-Mometasone
Lotn 0.1% IRIAMCINOLONE ACETONIDE Crm 0.02%	1.78 3.42 7.35	15 g OP 45 g OP	 ✓ <u>m-Mometasone</u> ✓ <u>m-Mometasone</u>
Lotn 0.1% TRIAMCINOLONE ACETONIDE Crm 0.02%	3.42 7.35	45 g OP	✓ m-Mometasone
RIAMCINOLONE ACETONIDE Crm 0.02%	7.35		
RIAMCINOLONE ACETONIDE Crm 0.02%		30 ml OP	Elocon
Crm 0.02%	6 63		
	6 63		
		100 g OP	✓ Aristocort
Oint 0.02%	6.69	100 g OP	✓ <u>Aristocort</u>
Corticosteroids - Combination			
BETAMETHASONE VALERATE WITH CLIOQUINOL - Only on a	prescription		
Crm 0.1% with clioquinol 3%		15 g OP	
	(4.90)	0 -	Betnovate-C
Oint 0.1% with clioquinol 3%		15 g OP	
	(4.90)	-	Betnovate-C
BETAMETHASONE VALERATE WITH FUSIDIC ACID			
Crm 0.1% with fusidic acid 2%	3.49	15 g OP	
	(10.45)	Ū	Fucicort
 a) Maximum of 15 g per prescription b) Only on a prescription 			
HYDROCORTISONE WITH MICONAZOLE – Only on a prescript		45 - 00	
Crm 1% with miconazole nitrate 2%		15 g OP	 Micreme H
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN - On	, , ,		
Crm 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP	Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	2.79	15 g OP	Pimafucort
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN		N	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg		15 ~ OD	
and gramicidin 250 mcg per g – Only on a prescription		15 g OP	Viaderm KC
	(0.00)		Maderini Ko
Disinfecting and Cleansing Agents			
CHLORHEXIDINE GLUCONATE – Subsidy by endorsement			
a) No more than 500 ml per month			
b) Only if prescribed for a dialysis patient and the prescription	is endorsed acc	cordingly.	
Handrub 1% with ethanol 70%		500 ml	✓ healthE
* Soln 4%	5.90	500 ml	✓ Orion
TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription			
b)	ioillin rociotort (Stophylesses	DOUROUD (MDCA) prior to alert
 a) Only if prescribed for a patient identified with Meth surgery in bospital and the prescription is endorsed. 		ыарпуюсоссия	aureus (IVINGA) prior to electi
surgery in hospital and the prescription is endorsed a b) Only if prescribed for a patient with recurrent Staph	accordingly, or	is infection and	d the prescription is endorsed a
cordingly	iyiococcus aulei		a are preseription is endorsed a
Soln 1%	4.50	500 ml OP	Pharmacy Health
	5.90		✓ healthE

	Subsidy		Fully	Brand or
	(Manufacturer's	Price) Sub	sidised	Generic
	\$	Per	~	Manufacturer
Barrier Creams and Emollients				
Barrier Creams				
INC AND CASTOR OIL Cont BP	3 83	500 g	🗸 M	ultichem
Emollients		000 g	•	
QUEOUS CREAM Crm	1.06	500 g	🗸 A	ET
	1.90	500 y	• <u>A</u>	<u>r1</u>
ETOMACROGOL Crm BP	2 15	500 g	V P	eM
		500 y	V F	5141
ETOMACROGOL WITH GLYCEROL	4 50		• 7 D	harmaay Haalth
Crm 90% with glycerol 10%	4.50	500 ml OP	VP	harmacy Health Sorbolene with Glycerin
	6.50	1,000 ml OP	✓ P	harmacy Health Sorbolene with Glycerin
MULSIFYING OINTMENT				
← Oint BP	3.04	500 g	✓ <u>A</u>	FT
DIL IN WATER EMULSION				
← Crm	2.63	500 g	🖌 <u>h</u>	ealthE Fatty Cream
IREA				
€ Crm 10%		100 g OP		ealthE Urea Cream
	3.07		V N	utraplus
VOOL FAT WITH MINERAL OIL - Only on a prescription				
 Lotn hydrous 3% with mineral oil 		250 ml OP		
	(3.50) 5.60	1 000 ml	Н	ydroderm Lotion
	(9.54)	1,000 ml	н	ydroderm Lotion
	1.40	250 ml OP		
	(4.53)		D	P Lotion
	5.60	1,000 ml		
	(11.95)			P Lotion
	(20.53)		A	pha-Keri Lotion
	1.40 (7.73)	250 ml OP	R	K Lotion
	5.60	1,000 ml	D	IX LOUOT
	(23.91)	1,000 111	В	K Lotion
Other Dermatological Bases	. ,			
ARAFFIN				
White soft – Only in combination	3 58	500 g		
	(7.78)	000 9	IF	W
	20.20	2,500 g	V IF	
	3.58	500 g		
				CM
Only in combination with a dermatological galenical or as	(8.69)			SM

	Subsidy (Manufacturer's I	Price) Sut	Fully Brand or osidised Generic
	(Manulactarci 31	Per	Manufacturer
Minor Skin Infections			
POVIDONE IODINE			
Oint 10%	3.27	25 g OP	Betadine
a) Maximum of 100 g per prescription		- 5 -	
b) Only on a prescription			
Antiseptic soln 10%	0.19	15 ml	
	(4.45)		Betadine
	1.28	100 ml	
	(8.25)		Betadine
	6.20	500 ml	Betadine
	1.28	100 ml	
	(4.20)	500 ml	Riodine
Skin propagation, polyidana jadina 100/ with 200/ alashal	6.20	500 ml	Riodine
Skin preparation, povidone iodine 10% with 30% alcohol		100 ml	Betadine Skin Prep
	(3.65) 10.00	500 ml	 Betadine Skin Prep Betadine Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol		100 ml	
	(6.04)	100 111	Orion
	8.13	500 ml	0
	(18.63)		Orion
Parasiticidal Preparations			
GAMMA BENZENE HEXACHLORIDE			
Crm 1%	3.50	50 g OP	Benhex
IVERMECTIN - Special Authority see SA1225 below - Retail pl	narmacy		
Tab 3 mg – Up to 100 tab available on a PSO		4	 Stromectol
1) PSO for institutional use only. Must be endorsed w		ne institution fo	r which the PSO is required and
valid Special Authority for patient of that institution.			
2) Ivermectin available on BSO provided the BSO inc			
 For the purposes of subsidy of ivermectin, institu facilities or penal institutions. 	nion means age	related reside	ntial care facilities, disability ca
·			
► SA1225 Special Authority for Subsidy			
Initial application — (Scabies) from any relevant practitioner. criteria:	Approvais valid i		applications meeting the following
Both:			
1 Applying clinician has discussed the diagnosis of scable	s with a dermatol	ogist infectiou	s disease physician or clinical n
crobiologist; and		ogiot, inteotiou	
2 Either:			
2.1 Both:			
2.1.1 The patient is in the community; and			
2.1.2 Any of the following:			
2.1.2.1 Patient has a severe scabies hyperin			
2.1.2.2 The community patient is physically	or mentally unat	ole to comply w	with the application instructions
topical therapy; or			
2.1.2.3 The patient has previously tried and	tailed to clear infe	estation using t	opical therapy; or
2.2 All of the following:			
2.2.1 The Patient is a resident in an institution; an			stad for a school of the
2.2.2 All residents of the institution with scabies of	r at risk of carria	ge are to be tre	
			continued.

Subsidy (Manufacturer			
\$	Per 🖌	Manufacturer	

continued...

- 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

- **Initial application (Other parasitic infections)** only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:
- Any of the following:
 - 1 Filaricides; or
 - 2 Cutaneous larva migrans (creeping eruption); or
 - 3 Strongyloidiasis.
- Renewal (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.
- Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Renewal — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

- Any of the following:
 - 1 Filaricides; or
 - 2 Cutaneous larva migrans (creeping eruption); or
 - 3 Strongyloidiasis.
- MALATHION

Liq 0.5% Shampoo 1%		200 ml OP 30 ml OP	A-LicesA-Lices
MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2%	.11.15	90 g OP	🗸 Para Plus
PERMETHRIN Crm 5% Lotn 5%		30 g OP 30 ml OP	✓ <u>Lyderm</u> ✓ <u>A-Scabies</u>

DERMATOLO	GICALS
-----------	--------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Psoriasis and Eczema Preparations				
ACITRETIN - Special Authority see SA0954 below - Retail pharr	nacy			
Cap 10 mg		100	🖌 No	eotigason
	38.66	60	🖌 N	ovatretin
Cap 25 mg		60	🖌 N	ovatretin
	85.40	100	🖌 No	eotigason

SA0954 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Fither:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
 - 3.2 Patient is male.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice: and
 - 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
 - 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment: or
 - 3.2 Patient is male.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Oint 500 mcg with calcipotriol 50 mcg		30 g OP	Daivobet
Topical gel 500 mcg with calcipotriol 50 mcg	26.12	30 g OP	Daivobet
CALCIPOTRIOL			
Crm 50 mcg per g		30 g OP	Daivonex
	45.00	100 g OP	Daivonex
Oint 50 mcg per g	45.00	100 g OP	Daivonex
Soln 50 mcg per ml	16.00	30 ml OP	 Daivonex
COAL TAR			

200 ml ✓ Midwest Up to 10 % Only in combination with a dermatological base or proprietary Topical Corticosteriod - Plain, refer, page 193 With or without other dermatological galenicals.

	Subsidy (Manufacturer's I	Price) Sut	Fully Brand or sidised Generic
	(Manulacturer 3 1 \$	Per	Manufacturer
COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULI	ЭНПВ		
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and			
allantoin crm 2.5%		30 g OP	
	(4.35)	00 9 01	Egopsoryl TA
	6.59	75 g OP	
	(8.00)	- 3 -	Egopsoryl TA
COAL TAR WITH SALICYLIC ACID AND SULPHUR	. ,		
Soln 12% with salicylic acid 2% and sulphur 4% oint	7.95	40 g OP	✔ Coco-Scalp
SALICYLIC ACID			e eee eeup
Powder – Only in combination	18.88	250 g	🖌 PSM
1) Only in combination with a dermatological base or p		0	
page 193	stophotaly topiot		
2) With or without other dermatological galenicals.			
3) Maximum 20 g or 20 ml per prescription when pres	cribed with white	soft paraffin o	r collodion flexible.
SULPHUR			
Precipitated – Only in combination	6.35	100 g	✓ Midwest
1) Only in combination with a dermatological base or			
2) With or without other dermatological galenicals.			
TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLU	ORESCEIN - O	nly on a prescr	iption
* Soln 2.3% with triethanolamine lauryl sulphate and fluores		, ,	
cein sodium		500 ml	Pinetarsol
	5.82	1,000 ml	✓ Pinetarsol
Scalp Preparations			
BETAMETHASONE VALERATE <pre>* Scalp app 0.1%</pre>	7 75	100	A Data Casla
		100 ml OP	✓ Beta Scalp
CLOBETASOL PROPIONATE			
* Scalp app 0.05%	6.96	30 ml OP	 Dermol
HYDROCORTISONE BUTYRATE			
Scalp lotn 0.1%	3.65	100 ml OP	Locoid
KETOCONAZOLE			
Shampoo 2%	3.08	100 ml OP	✓ Sebizole
 a) Maximum of 100 ml per prescription 			
b) Only on a prescription			
Sunscreens			
SUNSCREENS, PROPRIETARY – Subsidy by endorsement			
Only if prescribed for a patient with severe photosensitivity	secondary to a	defined clinica	condition and the prescription is
endorsed accordingly. Crm	0.55	100 ~ 00	
	2.55 (5.89)	100 g OP	Hamilton Sunscreen
Lotn	()	100 ml OP	✓ Marine Blue Lotion
EV01	2.00		SPF 30+
	5.10	200 ml OP	✓ Marine Blue Lotion
	5.10	200 111 01	SPF 30+
	3.19	125 ml OP	
	(6.94)		Aquasun 30+
	. /		·

	Subsidy (Manufacturer's Pri \$	ice) Sub Per	Fully osidised	Brand or Generic Manufacturer
Nart Preparations				
or salicylic acid preparations refer to PSORIASIS AND ECZEM	A PREPARATIONS	S, page 73		
IIQUIMOD – Special Authority see SA0923 below – Retail pha	rmacy			
Crm 5%	62.00	12	✓ <u>A</u>	<u>Idara</u>
SA0923 Special Authority for Subsidy				
itial application from any relevant practitioner. Approvals valid	for 4 months for a	pplications m	eeting t	he following criteria:
ny of the following:				
 The patient has external anogenital warts and podophylloi The patient has external anogenital warts and podophylloi The patient has confirmed superficial basal cell carcinoma contraindicated or inappropriate. 	toxin is unable to b	e applied acc	curately	to the site; or
 Superficial basal cell carcinoma Surgical excision remains first-line treatment for superficia and allows histological assessment of tumour clearance. 			-	
 Imiquimod has not been evaluated for the treatment of s nose, mouth or ears. 				1 cm of the hairline, e
 Imiquimod is not indicated for recurrent, invasive, infiltratin kternal anogenital warts 	ig, or nodular basa	I cell carcinoi	na.	
 Imiguimod is only indicated for external genital and perian 	al warts (condvlom	na acuminata).	
enewal from any relevant practitioner. Approvals valid for 4 mo	· ·		,	ng criteria:
ny of the following:				
 Inadequate response to initial treatment for anogenital wa New confirmed superficial basal cell carcinoma where oth 		ents. includin	a suraio	al excision. are contrai
cated or inappropriate; or		,	3 -	···· , ··· , ··· ···
3 Inadequate response to initial treatment for superficial bas				
ote: Every effort should be made to biopsy the lesion to confirm	n that it is a superfi	cial basal cel	l carcino	oma.
ODOPHYLLOTOXIN Soln 0.5%	22.60	3.5 ml OP		ondyline
a) Maximum of 3.50 ml per prescription		3.5 III OF		ondynne
b) Only on a prescription				
Other Skin Preparations				
Antineoplastics				
LUOROURACIL SODIUM				
Crm 5%	25.16	20 g OP	✓ <u>E</u>	fudix
Nound Management Products				
AGNESIUM SULPHATE				
	0.00	00 a		
Paste	2.98	80 g		
Paste PSM Paste to be delisted 1 January 2014)	(4.90)	ou y	Р	SM

DERMATOLOGICALS

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Contraceptives - Non-hormonal				
Condoms				
DNDOMS				
49 mm – Up to 144 dev available on a PSO	13.36	144		rquisTantiliza ield 49
52 mm - Up to 144 dev available on a PSO	13.36	144	🖌 Ma	rquis Selecta rquis Sensolite
50 mm overa otranath Up to 144 dov ovailable on a BCO	10.06	144		rquis Supalite rquis Protecta
52 mm extra strength – Up to 144 dev available on a PSO 53 mm – Up to 144 dev available on a PSO		144		ield Blue
55 mm - υριο 144 θεν avaliable υΠα FOU		144		ield Blue
	1.11	144		ld Knight
	13.36	144		ld Knight
	13.30	144	🖌 Ma	rquis Black rquis Titillata
53 mm (chocolate) – Up to 144 dev available on a PSO		12		ld Knight
	13.36	144		ld Knight
53 mm (strawberry) – Up to 144 dev available on a PSO		12		ld Knight
	13.36	144		ld Knight
54 mm, shaped – Up to 144 dev available on a PSO		12		0
,	(1.24)		Life	estyles Flared
	13.36	144		
	(14.84)		Life	estyles Flared
55 mm – Up to 144 dev available on a PSO	()	144		rquis Conforma
56 mm – Up to 144 dev available on a PSO		12		ld Knight
	13.36	144		ld Knight
			🖌 Du	rex Extra Safe
			🖌 Du	rex Select lavours
56 mm, shaped – Up to 144 dev available on a PSO		12	-	rex Confidence
	13.36	144	• = •	rex Confidence
60 mm - Up to 144 dev available on a PSO		144	• = •	ield XL
Contraceptive Devices				
APHRAGM – Up to 1 dev available on a PSO				
One of each size is permitted on a PSO.	40.00			
65 mm		1		tho All-flex
70 mm		1		tho All-flex
75 mm		1		tho All-flex
80 mm		1	V Or	tho All-flex
TRA-UTERINE DEVICE				
a) Up to 40 dev available on a PSO				
b) Only on a PSO				
IÚD		1	🖌 Mu	Itiload Cu 375

GENITO-URINARY SYSTEM

Fullv

~

Subsidised

Subsidy	
(Manufacturer's Price)	
\$	Per

Brand or Generic Manufacturer

Contraceptives - Hormonal

Combined Oral Contraceptives

SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient is on a Social Welfare benefit; or

2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

• on a Social Welfare benefit; or

• have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

*	Tab 20 mcg with desogestrel 150 mcg and 7 inert tab	6 62	84	
*	Tab 20 mcg with desogestier 150 mcg and 7 mentiab		04	Manailan 00
		(16.50)		Mercilon 28
	 a) Higher subsidy of \$13.80 per 84 tab with Special Authorit 	y see SA0500 a	above	
	b) Up to 84 tab available on a PSO			
*	Tab 30 mcg with desogestrel 150 mcg and 7 inert tab	6.62	84	
		(16.50)	•	Marvelon 28
		· · ·		
	 a) Higher subsidy of \$13.80 per 84 tab with Special Authority 	y see SA0500 a	above	
	 b) Up to 84 tab available on a PSO 			
ETI	HINYLOESTRADIOL WITH LEVONORGESTREL			
*	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab – Up			
	to 84 tab available on a PSO	2.95	84	🖌 Ava 20 ED
*	Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab – Up		•	· <u></u>
不	5 5 1	o 15	~ ~ ~	
	to 84 tab available on a PSO		84	Microgynon 50 ED
*	Tab 30 mcg with levonorgestrel 150 mcg	6.62	63	
		(16.50)		Microgynon 30
	a) Higher subsidy of \$15.00 per 63 tab with Special Authorit	v see SA0500 a	above	
	b) Up to 63 tab available on a PSO	,		
×	, 1			
*	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab – Up	o 15	~ ~ ~	() 00 55
	to 84 tab available on a PSO	2.45	84	Ava 30 ED

		Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic	
ET	HINYLOESTRADIOL WITH NORETHISTERONE					
*	Tab 35 mcg with norethisterone 1 mg – Up to 63 tab available on a PSO	6.62	63	~	Brevinor 1/21	
*	Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO	6.62	84	~	Brevinor 1/28	
*	Tab 35 mcg with norethisterone 500 mcg – Up to 63 tab avail- able on a PSO	6.62	63	~	Brevinor 21	
*	Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – Up to 84 tab available on a PSO	6.62	84	~	Norimin	
NO	RETHISTERONE WITH MESTRANOL					
*	Tab 1 mg with mestranol 50 mcg and 7 inert tab	6.62	84			
		(13.80)			Norinyl-1/28	
	a) Higher subsidy of \$13.80 per 84 tab with Special Author	ity see SA0500 on th	e pre	vious page	9	

b) Up to 84 tab available on a PSO

(Norinyl-1/28 Tab 1 mg with mestranol 50 mcg and 7 inert tab to be delisted 1 March 2014)

Progestogen-only Contraceptives

► SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and

2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

LEVONORGESTREL

*	Tab 30 mcg	6.62	84	
		(16.50)		Microlut
	a) Higher subsidy of \$13.80 per 84 tab with Special Authority se	e SA0500 abov	е	
	 b) Up to 84 tab available on a PSO 			
*	Subdermal implant (2 \times 75 mg rods)	133.65	1	✓ Jadelle
ME	DROXYPROGESTERONE ACETATE			
*	Inj 150 mg per ml, 1 ml syringe - Up to 5 inj available on a PSO	7.00	1	Depo-Provera
NO	RETHISTERONE			
*	Tab 350 mcg – Up to 84 tab available on a PSO	6.00	84	Noriday 28

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Pri		Fully Brand or osidised Generic
	\$	Per	Manufacturer
Emergency Contraceptives			
LEVONORGESTREL * Tab 1.5 mg a) Up to 5 tab available on a PSO b) Maximum of 2 tab per prescription	3.50	1	✓ Postinor-1
Antiandrogen Oral Contraceptives			
Prescribers may code prescriptions "contraceptive" (code "O") wh prescription charge will be as per other contraceptives, as follows: • \$5.00 prescription charge (patient co-payment) will apply. • prescription may be written for up to six months supply. Prescriptions coded in any other way are subject to the non contr of supply. ie. Prescriptions may be written for up to three months CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL	: raceptive prescript		
* Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs – Up to 84 tab available on a PSO		84	✓ Ginet 84
Gynaecological Anti-infectives		01	
ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC A			
Jelly with glacial acetic acid 0.94%, hydroxyquinoline sul- phate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator		100 g OP	
	(24.00)	0	Aci-Jel
CLOTRIMAZOLE Vaginal crm 1% with applicators Vaginal crm 2% with applicators 		35 g OP 20 g OP	✓ Clomazol✓ Clomazol
MICONAZOLE NITRATE * Vaginal crm 2% with applicator	2.75 (4.10)	40 g OP	Micreme
NYSTATIN	. ,		
Vaginal crm 100,000 u per 5 g with applicator(s)	4.71	75 g OP	✓ Nilstat
Myometrial and Vaginal Hormone Preparations ERGOMETRINE MALEATE Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO	31.00	5	✓ DBL Ergometrine
OESTRIOL		5	• DDL Ligomeanie
K Crm 1 mg per g with applicator Pessaries 500 mcg		15 g OP 15	✔ Ovestin✔ Ovestin
OXYTOCIN – Up to 5 inj available on a PSO Inj 5 iu per ml, 1 ml ampoule		5	✓ Oxytocin BNM
Inj 10 iu per ml, 1 ml ampoule	5.94 5.98 7.48	5	 Syntocinon Oxytocin BNM Syntocinon
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml		5	✓ <u>Syntometrine</u>

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Pr	ice) Subs		nd or heric
	(Manulacturers Fr	Per		nufacturer
Pregnancy Tests - hCG Urine				
PREGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO Cassette	22.80	40 test OP	Step	icon hCG One Pregnancy
Urinary Agents			Test	
For urinary tract Infections refer to INFECTIONS, Antibacterials,	page 110			
5-Alpha Reductase Inhibitors				
FINASTERIDE – Special Authority see SA0928 below – Retail * Tab 5 mg SA0928 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals va the following criteria: Both:	5.10	30 enewal unless	✓ <u>Rex M</u> notified for	
 Patient has symptomatic benign prostatic hyperplasia; an Either: The patient is intolerant of non-selective alpha blog Symptoms are not adequately controlled with non-Note: Patients with enlarged prostates are the appropriate cand Alpha-1A Adrenoreceptor Blockers 	ckers or these are c selective alpha blo	ckers.		
	000 kalan Datail			
TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1 * Cap 400 mcg SA1032 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals va	13.51	100		applications meeting
the following criteria: Both: 1 Patient has symptomatic benign prostatic hyperplasia; an 2 The patient is intolerant of non-selective alpha blockers o	ıd			
Other Urinary Agents				
OXYBUTYNIN * Tab 5 mg * Oral liq 5 mg per 5 ml POTASSIUM CITRATE	56.45	500 473 ml		<u>xybutynin</u> xybutynin
Oral liq 3 mmol per ml – Special Authority see SA1083 belo – Retail pharmacy		200 ml OP	🖌 Biome	d
 SA1083 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Both: The patient has recurrent calcium oxalate urolithiasis; and 2 The patient has had more than two renal calculi in the two remains that the two remains the two remains that the two remains t	d		eeting the f	ollowing criteria:

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

	Subsidy		Full	
	(Manufacturer's Price		Subsidise	
	\$	Per	~	Manufacturer
SODIUM CITRO-TARTRATE				
* Grans eff 4 g sachets	2.71	28	~	Ural
SOLIFENACIN SUCCINATE – Special Authority see SA0998 belo	ow – Retail pharma	CV		
Tab 5 mg		30	~	Vesicare
Tab 10 mg		30	~	Vesicare
➡SA0998 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals vali	d without further re	enewal	unless no	tified where the patient ha
overactive bladder and a documented intolerance of, or is non-res	ponsive to oxybuty	nin.		
OLTERODINE – Special Authority see SA1272 below – Retail pl	harmacy			
Tab 1 mg		56	~	Arrow-Tolterodine
Tab 2 mg	14.56	56	~	Arrow-Tolterodine
SA1272 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals valid	without further rene	ewal unl	ess notifie	ed where patient has overa
ive bladder and a documented intolerance of, or is non-responsive	e to oxybutynin.			
Detection of Substances in Urine				
ORTHO-TOLIDINE				
* Compound diagnostic sticks		60 test C		
	(8.25)			Hemastix
TETRABROMOPHENOL				
* Blue diagnostic strips		00 test (OP	

(13.92)

GENITO-URINARY SYSTEM

Albustix

	Subsidy (Manufacturer's D	rian) Curk	Fully Brand or
	(Manufacturer's Pr \$	Per Suc	osidised Generic Manufacturer
	Ŷ		
Calcium Homeostasis			
ALCITONIN			
Inj 100 iu per ml, 1 ml	110.00	5	✓ Miacalcic
Corticosteroids and Related Agents for System			
Solucosteroids and helated Agents for System			
ETAMETHASONE SODIUM PHOSPHATE WITH BETAMETH.	ASONE ACETATE		
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml		5	
	(33.60)		Celestone
			Chronodose
EXAMETHASONE			
Tab 1 mg – Retail pharmacy-Specialist		100	✓ Douglas
Up to 30 tab available on a PSO			
Tab 4 mg – Retail pharmacy-Specialist	8.16	100	✓ Douglas
Up to 30 tab available on a PSO			
Oral liq 1 mg per ml – Retail pharmacy-Specialist	45.00	25 ml OP	Biomed
Oral liq prescriptions:			
1) Must be written by a Paediatrician or Paediatric C	•		
2) On the recommendation of a Paediatrician or Pae	diatric Cardiologist.		
EXAMETHASONE SODIUM PHOSPHATE			
Dexamethasone sodium phosphate injection will not be fun	ded for oral use.		
Inj 4 mg per ml, 1 ml – Up to 5 inj available on a PSO	21.50	5	 Hospira
Inj 4 mg per ml, 2 ml – Up to 5 inj available on a PSO	31.00	5	Hospira
LUDROCORTISONE ACETATE			
Tab 100 mcg	14.32	100	 Florinef
YDROCORTISONE			
• Tab 5 mg	8 10	100	✓ Douglas
Tab 20 mg – For hydrocortisone oral liquid formulation refe		100	· <u>Dougluo</u>
page 194		100	✓ Douglas
Inj 100 ml vial		1	Solu-Cortef
a) Up to 5 inj available on a PSO			
b) Only on a PSO			
ETHYLPREDNISOLONE – Retail pharmacy-Specialist			
Tab 4 mg		100	✓ Medrol
Tab 100 mg		20	✓ Medrol
		-	
Inj 40 mg per ml, 1 ml	6 70	1	Depo-Medrol
		1	
ETHYLPREDNISOLONE ACETATE WITH LIDOCAINE [LIGN			
Inj 40 mg per ml with lidocaine [lignocaine] 1 ml	7.50	1	Depo-Medrol with
			Lidocaine
ETHYLPREDNISOLONE SODIUM SUCCINATE - Retail pha			
Inj 40 mg per ml, 1 ml		1	Solu-Medrol
Inj 62.5 mg per ml, 2 ml		1	Solu-Medrol
Inj 500 mg		1	Solu-Medrol
lnj 1 g		1	Solu-Medrol
REDNISOLONE SODIUM PHOSPHATE			
Oral liq 5 mg per ml – Up to 30 ml available on a PSO	10.45	30 ml OP	Redipred
Restricted to children under 12 years of age.			

()	Subsidy /anufacturer's Price) \$	Per	Full Subsidise	
PREDNISONE				
* Tab 1 mg	2.13	100	~	Apo-Prednisone S29 S29
	10.68	500	~	Apo-Prednisone
* Tab 2.5 mg	12.09	500		Apo-Prednisone
 * Tab 5 mg – Up to 30 tab available on a PSO 	11.09	500		Apo-Prednisone
* Tab 20 mg	29.03	500	~	Apo-Prednisone
TETRACOSACTRIN				
* Inj 250 mcg per ml, 1 ml ampoule	17.71	1	V	Synacthen
	177.18	10	~	Synacthen
* Inj 1 mg per ml, 1 ml	29.56	1	~	Synacthen Depot
TRIAMCINOLONE ACETONIDE				
Inj 10 mg per ml, 1 ml	21.90	5	~	Kenacort-A
Inj 40 mg per ml, 1 ml		5	V	Kenacort-A40
Sex Hormones Non Contraceptive Androgen Agonists and Antagonists				
CYPROTERONE ACETATE – Retail pharmacy-Specialist				
Tab 50 mg	18.80	50	~	Siterone
Tab 100 mg		50 50		Siterone
5	04.20	00	•	
TESTOSTERONE Transdermal patch, 2.5 mg per day	80.00	60	~	Androderm
TESTOSTERONE CYPIONATE – Retail pharmacy-Specialist Inj long-acting 100 mg per ml, 10 ml	76.50	1	~	Depo-Testosterone
TESTOSTERONE ESTERS – Retail pharmacy-Specialist				
Inj 250 mg per ml, 1 ml	12.98	1	~	Sustanon Ampoules
TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist				
Cap 40 mg	31.17	60	V	Andriol Testocaps
Inj 250 mg per ml, 4 ml		1		Reandron 1000

Hormone Replacement Therapy - Systemic

➡SA1018 Special Authority for Alternate Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following:

- 1 acute or significant liver disease where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia documented evidence must be kept on file that triglyceride levels increased to at least $2 \times$ normal triglyceride levels post oral oestrogens; or
- 4 Somatropin co-therapy patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

Renewal from any relevant practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment, or the patient remains on subsidised somatropin co-therapy.

	Subsidy (Manufacturer's F \$	Price) Su Per	Fully Brand or ubsidised Generic Manufacturer
rescribing Guideline			
RT should be taken at the lowest dose for the shortest per monthly in line with the updated NZGG "Evidence-base 004".			
Destrogens			
ESTRADIOL – See prescribing guideline above			
F Tab 1 mg	4.12	28 OP	
-	(10.55)		Estrofem
Tab 2 mg	4.12	28 OP	
	(10.55)		Estrofem
TDDS 25 mcg per day	3.01	8	
	(10.86)		Estradot
 a) Higher subsidy of \$10.86 per 8 patch with Specia 	I Authority see SA1018	on the previ	ous page
b) No more than 2 patch per week			
 c) Only on a prescription 			
TDDS 3.9 mg (releases 50 mcg of oestradiol per day)		4	
	(13.18)		Climara 50
	(32.50)		Femtran 50
 a) Higher subsidy of \$13.18 per 4 patch with Specia 	I Authority see SA1018	on the previ	ous page
 b) No more than 1 patch per week 			
 c) Only on a prescription 			
TDDS 50 mcg per day	4.12	8	
	(13.18)		Estradot 50 mcg
 a) Higher subsidy of \$13.18 per 8 patch with Specia b) No more than 2 patch per week 	I Authority see SA1018	3 on the previ	bus page
c) Only on a prescription			
 TDDS 7.8 mg (releases 100 mcg of oestradiol per day) 		4	
	(16.14)		Climara 100
	(35.00)		Femtran 100
 a) Higher subsidy of \$16.14 per 4 patch with Specia b) No more than 1 patch per week c) Only on a prescription 	I Authority see SA1018	s on the previ	bus page
 TDDS 100 mcg per day 	7.05	8	
TDDS 100 micg per day	(16.14)	0	Estradot
a) Higher subsidy of \$16.14 per 8 patch with Specia	(/	on the provid	
	I AULIOTILY SEE SATUTO	on the previ	Jus page
b) No more than 2 patch per week			
b) No more than 2 patch per weekc) Only on a prescription)VA		
 b) No more than 2 patch per week c) Only on a prescription ESTRADIOL VALERATE – See prescribing guideline about the prescription of the prescriptic dual term of the prescriptic dual term of the prescription		56	
 b) No more than 2 patch per week c) Only on a prescription ESTRADIOL VALERATE – See prescribing guideline about the prescription of the prescriptic dual term of the prescriptic dual term of the prescription	8.24	56 84	✓ Progynova
b) No more than 2 patch per week c) Only on a prescription ESTRADIOL VALERATE – See prescribing guideline ab Tab 1 mg	8.24 12.36	84	Progynova
b) No more than 2 patch per week c) Only on a prescription ESTRADIOL VALERATE – See prescribing guideline ab Tab 1 mg		84 56	 Progynova Progynova
 b) No more than 2 patch per week c) Only on a prescription ESTRADIOL VALERATE – See prescribing guideline abies Tab 1 mg Tab 2 mg Progynova Tab 1 mg to be delisted 1 June 2014) 	8.24 12.36	84	Progynova
 b) No more than 2 patch per week c) Only on a prescription ESTRADIOL VALERATE – See prescribing guideline abiestrab 1 mg Tab 1 mg Tab 2 mg Progynova Tab 1 mg to be delisted 1 June 2014) Progynova Tab 2 mg to be delisted 1 June 2014) 		84 56	 Progynova Progynova
 b) No more than 2 patch per week c) Only on a prescription ESTRADIOL VALERATE – See prescribing guideline abiestrab 1 mg Tab 1 mg Tab 2 mg Progynova Tab 1 mg to be delisted 1 June 2014) Progynova Tab 2 mg to be delisted 1 June 2014) ESTROGENS – See prescribing guideline above 	8.24 12.36 8.24 12.36	84 56 84	 Progynova Progynova
 b) No more than 2 patch per week c) Only on a prescription ESTRADIOL VALERATE – See prescribing guideline abies Tab 1 mg Tab 2 mg Progynova Tab 1 mg to be delisted 1 June 2014) Progynova Tab 2 mg to be delisted 1 June 2014) ESTROGENS – See prescribing guideline above 		84 56	 Progynova Progynova Progynova
 b) No more than 2 patch per week c) Only on a prescription ESTRADIOL VALERATE – See prescribing guideline abies Tab 1 mg Tab 2 mg Progynova Tab 1 mg to be delisted 1 June 2014) Progynova Tab 2 mg to be delisted 1 June 2014) ESTROGENS – See prescribing guideline above Conjugated, equine tab 300 mcg 		84 56 84 28	 Progynova Progynova
 b) No more than 2 patch per week c) Only on a prescription DESTRADIOL VALERATE – See prescribing guideline abies Tab 1 mg Tab 2 mg Progynova Tab 1 mg to be delisted 1 June 2014) Progynova Tab 2 mg to be delisted 1 June 2014) DESTROGENS – See prescribing guideline above 		84 56 84	 Progynova Progynova Progynova

	Subsidy (Manufacturer's P	rice) Su	Fully Brand or bsidised Generic	
	(Manulacturer 3 1	Per	Manufacturer	
Progestogens				
MEDROXYPROGESTERONE ACETATE – See prescribing g	uideline on the previ	ous page		
* Tab 2.5 mg		30	Provera	
* Tab 5 mg		100	Provera	
* Tab 10 mg	6.85	30	✓ Provera	
Progestogen and Oestrogen Combined Prepa	rations			
DESTRADIOL WITH NORETHISTERONE – See prescribing	guideline on the pre	vious page		
* Tab 1 mg with 0.5 mg norethisterone acetate	•	28 OP		
	(14.52)		Kliovance	
* Tab 2 mg with 1 mg norethisterone acetate	5.40	28 OP		
-	(14.52)		Kliogest	
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2				
oestradiol tab (12) and 1 mg oestradiol tab (6)	5.40	28 OP		
	(14.52)		Trisequens	
DESTROGENS WITH MEDROXYPROGESTERONE – See p	prescribing guideline	on the previo	us page	
* Tab 625 mcg conjugated equine with 2.5 mg medroxyprog			-	
terone acetate tab (28)		28 OP		
	(22.96)		Premia 2.5	
			Continuous	
* Tab 625 mcg conjugated equine with 5 mg medroxyprog	es-			
terone acetate tab (28)		28 OP		
	(22.96)		Premia 5 Contin	uous
Other Oestrogen Preparations				
ETHINYLOESTRADIOL				
* Tab 10 mcg		100	NZ Medical and	
5			Scientific	
DESTRIOL				
* Tab 2 mg	7.00	30	 Ovestin 	
Other Progestogen Preparations				
other Progestogen Preparations				
LEVONORGESTREL				
 Levonorgestrel - releasing intrauterine system 20 mcg/24 h 	ır —			
Special Authority see SA0782 below – Retail pharma		1	 Mirena 	
SA0782 Special Authority for Subsidy				
nitial application - (No previous use) only from a relevant	nt specialist or gene	ral practitione	r. Approvals valid for 6	months f
applications meeting the following criteria:				
All of the following:				
1 The patient has a clinical diagnosis of heavy menstrual	bleeding; and			
2 The patient has failed to respond to or is unable to tol	erate other appropri	iate pharmac	eutical therapies as per	the Heav
Menstrual Bleeding Guidelines; and				
3 Either:				
3.1 serum ferritin level < 16 mcg/l (within the last 12	months); or			
3.2 haemoglobin level < 120 g/l.	ntropontion avaget	uboro thay	ant the above evitoria	
Note: Applications are not to be made for use in patients as co	muaception except	where they m		
			C	ontinued

Subsidy	Fu	Ily	Brand or	
(Manufacturer's Price)	Subsidis	ed	Generic	
\$	Per	~	Manufacturer	

continued...

Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and
- 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and
- 3 Applicant to state date of the previous insertion.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:

- 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or
- 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion.

MEDROXYPROGESTERONE ACETATE

* Tab 100 mg – Retail pharmacy-Specialist	96.50	100	Provera
* Tab 200 mg - Retail pharmacy-Specialist	70.50	30	✓ Provera
NORETHISTERONE			
* Tab 5 mg – Up to 30 tab available on a PSO	26.50	100	Primolut N
PROGESTERONE			
Cap 100 mg – Special Authority see SA1392 below – Retail			
pharmacy	16.50	30	 Utrogestan

➡SA1392 Special Authority for Subsidy

Initial application only from an obstetrician or gynaecologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 For the prevention of pre-term labour*; and
- 2 Either:
 - 2.1 The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or

2.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 4.6)

Thyroid and Antithyroid Agents

CARBIMAZOLE		
Tab 5 mg10.8	0 100	Neo-Mercazole
LEVOTHYROXINE		
* Tab 25 mcg	9 90	Synthroid
‡ Safety cap for extemporaneously compounded oral liquid preparation	ins.	-
* Tab 50 mcg1.7	1 28	Mercury Pharma
4.0	5 90	Synthroid
64.2	8 1,000	 Eltroxin
‡ Safety cap for extemporaneously compounded oral liquid preparation	ins.	
* Tab 100 mcg1.7	8 28	Mercury Pharma
4.2	1 90	Synthroid
66.7	8 1,000	 Eltroxin
+ Safety can for extemporaneously compounded oral liquid preparation	ine	

‡ Safety cap for extemporaneously compounded oral liquid preparations.

	Subsidy (Manufacturer's Price \$) S Per	Fully ubsidised	Brand or Generic Manufacturer
PROPYLTHIOURACIL – Special Authority see SA1199 be Propylthiouracil is not recommended for patients under are contraindicated.		the pati	ent is preg	nant and other treatmen
Tab 50 mg		100	V P	TU \$29
 SA1199 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals Both: The patient has hyperthyroidism; and The patient is intolerant of carbimazole or carbimazole Renewal from any relevant practitioner. Approvals valid for 	ble is contraindicated.			
enefitting from the treatment.				
Trophic Hormones				
Growth Hormones				
		rmac co	vt nz or:	
pecial Authority approved by the Growth Hormone Comm lotes: Application details may be obtained from PHARMA(IZGHC Coordinator HARMAC, PO Box 10-254, WELLINGTON el: 0800 808 476, Fax: (09) 929 3221, Email: growthhorm OMATROPIN – Special Authority see SA1279 above Inj cartridge 16 iu (5.3 mg)	C's website http://www.pha	1	✓ <u>G</u>	enotropin
otes: Application details may be obtained from PHARMAC ZGHC Coordinator HARMAC, PO Box 10-254, WELLINGTON el: 0800 808 476, Fax: (09) 929 3221, Email: growthhorm OMATROPIN – Special Authority see SA1279 above Inj cartridge 16 iu (5.3 mg)	C's website http://www.pha		✓ <u>G</u>	enotropin enotropin
otes: Application details may be obtained from PHARMA(ZGHC Coordinator HARMAC, PO Box 10-254, WELLINGTON el: 0800 808 476, Fax: (09) 929 3221, Email: growthhorn OMATROPIN – Special Authority see SA1279 above inj cartridge 16 iu (5.3 mg)	C's website http://www.pha	1	✓ <u>G</u>	
otes: Application details may be obtained from PHARMAG ZGHC Coordinator HARMAC, PO Box 10-254, WELLINGTON el: 0800 808 476, Fax: (09) 929 3221, Email: growthhorm OMATROPIN – Special Authority see SA1279 above inj cartridge 16 iu (5.3 mg) inj cartridge 36 iu (12 mg) GRRH Analogues	C's website <u>http://www.pha</u> none@pharmac.govt.nz 	1	✓ <u>G</u> ✓ <u>G</u>	
btes: Application details may be obtained from PHARMAG ZGHC Coordinator HARMAC, PO Box 10-254, WELLINGTON H: 0800 808 476, Fax: (09) 929 3221, Email: growthhorm DMATROPIN – Special Authority see SA1279 above Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) SARRH Analogues DSERELIN ACETATE Inj 3.6 mg Inj 10.8 mg	C's website <u>http://www.pha</u> none@pharmac.govt.nz 	1 1 1 1	✓ <u>G</u> ✓ <u>G</u> ✓ Zı ✓ Zı	enotropin Dladex Dladex
otes: Application details may be obtained from PHARMA(ZGHC Coordinator HARMAC, PO Box 10-254, WELLINGTON I: 0800 808 476, Fax: (09) 929 3221, Email: growthhorn DMATROPIN – Special Authority see SA1279 above Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) SARH Analogues DSERELIN ACETATE Inj 3.6 mg Inj 10.8 mg UPRORELIN Inj 3.75 mg	C's website <u>http://www.pha</u> none@pharmac.govt.nz 	1 1 1 1 1	✓ <u>G</u> ✓ <u>G</u> ✓ Z ✓ Z	enotropin oladex oladex ucrin Depot
otes: Application details may be obtained from PHARMA(ZGHC Coordinator HARMAC, PO Box 10-254, WELLINGTON I: 0800 808 476, Fax: (09) 929 3221, Email: growthhorn DMATROPIN – Special Authority see SA1279 above Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) SARH Analogues DSERELIN ACETATE Inj 3.6 mg Inj 10.8 mg UPRORELIN Inj 3.75 mg Inj 3.75 mg prefilled syringe	C's website <u>http://www.pha</u> none@pharmac.govt.nz 	1 1 1 1	✓ <u>G</u> ✓ <u>G</u> ✓ Z ✓ Z ✓ L ✓ L	enotropin oladex oladex ucrin Depot ucrin Depot PDS
Application details may be obtained from PHARMAG ARMAC, PO Box 10-254, WELLINGTON Is 0800 808 476, Fax: (09) 929 3221, Email: growthhorn DMATROPIN – Special Authority see SA1279 above Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) SARH Analogues DSERELIN ACETATE Inj 3.6 mg UPRORELIN Inj 3.75 mg Inj 1.25 mg	C's website <u>http://www.pha</u> none@pharmac.govt.nz 	1 1 1 1 1 1	レ <u>G</u> レ <u>G</u> レ Z レ レ レ レ レ レ レ レ レ レ レ レ レ フ レ フ レ フ ロ レ フ ロ レ ロ レ	enotropin oladex oladex ucrin Depot
Application details may be obtained from PHARMAG ARMAC, PO Box 10-254, WELLINGTON Is 0800 808 476, Fax: (09) 929 3221, Email: growthhorn DMATROPIN – Special Authority see SA1279 above Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) SERELIN ACETATE Inj 3.6 mg UPRORELIN Inj 3.75 mg Inj 3.75 mg Inj 3.75 mg Inj 11.25 mg Inj 11.25 mg prefilled syringe Inj 11.25 mg prefilled syringe	C's website <u>http://www.pha</u> none@pharmac.govt.nz 	1 1 1 1 1 1 1 1 1		enotropin Dladex Dladex ucrin Depot ucrin Depot PDS ligard ucrin Depot pot PDS
bees: Application details may be obtained from PHARMAG ZGHC Coordinator HARMAC, PO Box 10-254, WELLINGTON H: 0800 808 476, Fax: (09) 929 3221, Email: growthhorn DMATROPIN – Special Authority see SA1279 above Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) Inj cartridge 36 iu (12 mg) SERELIN ACETATE Inj 3.6 mg Inj 10.8 mg UPRORELIN Inj 3.75 mg Inj 3.75 mg prefilled syringe Inj 7.5 mg Inj 11.25 mg Inj 11.25 mg Inj 11.25 mg	C's website <u>http://www.pha</u> none@pharmac.govt.nz 	1 1 1 1 1 1 1 1 1 1		enotropin Dladex Dladex ucrin Depot ucrin Depot PDS ligard ucrin Depot ucrin Depot PDS ligard
otes: Application details may be obtained from PHARMAG ZGHC Coordinator HARMAC, PO Box 10-254, WELLINGTON el: 0800 808 476, Fax: (09) 929 3221, Email: growthhorn OMATROPIN – Special Authority see SA1279 above inj cartridge 16 iu (5.3 mg) inj cartridge 36 iu (12 mg) GRRH Analogues OSERELIN ACETATE Inj 3.6 mg Inj 10.8 mg EUPRORELIN Inj 3.75 mg prefilled syringe Inj 3.75 mg prefilled syringe Inj 11.25 mg Inj 11.25 mg Inj 22.5 mg Inj 30 mg	C's website <u>http://www.pha</u> none@pharmac.govt.nz 160.00 360.00 166.20 443.76 221.60 221.60 166.20 591.68 591.68 591.68 591.68	1 1 1 1 1 1 1 1 1 1 1 1		enotropin Dladex Dladex ucrin Depot ucrin Depot PDS ligard ucrin Depot ucrin Depot PDS ligard ligard
otes: Application details may be obtained from PHARMAC ZGHC Coordinator HARMAC, PO Box 10-254, WELLINGTON el: 0800 808 476, Fax: (09) 929 3221, Email: growthhorn OMATROPIN – Special Authority see SA1279 above inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) GRRH Analogues IOSERELIN ACETATE Inj 3.6 mg Inj 10.8 mg EUPRORELIN Inj 3.75 mg prefilled syringe Inj 7.5 mg Inj 11.25 mg Inj 11.25 mg Inj 22.5 mg	C's website <u>http://www.pha</u> none@pharmac.govt.nz 	1 1 1 1 1 1 1 1 1 1		enotropin Dladex Dladex ucrin Depot ucrin Depot PDS ligard ucrin Depot ucrin Depot pot PDS ligard

(Lucrin Depot Inj 3.75 mg to be delisted 1 February 2014) (Lucrin Depot Inj 11.25 mg to be delisted 1 February 2014)

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	
Vasopressin Agonists				
DESMOPRESSIN				
Tab 100 mcg – Special Authority see SA1401 below – Retail pharmacy		30	~ 1	Minirin
Tab 200 mcg – Special Authority see SA1401 below – Retail pharmacy		30 .5 ml O	• . •	Minirin Minirin
▲ Nasal spray 10 mcg per dose – Retail pharmacy-Specialist		6 ml OF	· • <u>·</u>	<u>Desmopressin-</u> PH&T
Inj 4 mcg per ml, 1 ml – Special Authority see SA1401 below – Retail pharmacy	67.18	10	• 1	Minirin

SA1401 Special Authority for Subsidy

Initial application — (Desmopressin tablets for Nocturnal enuresis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has primary nocturnal enuresis; and
- 2 The nasal forms of desmopressin are contraindicated; and
- 3 An enuresis alarm is contraindicated.

Initial application — (Desmopressin tablets for Diabetes insipidus) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 The patient has cranial diabetes insipidus; and

2 The nasal forms of desmopressin are contraindicated.

Renewal — (Desmopressin tablets) from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from the treatment.

Initial application — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

Renewal — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Other Endocrine Agents

CABERGOLINE

Tab 0.5 mg	- Maximum of 2 tab per prescription; can be	
waivad h	ny Special Authority see SA1370 below	6 25

Dostinex	2	waived by Special Authority see SA1370 below
Dostinex	8	25.00

➡SA1370 Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 pathological hyperprolactinemia; or

2 acromegaly*.

Renewal — (for patients who have previously been funded under Special Authority form SA1031) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment.

Note: Indication marked with * is an Unapproved indication.

CLOMIPHENE CITRATE

Tab 50 mg	29.84	10	Serophene
-----------	-------	----	-----------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
DANAZOL				
Cap 100 mg		100	🗸 A	zol
Cap 200 mg	97.83	100	🗸 A	zol
METYRAPONE Cap 250 mg – Retail pharmacy-Specialist		50	✔ N	letopirone

(1	Subsidy Manufacturer's I	Price) Su	Fully Brand or bsidised Generic
(*	\$	Per	Manufacturer
Anthelmintics			
LBENDAZOLE – Special Authority see SA1318 below – Retail pha	armacy		
Tab 400 mg		60	Eskazole S29
Special Authority for Subsidy Itial application only from an infectious disease specialist or cli		ologist. Appro	vals valid for 6 months where t
atient has hydatids. enewal only from an infectious disease specialist or clinical micro mains appropriate and the patient is benefitting from the treatment		pprovals valid	for 6 months where the treatme
EBENDAZOLE – Only on a prescription			
Tab 100 mg		24	✓ <u>De-Worm</u>
Oral liq 100 mg per 5 ml	(15 ml	Vormou
	(7.17)		Vermox
RAZIQUANTEL Tab 600 mg	68.00	8	✓ Biltricide
•		0	• Billioide
Antibacterials			
For topical antibacterials, refer to DERMATOLOGICALS, page 66			
For anti-infective eye preparations, refer to SENSORY ORGANS,	page 188		
Cephalosporins and Cephamycins			
EFACLOR MONOHYDRATE			
Cap 250 mg	26.00	100	Ranbaxy-Cefaclor
Grans for oral liq 125 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17	3.53	100 ml	Ranbaxy-Cefaclor
EFALEXIN MONOHYDRATE			
Cap 500 mg	5.70	20	Cephalexin ABM
Grans for oral liq 125 mg per 5 ml – Wastage claimable – see	0.50	100 ml	A Cofelexin Conden
rule 3.3.2 on page 17	8.50	100 ml	✓ Cefalexin Sandoz
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see			
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17		100 ml 100 ml	 ✓ <u>Cefalexin Sandoz</u> ✓ <u>Cefalexin Sandoz</u>
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 FAZOLIN SODIUM – Subsidy by endorsement	11.50	100 ml	 Cefalexin Sandoz
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 EFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a DI ingly.	11.50 HB approved	100 ml	 Cefalexin Sandoz
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 FAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a DI ingly. Inj 500 mg	11.50 HB approved 3.99	100 ml protocol and th 5	Cefalexin Sandoz
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 EFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a Dl ingly. Inj 500 mg Inj 1 g	11.50 HB approved 3.99	100 ml protocol and th	Cefalexin Sandoz ne prescription is endorsed according
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 EFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a Dl ingly. Inj 500 mg EFTRIAXONE SODIUM – Subsidy by endorsement	11.50 HB approved 3.99	100 ml protocol and th 5	Cefalexin Sandoz
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 EFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a Dl ingly. Inj 500 mg Inj 1 g EFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO	11.50 HB approved 3.99 3.99	100 ml protocol and th 5 5	Cefalexin Sandoz
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 EFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a Dl ingly. Inj 500 mg Inj 1 g EFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis	11.50 HB approved 3.99 3.99	100 ml protocol and th 5 5 he treatment of	Cefalexin Sandoz e prescription is endorsed acco <u>✓ AFT</u> <u>✓ AFT</u> of gonorrhoea, or the treatment
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 EFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a Dl ingly. Inj 500 mg Inj 1 g EFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis pelvic inflammatory disease, or the treatment of suspected mer	11.50 HB approved 3.99 3.99	100 ml protocol and th 5 5 he treatment of	Cefalexin Sandoz e prescription is endorsed acco <u>✓ AFT</u> <u>✓ AFT</u> of gonorrhoea, or the treatment
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 EFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a Dl ingly. Inj 500 mg Inj 1 g EFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis	11.50 HB approved 3.99 3.99 s patient, or t hingitis in pati	100 ml protocol and th 5 5 he treatment of	Cefalexin Sandoz e prescription is endorsed acco <u>✓ AFT</u> <u>✓ AFT</u> of gonorrhoea, or the treatment
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 EFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a Dl ingly. Inj 500 mg Inj 1 g EFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis pelvic inflammatory disease, or the treatment of suspected men the prescription or PSO is endorsed accordingly.	11.50 HB approved 3.99 3.99 s patient, or t hingitis in pati 2.70	100 ml protocol and th 5 5 he treatment o ients who have	✓ <u>Cefalexin Sandoz</u> the prescription is endorsed acco ✓ <u>AFT</u> ✓ <u>AFT</u> of gonorrhoea, or the treatment the a known allergy to penicillin, a
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 EFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a Dl ingly. Inj 500 mg Inj 1 g EFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis pelvic inflammatory disease, or the treatment of suspected men the prescription or PSO is endorsed accordingly. Inj 500 mg Inj 1 g EFUROXIME AXETIL – Subsidy by endorsement	11.50 HB approved 3.99 3.99 : patient, or t hingitis in pati 2.70 10.49	100 ml protocol and th 5 5 he treatment o ients who have 1 5	 Cefalexin Sandoz cefalexin Sandoz e prescription is endorsed accord <u>AFT</u> <u>AFT</u> AFT of gonorrhoea, or the treatment a known allergy to penicillin, a Veracol Aspen Ceftriaxone
rule 3.3.2 on page 17 Grans for oral liq 250 mg per 5 ml – Wastage claimable – see rule 3.3.2 on page 17 EFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance with a Dl ingly. Inj 500 mg Inj 1 g EFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis pelvic inflammatory disease, or the treatment of suspected men the prescription or PSO is endorsed accordingly. Inj 500 mg	11.50 HB approved 3.99 3.99 : patient, or t hingitis in pati 2.70 10.49 ption is endo	100 ml protocol and th 5 5 he treatment o ients who have 1 5	 Cefalexin Sandoz cefalexin Sandoz e prescription is endorsed accord <u>AFT</u> <u>AFT</u> AFT of gonorrhoea, or the treatment a known allergy to penicillin, a Veracol Aspen Ceftriaxone

	Subsidy		Fully Brand or	
	(Manufacturer's Pi \$	rice) Su Per	bsidised Generic Manufacturer	
	φ	FEI		
CEFUROXIME SODIUM				
Inj 750 mg – Maximum of 1 inj per prescription; can be waive	ed			
by endorsement		5	m-Cefuroxime	
Waiver by endorsement must state that the prescription		stic fibrosis pa		
Macrolides				
macronues				
AZITHROMYCIN – Maximum of 5 days treatment per prescript	ion: can be waived	by endorsem	ent	
For Endorsement, patient has either:	ion, our po nariou	2) 0114010011		
1) Received a lung transplant and requires treatment or pro	onhylaxis for bronch	iolitis oblitera	ns syndrome*: or	
2) Cystic fibrosis and has chronic infection with Pseudomon				nisms'
Indications parked with * are Unapproved Indications	ue uerugineeu er r	coudomente	related grain negative erga	
Tab 250 mg	10.00	30	Apo-Azithromycin	
Tab 500 mg – Up to 8 tab available on a PSO		2	✓ Apo-Azithromycin	
Grans for oral liq 200 mg per 5 ml – Wastage claimable – se		-	· <u>ripo rizinironiyoni</u>	
rule 3.3.2 on page 17		15 ml	Zithromax	
CLARITHROMYCIN – Maximum of 500 mg per prescription; ca	• •			
Tab 250 mg		14	Apo-Clarithromycin	1
Grans for oral liq 125 mg per 5 ml – Wastage claimable – se	Эе			
rule 3.3.2 on page 17	23.12	70 ml	Klacid	
►SA1131 Special Authority for Waiver of Rule				
Initial application — (Mycobacterial infections) only from a	respiratory speciali	st. infectious	disease specialist or paedia	atriciar
Approvals valid for 2 years for applications meeting the following		-,	· · · · · · · · · · · · · · · · · · ·	
Either:	,			
1 Atypical mycobacterial infection; or				
2 Mycobacterium tuberculosis infection where there is drug	g-resistance or intol	lerance to sta	ndard pharmaceutical agen	its.
Renewal - (Mycobacterial infections) only from a respiratory	specialist, infection	us disease sp	pecialist or paediatrician. Ap	proval
valid for 2 years where the treatment remains appropriate and t	he patient is benefit	ting from trea	tment.	
ERYTHROMYCIN ETHYL SUCCINATE	•	U U		
Tab 400 mg	16.95	100	E-Mycin	
a) Up to 20 tab available on a PSO	10.00	100	• =,•	
b) Up to 2 x the maximum PSO guantity for RFPP – see	rule 5.2.6 on page	21		
Grans for oral liq 200 mg per 5 ml		100 ml	E-Mycin	
a) Up to 300 ml available on a PSO	4.00	100 111		
b) Up to 2 x the maximum PSO quantity for RFPP – see				
D D D D Z X U	rulo 5 2 6 on page	01		
	rule 5.2.6 on page	21		
c) Wastage claimable - see rule 3.3.2 on page 17				
c) Wastage claimable – see rule 3.3.2 on page 17 Grans for oral liq 400 mg per 5 ml		21 100 ml	✔ E-Mycin	
 c) Wastage claimable – see rule 3.3.2 on page 17 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO 			✔ E-Mycin	
 c) Wastage claimable – see rule 3.3.2 on page 17 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 17 			✔ E-Mycin	
 c) Wastage claimable – see rule 3.3.2 on page 17 Grans for oral liq 400 mg per 5 mla) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 17 ERYTHROMYCIN LACTOBIONATE 	5.85	100 ml	·	
 c) Wastage claimable – see rule 3.3.2 on page 17 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 17 	5.85		 E-Mycin Erythrocin IV 	
 c) Wastage claimable – see rule 3.3.2 on page 17 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 17 ERYTHROMYCIN LACTOBIONATE Inj 1 g 	5.85	100 ml	·	
 c) Wastage claimable – see rule 3.3.2 on page 17 Grans for oral liq 400 mg per 5 mla) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 17 ERYTHROMYCIN LACTOBIONATE Inj 1 g ERYTHROMYCIN STEARATE 	5.85	100 ml	·	
 c) Wastage claimable – see rule 3.3.2 on page 17 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 17 ERYTHROMYCIN LACTOBIONATE Inj 1 g 	5.85	100 ml 1	·	
c) Wastage claimable – see rule 3.3.2 on page 17 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 17 ERYTHROMYCIN LACTOBIONATE Inj 1 g ERYTHROMYCIN STEARATE		100 ml 1	Erythrocin IV	
 c) Wastage claimable – see rule 3.3.2 on page 17 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 17 ERYTHROMYCIN LACTOBIONATE Inj 1 g ERYTHROMYCIN STEARATE Tab 250 mg – Up to 30 tab available on a PSO 		100 ml 1 100	Erythrocin IV	

	Subsidy	Dirica) Out	Fully Brand or
	(Manufacturer's F \$	Price) Sut Per	osidised Generic Manufacturer
OXITHROMYCIN			
Tab 150 mg	7.48	50	✓ <u>Arrow-</u> <u>Roxithromycin</u>
Tab 300 mg	14.40	50	Arrow- <u>Roxithromycin</u>
Penicillins			
MOXYCILLIN			
Cap 250 mg		500	Alphamox
a) Up to 30 cap available on a PSO			
b) Up to 10 x the maximum PSO quantity for RFPP - s	ee rule 5.2.6 on paç	ge 21	
Cap 500 mg		500	Alphamox
a) Up to 30 cap available on a PSO			
b) Up to 10 x the maximum PSO quantity for RFPP – set	ee rule 5.2.6 on paç	ge 21	
Grans for oral liq 125 mg per 5 ml	1.55	100 ml	Ospamox
a) Up to 200 ml available on a PSO			
 b) Wastage claimable – see rule 3.3.2 on page 17 			
Grans for oral liq 250 mg per 5 ml	1.10	100 ml	Ospamox
 a) Up to 300 ml available on a PSO 			
b) Up to 10 x the maximum PSO quantity for RFPP – set	ee rule 5.2.6 on paç	ge 21	
c) Wastage claimable – see rule 3.3.2 on page 17			
Drops 125 mg per 1.25 ml	4.00	30 ml OP	 Ospamox Paediatric
			Drops
Inj 250 mg		10	Ibiamox
Inj 500 mg		10	✓ Ibiamox
Inj 1 g – Up to 5 inj available on a PSO		10	Ibiamox
Ospamox Paediatric Drops Drops 125 mg per 1.25 ml to be d	elisted 1 January 2	014)	
MOXYCILLIN CLAVULANATE			
Tab amoxycillin 500 mg with potassium clavulanate 125	ma		
- Up to 30 tab available on a PSO	0	100	🗸 Curam Duo
Grans for oral liq amoxycillin 125 mg with potassium cla			
lanate 31.25 mg per 5 ml		100 ml	✓ Augmentin
a) Up to 200 ml available on a PSO		100 111	* <u>Awgmontin</u>
b) Wastage claimable – see rule 3.3.2 on page 17			
Grans for oral liq amoxycillin 250 mg with potassium cla	vu-		
lanate 62.5 mg per 5 ml		100 ml	Augmentin
a) Up to 200 ml available on a PSO			
b) Wastage claimable – see rule 3.3.2 on page 17			
		10	✓ Bicillin LA
Ini 1.2 maga u par 2.3 ml - Up to 5 ini available on a DSC) 315.00		
Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSC)315.00	10	
Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSC ENZYLPENICILLIN SODIUM (PENICILLIN G) Inj 600 mg – Up to 5 inj available on a PSO		10	✓ Sandoz

anufacturer's P \$ 22.00 74.00 3.25 10.86 11.32 14.28 14.28 315.00 9.71 9.71 9.71	Per 250 500 100 ml 100 ml 10 10 10 10 10 50	 Staphlex Staphlex Staphlex Staphlex AFT AFT AFT AFT AFT Flucloxin Flucloxin Flucloxin Bicillin LA
74.00 2.49 3.25 10.86 11.32 14.28 315.00 9.71	500 100 ml 100 ml 10 10 10 10	 <u>Staphlex</u> <u>AFT</u> <u>AFT</u> <u>AFT</u> <u>AFT</u> <u>Flucloxin</u> <u>Flucloxin</u> <u>Flucloxin</u> <u>Bicillin LA</u>
74.00 2.49 3.25 10.86 11.32 14.28 315.00 9.71	500 100 ml 100 ml 10 10 10 10	 Staphlex <u>AFT</u> <u>AFT</u> <u>AFT</u> <u>AFT</u> <u>Flucloxin</u> <u>Flucloxin</u> <u>Flucloxin</u> <u>Flucloxin</u> <u>Bicillin LA</u>
2.49 3.25 10.86 11.32 14.28 315.00 9.71	100 ml 100 ml 10 10 10 10	 ✓ AFT ✓ AFT ✓ AFT ✓ AFT ✓ Flucloxin ✓ Flucloxin ✓ Flucloxin ✓ Flucloxin ✓ Bicillin LA
3.25 10.86 11.32 14.28 315.00 9.71	100 ml 10 10 10 10	 ✓ AFT ✓ AFT ✓ AFT ✓ AFT ✓ Flucloxin ✓ Flucloxin ✓ Flucloxin ✓ Flucloxin ✓ Bicillin LA
10.86 11.32 14.28 315.00 9.71	10 10 10 10	✓ <u>AFT</u> ✓ <u>AFT</u> ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ Bicillin LA
10.86 11.32 14.28 315.00 9.71	10 10 10 10	 ✓ <u>AFT</u> ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ Bicillin LA
10.86 11.32 14.28 315.00 9.71	10 10 10 10	 ✓ <u>AFT</u> ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ Bicillin LA
11.32 14.28 315.00 9.71	10 10 10	 ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ Bicillin LA
11.32 14.28 315.00 9.71	10 10 10	 ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ Bicillin LA
11.32 14.28 315.00 9.71	10 10 10	 ✓ <u>Flucloxin</u> ✓ <u>Flucloxin</u> ✓ Bicillin LA
11.32 14.28 315.00 9.71	10 10 10	 Flucloxin Flucloxin Bicillin LA
14.28 315.00 9.71	10 10	 ✓ <u>Flucloxin</u> ✓ Bicillin LA
315.00 9.71	10	✓ Bicillin LA
9.71		
9.71		
	50	
	50	
	50	
11.70	50	✓ Cilicaine VK
	50	Cilicaine VK
2 6 on nage	91	
		🖌 AFT
	100 111	¥ ALI
1.78	100 ml	🖌 AFT
.2.6 on page	21	
123.50	5	✓ <u>Cilicaine</u>
2 90	30	
	00	Doxy-50
	250	✓ Doxine
		· <u></u>
5 70	60	
	00	Mino-tabs
	100	
(52.04)		Minomycin
. ,		
rithout further	r renewal unle	ess notified where the patient has
- Retail pharn	nacv	
•	30	 Tetracyclin
		Wolff \$29
	.2.6 on page 1.68 .2.6 on page 2.90 (6.00) 7.95 7.95 (12.05) 19.32 (52.04) rithout further	11.70 50 1.68 100 ml 1.68 100 ml 1.78 100 ml 1.78 100 ml 1.78 100 ml 1.78 100 ml

	Subsidy (Manufacturer's Price \$) S Per	Fully Subsidised	Brand or Generic Manufacturer
SA1332 Special Authority for Subsidy itial application from any relevant practitioner. Approvals valid oth:	for 3 months for app	lications	meeting t	he following criteria:
 For the eradication of helicobacter pylori following unsucce For use only in combination with bismuth as part of a quac 			ate first-lir	ne therapy; and
Other Antibiotics				
or topical antibiotics, refer to DERMATOLOGICALS, page 66				
IPROFLOXACIN Recommended for patients with any of the following: i) microbiologically confirmed and clinically significant pseud ii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea.	omonas infection; or			
Tab 250 mg – Up to 5 tab available on a PSO	2.20	28	V C	ipflox
Tab 500 mg – Up to 5 tab available on a PSO		28		ipflox
	10.71	100		ipflox
Tab 750 mg	5.15 5.52	28 30		ipflox iprofloxacin Rex
	0.02	30	• 0	
LINDAMYCIN Cap hydrochloride 150 mg – Maximum of 4 cap per prescrip- tion; can be waived by endorsement - Retail pharmacy - Specialist	5.80	16	<u>√ c</u>	lindamycin ABM
Inj phosphate 150 mg per ml, 4 ml - Retail pharmacy- Specialist		10	✓ <u>D</u>	alacin C
O-TRIMOXAZOLE				
 Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO 		500	🗸 Ti	risul
 Oral lig trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml – Up to 200 ml available on a PSO 		100 ml	🗸 D	eprim
OLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – S	ubsidv bv endorsem	ent		•
Only if prescribed for dialysis or cystic fibrosis patient and the Inj 150 mg	e prescription is endo	orsed acc 1		olistin-Link
USIDIC ACID				
Tab 250 mg - Retail pharmacy-Specialist		12		ucidin
Prescriptions must be written by, or on the recommendation	on of, an infectious di	sease pr	nysician o	r a clinical microbiologist
ENTAMICIN SULPHATE Inj 10 mg per ml, 1 ml – Subsidy by endorsement	8 56	5	• н	ospira
Only if prescribed for a dialysis or cystic fibrosis patient or o accordingly.				•
Inj 10 mg per ml, 2 ml – Subsidy by endorsement	175.10	25	🗸 A	PP Pharmaceuticals 529
Only if prescribed for a dialysis or cystic fibrosis patient or o accordingly.	complicated urinary ti	ract infec	tion and th	ne prescription is endors
Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient or o		10 ract infec	tion and th	

	Subsidy (Manufacturer's Price) \$	Subsi Per	Fully idised	Brand or Generic Manufacturer
LINCOMYCIN – Retail pharmacy-Specialist Prescriptions must be written by, or on the recommendation of Inj 300 mg per ml, 2 ml (Lincocin Inj 300 mg per ml, 2 ml to be delisted 1 January 2014)		e physicia 5		clinical microbiologist ncocin
MOXIFLOXACIN – Special Authority see SA1358 below – Retail No patient co-payment payable Tab 400 mg		5	🖌 Av	velox
► SA1358 Special Authority for Subsidy Initial application — (Tuberculosis) only from a respiratory spectra for applications meeting the following criteria: Either: 1 Both:		sease spe	cialist.	Approvals valid for 1 year
 1.1 Active tuberculosis*; and 1.2 Any of the following: 1.2.1 Documented resistance to one or more first- 1.2.2 Suspected resistance to one or more first- 1.2.2 Suspected resistance to one or more first- 1.2.3 Impaired visual acuity (considered to preclud 2.4 Significant pre-existing liver disease or hepat 2.5 Significant documented intolerance and/or si 2 Mycobacterium avium-intracellulare complex not respondir Note: Indications marked with * are Unapproved Indications (refettions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease appropriate and the patient is benefiting from treatment. Initial application — (Mycoplasma genitalium) from any relet meeting the following: Has nucleic acid amplification test (NAAT) confirmed Mycoc Has nucleic acid amplification test (NAAT) confirmed Mycoc Has nucleic acid amplification test (NAAT) confirmed Mycoc Initial application — (Penetrating eye injury) only from an or requires prophylaxis following a penetrating eye injury and treatment. Initial application marked with * are Unapproved Indications (refetions) and Part IV (Miscellaneous Provisions) rule 4.6). PAROMOMYCIN – Special Authority see SA1324 below – Retail 	e medications (tubercu ontaining other second le ethambutol use); or totoxicity from tubercul de effects following a u og to other therapy or v er to Section A: Gener pecialist. Approvals va evant practitioner. Ap plasma genitalium*; a nd ophthalmologist. Appr ent is for 5 days only. er to Section A: Gener	d-line agen losis medic reasonable where such al Rules, F alid for 1 yo oprovals va nd rovals valic	ts; or cations trial of therap Part I (I ear who alid for 1 for 1	; or f first-line medications; or py is contraindicated.*. nterpretations and Defini- ere the treatment remains 1 month for applications month where the patient
Cap 250 mg		16	🖌 Hu	umatin S29
►SA1324 Special Authority for Subsidy Initial application only from an infectious disease specialist or clin has confirmed cryptosporidium infection. Renewal only from an infectious disease specialist or clinical m confirmed cryptosporidium infection.	0			
PYRIMETHAMINE – Special Authority see SA1328 on the next p	age – Retail pharmac	v		
Tab 25 mg		30	🖌 Da	araprim S29

	Subsidy (Manufacturer's Price) \$	Sul Per	Fully osidised	Brand or Generic Manufacturer
SA1328 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals val ne following criteria:	lid without further rene	ewal unles	s notifie	d for applications meeting
 any of the following: 1 For the treatment of toxoplasmosis in patients with HIV fo 2 For pregnant patients for the term of the pregnancy; or 3 For infants with congenital toxoplasmosis until 12 months 		; or		
SULFADIAZINE SODIUM - Special Authority see SA1331 below	w – Retail pharmacy			
Tab 500 mg	221.00	56	🗸 M	ockhardt S29
 nitial application from any relevant practitioner. Approvals value following criteria: (ny of the following: 1 For the treatment of toxoplasmosis in patients with HIV for 2 For pregnant patients for the term of the pregnancy; or 3 For infants with congenital toxoplasmosis until 12 months 	or a period of 3 months		s notifie	d for applications meeting
OBRAMYCIN		_	4 -	
Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and		5 Idorsed ad		BL Tobramycin ^{y.}
RIMETHOPRIM ₭ Tab 300 mg – Up to 30 tab available on a PSO	9.28	50	🗸 TI	MP
(ANCOMYCIN HYDROCHLORIDE – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient or for following metronidazole failure and the prescription is endor		arditis or	for treatn	nent of Clostridium difficile
Inj 500 mg	0,7	1	✓ <u>M</u>	ylan
Antifungals				
 For topical antifungals refer to DERMATOLOGICALS, page 66 For topical antifungals refer to GENITO URINARY, page 79 LUCONAZOLE 	6			
Cap 50 mg – Retail pharmacy-Specialist	4.77	28	🗸 0;	zole
Cap 150 mg - Subsidy by endorsement		1	✓ 0:	zole
 a) Maximum of 1 cap per prescription; can be waived by b) Patient has vaginal candida albicans and the practitio recommended and the prescription is endorsed accordin 	oner considers that a to	opical imi	dazole (ι	used intra-vaginally) is no
Cap 200 mg – Retail pharmacy-Specialist		28	✓ 0:	
	ty			

SA1359 Special Authority for Subsidy

Initial application — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Initial application — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

continued...

	Subsidy		Fully Brand	or
	(Manufacturer's F \$	rice) Sut Per	osidised Gener Manuf	ic acturer
continued				
All of the following:				
 Patient is immunocompromised; and Patient is at moderate to high risk of invasive fungal 	infection: and			
3 Patient is unable to swallow capsules.	inection, and			
Renewal — (Systemic candidiasis) from any relevant p	practitioner. Approvals	valid for 6 w	eeks for applic	ations meeting the
following criteria:				Ũ
Both:				
1 Patient requires prophylaxis for, or treatment of syste	emic candidiasis; and			
2 Patient is unable to swallow capsules. Renewal — (Immunocompromised) from any relevant p	aractitioner Approvale	valid for 6 m	onthe for annlie	ations meeting the
following criteria:	Jiacilionel. Appiovais		unis ior applic	allons meeting the
All of the following:				
1 Patient remains immunocompromised; and				
2 Patient remains at moderate to high risk of invasive f	ungal infection; and			
3 Patient is unable to swallow capsules.				
ITRACONAZOLE	0.00	45		
Cap 100 mg – Subsidy by endorsement Funded for tinea vesicolor where topical treatment ha		15 and diagnosis	✓ <u>Itrazole</u>	irmod by mycology
or for tinea unguium where terbinafine has not beer	as not been succession	tion or the nat	ient is intoleran	t to terbinafine and
diagnosis has been confirmed by mycology and the				
Retail pharmacy - Specialist Specialist must be an ir				
or dermatologist.				
Oral liq 10 mg per ml – Special Authority see SA1322		150		
- Retail pharmacy	141.80	150 ml OP	 Sporance 	X
► SA1322 Special Authority for Subsidy Initial application only from an infectious disease specialist	olinical microbiologiat	olinical immu	a alagiat ar apur	alovant prostitiona
on the recommendation of a infectious disease physician,				
months where the patient has a congenital immune deficier			manologist. 74	
Renewal from any relevant practitioner. Approvals valid for		reatment rema	ains appropriate	e and the patient is
benefitting from the treatment.				
KETOCONAZOLE				
Tab 200 mg – Retail pharmacy-Specialist		30	 Nizoral 	
Prescriptions must be written by, or on the recom	mendation of, an infec	tious disease	physician, clin	ical microbiologist
dermatologist, endocrinologist or oncologist				
NYSTATIN Tab 500.000 u	14.16	50	Nilstat	
Cap 500,000 u		50 50	✓ Nilstat	
		50	• Milotat	
POSACONAZOLE – Special Authority see SA1285 below – Oral liq 40 mg per ml		105 ml OP	Noxafil	
			• Hexam	
► SA1285 Special Authority for Subsidy	diagona anasialist Arr	rovolo volid f-	r 6 wooles for -	onligations mosting
Initial application only from a haematologist or infectious of the following criteria:	uisease specialist. App	iovais valid to	I O WEEKS TOP A	oplications meeting
Either:				
1 Patient has acute myeloid leukaemia and is to be tru	eated with high dose re	emission induc	ction, re-inducti	on or consolidatior

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*.

continued...

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (≥ 1 mg per kilogram of body weight per day for patients with acute GVHD or ≥ 0.8 mg per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

TERBINAFINE

 Tab 250 mg – For terbinafine oral liquid formulation refer, page 194	14	✓ <u>Dr Reddy's</u> <u>Terbinafine</u>
VORICONAZOLE – Special Authority see SA1273 below – Retail pharmacy		
Tab 50 mg730.00	56	Vfend
Tab 200 mg2,930.00	56	Vfend
Powder for oral suspension 40 mg per ml - Wastage		
claimable – see rule 3.3.2 on page 17	70 ml	Vfend

SA1273 Special Authority for Subsidy

Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient has proven or probable invasive aspergillus infection; or
 - 3.2 Patient has possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
 - 3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Antimalarials

98

PRIMAQUINE PHOSPHATE – Special Authority see SA1326 on the next page – Retail pharmacy

	Subsidy (Manufacturer's Price \$	e) Sul Per	Fully Brand or psidised Generic Manufacturer
►SA1326 Special Authority for Subsidy Initial application only from an infectious disease specialist or cli meeting the following criteria: Both:	nical microbiologist	. Approval	s valid for 1 month for applications
1 The patient has vivax or ovale malaria; and 2 Primaquine is to be given for a maximum of 21 days.			
Antiparasitics			
Antiprotozoals			
QUININE SULPHATE * Tab 300 mg ‡ Safety cap for extemporaneously compounded oral liquid		500	✔ Q 300
Antitrichomonal Agents			
METRONIDAZOLE Tab 200 mg – Up to 30 tab available on a PSO Tab 400 mg Oral liq benzoate 200 mg per 5 ml Suppos 500 mg		100 100 100 ml 10	 ✓ Trichozole ✓ Trichozole ✓ Flagyl-S ✓ Flagyl
ORNIDAZOLE			
Tab 500 mg		10	Arrow-Ornidazole
 Note: There is no co-payment charge for all pharmaceuticals list immigration status. CLOFAZIMINE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendati dermatologist. * Cap 50 mg 	on of, an infectious		
CYCLOSERINE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendati respiratory physician. Cap 250 mg		s disease p 100	ohysician, clinical microbiologist or
DAPSONE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendati dermatologist		s disease p	ohysician, clinical microbiologist or
Tab 25 mg Tab 100 mg		100 100	✓ Dapsone✓ Dapsone
ETHAMBUTOL HYDROCHLORIDE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendati		s disease r	
respiratory physician			-
Tab 100 mg Tab 400 mg		56 56	 Myambutol \$29 Myambutol \$29
1au +00 IIIg	43.04	50	

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
 SONIAZID – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation biologist, dermatologist or public health physician Tab 100 mg Tab 100 mg with rifampicin 150 mg 		100 100	✓ <u>P</u> ✓ R	<u>SM</u> ifinah
Tab 150 mg with rifampicin 300 mg	179.57	100	V R	ifinah
 ARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist a) No patient co-payment payable b) Specialist must be an infectious disease specialist, clinical Grans for oral liq 4 g sachet 	0	spiratory 30		aser S29
ROTIONAMIDE – Retail pharmacy-Specialist a) No patient co-payment payable b) Specialist must be an infectious disease specialist, clinical Tab 250 mg		spiratory 100	•	eteha S29
 YRAZINAMIDE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation respiratory physician Tab 500 mg – For pyrazinamide oral liquid formulation refer 	tion of, an infectious			
page 194		100	🗸 A	FT-Pyrazinamide
 IFABUTIN – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommenda gastroenterologist Cap 150 mg – For rifabutin oral liquid formulation refer, page 194 	•	diseas 30		n, respiratory physician o ycobutin
 IFAMPICIN – Subsidy by endorsement a) No patient co-payment payable b) For confirmed recurrent Staphylococcus aureus infection in based on susceptibilities and the prescription is endorsed a Specialist. Specialist must be an internal medicine physicia health physician. 	accordingly; can be	waived	by endorse	ment - Retail pharmacy
Tab 600 mg Cap 150 mg Cap 300 mg Oral liq 100 mg per 5 ml	58.66 122.36	30 100 100 60 ml	✓ R ✓ R	ifadin ifadin ifadin ifadin
Antivirals				
or eye preparations refer to Eye Preparations, Anti-Infective Pre	parations, page 188			

Hepatitis B Treatment

ADEFOVIR DIPIVOXIL - Special Authority see SA0829 on the r	next page – Retail pł	narmacy	
Tab 10 mg	670.00	30	 Hepsera

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

➡SA0829 Special Authority for Subsidy

Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine. defined as:
- 2 Patient has raised serum ALT (> 1 \times ULN); and
- 3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load \geq 10 fold over nadir; and
- 4 Detection of M204I or M204V mutation; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 Patient is cirrhotic; and
 - 5.1.2 adefovir dipivoxil to be used in combination with lamivudine; or
 - 5.2 Both:
 - 5.2.1 Patient is not cirrhotic; and
 - 5.2.2 adefovir dipivoxil to be used as monotherapy.

Renewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment.

Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as:

- i) raised serum ALT (> 1 \times ULN); and
- ii) HBV DNA greater than 100,000 copies per mL, or viral load \geq 10 fold over nadir; and
- iii) Detection of N236T or A181T/V mutation.

Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil.

The recommended dose of adefovir dipivoxil is no more than 10mg daily.

In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines. Adefovir dipivoxil should be avoided in pregnant women and children.

ENTECAVIR - Special Authority see SA1361 below - Retail pharmacy

Tab 0.5 mg	400.00	30	Baraclude
------------	--------	----	-----------

SA1361 Special Authority for Subsidy

Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and
- 3 Entecavir dose 0.5 mg/day; and
- 4 Either:
 - 4.1 ALT greater than upper limit of normal; or
 - 4.2 Bridging fibrosis (Metavir stage 3 or greater or moderate fibrosis) or cirrhosis on liver histology; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and
- 6 No continuing alcohol abuse or intravenous drug use; and
- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

Notes:

continued...

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

- Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4).
- Entecavir should be taken on an empty stomach to improve absorption.

LAMIVUDINE - Special Authority see SA1360 below - Retail pharmacy

Tab 100 mg	32.50	28	Zetlam
Oral liq 5 mg per ml	90.00	240 ml	 Zeffix

SA1360 Special Authority for Subsidy

Initial application only from a gastroenterologist, infectious disease specialist, paediatrician, general physician or medical practitioner on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 HBV DNA positive cirrhosis prior to liver transplantation; or
- 2 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
- 3 Hepatitis B virus naive patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or
- 4 Hepatitis B surface antigen (HbsAg) positive patient who is receiving chemotherapy for a malignancy, or high dose steroids (at least 20mg/day for at least 7 days), or who has received such treatment within the previous two months; or
- 5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or
- 6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).

Renewal only from a gastroenterologist, infectious disease specialist, paediatrician, general physician or medical practitioner on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

Renewal for patients who have maintained continuous treatment and response to lamivudine

- 1 All of the following:
 - 1.1 Have maintained continuous treatment with lamivudine; and
 - 1.2 Most recent test result shows continuing biochemical response (normal ALT); and
 - 1.3 HBV DNA <100,00 copies per ml by quantitative PCR at a reference laboratory; or
- Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine 2 All of the following:
 - 2.1 Lamivudine to be used in combination with adefovir dipivoxil; and
 - 2.2 Patient is cirrhotic; and
 - Documented resistance to lamivudine, defined as:
 - 2.3 Patient has raised serum ALT (> 1 \times ULN); and
 - 2.4 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
 - 2.5 Detection of M204I or M204V mutation; or
 - Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil
- 3 All of the following:
 - 3.1 Lamivudine to be used in combination with adefovir dipivoxil; and Documented resistance to adefovir, defined as:
 - 3.2 Patient has raised serum ALT (> 1 $\times\,$ ULN); and
 - 3.3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
 - 3.4 Detection of N236T or A181T/V mutation.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Herpesvirus Treatments				
ACICLOVIR				
* Tab dispersible 200 mg	1.78	25	V L	ovir
* Tab dispersible 400 mg	5.98	56	🖌 🗌	ovir
* Tab dispersible 800 mg	6.64	35	• L	ovir
VALACICLOVIR - Special Authority see SA1363 below - Retail ph	armacy			
Tab 500 mg	102.72	30	🖌 V	altrex
BACA1262 Encoded Authority for Subsidy				

SA1363 Special Authority for Subsidy

Initial application — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.

Renewal — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (ophthalmic zoster) from any medical practitioner. Approvals valid without further renewal unless notified where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.

Initial application — (CMV prophylaxis) from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation.

Initial application — (immunocompromised patients) from any medical practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patients is immunocompromised; and
- 2 Patient has herpes zoster; and
- 3 Valaciclovir is to be given for a maximum of 7 days per course.

VALGANCICLOVIR – Special Authority see SA1404 below – Retail pharmacy		
Tab 450 mg	60	(

SA1404 Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Renewal — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

- Both:
 - 1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
 - 2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin.

Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:

continued...

Valcvte

Subsidy (Manufacturer's Price)	Sul	Fully bsidised	Brand or Generic	
\$	Per	v	Manufacturer	

continued...

- 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
- 2.2 The recipient is cytomegalovirus positive.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Hepatitis B/ HIV/AIDS Treatment

TENOFOVIR DISOPROXIL FUMARATE – Subsidy by endorsement; can be waived by Special Authority see SA1362 below Endorsement for treatment of HIV: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1364 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Tenofovir disoproxil furnarate prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1364, page 106

SA1362 Special Authority for Waiver of Rule

Initial application — (Chronic Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased $\geq~$ 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV; or
- 3 Patient has decompensated cirrhosis with a Mayo score >20.

Initial application — (Pregnant, Active hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months for applications meeting the following criteria: Both:

1 Patient is HBsAg positive and pregnant; and

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

2 HBV DNA > 20,000 IU/mL and ALT > ULN.

Renewal — (Confirmed Hepatitis B following funded tenofovir treatment for pregnancy within the previous two years) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV.

Renewal — (Subsequent pregnancy or Breastfeeding, Active hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant or breastfeeding; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

Initial application — (Pregnant, prevention of vertical transmission) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Renewal — (Subsequent pregnancy, prevention of vertical transmission) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Notes:

- Tenofovir disoproxil fumarate should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg
 positive prior to commencing this agent and 6 months following HBsAg seroconversion for patients who were HBeAg negative
 prior to commencing this agent.
- The recommended dose of Tenofovir disoproxil fumarate for the treatment of all three indications is 300 mg once daily.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Tenofovir disoproxil fumarate dose should be reduced in accordance with the approved Medsafe datasheet guidelines.
- Tenofovir disoproxil fumarate is not approved for use in children.

Hepatitis C Treatment

BOCEPREVIR - Special Authority see SA1402 on the next page - Retail pharmacy

Cap 200 mg - Wastage claimable - see rule 3.3.2 on page

15.00 336

✓ Victrelis

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

SA1402 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, first-line) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has not received prior pegylated interferon treatment; and
- 3 Patient has IL-28B genotype CT or TT; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Patient is hepatitis C protease inhibitor treatment-naive; and
- 6 Maximum of 44 weeks therapy.

Initial application — (chronic hepatitis C - genotype 1, second-line) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has received pegylated interferon treatment; and
- 3 Any of the following:
 - 3.1 Patient was a responder relapser; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received pegylated interferon prior to 2004; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Maximum of 44 weeks therapy.

Notes:

• Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count < 100 x10⁹ /l or Albumin <35 g/l

• The wastage rule applies to boceprevir to allow dispensing to occur more frequently than monthly

Antiretrovirals

SA1364 Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 \times total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts $< 500 \text{ cells/mm}^3$.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

continued...

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

- Either:
 - 1 Prevention of maternal foetal transmission; or
 - 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

	Subsidy (Manufacturer's F \$	rice) Sub Per	Fully Brand or sidised Generic ✔ Manufacturer
Non-nucleosides Reverse Transcriptase Inhibito	ors		
EFAVIRENZ - Special Authority see SA1364 on page 106 - Reta	ail pharmacy		
Tab 50 mg		30	✓ Stocrin S29
Tab 200 mg		90	✓ Stocrin
Tab 600 mg		30	✓ Stocrin
Oral liq 30 mg per ml		180 ml OP	Stocrin S29
ETRAVIRINE – Special Authority see SA1364 on page 106 – Re Tab 200 mg		60	✓ Intelence
NEVIRAPINE - Special Authority see SA1364 on page 106 - Re	tail pharmacy		
Tab 200 mg - Brand switch fee payable (Pharmacode			
2433265) - see page 192 for details	95.94	60	✓ <u>Nevirapine</u> <u>Alphapharm</u>
Oral suspension 10 mg per ml		240 ml	✓ Viramune Suspension
Nucleosides Reverse Transcriptase Inhibitors			
ABACAVIR SULPHATE - Special Authority see SA1364 on page	106 – Retail pha	armacy	
Tab 300 mg		60	✓ <u>Ziagen</u>
Oral liq 20 mg per ml	50.00	240 ml OP	✓ <u>Ziagen</u>
ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authority Note: abacavir with lamivudine (combination tablets) counts retroviral Special Authority.			ions for the purposes of the anti-
Tab 600 mg with lamivudine 300 mg	630.00	30	Kivexa
DIDANOSINE [DDI] - Special Authority see SA1364 on page 106			
Cap 125 mg		30	Videx EC
Cap 200 mg		30	Videx EC
Cap 250 mg		30	Videx EC
Cap 400 mg		30	Videx EC
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPR – Retail pharmacy			
Note: Efavirenz with emtricitabine and tenofovir disoproxil furr of the anti-retroviral Special Authority		three anti-retro	wiral medications for the purposes
Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg		30	✓ Atripla
EMTRICITABINE – Special Authority see SA1364 on page 106 –		1	
Cap 200 mg		30	Emtriva
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE Note: Emtricitabine with tenofovir disoproxil fumarate counts retroviral Special Authority			
Tab 200 mg with tenofovir disoproxil fumarate 300 mg		30	🖌 Truvada
LAMIVUDINE – Special Authority see SA1364 on page 106 – Re Tab 150 mg		60	✓ Lamivudine
	150.00		Alphapharm
Oral liq 10 mg per ml	153.60 102.50	240 ml OP	✓ 3TC ✓ <u>3TC</u>

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer
TAVUDINE [D4T] – Special Authority see SA1364 on page 10	6 – Retail pharm	асу	
Cap 40 mg Powder for oral soln 1 mg per ml		60 200 ml OP	✓ Zerit ✓ Zerit S29
IDOVUDINE [AZT] – Special Authority see SA1364 on page 1			
Cap 100 mg Oral liq 10 mg per ml		100 200 ml OP	 ✓ <u>Retrovir</u> ✓ <u>Retrovir</u>
IDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority se Note: zidovudine [AZT] with lamivudine (combination tablets anti-retroviral Special Authority.	s) counts as two		,
Tab 300 mg with lamivudine 150 mg	667.20	60	 ✓ <u>Alphapharm</u> ✓ Combivir
Combivir Tab 300 mg with lamivudine 150 mg to be delisted 1 J	une 2014)		
Protease Inhibitors			
TAZANAVIR SULPHATE – Special Authority see SA1364 on p	•	pharmacy	
Cap 150 mg Cap 200 mg		60 60	 ✓ Reyataz ✓ Reyataz
ARUNAVIR - Special Authority see SA1364 on page 106 - Re		00	• Neyataz
Tab 400 mg	, ,	60	✓ Prezista
Tab 600 mg	1,190.00	60	Prezista
NDINAVIR – Special Authority see SA1364 on page 106 – Reta		000	
Cap 200 mg Cap 400 mg		360 180	 Crixivan Crixivan
OPINAVIR WITH RITONAVIR – Special Authority see SA1364	on page 106 - F	Retail pharmacy	
Tab 100 mg with ritonavir 25 mg		60	✓ Kaletra
Tab 200 mg with ritonavir 50 mg Oral liq 80 mg with ritonavir 20 mg per ml		120 300 ml OP	 ✓ Kaletra ✓ Kaletra
NTONAVIR – Special Authority see SA1364 on page 106 – Re			• Naletta
Tab 100 mg		30	✓ Norvir
Oral liq 80 mg per ml		90 ml OP	✓ Norvir
Strand Transfer Inhibitors			
ALTEGRAVIR POTASSIUM – Special Authority see SA1364 o Tab 400 mg		tail pharmacy 60	✓ Isentress
Antiretrovirals - Additional Therapies			
HIV Fusion Inhibitors			
NFUVIRTIDE – Special Authority see SA0845 on the next page Powder for inj 90 mg per ml \times 60		acy 1	✔ Fuzeon

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

➡SA0845 Special Authority for Subsidy

Initial application only from a named specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
 - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
 - 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
 - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
 - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
 - 5.3 Previous treatment with a protease inhibitor has failed.

Renewal only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 Evidence of at least a 10 fold reduction in viral load at 12; and
 - 2 The treatment remains appropriate and the patient is benefiting from treatment.

Immune Modulators

Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects.

Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

1) Diagnosis

- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.

Exclusion Criteria

- 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
- 2) Pregnancy.
- 3) Neutropenia (<2.0 \times 10⁹) and/or thrombocytopenia.
- 4) Continuing alcohol abuse and/or continuing intravenous drug users.

Dosage

The current recommended dosage is 3 million units of interferon alfa-2a or interferon alfa-2b administered subcutaneously 3 times a week for 52 weeks (twelve months)

Exit Criteria

The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

	Subsidy		Fully	Brand or
	(Manufacturer's Price)		Subsidised	Generic
	\$	Per	~	Manufacturer
INTERFERON ALFA-2A – PCT – Retail pharmacy-Specialist				
a) See prescribing guideline on the previous page				
b) Prescriptions must be written by, or on the recommendation	n of an internal medi	cino r	hvsician or	onhthalmologist
Inj 3 m iu prefilled svringe		1		Roferon-A
, , , ,		•	• •	Roferon-A
Inj 6 m iu prefilled syringe		1	• •	
Inj 9 m iu prefilled syringe		1	v F	Roferon-A
(Roferon-A Inj 6 m iu prefilled syringe to be delisted 1 February 2				
(Roferon-A Inj 9 m iu prefilled syringe to be delisted 1 February 2	014)			
INTERFERON ALFA-2B – PCT – Retail pharmacy-Specialist				
a) See prescribing guideline on the previous page				
b) Prescriptions must be written by, or on the recommendation	n of an internal medi	cine r	hvsician or	onhthalmologist
Inj 18 m iu, 1.2 ml multidose pen		1		ntron-A
Inj 30 m iu, 1.2 ml multidose pen		1	• •	ntron-A
		1	• •	ntron-A
Inj 60 m iu, 1.2 ml multidose pen	020.40	1	V 1	ntron-A
PEGYLATED INTERFERON ALFA-2A - Special Authority see SA	A1400 below – Retail	pharr	nacy	
See prescribing guideline on the previous page				
Inj 135 mcg prefilled syringe	1,448.00	4	🖌 F	Pegasys
Inj 180 mcg prefilled syringe		4	🖌 🗸 F	Pegasys
Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 mg \times			-	• •
112		1 OP		egasys RBV
112	1,700.00	101	• 1	Combination Pack
Inj 135 mcg prefilled syringe $ imes$ 4 with ribavirin tab 200 mg $ imes$				COMDITIATION FACK
168		1 OP		Degeove BBV
100	1,975.00	I UF	• -	Pegasys RBV Combination Pack
lai 100 menu musfillad avrinana v 4 with ribeviria tab 000 menu				Combination Pack
Inj 180 mcg prefilled syringe \times 4 with ribavirin tab 200 mg \times		4 00		
112	1,159.84	1 OP	v <u>F</u>	Pegasys RBV
				Combination Pack
Inj 180 mcg prefilled syringe $ imes$ 4 with ribavirin tab 200 mg $ imes$				
168	1,290.00	1 OP	✓ <u>F</u>	Pegasys RBV
				Combination Pack

SA1400 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
 - 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and
- 2 Maximum of 48 weeks therapy.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Renewal — (Chronic hepatitis C - genotype 1 infection) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	

continued...

- 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

- Approved dose is 180 mcg once weekly.
- The recommended dose of Pegylated Interferon-alfa 2a is 180 mcg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alfa 2a dose should be reduced to 135 mcg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alfa 2a is not approved for use in children.

Urinary Tract Infections

HEXAMINE HIPPURATE

*	Tab 1 g	100	
	(38.10)		Hiprex

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
NITROFURANTOIN				
* Tab 50 mg - For nitrofurantoin oral liquid formulation refer,				
page 194		100	~ 1	lifuran
* Tab 100 mg		100	~ 1	lifuran
NORFLOXACIN				
Tab 400 mg - Maximum of 6 tab per prescription; can be				
waived by endorsement - Retail pharmacy - Specialist		100	V <u>I</u>	Arrow-Norfloxacin

MUSCULOSKELETAL SYSTEM

	Subsidy	、 · ·	Fully	
	(Manufacturer's Price \$		Subsidised	
	ð	Per		Manufacturer
Anticholinesterases				
Antichonnesterases				
EOSTIGMINE METILSULFATE				
Inj 2.5 mg per ml, 1 ml ampoule	140.00	50	1	AstraZeneca
	140.00	50	•	ASIIaZeneca
YRIDOSTIGMINE BROMIDE				
Tab 60 mg		100	/	<u>Mestinon</u>
Non-Steroidal Anti-Inflammatory Drugs				
Non-Steroidal Anti-Innaninatory Drugs				
SA1038 Special Authority for Manufacturers Price				
bte: Subsidy for patients with existing approvals prior to 1 Septem	her 2010 Approva	s valid w	ithout fur	ther renewal unless notif
p new approvals will be granted from 1 September 2010.		o valia w	iniout iui	
CLOFENAC SODIUM Tab EC 25 mg				
	4.00	100	V	Apo-Diclo
Tab 50 mg dispersible – Additional subsidy by Special Au-				
thority see SA1038 above – Retail pharmacy	1.50	20		
	(8.00)		١	Voltaren D
Tab EC 50 mg		500	~	Apo-Diclo
Tab long-acting 75 mg	24.52	500	~	Diclax SR
Tab long-acting 100 mg		500	~	Diclax SR
Inj 25 mg per ml, 3 ml		5	-	Voltaren
Up to 5 inj available on a PSO		Ũ	• -	<u>vontaron</u>
Suppos 12.5 mg	1.85	10	~	Voltaren
		10	-	Voltaren
- · · · · · · · · · · · · · · · · · · ·				
		10	V _	Voltaren
Up to 10 supp available on a PSO Suppos 100 mg	0.00	40		1-11
Suppos 100 mg		10	V	Voltaren
UPROFEN				
Tab 200 mg		1,000	~	Arrowcare
Tab 400 mg - Additional subsidy by Special Authority see		,		
SA1038 above – Retail pharmacy	0 77	30		
	(4.56)	00	r	Brufen
Tab COO man Additional subside by Onasial Arthouity as	(4.50)			Diuleii
Tab 600 mg – Additional subsidy by Special Authority see	4.45			
SA1038 above – Retail pharmacy		30		_ /
	(6.84)			Brufen
Tab long-acting 800 mg		30		Brufen SR
t Oral liq 20 mg per ml	2.69	200 ml	~	Fenpaed
TOPROFEN				
Cap long-acting 100 mg	21.56	100	~	Oruvail SR
Cap long-acting 200 mg		100		Oruvail SR
EFENAMIC ACID – Additional subsidy by Special Authority see			irmacy	
Cap 250 mg		20		
	(5.60)		I	Ponstan
	1.25	50		
	(9.16)		I	Ponstan
APROXEN				
-	01.05	500		Noflam 250
Tab 250 mg		500		
Tab 500 mg		250		Noflam 500
Tab long-acting 750 mg		90 90		Naprosyn SR 750 Naprosyn SR 1000
Tab long-acting 1,000 mg				

	Subsidy (Manufacturer's Pric	e) Si	,	brand or Generic
	\$	Per	🖌 N	lanufacturer
ULINDAC - Additional subsidy by Special Authority see S	SA1038 on the previous p	age – Reta	ail pharmacy	
← Tab 100 mg	2.66	50		
	(8.55)		Aclir	1
 Tab 200 mg 		50		
	(15.10)		Aclir	1
ENOXICAM				
 Tab 20 mg 		100	 Tilco 	
Inj 20 mg vial		1	🖌 AFT	
IAPROFENIC ACID				
 Tab 300 mg 		60	🗸 Surg	gam
NSAIDs Other				
IELOXICAM – Special Authority see SA1034 below – Ret	ail pharmacy			
• Tab 7.5 mg	11.50	30	🖌 Arro	w-Meloxicam
SA1034 Special Authority for Subsidy				
itial application from any relevant practitioner. Approval	Is valid without further re	newal unle	ss notified f	or applications meeting
e following criteria:				
II of the following:				
 The patient has moderate to severe haemophilia with and 	n less than or equal to 5%	or normal	circulating f	unctional clotting facto
and				
 2 The patient has haemophilic arthropathy; and 3 Pain and inflammation associated with haemophilic 	arthronathy is inadequat	elv control	led by alter	nativo fundod troatme
3 Pain and inflammation associated with haemophilic		ely control	led by alterr	native funded treatme
3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of	contraindicated.	ely control	led by alterr	native funded treatme
3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of	contraindicated.	ely control	led by alterr	native funded treatme
3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pai	contraindicated.	ely control	led by alterr	native funded treatme
3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pai APSAICIN Crm 0.025% – Special Authority see SA1289 below –	contraindicated. in Retail	ely control	led by alterr	native funded treatme
3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pai APSAICIN	contraindicated. in Retail	ely control 45 g OP	led by alterr	
3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pai APSAICIN Crm 0.025% – Special Authority see SA1289 below – pharmacy	contraindicated. in Retail			
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pai APSAICIN Crm 0.025% - Special Authority see SA1289 below - pharmacy →SA1289 Special Authority for Subsidy 	contraindicated. In Retail 9.95	45 g OP	✔ Zost	rix
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pail APSAICIN Crm 0.025% - Special Authority see SA1289 below - pharmacy →SA1289 Special Authority for Subsidy hitial application from any relevant practitioner. Approva 	contraindicated. In Retail 9.95 als valid without further r	45 g OP enewal un	✓ Zost	r ix where the patient h
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of the second se	contraindicated. In Retail 9.95 als valid without further r	45 g OP enewal un	✓ Zost	r ix where the patient h
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pail APSAICIN Crm 0.025% - Special Authority see SA1289 below - pharmacy →SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvasteoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents 	contraindicated. In Retail 9.95 als valid without further r	45 g OP enewal un	✓ Zost	r ix where the patient h
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Paint APSAICIN Crm 0.025% – Special Authority see SA1289 below – pharmacy SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvasteoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN 	contraindicated. In Retail 9.95 als valid without further r I non-steroidal anti-inflam	45 g OP enewal un matories a	✓ Zost less notified re contraind	r ix where the patient h icated.
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pail APSAICIN Crm 0.025% - Special Authority see SA1289 below - pharmacy →SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvasteoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents 	contraindicated. In Retail 9.95 als valid without further r I non-steroidal anti-inflam	45 g OP enewal un	✓ Zost less notified re contraind	r ix where the patient h
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of copical Products for Joint and Muscular Paint APSAICIN Crm 0.025% - Special Authority see SA1289 below - pharmacy →SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvateoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN Tab 3 mg YDROXYCHLOROQUINE 	contraindicated. in Retail9.95 als valid without further r I non-steroidal anti-inflam68.99	45 g OP enewal un matories a	Zost less notified re contraind Kida	where the patient h icated. nura s29 529
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Paint APSAICIN Crm 0.025% – Special Authority see SA1289 below – pharmacy ⇒SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvate stee arthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN Tab 3 mg YDROXYCHLOROQUINE 	contraindicated. in Retail9.95 als valid without further r I non-steroidal anti-inflam68.99	45 g OP enewal un matories a	✓ Zost less notified re contraind	where the patient h icated. nura s29 529
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pal APSAICIN Crm 0.025% – Special Authority see SA1289 below – pharmacy ⇒SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvasteoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN Tab 3 mg YDROXYCHLOROQUINE Tab 200 mg 	contraindicated. in Retail9.95 als valid without further r I non-steroidal anti-inflam68.99	45 g OP enewal un matories a 60	Zost less notified re contraind Kida	where the patient h icated. nura s29 529
3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pa APSAICIN Crm 0.025% – Special Authority see SA1289 below – pharmacy SA1289 Special Authority for Subsidy hitial application from any relevant practitioner. Approva steoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN Tab 3 mg YDROXYCHLOROQUINE Tab 200 mg 	contraindicated. In Retail9.95 als valid without further r I non-steroidal anti-inflam68.99	45 g OP enewal un matories a 60	Zost less notified re contraind Kida	trix where the patient h icated. nura s29 529 uuenil
3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pai APSAICIN Crm 0.025% – Special Authority see SA1289 below – pharmacy Description Subsidy Ditial application from any relevant practitioner. Approva steoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN Tab 3 mg YDROXYCHLOROQUINE F Tab 200 mg EFLUNOMIDE	contraindicated. In Retail9.95 als valid without further r I non-steroidal anti-inflam68.9968.00	45 g OP enewal un matories a 60 100	✓ Zost less notified re contraind ✓ Rida ✓ <u>Plac</u>	trix where the patient h icated. nura s29 s29 uenil
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pail APSAICIN Crm 0.025% – Special Authority see SA1289 below – pharmacy SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvasteoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN	contraindicated. In Retail9.95 als valid without further r I non-steroidal anti-inflam68.9968.90	45 g OP enewal un matories a 60 100 30	✓ Zost less notified re contraind ✓ Rida ✓ <u>Plaq</u> ✓ Arav	trix where the patient h icated. nura s29 s29 uenil uenil va
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Paint APSAICIN APSAICIN Crm 0.025% - Special Authority see SA1289 below - pharmacy SA1289 Special Authority for Subsidy bitial application from any relevant practitioner. Approvasteoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN Tab 3 mg YDROXYCHLOROQUINE Tab 10 mg Tab 100 mg 	contraindicated. In Retail9.95 als valid without further r I non-steroidal anti-inflam68.9968.90	45 g OP enewal un matories a 60 100 30 30	✓ Zost less notified re contraind ✓ Rida ✓ Plaq ✓ Arav ✓ Arav	trix where the patient h icated. nura s29 s29 uenil uenil va
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Paint (APSAICIN) APSA1289 Special Authority see SA1289 below – pharmacy ⇒SA1289 Special Authority for Subsidy and inflammation from any relevant practitioner. Approvasteoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN Tab 3 mg IVDROXYCHLOROQUINE Tab 200 mg EFLUNOMIDE Tab 100 mg Tab 100 mg 	contraindicated. In Retail9.95 als valid without further r I non-steroidal anti-inflam68.9968.99	45 g OP enewal un matories a 60 100 30 30	✓ Zost less notified re contraind ✓ Rida ✓ Plaq ✓ Arav ✓ Arav ✓ Arav	trix where the patient h icated. nura s29 s29 uenil uenil va
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pail APSAICIN Crm 0.025% – Special Authority see SA1289 below – pharmacy Description from any relevant practitioner. Approvasteoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN Tab 20 mg Tab 20 mg Tab 10 mg Tab 10 mg ENICILLAMINE 	contraindicated. Retail9.95 als valid without further r I non-steroidal anti-inflam68.9968.9968.00	45 g OP enewal un matories a 60 100 30 30 30 3	Zost less notified re contraind Rida <u>Plaq</u> Arav Arav Arav Arav Arav	trix where the patient h icated. nura s29 s29 uenil uenil va va
3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% – Special Authority see SA1289 below – pharmacy	contraindicated. Retail9.95 als valid without further r I non-steroidal anti-inflam68.9968.9968.00	45 g OP enewal un matories a 60 100 30 30 30 3 3 100	Zost less notified re contraind Rida <u>Plaq</u> Arav Arav Arav Arav Arav	trix where the patient h icated. nura s29 s29 uenil va va va va
 3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pail CAPSAICIN Crm 0.025% - Special Authority see SA1289 below - pharmacy SA1289 Special Authority for Subsidy Dital application from any relevant practitioner. Approvasteoarthritis that is not responsive to paracetamol and oral Antirheumatoid Agents URANOFIN	contraindicated. In Retail 	45 g OP enewal un matories a 60 100 30 30 30 3 3 100	Zost less notified re contraind Rida <u>Plaq</u> Arav Arav Arav Arav Arav	trix where the patient h icated. uura s29 529 uuenil va va enamine enamine
3 Pain and inflammation associated with haemophilic options, or alternative funded treatment options are of Topical Products for Joint and Muscular Pain CAPSAICIN Crm 0.025% – Special Authority see SA1289 below – pharmacy	contraindicated. In Retail9.95 als valid without further r I non-steroidal anti-inflam68.9968.9968.00	45 g OP enewal un matories a 60 100 30 30 30 3 3 100 100	Zost less notified re contraind Rida Plaq Arav Arav Arav Arav D-Pe D-Pe	trix where the patient h icated. nura s29 s29 uenil va va va enamine enamine crisin crisin

MUSCULOSKELETAL SYSTEM

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	Subsidised	Generic
\$	Per	~	Manufacturer

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

SA1039 Special Authority for Subsidy

Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or raloxifene.

Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause glucocorticosteroid therapy) or raloxifene.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents).

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene.

Notes:

a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

continued...

MUSCULOSKELETAL SYSTEM

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- b) Evidence suggests patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM – Special Authority see SA1039 on the previous page – Retail pharmacy

*	Tab 70 mg		4	🖌 Fosamax
---	-----------	--	---	-----------

AL	ENDRONATE SODIUM WITH CHOLECALCIFEROL	- Special Authority see SA10	39 on th	ne previous page – Retail pharmacy
*	Tab 70 mg with cholecalciferol 5,600 iu	22.90	4	Fosamax Plus

Alendronate for Paget's Disease

SA0949 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
 - 2.5 Preparation for orthopaedic surgery.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

ALE	ALENDRONATE SODIUM – Special Authority see SA0949 above – Retail pharmacy					
*	Tab 40 mg		30	Fosamax		
0						

Other Treatments

ETIDRONATE DISODIUM – See prescribing guideline below

* Tab 200 mg15.80

Prescribing Guidelines

Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water.

PAMIDRONATE D	ISODIUM
---------------	---------

Inj 3 mg per ml, 5 ml		1	Pamisol
Inj 3 mg per ml, 10 ml		1	Pamidronate BNM
Inj 6 mg per ml, 10 ml		1	Pamidronate BNM
Inj 9 mg per ml, 10 ml		1	Pamidronate BNM
RALOXIFENE HYDROCHLORIDE - Special Authority see SA1	138 on the next pag	e – Retail	pharmacy
* Tab 60 mg	53.76	28	🖌 Evista

100

Arrow-Etidronate

Subsidy		Fully	Brand or
(Manufacturer's Price)	Su	ubsidised	Generic
\$	Per	~	Manufacturer

SA1138 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Any of the following:
 - 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Notes); or
 - 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 4 Documented T-Score \leq -3.0 (see Notes); or
 - 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
 - 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or alendronate (Underlying cause Osteoporosis).

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score \leq -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

RISEDRONATE SODIUM

Tab 35 mg4.00	4	 Risedronate Sandoz
TERIPARATIDE – Special Authority see SA1139 below – Retail pharmacy		
Inj 250 mcg per ml, 2.4 ml	1	✓ Forteo

➡SA1139 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

continued...

MUSCULOSKELETAL SYSTEM

Aclasta

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID – Special Authority see SA1187 below – Retail pharmacy	
Soln for infusion 5 mg in 100 ml	100 ml OP

SA1187 Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score $\leq~$ -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) or raloxifene; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

continued...

119

Subsidy	Fully	Brand or	_
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is continuing systemic glucocorticosteriod therapy (\geq 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Hyperuricaemia and Antigout

ALLOPURINOL			
* Tab 100 mg	15.90	1,000	Apo-Allopurinol
* Tab 300 mg - For allopurinol oral liquid formulation refer	,		
page 194	16.75	500	Apo-Allopurinol

MUSCULOSKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
BENZBROMARONE – Special Authority see SA1319 below – F Tab 100 mg	, ,	100	✔ В	enzbromaron AL 100 629

➡SA1319 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or
 - 1.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or
 - 1.3 Both:
 - 1.3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
 - 1.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
 - 1.4 All of the following:
 - 1.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
 - 1.4.2 Allopurinol is contraindicated; and
 - 1.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
- 2 The patient is receiving monthly liver function tests.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefitting from the treatment; and
- 2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity.

Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at http://www.rheumatology.org.nz/benzbromarone_prescriber_information.cfm

COLCHICINE * Tab 500 mcg	8 100	✓ <u>Colgout</u>
PROBENECID	0 100	
* Tab 500 mg55.0	0 100	Probenecid-AFT
Muscle Relaxants		
BACLOFEN		
* Tab 10 mg – For baclofen oral liquid formulation refer, page		
194	5 100	Pacifen
DANTROLENE		
* Cap 25 mg65.0		Dantrium
* Cap 50 mg	0 100	Dantrium
ORPHENADRINE CITRATE		
Tab 100 mg18.5	4 100	✓ Norflex

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
Agents for Parkinsonism and Related Disorder	S		
Dopamine Agonists and Related Agents			
AMANTADINE HYDROCHLORIDE			
▲ Cap 100 mg		60	Symmetrel
APOMORPHINE HYDROCHLORIDE			
Inj 10 mg per ml, 2 ml	110.00	5	Apomine
BROMOCRIPTINE MESYLATE			
₭ Tab 2.5 mg		100	Apo-Bromocriptine
* Cap 5 mg	60.43	100	Apo-Bromocriptine
INTACAPONE			
▲ Tab 200 mg	47 92	100	✓ Entapone
5		100	
EVODOPA WITH BENSERAZIDE	40.00	100	
* Tab dispersible 50 mg with benserazide 12.5 mg		100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg		100	Madopar 62.5
Cap 100 mg with benserazide 25 mg		100	✓ Madopar 125
Cap long-acting 100 mg with benserazide 25 mg		100 100	✓ Madopar HBS
Cap 200 mg with benserazide 50 mg	25.00	100	 Madopar 250
EVODOPA WITH CARBIDOPA			
* Tab 100 mg with carbidopa 25 mg – For levodopa with ca			
bidopa oral liquid formulation refer, page 194	10.00	50	Sindopa
	20.00	100	Sinemet
* Tab long-acting 200 mg with carbidopa 50 mg		100	 Sinemet CR
* Tab 250 mg with carbidopa 25 mg	40.00	100	 Sinemet
ISURIDE HYDROGEN MALEATE			
Tab 200 mcg		30	Dopergin
ERGOLIDE			
Tab 0.25 mg	48.00	100	Permax
Tab 1 mg		100	✓ Permax
•		100	
RAMIPEXOLE HYDROCHLORIDE	7.00	~~	
Tab 1 mg	7.20	30	✓ Dr Reddy's
			Pramipexole
Tel: 0.405 mm	24.39	100	Ramipex S29
Tab 0.125 mg	1.95	30	✓ Dr Reddy's
			Pramipexole
Tab 0.25 mg	2.40	30	✓ Dr Reddy's
			Pramipexole
	7.20	100	Ramipex S29
Tab 0.5 mg	4.20	30	✓ Dr Reddy's
			Pramipexole

	Subsidy (Manufacturer's Price) \$	Per	Ful Subsidise	
ROPINIROLE HYDROCHLORIDE				
Tab 0.25 mg	2.36	100	~	Apo-Ropinirole
·	6.20	84		Ropin
Tab 1 mg	5.32	100	~	Apo-Ropinirole
	15.95	84	~	' Ropin
Tab 2 mg	7.72	100	~	' Apo-Ropinirole
	24.95	84	~	' Ropin
Tab 5 mg	14.48	100	~	Apo-Ropinirole
	38.00	84	~	' Ropin
SELEGILINE HYDROCHLORIDE				
* Tab 5 mg		100	~	Apo-Selegiline
				Apo-Selegiline
			•	S29 S29
				OLJOLO
TOLCAPONE				
▲ Tab 100 mg		100	~	<u>Tasmar</u>
Anticholinergics				
BENZTROPINE MESYLATE				
Tab 2 mg	7 99	60	~	Benztrop
Inj 1 mg per ml, 2 ml		5		Cogentin
a) Up to 5 inj available on a PSO		Ũ	•	oogonan
b) Only on a PSO				
ORPHENADRINE HYDROCHLORIDE				
	25.15	250		Disinal
Tab 50 mg		200	V	' Disipal
PROCYCLIDINE HYDROCHLORIDE				
Tab 5 mg	7.40	100	~	' Kemadrin
Agents for Essential Tremor, Chorea and Relate	d Disorders			
RILUZOLE – Special Authority see SA1403 below – Retail pharr	macy			
Wastage claimable – see rule 3.3.2 on page 17	nacy			
Tab 50 mg	400.00	56	~	' Rilutek
1ab 00 mg		50	•	Index

➡SA1403 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
 - 5.1 The patient is ambulatory; or
 - 5.2 The patient is able to use upper limbs; or
 - 5.3 The patient is able to swallow.

Renewal from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and

continued...

NERVOUS SYSTEM

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
ontinued				
3 Any of the following:				
3.1 The patient is ambulatory; or				
3.2 The patient is able to use upper limbs; or3.3 The patient is able to swallow.				
ETRABENAZINE				
Tab 25 mg	118.00	112	V N	lotetis
Anaesthetics			• <u> </u>	
Local				
DOCAINE [LIGNOCAINE]				
Gel 2%, 10 ml urethral syringe – Subsidy by endorsement a) Up to 5 each available on a PSO	43.26	10	🗸 P	fizer
b) Subsidised only if prescribed for urethral or cervical adm	ninistration and the p	orescri	ption is endo	orsed accordingly.
DOCAINE [LIGNOCAINE] HYDROCHLORIDE				
Viscous soln 2%		200 m		vlocaine Viscous
Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO		25	✓ L	idocaine-Claris
	17.50	50	V	Steader.
Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO	(35.00)	25		ylocaine idocaine-Claris
Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO		25 1		idocaine-Claris
	12.00	5	• -	
	(20.00)	Ŭ	х	vlocaine
Inj 2%, 20 ml ampoule - Up to 5 inj available on a PSO	· /	1		idocaine-Claris
DOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE				
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes -				
Subsidy by endorsement		10	🖌 P	fizer
a) Up to 5 each available on a PSO				
b) Subsidised only if prescribed for urethral or cervical adm	ninistration and the p	orescri	ption is ende	orsed accordingly.
DOCAINE [LIGNOCAINE] WITH PRILOCAINE - Special Author	ority see SA0906 bel	ow – F	Retail pharm	acy
Crm 2.5% with prilocaine 2.5%		30 g O		
Crm 2.5% with prilocaine 2.5% (5 g tubes)	45.00	5	🖌 E	MLA
SA0906 Special Authority for Subsidy				
itial application from any relevant practitioner. Approvals valid	d for 2 years where	the pa	atient is a ch	hild with a chronic med
ndition requiring frequent injections or venepuncture.				
enewal from any relevant practitioner. Approvals valid for 2 ye	ars where the treat	ment r	emains app	propriate and the patier
enefiting from treatment.				
Analgesics				
r Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, pa	ao 11/			

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 114

Non-opioid Analgesics

AS	PIRIN			
*	Tab EC 300 mg	2.00	100	
	-	(8.10)		Aspec 300
*	Tab dispersible 300 mg - Up to 30 tab available on a PSO	2.00	100	 Ethics Aspirin

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or osidised Generic Manufacturer
CAPSAICIN – Subsidy by endorsement a) For aspirin & chloroform application refer, page 197 b) Subsidised only if prescribed for post-herpetic neuralgia o accordingly.	r diabetic periph	eral neuropath	y and the prescription is endorsed
Crm 0.075%	12.50	45 g OP	✓ Zostrix HP
NEFOPAM HYDROCHLORIDE Tab 30 mg		90	✓ Acupan
PARACETAMOL			
* Tab 500 mg – Up to 30 tab available on a PSO	9.38	1,000	✓ Parafast
*‡ Oral liq 120 mg per 5 ml	2.21	500 ml	 Ethics Paracetamol
a) Up to 200 ml available on a PSO b) Not in combination			
*‡ Oral liq 250 mg per 5 ml	6.70	1,000 ml	 Paracare Double Strength
a) Up to 100 ml available on a PSO			ottengui
b) Not in combination			
* Suppos 125 mg		20	Panadol
* Suppos 250 mg		20	✓ Panadol
* Suppos 500 mg	20.70	50	✓ Paracare
Opioid Analgesics			
CODEINE PHOSPHATE - Safety medicine; prescriber may dete	rmine dispensin	g frequency	
Tab 15 mg		100	✓ <u>PSM</u>
Tab 30 mg		100	✓ <u>PSM</u>
Tab 60 mg	12.50	100	✓ PSM
DIHYDROCODEINE TARTRATE			
Tab long-acting 60 mg	13.64	60	DHC Continus
FENTANYL			
a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing free		10	A Develop and Main
Inj 50 mcg per ml, 2 ml Inj 50 mcg per ml, 10 ml		10 10	 Boucher and Muir Boucher and Muir
Transdermal patch 12.5 mcg per hour		5	Mylan Fentanyl
nansuermai pateri 12.5 meg per nour	0.00	5	Patch
Transdermal patch 25 mcg per hour	9.15	5	✓ Mylan Fentanyl Patch
Transdermal patch 50 mcg per hour	11.50	5	✓ Mylan Fentanyl Patch
Transdermal patch 75 mcg per hour		5	 Mylan Fentanyl
Transdermal patch 100 mcg per hour	14.50	5	Patch ✔ Mylan Fentanyl Patch

		Subsidy		Fully	
		(Manufacturer's F \$	Price) Su Per	bsidised ✓	Generic Manufacturer
ETH	ADONE HYDROCHLORIDE				
	Only on a controlled drug form				
	No patient co-payment payable				
	Safety medicine; prescriber may determine dispensing free	auencv			
	Extemporaneously compounded methadone will only be r		arate of the ch	neapest	form available (methad
	owder, not methadone tablets).				
e)	For methadone hydrochloride oral liquid refer, page 197				
	ab 5 mg	1.85	10	~ 1	Vethatabs
0	ral liq 2 mg per ml	5.55	200 ml	/ E	Biodone
0	ral liq 5 mg per ml	5.55	200 ml	<i>L L</i>	Biodone Forte
0	ral liq 10 mg per ml	6.55	200 ml	 Image: A second s	Biodone Extra Forte
In	j 10 mg per ml, 1 ml	61.00	10	V	AFT
ORF	PHINE HYDROCHLORIDE				
-	Only on a controlled drug form				
	No patient co-payment payable				
	Safety medicine; prescriber may determine dispensing free	quency			
	ral lig 1 mg per ml		200 ml	🖌 F	RA-Morph
	ral lig 2 mg per ml		200 ml	-	RA-Morph
0	ral lig 5 mg per ml	14.65	200 ml		RA-Morph
0	ral liq 10 mg per ml	21.55	200 ml	/	RA-Morph
	PHINE SULPHATE				
-	Only on a controlled drug form				
,	No patient co-payment payable				
	Safety medicine; prescriber may determine dispensing free	nuency			
	ab immediate-release 10 mg		10	~ 5	Sevredol
	ab long-acting 10 mg		10		Arrow-Morphine LA
	ab immediate-release 20 mg			• •	
Ta		5.52	10	v 9	Sevredol
			10 10		Sevredol Arrow-Morphine LA
Ta	ab long-acting 30 mg	2.98	10 10 10	V [Arrow-Morphine LA
Ta Ta	ab long-acting 30 mgab long-acting 60 mg	2.98 5.75	10		Arrow-Morphine LA Arrow-Morphine LA
Ta Ta Ta	ab long-acting 30 mgab long-acting 60 mgab long-acting 60 mgab long-acting 100 mg	2.98 5.75 6.45	10 10		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA
Ta Ta Ta Ca	ab long-acting 30 mgab long-acting 60 mgab long-acting 100 mgab long-acting 10 mgap long-acting 10 mg	2.98 5.75 6.45 1.70	10 10 10		Arrow-Morphine LA Arrow-Morphine LA
Ta Ta Ca Ca	ab long-acting 30 mgab long-acting 60 mgab long-acting 100 mgab long-acting 10 mgap long-acting 10 mgap long-acting 30 mg	2.98 5.75 6.45 1.70 2.50	10 10 10 10		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA n-Eslon
Ta Ta Ca Ca	ab long-acting 30 mg ab long-acting 60 mg ab long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg	2.98 5.75 6.45 1.70 2.50 5.40	10 10 10 10 10		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA n-Eslon n-Eslon
Ta Ta Ca Ca Ca	ab long-acting 30 mg ab long-acting 60 mg ab long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 100 mg	2.98 6.45 	10 10 10 10 10 10		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA m-Eslon n-Eslon n-Eslon
Ta Ta Ca Ca Ca	ab long-acting 30 mg ab long-acting 60 mg ab long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg	2.98 6.45 	10 10 10 10 10 10 10		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA m-Eslon n-Eslon n-Eslon n-Eslon
Ta Ta Ci Ci Ci Ci In	ab long-acting 30 mg ab long-acting 60 mg ab long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 100 mg		10 10 10 10 10 10 10		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA m-Eslon m-Eslon m-Eslon m-Eslon DBL Morphine
Ta Ta Ci Ci Ci Ci In	ab long-acting 30 mg ab long-acting 60 mg ab long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 100 mg j 5 mg per ml, 1 ml – Up to 5 inj available on a PSO		10 10 10 10 10 10 10 5		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA m-Eslon m-Eslon m-Eslon m-Eslon DBL Morphine Sulphate
Ta Ta Ci Ci Ci Ci In	ab long-acting 30 mg ab long-acting 60 mg ab long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 100 mg j 5 mg per ml, 1 ml – Up to 5 inj available on a PSO		10 10 10 10 10 10 10 5		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA m-Eslon m-Eslon m-Eslon m-Eslon DBL Morphine Sulphate DBL Morphine
Ta Ta Ci Ci Ci Ci In	ab long-acting 30 mg ab long-acting 60 mg ab long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 60 mg j 5 mg per ml, 1 ml – Up to 5 inj available on a PSO j 10 mg per ml, 1 ml – Up to 5 inj available on a PSO		10 10 10 10 10 10 10 5 5		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA m-Eslon m-Eslon m-Eslon DBL Morphine Sulphate DBL Morphine Sulphate Sulphate
Ta Ta Ci Ci Ci Ci Ci In In	ab long-acting 30 mg ab long-acting 60 mg ab long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 60 mg j 5 mg per ml, 1 ml – Up to 5 inj available on a PSO j 10 mg per ml, 1 ml – Up to 5 inj available on a PSO		10 10 10 10 10 10 10 5 5		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA m-Eslon m-Eslon m-Eslon DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine
Ta Ta Ci Ci Ci Ci Ci In In	ab long-acting 30 mg ab long-acting 60 mg ap long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 100 mg j 5 mg per ml, 1 ml – Up to 5 inj available on a PSO j 10 mg per ml, 1 ml – Up to 5 inj available on a PSO j 15 mg per ml, 1 ml – Up to 5 inj available on a PSO		10 10 10 10 10 10 5 5 5		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA n-Eslon n-Eslon m-Eslon DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate
Ta Ta Ci Ci Ci Ci Ci In In In	ab long-acting 30 mg ab long-acting 60 mg ap long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 100 mg j 5 mg per ml, 1 ml – Up to 5 inj available on a PSO j 10 mg per ml, 1 ml – Up to 5 inj available on a PSO j 15 mg per ml, 1 ml – Up to 5 inj available on a PSO		10 10 10 10 10 10 5 5 5		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA n-Eslon n-Eslon m-Eslon DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine
Ta Ta Ci Ci Ci Ci Ci Ci In In In In ORF	ab long-acting 30 mg ab long-acting 60 mg ap long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 100 mg j 5 mg per ml, 1 ml – Up to 5 inj available on a PSO j 10 mg per ml, 1 ml – Up to 5 inj available on a PSO j 15 mg per ml, 1 ml – Up to 5 inj available on a PSO j 30 mg per ml, 1 ml – Up to 5 inj available on a PSO j 30 mg per ml, 1 ml – Up to 5 inj available on a PSO		10 10 10 10 10 10 5 5 5		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA n-Eslon n-Eslon m-Eslon DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine
Ta Ta Ta Ci Ci Ci Ci Ci Ci Ci Ci Ci Ci Ci Ci Ci	ab long-acting 30 mg ab long-acting 60 mg ap long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 100 mg ap long-acting 100 mg j 5 mg per ml, 1 ml – Up to 5 inj available on a PSO j 10 mg per ml, 1 ml – Up to 5 inj available on a PSO j 15 mg per ml, 1 ml – Up to 5 inj available on a PSO j 30 mg per ml, 1 ml – Up to 5 inj available on a PSO PHINE TARTRATE Only on a controlled drug form		10 10 10 10 10 10 5 5 5		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA n-Eslon n-Eslon m-Eslon DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine
Ta Ta Ca Ca Ca Ca Ca Ca Ca Ca Ca Ca Ca Ca Ca	ab long-acting 30 mg ab long-acting 60 mg ap long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 100 mg ap long-acting 100 mg j 5 mg per ml, 1 ml – Up to 5 inj available on a PSO j 10 mg per ml, 1 ml – Up to 5 inj available on a PSO j 15 mg per ml, 1 ml – Up to 5 inj available on a PSO j 30 mg per ml, 1 ml – Up to 5 inj available on a PSO PHINE TARTRATE Only on a controlled drug form No patient co-payment payable	2.98 5.75 6.45 	10 10 10 10 10 10 5 5 5		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA n-Eslon n-Eslon m-Eslon DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine
Ta Ta Ci Ci Ci Ci Ci Ci Ci Ci Ci Ci Ci Ci Ci	ab long-acting 30 mg ab long-acting 60 mg ap long-acting 100 mg ap long-acting 10 mg ap long-acting 30 mg ap long-acting 60 mg ap long-acting 100 mg ap long-acting 100 mg j 5 mg per ml, 1 ml – Up to 5 inj available on a PSO j 10 mg per ml, 1 ml – Up to 5 inj available on a PSO j 15 mg per ml, 1 ml – Up to 5 inj available on a PSO j 30 mg per ml, 1 ml – Up to 5 inj available on a PSO PHINE TARTRATE Only on a controlled drug form	2.98 5.75 6.45 1.70 5.40 6.38 5.51 4.79 5.01 5.30 quency	10 10 10 10 10 10 5 5 5		Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA n-Eslon n-Eslon m-Eslon DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine

	Subsidy (Manufacturer's Pri \$	ce) Per	Fully Subsidised	Brand or Generic Manufacturer
OXYCODONE HYDROCHLORIDE				
 a) Only on a controlled drug form 				
 b) See prescribing guideline below 				
c) No patient co-payment payable				
d) Safety medicine; prescriber may determine dispensing free	quency			
Tab controlled-release 5 mg	7.51	20	V 0	xyContin
Tab controlled-release 10 mg	6.75	20	V 0	xydone BNM
	(11.14)		0	xyContin
Tab controlled-release 20 mg	11.50	20	V 0	xydone BNM
	(18.93)		0	xyContin
Tab controlled-release 40 mg		20	V 0	xydone BNM
	(33.29)		0	xyContin
Tab controlled-release 80 mg	34.00	20	V 0	xydone BNM
	(58.03)		0	xyContin
Cap immediate-release 5 mg	2.83	20	V 0	xyNorm
Cap immediate-release 10 mg	5.58	20	V 0	xyNorm
Cap immediate-release 20 mg	9.77	20	V 0	xyNorm
the second	11.20	250 ml	V 0	xyNorm
Inj 10 mg per ml, 1 ml	10.08	5	✓ <u>0</u>	xycodone Orion
Inj 10 mg per ml, 2 ml	19.87	5	✓ 0	xycodone Orion
Inj 50 mg per ml, 1 ml	60.00	5	✓ <u>0</u>	<u>xyNorm</u>
(OxyContin Tab controlled-release 10 mg to be delisted 1 January	y 2014)			
(OxyContin Tab controlled-release 20 mg to be delisted 1 January	y 2014)			
(OxyContin Tab controlled-release 40 mg to be delisted 1 January	y 2014)			
(OxyContin Tab controlled-release 80 mg to be delisted 1 January	y 2014)			

Prescribing Guideline

Prescribers should note that oxycodone is significantly more expensive than long-acting morphine sulphate and clinical advice suggests that it is reasonable to consider this as a second-line agent to be used after morphine. PABACETAMOL WITH CODEINE – Safety medicine: prescriber may determine dispensing frequency.

PARACE IAMOL WITH CODEINE – Safety medicine; prescriber may determin	e aispensing freq	uency
* Tab paracetamol 500 mg with codeine phosphate 8 mg2.70	100	✓ Paracetamol +
		Codeine (Relieve)
PETHIDINE HYDROCHLORIDE		
a) Only on a controlled drug form		
b) No patient co-payment payable		
c) Safety medicine; prescriber may determine dispensing frequency		
Tab 50 mg	10	🖌 PSM
Tab 100 mg5.80	10	V PSM
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	5	✓ DBL Pethidine
		Hydrochloride
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5	✓ DBL Pethidine
		Hydrochloride
TRAMADOL HYDROCHLORIDE		
Tab sustained-release 100 mg2.14	20	Tramal SR 100
Tab sustained-release 150 mg	20	Tramal SR 150
Tab sustained-release 200 mg4.28	20	Tramal SR 200
Cap 50 mg4.95	100	✓ Arrow-Tramadol

NERVOUS SYSTEM

	Subsidy Fully Brand (Manufacturer's Price) Subsidised Gener \$ Per 🖌 Manuf	
Antidepressants		
Cyclic and Related Agents		
AMITRIPTYLINE - Safety medicine; prescriber may		
Tab 10 mg		mitriptyline
Tab 25 mg		
Tab 50 mg		
	dicine; prescriber may determine dispensing frequency	
Tab 10 mg		
Tab 25 mg		mipramine
DOTHIEPIN HYDROCHLORIDE – Safety medicine		
Tab 75 mg	•	
Cap 25 mg		1
DOXEPIN HYDROCHLORIDE – Safety medicine; p	prescriber may determine dispensing frequency	
Cap 10 mg		
Cap 25 mg		
Cap 50 mg		
MIPRAMINE HYDROCHLORIDE – Safety medicin	e; prescriber may determine dispensing frequency	
Tab 10 mg		
	6.58 60 ✓ Tofranil	
Tab 25 mg		
MAPROTILINE HYDROCHLORIDE - Safety medic	ine; prescriber may determine dispensing frequency	
Tab 25 mg		I
Tab 75 mg		
	21.01 30 🖌 Ludiomi	I
IANSERIN HYDROCHLORIDE – Safety medicine	; prescriber may determine dispensing frequency	
Tab 30 mg		
NORTRIPTYLINE HYDROCHLORIDE – Safety me	dicine; prescriber may determine dispensing frequency	
Tab 10 mg		s
Tab 25 mg		
Monoamine-Oxidase Inhibitors (MAOI	s) - Non Selective	
PHENELZINE SULPHATE		
* Tab 15 mg	95.00 100 🖌 Nardil	
FRANYLCYPROMINE SULPHATE		
₭ Tab 10 mg		
Monoamine-Oxidase Type A Inhibitors		
NOCLOBEMIDE		
Note: There is a significant cost differential betw	veen moclobemide and fluoxetine (moclobemide being about fore more cost-effective to start treatment with fluoxetine find find the find the start treatment with fluoxetine find the start treatment wi	
3 , 3	81.83 500 🖌 Apo-Moo	clohemide

*	Tab 150 mg	81.83	500	Apo-Moclobemide
*	Tab 300 mg	29.51	100	Apo-Moclobemide

	Subsidy (Manufacturer's Price)	Su	Fully bsidised	Brand or Generic
	\$	Per	~	Manufacturer
Selective Serotonin Reuptake Inhibitors				
CITALOPRAM HYDROBROMIDE				
* Tab 20 mg	2.34	84	✓ <u>A</u>	rrow-Citalopram
ESCITALOPRAM				
🖌 Tab 10 mg	2.65	28	• -	oxalate
* Tab 20 mg	4.20	28	🖌 Lo	oxalate
FLUOXETINE HYDROCHLORIDE				
* Tab dispersible 20 mg, scored – Subsidy by endorsement	2.50	30	🗸 Fl	uox
Subsidised by endorsement		الألمحيم مما		
 When prescribed for a patient who cannot swallow v ingly; or 	vnole tablets or capsu	ies and t	ne presci	iption is endorsed accor
2) When prescribed in a daily dose that is not a mu				
endorsed. Note: Tablets should be combined with c Cap 20 mg		84	ai 10 mg V Fl	
	2.70	04	• 11	uux
PAROXETINE HYDROCHLORIDE * Tab 20 mg	0.00	30		oxamine
* Tab 20 Tig	4.32	30 90		oxamine
	4.02	00	• -	Xamme
SERTRALINE * Tab 50 mg	3.64	90		rrow-Sertraline
* Tab 100 mg		90		rrow-Sertraline
ů.				
Other Antidepressants				
MIRTAZAPINE – Special Authority see SA0994 below – Retail pl	harmacy			
Tab 30 mg	8.78	30	✓ <u>A</u>	vanza
Tab 45 mg	13.95	30	✓ <u>A</u>	vanza
SA0994 Special Authority for Subsidy				

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 The patient has a severe major depressive episode; and

2 Either:

2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or

2.2 Both:

- 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
- 2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.

Renewal from any relevant practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	d Generic
VENLAFAXINE				
Tab 37.5 mg	5.06	28	~	Arrow-Venlafaxine XR
Tab 75 mg	6.44	28	~	Arrow-Venlafaxine XR
Tab 150 mg	8.86	28	~	Arrow-Venlafaxine XR
Tab 225 mg	14.34	28	~	Arrow-Venlafaxine XR
Cap 37.5 mg – Special Authority see SA1061 below – Retail				
pharmacy		28	~	Efexor XR
Cap 75 mg – Special Authority see SA1061 below – Retail pharmacy		28	~	Efexor XR
Cap 150 mg – Special Authority see SA1061 below – Retail				
pharmacy	21.35	28	~	Efexor XR

SA1061 Special Authority for Subsidy

Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has 'treatment-resistant' depression; and
- 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

Renewal from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

Antiepilepsy Drugs

Agents for Control of Status Epilepticus

CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency Inj 1 mg per ml, 1 ml	5	🖌 Rivotril
DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency		
Inj 5 mg per ml, 2 ml – Subsidy by endorsement	5	 Hospira
a) Up to 5 inj available on a PSO		
b) Only on a PSO		
c) PSO must be endorsed "not for anaesthetic procedures". Rectal tubes 5 mg – Up to 5 tube available on a PSO	5	Stesolid
Rectal tubes 10 mg – Up to 5 tube available on a PSO	5	✓ Stesolid
5	5	• Stesoliu
PARALDEHYDE	_	4 · · · ·
* Inj 5 ml1,500.00	5	🗸 AFT
PHENYTOIN SODIUM		
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO69.24	5	Hospira
Inj 50 mg per ml, 5 ml – Up to 5 inj available on a PSO77.27	5	 Hospira

	0.1.11			
	Subsidy (Manufacturer's Pr \$	rice) Sub Per	Fully osidised	Brand or Generic Manufacturer
Control of Epilepsy				
CARBAMAZEPINE				
* Tab 200 mg		100	🖌 Te	egretol
* Tab long-acting 200 mg		100	🖌 Te	egretol CR
* Tab 400 mg		100	🖌 Te	egretol
* Tab long-acting 400 mg		100		egretol CR
*‡ Oral liq 100 mg per 5 ml		250 ml	🗸 Te	egretol
CLOBAZAM - Safety medicine; prescriber may determine disper	nsing frequency			
Tab 10 mg	9.12	50	🖌 Fi	risium
‡ Safety cap for extemporaneously compounded oral liquid	d preparations.			
CLONAZEPAM - Safety medicine; prescriber may determine dis	pensing frequenc	y		
Oral drops 2.5 mg per ml		10 ml OP	🖌 R	ivotril
ETHOSUXIMIDE				
* Cap 250 mg		200	🖌 Za	arontin
*‡ Oral liq 250 mg per 5 ml		200 ml	V Za	arontin
GABAPENTIN – Special Authority see SA1071 below – Retail ph				
▲ Cap 100 mg		100	✓ A	rrow-Gabapentin
		100		upentin
 Cap 300 mg – For gabapentin oral liquid formulation refer, 				
page 194		100	🗸 A	rrow-Gabapentin
	11.50			upentin
▲ Cap 400 mg		100		rrow-Gabapentin
	14.75		🖌 N	upentin

SA1071 Special Authority for Subsidy

Initial application — (Epilepsy) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Initial application — (Neuropathic pain) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant.

Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic Manufacturer
GABAPENTIN (NEURONTIN) – Special Authority see SA0973 b	elow – Retail pharma	су	
▲ Tab 600 mg	67.50	100	Neurontin
▲ Cap 100 mg		100	Neurontin
▲ Cap 300 mg - For gabapentin (neurontin) oral liquid formu	-		
lation refer, page 194		100	Neurontin
▲ Cap 400 mg	53.01	100	 Neurontin

SA0973 Special Authority for Subsidy

Notes: Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 August 2009.

LACOSAMIDE - Special Authority see SA1125 below - Retail pharmacy

Tab 50 mg	25.04	14	Vimpat
Tab 100 mg		14	Vimpat
0	200.24	56	Vimpat
Tab 150 mg	75.10	14	Vimpat
C C	300.40	56	Vimpat
Tab 200 mg	400.55	56	 Vimpat

SA1125 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

LAMOTRIGINE

▲ Tab dispersible 2 mg	6.74	30	Lamictal
▲ Tab dispersible 5 mg	9.64	30	Lamictal
	15.00	56	Arrow-Lamotrigine
▲ Tab dispersible 25 mg		56	✓ Logem
	20.40		Arrow-Lamotrigine
			✓ Mogine
	29.09		Lamictal
▲ Tab dispersible 50 mg		56	Logem
	34.70		Arrow-Lamotrigine
			✓ Mogine
	47.89		Lamictal
▲ Tab dispersible 100 mg		56	Logem
	59.90		Arrow-Lamotrigine
			✓ Mogine
	79.16		✓ Lamictal

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Full <u>y</u> Subsidised	d Generic
LEVETIRACETAM				
Tab 250 mg		60	~	Levetiracetam-Rex
Tab 500 mg - For levetiracetam oral liquid formulation refer,				
page 194		60	~	Levetiracetam-Rex
Tab 750 mg		60	~	Levetiracetam-Rex
PHENOBARBITONE				
For phenobarbitone oral liquid refer, page 197				
* Tab 15 mg		500	~	PSM
* Tab 30 mg		500	~	PSM
PHENYTOIN SODIUM				
* Tab 50 mg		200	~	Dilantin Infatab
* Cap 30 mg		200	V	Dilantin
* Cap 100 mg		200	~	Dilantin
*‡ Oral liq 30 mg per 5 ml		500 ml	~	Dilantin
PRIMIDONE				
* Tab 250 mg		100	~	Apo-Primidone
SODIUM VALPBOATE			-	
* Tab 100 mg	13.65	100	~	Epilim Crushable
* Tab 200 mg EC		100		Epilim
* Tab 500 mg EC		100		Epilim
*± Oral lig 200 mg per 5 ml		300 ml		Epilim S/F Liquid
				Epilim Syrup
* Inj 100 mg per ml, 4 ml		1		Epilim IV
STIRIPENTOL – Special Authority see SA1330 below – Retail pha				
Cap 250 mg		60		Diacomit S29
			-	Diacomit S29
Powder for oral liq 250 mg sachet		60	V	Diacomiti 529

➡SA1330 Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE

▲ Tab 25 mg	11.07	60	Arrow-Topiramate
Ŭ	26.04		Topamax
▲ Tab 50 mg		60	Arrow-Topiramate
-	44.26		Topamax
Tab 100 mg		60	Arrow-Topiramate
-	75.25		Topamax
Tab 200 mg		60	Arrow-Topiramate
ů.	129.85		Topamax
Sprinkle cap 15 mg		60	Topamax
Sprinkle cap 25 mg		60	Topamax
/IGABATRIN – Special Authority see SA1072 on th	e next page – Retail pharmacy	,	
▲ Tab 500 mg	10 1 2	100	Sabril

Subsidy (Manufacturer's Price)	Sub	Fully sidised	Brand or Generic	
\$	Per	~	Manufacturer	

SA1072 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient has infantile spasms; or
- 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

- 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
- 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 114

Acute Migraine Treatment

ERGOTAMINE TARTRATE WITH CAFFEINE Tab 1 mg with caffeine 100 mg31.00	100	✓ Cafergot
METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL Tab 5 mg with paracetamol 500 mg6.77	60	✓ Paramax
RIZATRIPTAN Tab orodispersible 10 mg18.00	30	✓ <u>Rizamelt</u>
SUMATRIPTAN		
Tab 50 mg	100	Arrow-Sumatriptan
Tab 100 mg54.80	100	Arrow-Sumatriptan
Inj 12 mg per ml, 0.5 ml cartridge – Maximum of 10 inj per prescription13.80	2 OP	✓ Arrow-Sumatriptan

	Subsidy (Manufacturer's Price) \$) Per	Fully Subsidised	Brand or Generic Manufacturer
Prophylaxis of Migraine				
For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYS	STEM, page 55			
PIZOTIFEN Tab 500 mcg 	23.21	100	✓ <u>s</u>	andomigran
Antinausea and Vertigo Agents				
For Antispasmodics refer to ALIMENTARY TRACT, page 26				
APREPITANT – Special Authority see SA0987 below – Retail pha Cap 2 × 80 mg and 1 × 125 mg		3 OP	√ E	mend Tri-Pack
chemotherapy and/or anthracycline-based chemotherapy for the tr Renewal from any relevant practitioner. Approvals valid for 12 moni apy and/or anthracycline-based chemotherapy for the treatment of BETAHISTINE DIHYDROCHLORIDE * Tab 16 mg	ths where the patien f malignancy.			hly emetogenic chemothe ergo 16
CYCLIZINE HYDROCHLORIDE Tab 50 mg	0.59	10	✓ <u>N</u>	ausicalm
CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml	14.95	5	🖌 N	lausicalm
DOMPERIDONE				
Tab 10 mg – For domperidone oral liquid formulation refer, page 194		100	✓ P	rokinex
HYOSCINE HYDROBROMIDE				
Inj 400 mcg per ml, 1 ml		5	🗸 Н	lospira
Patch 1.5 mg – Special Authority see SA1387 below – Retail pharmacy		2	√ s	copoderm TTS
►SA1387 Special Authority for Subsidy				

➡SA1387 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or

2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective. **Renewal** from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

METOCLOPRAMIDE HYDROCHLORIDE

*	Tab 10 mg – For metoclopramide hydrochloride oral liquid			
	formulation refer, page 194	3.95	100	Metamide
*	Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO4	1.50	10	✓ Pfizer

NERVOUS SYSTEM

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
DNDANSETRON				
₭ Tab 4 mg	5.10	30	•	Dr Reddy's Ondansetron
	5.51	50	V	Onrex
₭ Tab disp 4 mg	1.70	10	~ 1	Dr Reddy's Ondansetron
	17.18		~	Zofran Zydis
₭ Tab 8 mg	1.70	10		Dr Reddy's Ondansetron
	6.19	50	~	Onrex
← Tab disp 8 mg	2.00	10	~ 1	Dr Reddy's Ondansetron
Zofran Zydis Tab disp 4 mg to be delisted 1 March 2014)				
ROCHLORPERAZINE				
K Tab 3 mg buccal		50		
3 • • • • 3 • • • • •	(15.00)		I	Buccastem
 Tab 5 mg – Up to 30 tab available on a PSO 	· /	500	~	Antinaus
Inj 12.5 mg per ml, 1 ml - Up to 5 inj available on a PSO	25.81	10	~	Stemetil
Suppos 25 mg		5	~	Stemetil
ROMETHAZINE THEOCLATE				
k Tab 25 mg	1.20 (6.24)	10		Avomine
ROPISETRON				
a) Maximum of 6 cap per prescription				
b) Maximum of 3 cap per dispensing				
c) Not more than one prescription per month.				
Ćap 5 mg	77.41	5	~	Navoban

Antipsychotics

Guidelines for the use of atypical antipsychotic agents

Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

General

AMISULPRIDE – Safety medicine; prescriber may deter	1 0 1	,	
Tab 100 mg	6.22	30	Solian
Tab 200 mg		60	Solian
Tab 400 mg		60	Solian
Oral liq 100 mg per ml		60 ml	Solian
ARIPIPRAZOLE – Special Authority see SA0920 on the Safety medicine; prescriber may determine dispensi		nacy	
	ing frequency	nacy 30	🖌 Abilify
Safety medicine; prescriber may determine dispensi	ing frequency 123.54		✔ Abilify ✔ Abilify
Safety medicine; prescriber may determine dispensi Tab 10 mg	ing frequency 123.54 175.28	30	

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsid	lised	Generic	
\$	Per	~	Manufacturer	

SA0920 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Patient is suffering from schizophrenia or related psychoses; and
- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

benefiting from treatment.			
CHLORPROMAZINE HYDROCHLORIDE - Safety medicine; pres	criber may dete	rmine dispens	sing frequency
Tab 10 mg – Up to 30 tab available on a PSO		100	 Largactil
Tab 25 mg – Up to 30 tab available on a PSO		100	Largactil
Tab 100 mg – Up to 30 tab available on a PSO		100	Largactil
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO		10	 Largactil
CLOZAPINE – Hospital pharmacy [HP4]			
Safety medicine; prescriber may determine dispensing freque	ncv		
Tab 25 mg		50	Clozaril
	26.74	100	✓ Clozaril
	6.69	50	✓ Clopine
	13.37	100	✓ Clopine
Tab 50 mg		50	✓ Clopine
	17.33	100	✓ Clopine
Tab 100 mg		50	✓ Clozaril
· · · · · · · · · · · · · · · · · ·	69.30	100	Clozaril
	17.33	50	✓ Clopine
	34.65	100	✓ Clopine
Tab 200 mg		50	 Clopine
·	69.30	100	 Clopine
Suspension 50 mg per ml		100 ml	✓ Clopine
HALOPERIDOL – Safety medicine; prescriber may determine disp		01	
Tab 500 mcg – Up to 30 tab available on a PSO		100	 Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO		100	✓ <u>Serenace</u>
Tab 5 mg $-$ Up to 30 tab available on a PSO		100	✓ <u>Serenace</u>
Oral lig 2 mg per ml – Up to 200 ml available on a PSO		100 ml	Serenace
Inj 5 mg per ml, 1 ml $-$ Up to 5 inj available on a PSO		10	Serenace
LEVOMEPROMAZINE MALEATE – Safety medicine; prescriber m			
Tab 25 mg		100	 Nozinan
Tab 100 mg		100	 Nozinan
Inj 25 mg per ml, 1 ml	73.68	10	Nozinan
LITHIUM CARBONATE - Safety medicine; prescriber may determ	nine dispensing	frequency	
Tab 250 mg		500	Lithicarb FC
Tab 400 mg	12.83	100	Lithicarb FC
Tab long-acting 400 mg	19.20	100	Priadel
Cap 250 mg	9.42	100	Douglas

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic Manufacturer
ANZAPINE – Safety medicine; prescriber may determin	•		• Wahaddardi
Tab 2.5 mg		28	✔ Dr Reddy's
		20	Olanzapine
			✓ Olanzine
			V Zypine
	(51.07)		Zyprexa
Tab 5 mg	. ,	28	✓ Dr Reddy's
-			Olanzapine
			 Olanzine
			Zypine
	(101.21)		Zyprexa
Tab orodispersible 5 mg	6.36	28	✓ Dr Reddy's
			Olanzapine
			 Olanzine-D
			Zypine ODT
Tab 10 mg	6.35	28	Dr Reddy's
			Olanzapine
			Olanzine
			Zypine
	(204.49)		Zyprexa
Tab orodispersible 10 mg	8.76	28	✓ Dr Reddy's
			Olanzapine
			Olanzine-D
			Zypine ODT
Wafer 5 mg	6.36	28	
	(102.19)		Zyprexa Zydis
Wafer 10 mg	8.76	28	
	(204.37)		Zyprexa Zydis
RICYAZINE - Safety medicine; prescriber may determi	ne dispensing frequency		
Tab 2.5 mg		100	Neulactil
Tab 10 mg		100	Neulactil
ETIAPINE – Safety medicine; prescriber may determin	e dispensing frequency		
Tab 25 mg	7.00	60	🖌 Dr Reddy's
-			Quetiapine
			 Seroquel
	10.50	90	✓ Quetapel
Tab 100 mg	14.00	60	 Seroquel
-	21.00	90	✓ Dr Reddy's
			Quetiapine
			V Quetapel
Tab 200 mg		60	✓ Dr Reddy's
-			Quetiapine
			 Seroquel
	36.00	90	Quetapel
Tab 300 mg		60	Dr Reddy's
Tab 300 mg		60	 Dr Reddy's Quetiapine
Tab 300 mg		60	

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
SPERIDONE – Safety medicine; prescriber may determine di	spensing frequency		
Tab orodispersible 0.5 mg - Special Authority see SA092			
below – Retail pharmacy	21.42	28	Risperdal Quicklet
Tab 0.5 mg	3.51	60	Apo-Risperidone
			Dr Reddy's
			Risperidone
			Ridal
	1.17	20	
	(2.86)		Risperdal
Tab 1 mg	6.00	60	Apo-Risperidone
			✓ Dr Reddy's
			Risperidone
	(10.00)		✓ Ridal
	(16.92)		Risperdal
Tab orodispersible 1 mg – Special Authority see SA0927 be			
low – Retail pharmacy		28	 Risperdal Quicklet
Tab 2 mg	11.00	60	✓ Apo-Risperidone
			✓ Dr Reddy's
			Risperidone
	(00.04)		✓ Ridal
Tele and diaman illa Oran Oran ist Authority and OA0007 h	(33.84)		Risperdal
Tab orodispersible 2 mg – Special Authority see SA0927 be		00	Dismondal Ossialdat
low – Retail pharmacy		28	Risperdal Quicklet
Tab 3 mg	15.00	60	 Apo-Risperidone Dr Reddy's
			Risperidone
			✓ Ridal
	(50.79)		Risperdal
Tab 4 mg	(50.78)	60	Apo-Risperidone
1ab 4 mg	20.00	00	✓ Dr Reddy's
			Risperidone
			✓ Ridal
	(67.68)		Risperdal
Oral lig 1 mg per ml	()	30 ml	✓ Apo-Risperidone
		00 11	✓ Apo-mispendone ✓ Risperon
	(25.26)		Risperdal
	(25.26)		Risperdal

➡SA0927 Special Authority for Subsidy

Initial application — (Acute situations) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

- Both:
 - 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
 - 2 The patient is under direct supervision for administration of medicine.

Initial application — (Chronic situations) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

continued...

NERVOUS STSTEM				
	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
continued				
Renewal from any relevant practitioner. Approvals valid for 1 y	ear for applications meet	ting the	following	criteria:
Both:				
 The patient is unable to take standard risperidone table or oral liquid; and 		stabiliz	ed refuses	to take risperidone tablet
2 The patient is under direct supervision for administration Note: Risperdal Quicklets cost significantly more than risperide		nlv he i	used where	e necessary
TRIFLUOPERAZINE HYDROCHLORIDE – Safety medicine; p		•		•
Tab 1 mg	•	100	• •	telazine
Tab 2 mg	14.64	100	🗸 S	telazine
Tab 5 mg	16.66	100	🖌 S	telazine
ZIPRASIDONE – Subsidy by endorsement				
a) Safety medicine; prescriber may determine dispensing t	irequency			
b) Ziprasidone is subsidised for patients suffering from scl	hizophrenia or related pa	sychos	es after a t	rial of an effective dose of
risperidone or quetiapine that has been discontinued, or is	in the process of being	discont	inued, bec	ause of unacceptable sid
effects or inadequate response, and the prescription is end	dorsed accordingly.			
Cap 20 mg		60	🗸 Z	eldox
Cap 40 mg	164.78	60	🗸 Z	eldox
Cap 60 mg	247.17	60	🗸 Z	eldox
Cap 80 mg		60	🗸 Z	eldox
ZUCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; p	rescriber may determine	dispe	nsing fregu	iency
Tab 10 mg		100	• •	lopixol
Depot Injections				
FLUPENTHIXOL DECANOATE – Safety medicine; prescriber	may determine dispensi	ng frea	uency	
Inj 20 mg per ml, 1 ml - Up to 5 inj available on a PSO		5	🖌 F	uanxol
Inj 20 mg per ml, 2 ml - Up to 5 inj available on a PSO		5		uanxol
Inj 100 mg per ml, 1 ml - Up to 5 inj available on a PSO	40.87	5	🖌 F	uanxol
FLUPHENAZINE DECANOATE - Safety medicine; prescriber	may determine dispensi	ng frec	uency	
Inj 12.5 mg per 0.5 ml, 0.5 ml - Up to 5 inj available on a F		5		odecate
Inj 25 mg per ml, 1 ml – Up to 5 inj available on a PSO		5	V M	odecate
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		5		odecate
HALOPERIDOL DECANOATE - Safety medicine; prescriber r	nav determine dispensin	a freai	iency	
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO		5	, 🗸 Н	aldol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		5		aldol Concentrate
OLANZAPINE – Special Authority see SA1146 below – Retail				
Safety medicine; prescriber may determine dispensing free				
Inj 210 mg		1	✓ 7·	yprexa Relprevv
Inj 200 mg		1		vprexa Relprevv
lnj 405 mg		1		prexa Relprevv
				······································

➡SA1146 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has schizophrenia; and
- 2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

continued...

Subsidy (Manufacturer's Pri	e)	Fully Subsidised	Brand or Generic	
\$	Per	 ✓ 	Manufacturer	

continued...

RI

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Fither:

- 1 Both:
 - 1.1 The patient has had less than 12 months' treatment with olanzapine depot injection; and
 - 1.2 There is no clinical reason to discontinue treatment: or
- 2 The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of olanzapine depot injection.

Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

PIPOTHIAZINE PALMITATE – Safety medicine; prescriber may determine dispensing frequer

Inj 50 mg per ml, 1 ml - Up to 5 inj available on a PSO		10	Piportil
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO		10	 Piportil
ISPERIDONE - Special Authority see SA0926 below - Ref	tail pharmacy		
Safety medicine; prescriber may determine dispensing fr	equency		
Inj 25 mg per 2 ml		1	Risperdal Consta
Inj 37.5 mg per 2 ml		1	Risperdal Consta
Inj 50 mg per 2 ml		1	Risperdal Consta

►SA0926 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has schizophrenia or other psychotic disorder; and
- 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents: and
- 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has had less than 12 months treatment with risperidone depot injection; and
- 1.2 There is no clinical reason to discontinue treatment: or
- 2 The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE - Safety medicine: prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO	19.80	5	🖌 Clopixol
Anxiolytics			
LPRAZOLAM – Safety medicine; prescriber may determine dispen	ising frequency	1	
Tab 250 mcg		50	Arrow-Alprazolam
v			🖌 Xanax
‡ Safety cap for extemporaneously compounded oral liquid pr	reparations.		
Tab 500 mcg		50	🖌 Xanax
v	4.10		Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid pr	reparations.		·
Tab 1 mg		50	Arrow-Alprazolam
·			🖌 Xanax
‡ Safety cap for extemporaneously compounded oral liquid pr	reparations.		

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	
BUSPIRONE HYDROCHLORIDE				
Tab 5 mg Tab 10 mg		100 100		Pacific Buspirone Pacific Buspirone
CLONAZEPAM - Safety medicine; prescriber may determine disp	ensing frequency			
Tab 500 mcg	6.68	100	~	Paxam
Tab 2 mg	12.75	100	~	Paxam
DIAZEPAM – Safety medicine; prescriber may determine dispensi	ing frequency			
Tab 2 mg ‡ Safety cap for extemporaneously compounded oral liquid	11.44	500	~	Arrow-Diazepam
Tab 5 mg ‡ Safety cap for extemporaneously compounded oral liquid		500	~	Arrow-Diazepam
ORAZEPAM – Safety medicine; prescriber may determine disper	nsing frequency			
Tab 1 mg		250	~	Ativan
‡ Safety cap for extemporaneously compounded oral liquid	preparations.			
Tab 2.5 mg ‡ Safety cap for extemporaneously compounded oral liquid		100	~	Ativan
OXAZEPAM – Safety medicine; prescriber may determine dispens	sing frequency			
Tab 10 mg	5.89	100	~	Ox-Pam
‡ Safety cap for extemporaneously compounded oral liquid				
Tab 15 mg		100	~	Ox-Pam
‡ Safety cap for extemporaneously compounded oral liquid	preparations.			

Multiple Sclerosis Treatments

➡SA1062 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC).

Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Appeals against MSTAC's decision and/or the processing of any application may be lodged with the MSTAC coordinator. Concerns that cannot be or have not been adequately addressed by MSTAC will be forwarded to a separate Appeal Committee if necessary. Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

continued...

Subsidy	Subsidy Fully	
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis should as a rule include MRI confirmation. For patients diagnosed before MRI was widely utilised in New Zealand, confirmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and
- 2) patients must have active relapsing MS (confirmed by MR scan where necessary) with or without underlying progression; and
- 3) patients must have either:
 - a) EDSS score 2.5 5.5 with 2+ relapses:
 - experienced at least 2 significant relapses of MS in the previous 12 months, and
 - an EDSS score of between 2.5 and 5.5 inclusive; or
 - b) EDSS score 2.0 with 3+ relapses:
 - experienced at least 3 significant relapses of MS in the previous 12 months, and
 - an EDSS score of 2.0; and
- 4) Each relapse must:
 - a) be confirmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) follow a period of stability of at least one month;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5°C); and
- 5) applications must be made at least four weeks after the date of the onset of the last known relapse; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping).
- applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient's neurologist or a general physician; and
- 8) patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and
- 9) patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate.

Stopping Criteria

- 1) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as any of:
 - a) an increase of 2 EDSS points where starting EDSS was 2.0; or
 - b) an increase of 1.5 EDSS points where starting EDSS was 2.5 or 3.0; or
 - c) an increase of 1 EDSS point where starting EDSS 3.5 or greater; or
 - d) an increase in EDSS score to 6.0 or more; or
- 2) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) pregnancy and/or lactation; or
- within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC; or

continued...

143

 Fully rice) Subsidised	
\$ Per 🖌	Manufacturer

continued...

6) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate.

Note: Patients who have a stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet any of the other Stopping Criteria at annual review may switch to a different class of funded treatment (i.e. patients may switch from either of the beta-interferons [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa). Patients may switch classes of treatment for this reason only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to stable or increasing relapse rate over 12 months of treatment).

GLATIRAMER ACETATE – Special Authority see SA1062 on pag Inj 20 mg prefilled syringe		28	 Copaxone
INTERFERON BETA-1-ALPHA - Special Authority see SA1062	on page 142		
Inj 6 million iu prefilled syringe		4	Avonex
Injection 6 million iu per 0.5 ml pen injector	1,320.87	4	Avonex Pen
Inj 6 million iu per vial	1,320.87	4	Avonex
INTERFERON BETA-1-BETA - Special Authority see SA1062 or	page 142		
Inj 8 million iu per 1 ml		15	 Betaferon
Sedatives and Hypnotics			
LORMETAZEPAM - Safety medicine; prescriber may determine	dispensina freauer	NCV	
Tab 1 mg	1 0 1	30	
0	(23.50)		Noctamid
‡ Safety cap for extemporaneously compounded oral liquid	d preparations.		
MIDAZOLAM - Safety medicine; prescriber may determine dispe	ensing frequency		
Inj 1 mg per ml, 5 ml		10	✓ Pfizer
	10.75		 Hypnovel
Inj 5 mg per ml, 3 ml	11.90	5	 Hypnovel
			 Pfizer
NITRAZEPAM - Safety medicine; prescriber may determine disp	ensing frequency		
Tab 5 mg	4.98	100	Nitrados
‡ Safety cap for extemporaneously compounded oral liquid	d preparations.		
PHENOBARBITONE SODIUM - Special Authority see SA1386 b	oelow – Retail phar	macy	
Inj 200 mg per ml, 1 ml ampoule		10	✓ Martindale S29
SA1386 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals valid	d without further re	enewal unle	ess notified for applications meeting
the following criteria:			5
Both:			
1 For the treatment of terminal agitation that is unresponsive	to other agents; a	nd	

2 The applicant is part of a multidisciplinary team working in palliative care.

TEMAZEPAM - Safety medicine; prescriber may determine dispensing frequ	ency	
Tab 10 mg1.27	25	Normison

‡ Safety cap for extemporaneously compounded oral liquid preparations.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
TRIAZOLAM – Safety medicine; prescriber may determine disper	nsing frequency			
Tab 125 mcg	5.10	100		
-	(7.25)		H	ypam
‡ Safety cap for extemporaneously compounded oral liquic	preparations.			
Tab 250 mcg	4.10	100		
	(8.70)		H	ypam
‡ Safety cap for extemporaneously compounded oral liquic	preparations.			
ZOPICLONE				
Tab 7.5 mg	1.90	30	🖌 A	po-Zopiclone
-	11.90	500		po-Zopiclone

Stimulants/ADHD Treatments

Stimulants/ADHD treatments

ATOMOXETINE - Special Authority see SA0951 below	 Retail pharmacy 		
Cap 10 mg		28	Strattera
Cap 18 mg		28	 Strattera
Cap 25 mg		28	 Strattera
Cap 40 mg		28	 Strattera
Cap 60 mg		28	 Strattera
Cap 80 mg		28	 Strattera
Cap 100 mg		28	 Strattera

➡SA0951 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexampletamine sulphate tablets.

DEXAMPHETAMINE SULPHATE - Special Authority see SA1149 on the next page - Retail pharmacy

- a) Only on a controlled drug form
- b) Safety medicine; prescriber may determine dispensing frequency

Tab 5 mg	16.50	100	✓ <u>PSM</u>
----------	-------	-----	--------------

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1149 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE - Special Authority see SA1150 below - Retail pharmacy

a) Only on a controlled drug form

b) Safetv	/ medicine:	prescriber may	/ determine	dispensing	freauencv

Tab immediate-release 5 mg		30	Rubifen
Tab immediate-release 10 mg	3.00	30	Ritalin
ũ			Rubifen
Tab immediate-release 20 mg	7.85	30	Rubifen
Tab sustained-release 20 mg		30	Rubifen SR
° °	50.00	100	🖌 Ritalin SR

➡SA1150 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Subsidy (Manutacturer's I	Price)	Fully Subsidised	Brand or Generic	
`\$	Per	~	Manufacturer	

continued...

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE - Special Authority see SA1151 below - Retail pharmacy

a) Only on a controlled drug form			
b) Safety medicine; prescriber may determine dispensing free	equency		
Tab extended-release 18 mg		30	Concerta
Tab extended-release 27 mg	65.44	30	Concerta
Tab extended-release 36 mg	71.93	30	Concerta
Tab extended-release 54 mg		30	Concerta
Cap modified-release 10 mg		30	Ritalin LA
Cap modified-release 20 mg		30	Ritalin LA
Cap modified-release 30 mg		30	Ritalin LA
Cap modified-release 40 mg		30	Ritalin LA

➡SA1151 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
 continued 1 The treatment remains appropriate and the patient is ben 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 	efiting from treatment;	; and		
2.2 Applicant is a medical practitioner and confirms the and has recommended treatment for the patient.	at a relevant specialis	t has	been consu	Ited within the last 2 year
IODAFINIL – Special Authority see SA1126 below – Retail pha Tab 100 mg	•	30	✔ M	odavigil
 SA1126 Special Authority for Subsidy nitial application only from a neurologist or respiratory special point only from a neurologist or respiratory special point of the following: The patient has a diagnosis of narcolepsy and has exact almost daily for three months or more; and Either: The patient has a multiple sleep latency test with more sleep onset rapid eye movement periods; or	cessive daytime sleep a mean sleep latency aralysis or hypnagogic nethylphenidate or dex ndicated.	iness of less halluc camph	associated s than or equicinations; an etamine has	with narcolepsy occurrin ual to 10 minutes and 2 d d s been trialled and discor
DONEPEZIL HYDROCHLORIDE				
 ₭ Tab 5 mg ₭ Tab 10 mg 		90 90		onepezil-Rex onepezil-Rex
Treatments for Substance Dependence				
BUPRENORPHRINE WITH NALOXONE – Special Authority se a) No patient co-payment payable b) Safety medicine; prescriber may determine dispensing fre	equency	tail ph	armacy	

		alopononing noquonoy	b) calledy medicine, precender may determine an
Suboxone	28		Tab sublingual 2 mg with naloxone 0.5 mg
 Suboxone 	28		Tab sublingual 8 mg with naloxone 2 mg

➡SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health...

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg	4.97	30	🖌 Zyban
DISULFIRAM	04.00	100	
Tab 200 mg		100	 Antabuse
NALTREXONE HYDROCHLORIDE – Special Authority see SA	1408 below – Retail	pharmacy	
Tab 50 mg	76.00	30	✓ Naltraccord

➡SA1408 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

	Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer	
NICOTINE					

Nicotine will not be funded under the Dispensing Frequency R	ule in amounts le	ess than 4 w	eeks of treatment.
Patch 7 mg - Up to 28 patch available on a PSO		28	Habitrol
Patch 14 mg - Up to 28 patch available on a PSO	18.81	28	Habitrol
Patch 21 mg - Up to 28 patch available on a PSO		28	Habitrol
Lozenge 1 mg – Up to 216 loz available on a PSO		216	Habitrol
Lozenge 2 mg - Up to 216 loz available on a PSO	24.27	216	Habitrol
Gum 2 mg (Classic) - Up to 384 piece available on a PSO		384	Habitrol
Gum 2 mg (Fruit) - Up to 384 piece available on a PSO		384	Habitrol
Gum 2 mg (Mint) - Up to 384 piece available on a PSO		384	Habitrol
Gum 4 mg (Classic) - Up to 384 piece available on a PSO		384	Habitrol
Gum 4 mg (Fruit) - Up to 384 piece available on a PSO		384	Habitrol
Gum 4 mg (Mint) - Up to 384 piece available on a PSO		384	Habitrol

VARENICLINE TARTRATE - Special Authority see SA1161 below - Retail pharmacy

a) Varenicline will not be funded under the Dispensing Frequency Rule in amounts less than 2 weeks of treatment.

b) A maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

Tab 1 mg67.74	28	Champix
135.48	56	Champix
Tab 0.5 mg \times 11 and 1 mg \times 1460.48	25 OP	 Champix

SA1161 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking: and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to guit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to guit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months: and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this: and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 3 months' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 The patient has not used funded varenicline in the last 12 months; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this: and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 3 months' funded varenicline (see note).

The patient must not have had an approval in the past 12 months.

Note: a maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

	Subsidy (Manufacturer's	Price) Sub	Fully osidised	Brand or Generic
	\$	Per	~	Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BUSULPHAN – PCT – Retail pharmacy-Specialist				
Tab 2 mg	59 50	100	🗸 M	lyleran
•		100	•	lyiciun
CARBOPLATIN – PCT only – Specialist Inj 10 mg per ml, 5 ml	20.00	1		arboplatin Ebewe
Inj 10 mg per ml, 15 ml		1		arbaccord
	22.50	I		arboplatin Ebewe
Inj 10 mg per ml, 45 ml		1		arbaccord
		I		arboplatin Ebewe
	00.00			BL Carboplatin
Inj 10 mg per ml, 100 ml		1		arboplatin Ebewe
Inj 1 mg for ECP		1 mg		axter
, ,				
ARMUSTINE – PCT only – Specialist Inj 100 mg	20/ 12	1	1 P	iCNU
Inj 100 mg for ECP		100 mg OP		axter
, ,	204.13	TOO HIS OF	V D	axiei
HLORAMBUCIL – PCT – Retail pharmacy-Specialist				
Tab 2 mg	22.35	25	✔ L	eukeran FC
ISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml		1	🖌 C	isplatin Ebewe
			🖌 Н	ospira
Inj 1 mg per ml, 100 ml	21.00	1	🖌 C	isplatin Ebewe
				ospira
Inj 1 mg for ECP	0.27	1 mg	🗸 В	axter
YCLOPHOSPHAMIDE				
Tab 50 mg – PCT – Retail pharmacy-Specialist	25.71	50	✔ C	vcloblastin
5 1 7 1	158.00	100		rocytox S29
Wastage claimable - see rule 3.3.2 on page 17	100100		• •	
Inj 1 g – PCT – Retail pharmacy-Specialist		1	🖌 E	ndoxan
	127.80	6		vtoxan
Inj 2 g – PCT only – Specialist		1	🖌 E	ndoxan
Inj 1 mg for ECP – PCT only – Specialist		1 mg	🖌 В	axter
Cycloblastin Tab 50 mg to be delisted 1 April 2014)		-		
OSFAMIDE – PCT only – Specialist				
Inj 1 g	96.00	1	🗸 н	oloxan
lnj 2 g		1		oloxan
Inj 1 mg for ECP		1 mg		axter
		9		
OMUSTINE – PCT only – Specialist	100 50	20		eeNU
Cap 10 mg		20 20		eenu
Cap 40 mg		20	• 0	CENU
IELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist		25		lkeran
Inj 50 mg – PCT only – Specialist	52.15	1	V A	lkeran

(IN	Subsidy Ianufacturer's Pric	e)	Full Subsidise	
ζ	\$	Per	·	
XALIPLATIN – PCT only – Specialist				
Inj 50 mg	15.32	1	~	Oxaliplatin Actavis 50
	55.00		~	Oxaliplatin Ebewe
	200.00			Eloxatin
Inj 100 mg		1	· · ·	Oxaliplatin Actavis
				100
	110.00			Oxaliplatin Ebewe
	400.00		-	Eloxatin
Inj 1 mg for ECP	0.28	1 mg	V	Baxter
HIOTEPA – PCT only – Specialist				
lnj 15 mg	CBS	1	~	Bedford S29
			~	THIO-TEPA S29
			~	Tepadina S29
Antimetabolites				
ALCIUM FOLINATE				
Tab 15 mg – PCT – Retail pharmacy-Specialist		10	~	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist		5		Hospira
Inj 50 mg – PCT – Retail pharmacy-Specialist		5	~	Calcium Folinate Ebewe
Inj 100 mg – PCT only – Specialist	9.75	1	~	Calcium Folinate Ebewe
Inj 300 mg – PCT only – Specialist	30.00	1	~	Calcium Folinate Ebewe
Inj 1 g – PCT only – Specialist	90.00	1	~	Calcium Folinate Ebewe
Inj 1 mg for ECP – PCT only – Specialist	0.10	1 mg	~	Baxter
APECITABINE – Retail pharmacy-Specialist		-		
Tab 150 mg	115.00	60	~	Xeloda
Tab 500 mg		120	~	Xeloda
LADRIBINE – PCT only – Specialist				
Inj 1 mg per ml, 10 ml	5,249.72	7	~	Leustatin
Inj 10 mg for ECP	749.96	10 mg O	P 🖌	Baxter
YTARABINE				
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist	55.00	5	~	Pfizer
	80.00		~	Hospira
Inj 500 mg – PCT – Retail pharmacy-Specialist		1		Pfizer
	95.36	5	~	Hospira
Inj 100 mg per ml, 10 ml vial – PCT – Retail pharmacy-	0.00			D"
Specialist		1		Pfizer
Ini 100 ma par mi 20 mi vial PCT. Pateil abormany	42.65		V	Hospira
Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy- Specialist	17 65	1		Pfizer
ορουαιιοι	17.05 34.47	I		Hospira
Inj 1 mg for ECP – PCT only – Specialist		10 mg		Baxter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist		00 mg 0		Baxter

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or bsidised Generic Manufacturer	
FLUDARABINE PHOSPHATE – PCT only – Specialist				
Tab 10 mg		20	🖌 Fludara Oral	
Inj 50 mg		5	 Fludarabine Ebewe 	
	1,430.00		Fludara	
Inj 50 mg for ECP		50 mg OP	Baxter	
FLUOROURACIL SODIUM				
Inj 50 mg per ml, 10 ml – PCT only – Specialist		5	Fluorouracil Ebewe	
Inj 50 mg per ml, 20 ml – PCT only – Specialist	7.50	1	Fluorouracil Ebewe	
Inj 25 mg per ml, 100 ml – PCT only – Specialist	13.55	1	 Hospira 	
Inj 50 mg per ml, 50 ml – PCT only – Specialist		1	Fluorouracil Ebewe	
Inj 50 mg per ml, 100 ml – PCT only – Specialist		1	Fluorouracil Ebewe	
Inj 1 mg for ECP – PCT only – Specialist	0.77	100 mg	Baxter	
GEMCITABINE HYDROCHLORIDE - PCT only - Specialist				
lnj 1 g		1	DBL Gemcitabine	
, .			 Gemcitabine Actavis 1000 	
			Gemcitabine Ebewe	
	349.20		 Gemzar 	
Inj 200 mg	12.50	1	 Gemcitabine Actavis 200 	
			Gemcitabine Ebewe	
	78.00		 Gemzar 	
Inj 1 mg for ECP	0.07	1 mg	Baxter	
IRINOTECAN – PCT only – Specialist				
Inj 20 mg per ml, 2 ml	9.34	1	 Irinotecan Actavis 40 	
	41.00		 Camptosar 	
Inj 20 mg per ml, 5 ml	23.34	1	 Irinotecan-Rex Irinotecan Actavis 	
			100	
	100.00		Camptosar	
			Irinotecan-Rex	
Inj 1 mg for ECP	0.24	1 mg	✓ Baxter	
MERCAPTOPURINE – PCT – Retail pharmacy-Specialist		-		
Tab 50 mg	49.41	25	✓ <u>Puri-nethol</u>	

	Subsidy (Manufacturer's Price)	Full Subsidise	
	\$	Per	•	Manufacturer
IETHOTREXATE				
Tab 2.5 mg – PCT – Retail pharmacy-Specialist		30	~	Methoblastin
 Tab 10 mg – PCT – Retail pharmacy-Specialist 		50		Methoblastin
Inj 2.5 mg per ml, 2 ml - PCT - Retail pharmacy-Specialist		5		Hospira
 Inj 7.5 mg prefilled syringe 		1		Methotrexate
Inj 10 mg prefilled syringe		1	V	Sandoz Methotrexate
				Sandoz
Inj 15 mg prefilled syringe		1	~	Methotrexate Sandoz
Inj 20 mg prefilled syringe		1	~	Methotrexate
			-	Sandoz
Inj 25 mg prefilled syringe		1	~	Methotrexate Sandoz
Inj 30 mg prefilled syringe		1	~	Methotrexate
				Sandoz
Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist		5	~	Hospira
Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist.		1		Hospira
Inj 100 mg per ml, 10 ml - PCT - Retail pharmacy-Specialist	t25.00	1	~	Methotrexate Ebewe
Inj 25 mg per ml, 40 ml - PCT - Retail pharmacy-Specialist		1	V	DBL
				Methotrexate \$29
Inj 100 mg per ml, 50 ml – PCT – Retail pharmacy-Specialist .	125.00	1	~	Methotrexate Ebewe
 Inj 1 mg for ECP – PCT only – Specialist 		1 mg		Baxter
 Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist. 		5 mg OF	· · .	Baxter
DBL Methotrexate \$29 Inj 25 mg per ml, 40 ml to be delisted 1 M		, nig Oi	•	Dariel
	nay 2014)			
HIOGUANINE – PCT – Retail pharmacy-Specialist				
Tab 40 mg	97.16	25	~	Lanvis
Other Cytotoxic Agents				
MSACRINE - PCT only - Specialist				
Inj 75 mg	CBS	6	~	Amsidine S29
NAGRELIDE HYDROCHLORIDE - PCT only - Specialist				
, , , , , , , , , , , , , , , , , , ,	CDC	100		A amplin COO
Cap 0.5 mg		100		Agrylin S29
			V	Teva S29
RSENIC TRIOXIDE – PCT only – Specialist				
Inj 10 mg	4.817.00	10	~	AFT S29
			•	
LEOMYCIN SULPHATE – PCT only – Specialist Inj 15,000 iu	100.00	4		
		1	V	DBL Bleomycin
ing 13,000 iu				Sulfate Baxter
	0.00			
Inj 1,000 iu for ECP		1,000 iu	V	Daxler
Inj 1,000 iu for ECP		,	V	Daxlei
Inj 1,000 iu for ECP	SA1127 on the next	,		Velcade
Inj 1,000 iu for ECP ORTEZOMIB – PCT only – Specialist – Special Authority see S	SA1127 on the next	page	V	

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

►SA1127 Special Authority for Subsidy

Initial application — (Treatment naive multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 The patient has treatment-naive symptomatic multiple myeloma; or
- 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and
- 2 Maximum of 9 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initial application — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 The patient has relapsed or refractory multiple myeloma; or
 - 1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

- 1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
- 2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

- a) a known therapeutic chemotherapy regimen and supportive treatments; or
- b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

COLASPASE [L-ASPARAGINASE] - PCT only - Specialist

Inj 10,000 iu Inj 10,000 iu for ECP	1 10,000 iu OP	LeunaseBaxter
DACARBAZINE – PCT only – Specialist Inj 200 mg vial Inj 200 mg for ECP	1 200 mg OP	✔ Hospira✔ Baxter
DACTINOMYCIN [ACTINOMYCIN D] – PCT only – Specialist Inj 0.5 mg Inj 0.5 mg for ECP	1 0.5 mg OP	✔ Cosmegen✔ Baxter
DAUNORUBICIN – PCT only – Specialist Inj 2 mg per ml, 10 ml Inj 20 mg for ECP	1 20 mg OP	✓ Pfizer✓ Baxter

	Subsidy (Manufacturer's Price)		Fully Brand or Subsidised Generic
	(Manulacturer's Frice \$	/ Per	
OCETAXEL – PCT only – Specialist			
Inj 20 mg		1	Docetaxel Ebewe
			Docetaxel Sandoz
Inj 20 mg per ml, 1 ml	48.75	1	Taxotere
Inj 20 mg per ml, 4 ml	195.00	1	Taxotere
Inj 80 mg	195.00	1	Docetaxel Ebewe
			Docetaxel Sandoz
Inj 1 mg for ECP	2.63	1 mg	 Baxter
Docetaxel Ebewe Inj 20 mg to be delisted 1 February 2014)			
Docetaxel Ebewe Inj 80 mg to be delisted 1 February 2014)			
DXORUBICIN – PCT only – Specialist			
Inj 10 mg	10.00	1	Doxorubicin Ebewe
Inj 50 mg	17.00	1	Arrow-Doxorubicin
	40.00		DBL Doxorubicin
			DBL Doxorubicin
			S29 S29
			Doxorubicin Ebewe
Inj 100 mg		1	Doxorubicin Ebewe
Inj 200 mg	65.00	1	Arrow-Doxorubicin
, ,	150.00		Adriamycin
			✓ Doxorubicin Ebewe
Inj 1 mg for ECP	0.37	1 mg	Baxter
PIRUBICIN – PCT only – Specialist		•	
Inj 2 mg per ml, 5 ml	25.00	1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml		1	✓ DBL Epirubicin
		•	Hydrochloride
	87.50		 Epirubicin Ebewe
lnj 2 mg per ml, 50 ml	•••••	1	✓ DBL Epirubicin
		•	Hydrochloride
	125.00		 Epirubicin Ebewe
Inj 2 mg per ml, 100 ml		1	✓ DBL Epirubicin
			Hydrochloride
	210.00		 Epirubicin Ebewe
Inj 1 mg for ECP		1 mg	Baxter
		y	+ Buntol
TOPOSIDE	240 72	20	A Vanacid
Cap 50 mg – PCT – Retail pharmacy-Specialist		20	Vepesid
Cap 100 mg – PCT – Retail pharmacy-Specialist		10 1	Vepesid
Inj 20 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist	612.20	10	✓ Hospira
Inj 1 mg for ECP – PCT only – Specialist			✓ Vepesid✓ Baxter
, , ,	0.30	1 mg	
TOPOSIDE PHOSPHATE – PCT only – Specialist			4 -
Inj 100 mg (of etoposide base)		1	Etopophos
Inj 1 mg (of etoposide base) for ECP	0.47	1 mg	Baxter
YDROXYUREA – PCT – Retail pharmacy-Specialist			
Cap 500 mg		100	Hydrea

	Subsidy (Manufacturer's F \$	Price) Per	Fully Subsidised	d Generic
	φ	Fei		
IDARUBICIN HYDROCHLORIDE – PCT only – Specialist	115.00	1		Zavadaa
Cap 5 mg Cap 10 mg		1		Zavedos Zavedos
Inj 5 mg		1		Zavedos Zavedos
Inj 10 mg		1	-	Zavedos Zavedos
Inj 1 mg for ECP		1 mg		Baxter
MESNA – PCT only – Specialist		•		
Tab 400 mg		50	~	Uromitexan
Tab 600 mg		50	~	Uromitexan
Inj 100 mg per ml, 4 ml ampoule		15	~	Uromitexan
Inj 100 mg per ml, 10 ml ampoule		15	~	Uromitexan
Inj 1 mg for ECP		100 mg	~	Baxter
MITOMYCIN C – PCT only – Specialist				
Inj 5 mg vial		1	~	Arrow
Inj 1 mg for ECP	16.43	1 mg	~	Baxter
MITOZANTRONE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml	110.00	1	~	Mitozantrone Ebewe
Inj 2 mg per ml, 10 ml		1	~	Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml	407.50	1	~	Onkotrone
Inj 1 mg for ECP	5.65	1 mg	~	Baxter
PACLITAXEL – PCT only – Specialist				
Inj 30 mg		5	~	Paclitaxel Ebewe
Inj 100 mg	91.67	1	~	Paclitaxel Actavis
			~	Paclitaxel Ebewe
Inj 150 mg		1	~	Anzatax
			~	Paclitaxel Actavis
			~	Paclitaxel Ebewe
Inj 300 mg	275.00	1	~	Anzatax
			~	Paclitaxel Actavis
			~	Paclitaxel Ebewe
Inj 600 mg	550.00	1	~	Paclitaxel Ebewe
Inj 1 mg for ECP		1 mg	~	Baxter
PEGASPARGASE - PCT only - Special Authority see SA132	5 below			
Inj 3,750 IU per 5 ml	3,005.00	1	~	Oncaspar S29
SA1325 Special Authority for Subsidy				
Initial application only from a relevant specialist or medical pravalid for 12 months for applications meeting the following criteri All of the following:		commenda	tion of a re	elevant specialist. Approvals
1 The patient has newly diagnosed acute lymphoblastic le	ukaemia; and			
2 Pegaspargase to be used with a contemporary intensive		otherapy tre	eatment p	rotocol; and
3 Treatment is with curative intent.				
Renewal only from a relevant specialist or medical practitioner 12 months for applications meeting the following criteria:	on the recommend	dation of a	relevant s	pecialist. Approvals valid for
All of the following:				
1 The patient has relapsed acute lymphoblastic leukaemia	and			
2 Pegaspargase to be used with a contemporary intensive		otherapy tre	eatment p	rotocol; and
3 Treatment is with curative intent.			P	- ,
PENTOSTATIN [DEOXYCOFORMYCIN] - PCT only - Specia	list			
Inj 10 mg	CBS	1	~	Nipent S29

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
PROCARBAZINE HYDROCHLORIDE - PCT only - Specialist				
Cap 50 mg	225.00	50	🖌 N	latulan S29
TEMOZOLOMIDE - Special Authority see SA1063 below - Retai	l pharmacy			
Cap 5 mg	8.00	5	🖌 T	emaccord
Cap 20 mg		5	🖌 T	emaccord
Cap 100 mg	175.00	5	✓ T	emaccord
Cap 250 mg	410.00	5	/ <u>T</u>	emaccord

SA1063 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m².

Notes: Indication marked with a * is an Unapproved Indication. Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved.

Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

THALIDOMIDE - PCT only - Specialist - Special Authority see SA1124 below

🖌 Thalomid	28	Cap 50 mg
Thalomid	28	Cap 100 mg1,008.00

➡SA1124 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period. Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen. Indication marked with * is an Unapproved Indication.

TRETINOIN

Cap 10 mg – PCT – Retail pharmacy-Specialist	100	 Vesanoid
VINBLASTINE SULPHATE		
Inj 10 mg – PCT – Retail pharmacy-Specialist	1	Hospira
137.50	5	 Hospira
Inj 1 mg for ECP – PCT only – Specialist	1 mg	 Baxter
VINCRISTINE SULPHATE		
Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist64.80	5	 Hospira
Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	5	Hospira
Inj 1 mg for ECP – PCT only – Specialist	1 mg	 Baxter

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
/INORELBINE – PCT only – Specialist				
Inj 10 mg per ml, 1 ml		1	V N	lavelbine
	42.00		🖌 V	inorelbine Ebewe
Inj 10 mg per ml, 5 ml	64.25	1	V N	lavelbine
	210.00		🖌 V	inorelbine Ebewe
Inj 1 mg for ECP	1.45	1 mg	🖌 В	axter
Protein-tyrosine Kinase Inhibitors				
ASATINIB – Special Authority see SA0976 below				
Tab 20 mg	3,774.06	60	🗸 S	prycel
Tab 50 mg		60	🖌 S	prycel
Tab 70 mg		60	🗸 S	prycel
Tab 100 mg		30	🗸 S	prycel

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz, and prescriptions should be sent to: The CML /CIST Co. ordinator Phone: (04) 460 4000

The CIVIL/GIST CO-Orumator	FIIONE. (04) 400 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: mary.chesterfield@pharmac.govt.nz
Mallington	

Wellinaton

Special Authority criteria for CML - access by application

- a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase,
- b) Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response. and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5×10^{9} /L, platelets > 100×10^{9} /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35%) metaphases), and absence of extramedullary disease); or
 - 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0×10^9 /L, platelets > $20 \times$ 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases). and absence of extramedullary disease): or
 - return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

ERLOTINIB HYDROCHLORIDE	- Retail pharmacy-Specialist - Special Authority	see SA104	4 on the next page
Tab 100 mg		30	 Tarceva
Tab 150 mg	3 950 00	30	

Subsidy (Manufacturer's Price)	Subs	Fully	Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1044 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has advanced, unresectable, Non Small Cell Lung Cancer (NSCLC); and
- 2 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
- 3 Erlotinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB - Retail pharmacy-Specialist

Tab 250 mg − Special Authority see SA1226 below......1,700.00 30 V Iressa

➡SA1226 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has treatment naive locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
 - 1.2 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
 - 1.3 Gefitinib is to be given for a maximum of 3 months; or
- 2 The patient received gefitinib treatment prior to 1 August 2012 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE - Special Authority see SA0643 below

Tab 100 mg	2,400.00	60	 Glivec
------------	----------	----	----------------------------

SA0643 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <u>http://www.pharmac.govt.nz</u>, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: mary.chesterfield@pharmac.govt.nz

Wellington

Special Authority criteria for CML – access by application

- a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- b) Maximum dose of 600 mg/day for accelerated or blast phase, and 400 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Guideline on discontinuation of treatment for patients with CML

a) Prescribers should consider discontinuation of treatment if after 6 months from initiating therapy a patient did not obtain a haematological response as defined as any one of the following three levels of response:

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > $1.5 \times 10^9/L$, platelets > $100 \times 10^9/L$, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
- 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0×10^9 /L, platelets > 20×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
- return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if after 18 months from initiating therapy a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

Special Authority criteria for GIST - access by application

- a) Funded for patients:
 - 1) with a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal turnour (GIST); and
 - 2) who have immunohistochemical documentation of c-kit (CD117) expression by the tumour.
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).
- LAPATINIB DITOSYLATE Special Authority see SA1191 below Retail pharmacy

SA1191 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Lapatinib not to be given in combination with trastuzumab; and
 - 1.4 Lapatinib to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on trastuzumab; and
 - 2.4 Lapatinib not to be given in combination with trastuzumab; and
 - 2.5 Lapatinib to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
- 3 Lapatinib not to be given in combination with trastuzumab; and
- 4 Lapatinib to be discontinued at disease progression.

PAZOPANIB – Special Authority see SA1190 on the next page – Retail pharmacy Tab 200 mg 1 334 70 30

Tab 200 mg	1,334.70	30	Votrient
Tab 400 mg	2,669.40	30	 Votrient

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

SA1190 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and

The patient has intermediate or poor prognosis defined as:

- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 \geq 2 sites of organ metastasis; and
- 6 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

SUNITINIB - Special Authority see SA1266 below - Retail pharmacy

Cap 12.5 mg2,315.38	28	Sutent
Cap 25 mg4,630.77	28	 Sutent
Cap 50 mg9,261.54	28	 Sutent

➡SA1266 Special Authority for Subsidy

Initial application — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and

Subsidy		Fully	Brand or
(Manufacturer's Price)	:	Subsidised	Generic
\$	Per	~	Manufacturer

continued...

The patient has intermediate or poor prognosis defined as:

- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 \geq 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and

2 Either:

- 2.1 The patient's disease has progressed following treatment with imatinib; or
- 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 No evidence of disease progression; and

2 The treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of ≥ 10% or decrease in tumour density in Hounsfield Units (HU) of ≥ 15% on CT and no new lesions and no obvious progression of non measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.
- Notes: RCC Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6

GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of $\geq 10\%$ and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Endocrine Therapy

For GnRH ANALOGUES – refer to HORMONE PREPARATIONS, Trophic Hormones, page 87

BICALUTAMIDE - Special Authority see SA0941 below - Retail pharmacy

Tab 50 mg10.00

Bicalaccord

SA0941 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the patient has advanced prostate cancer.

28

(Subsidy Manufacturer's Price \$) Per	Ful Subsidise	1
FLUTAMIDE – Retail pharmacy-Specialist				
Tab 250 mg	16.50	30	~	Flutamin S29 S29
	55.00	100	~	Flutamin
MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg	51.55	30	~	Apo-Megestrol
DCTREOTIDE (SOMATOSTATIN ANALOGUE) Inj 50 mcg per ml, 1 ml	19 24	5	~	Octreotide MaxRx
Inj 100 mcg per ml, 1 ml		5		Octreotide MaxRx
Inj 500 mcg per ml, 1 ml		5	V	Octreotide MaxRx
OCTREOTIDE LAR (SOMATOSTATIN ANALOGUE) – Special Auth	ority see SA1016	below	– Retail p	bharmacy
Inj LAR 10 mg prefilled syringe	.1,772.50	1	V	Sandostatin LAR
Inj LAR 20 mg prefilled syringe		1	~	Sandostatin LAR
Inj LAR 30 mg prefilled syringe	.2,951.25	1	~	Sandostatin LAR

SA1016 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.
- Note: Indications marked with * are Unapproved Indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 The patient has acromedaly: and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 VIPomas and Glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.1 Gastrinoma; and
- 2.2 Either:
 - 2.2.1 Patient has failed surgery; or

2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or

3 Both:

- 3.1 Insulinomas; and
- 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

TAMOXIFEN CITRATE

*	Tab 10 mg2.63	60	Genox
	17.50	100	Genox
*	Tab 20 mg2.63	30	Genox
	8.75	100	✓ Genox

Aromatase Inhibitors

ANASTROZOLE * Tab 1 mg26.55	30	 ✓ Aremed ✓ Arimidex ✓ DP-Anastrozole
EXEMESTANE * Tab 25 mg22.57	30	✓ <u>Aromasin</u>
LETROZOLE * Tab 2.5 mg4.85	30	✓ Letraccord

Immunosuppressants

Cytotoxic Immunosuppressants

AZATHIOPRINE – Retail pharmacy-Specialist			
* Tab 50 mg – For azathioprine oral liquid formulation refer,			
page 194	18.45	100	 Imuprine Imuran
* Inj 50 mg (Imuran Tab 50 mg to be delisted 1 March 2014)	60.00	1	 Imuran

	Subsidy (Manufacturer's Pric \$	e) Sub Per	Fully osidised	Brand or Generic Manufacturer
MYCOPHENOLATE MOFETIL – Special Authority see SA1041 k	oelow – Retail pharr	nacy		
Dispensing pharmacy should check which brand to dispense	with the prescriber	if prescribe	d generi	ically.
Tab 500 mg		50	V C	ellcept
-			🖌 M	yaccord
	(60.00)		С	eptolate
Cap 250 mg		100	V C	ellcept
				vaccord
	12.50	50		,
	(30.00)		С	eptolate
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement	· · · ·	165 ml OP		ellcept

Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

(Myaccord Tab 500 mg to be delisted 1 February 2014)

(Ceptolate Tab 500 mg to be delisted 1 February 2014)

(Myaccord Cap 250 mg to be delisted 1 February 2014)

(Ceptolate Cap 250 mg to be delisted 1 February 2014)

SA1041 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Transplant recipient; or
- 2 Both:
 - Patients with diseases where
 - 2.1 Steroids and azathioprine have been trialled and discontinued because of unacceptable side effects or inadequate clinical response; and
 - 2.2 Either:
 - Patients with diseases where
 - 2.2.1 Cyclophosphamide has been trialled and discontinued because of unacceptable side effects or inadequate clinical response; or
 - 2.2.2 Cyclophosphamide treatment is contraindicated.

Fusion Proteins

ETANERCEPT – Special Authority see SA1372 below – Retail pharmacy		
Inj 25 mg	4	 Enbrel
Inj 50 mg autoinjector1,899.92	4	 Enbrel
Inj 50 mg prefilled syringe1,899.92	4	 Enbrel

➡SA1372 Special Authority for Subsidy

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
- 2 All of the following:

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

- 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
- 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and 1.2 Fither:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
- 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

- 18-24 years Male: 7.0 cm; Female: 5.5 cm
- 25-34 years Male: 7.5 cm; Female: 5.5 cm
- 35-44 years Male: 6.5 cm; Female: 4.5 cm
- 45-54 years Male: 6.0 cm; Female: 5.0 cm
- 55-64 years Male: 5.5 cm; Female: 4.0 cm
- 65-74 years Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:

Subsidy (Manufacturer)		
\$	Per 🖌	Manufacturer

continued...

- 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
 - 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
 - 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.
- Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

Subsidy	Fully		
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

- 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Either:

- 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist Inj 50 mg per ml, 5 ml2,137.50	5	🖌 ATGAM
BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist Subsidised only for bladder cancer. Inj 2-8 × 100 million CFU	1	✔ OncoTICE
Monoclonal Antibodies		
ADALIMUMAB – Special Authority see SA1371 below – Retail pharmacy		
Inj 20 mg per 0.4 ml prefilled syringe1,799.92	2	🖌 Humira
Inj 40 mg per 0.8 ml prefilled pen1,799.92	2	HumiraPen
Inj 40 mg per 0.8 ml prefilled syringe1,799.92	2	🖌 Humira

SA1371 Special Authority for Subsidy

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or

2 All of the following:

- 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
- 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
\$	Per	~	Manufacturer

continued...

- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

- 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
- 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (Crohn's disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and

1.2 Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1.2.1 The patient has experienced intolerable side effects from etanercept; or
- 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for juvenile idiopathic arthritis; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient diagnosed with JIA; and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Initial application — (fistulising Crohn's disease) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

- 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
- 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application; and
- 4 The patient will be assessed for response to treatment after 4 months' adalimumab treatment (see Note).

Note: A maximum of 4 months' adalimumab will be subsidised on an initial Special Authority approval for fistulising Crohn's disease. **Renewal** — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
 - 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Renewal — (Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

Subsidy (Manufacturer's Price)	Sub	Fully sidised	Brand or Generic
\$	Per	~	Manufacturer

continued...

- 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
- 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
 - 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Either:

- 1.1 Applicant is a named specialist or rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:

Subsidy	Fu	y Brand or	
(Manufacturer's	Price) Subsidise	d Generic	
\$	Per	 Manufacturer 	

continued...

- 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both: 1 Either:

- 1.1 Applicant is a gastroenterologist; or
- 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Either:

- 2.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

RITUXIMAB - PCT only - Specialist - Special Authority see SA1152 below

Inj 100 mg per 10 ml vial	2	 Mabthera
Inj 500 mg per 50 ml vial2,688.30	1	 Mabthera
Inj 1 mg for ECP5.64	1 mg	 Baxter

➡SA1152 Special Authority for Subsidy

Initial application — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.
- Note: Indications marked with * are Unapproved Indications.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 6 treatment cycles; or

2 Both:

- 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or

2 Both:

2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and

2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

Initial application — (Chronic Lymphocytic Leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance \geq 30 ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Renewal — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

TRASTUZUMAB	- PCT only - Specialist - Special Authority see SA1192 on	the next page	
lnj 150 mg vial		1	 Herceptin
Inj 440 mg vial		1	 Herceptin
Inj 1 mg for EC	P9.36	1 mg	 Baxter

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

➡SA1192 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Trastuzumab not to be given in combination with lapatinib; and
 - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on lapatinib; and
 - 2.4 Trastuzumab not to be given in combination with lapatinib; and
 - 2.5 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

Initial application — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
 - 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
 - 3 Any of the following:
 - 3.1 All of the following:
 - 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
 - 3.1.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.1.3 Trastuzumab to be discontinued at disease progression; or
 - 3.2 All of the following:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
- 3.2.2 The cancer did not progress whilst on lapatinib; and
- 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
- 3.2.4 Trastuzumab to be discontinued at disease progression; or
- 3.3 All of the following:
 - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.3.3 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Other Immunosuppressants

CYCLOSPORIN

Cap 25 mg Cap 50 mg Cap 100 mg		50 50 50	 ✓ Neoral ✓ Neoral ✓ Neoral
Oral liq 100 mg per ml SIROLIMUS – Special Authority see SA0866 below – Retail		50 ml OP	✓ <u>Neoral</u>
Tab 1 mg	, ,	100	 Rapamune
Tab 2 mg Oral liq 1 mg per ml		100 60 ml OP	RapamuneRapamune

➡SA0866 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR<30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- . HUS or TTP; or
- · Leukoencepthalopathy; or
- Significant malignant disease

TACROLIMUS – Special Authority see SA0669 below – Retail pharmacy

Cap 0.5 mg	214.00	100	Prograf
Cap 1 mg	428.00	100	Prograf
Cap 5 mg - For tacrolimus oral liquid formulation refer, page			
194	1,070.00	50	 Prograf

►SA0669 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

Subsidy (Manufacturer's F \$	Price) Su Per	Fully Brand or Ibsidised Generic Manufacturer
Antiallergy Preparations		
SA1367 Special Authority for Subsidy		
Initial application only from a relevant specialist. Approvals valid for 2 years for a	pplications m	eeting the following criteria:
Both:		
 RAST or skin test positive; and Patient has had severe generalised reaction to the sensitising agent. 		
Renewal only from a relevant specialist. Approvals valid for 2 years where the t benefiting from treatment.	reatment rem	ains appropriate and the patient is
BEE VENOM ALLERGY TREATMENT – Special Authority see SA1367 above – I Maintenance kit - 6 vials 120 mcg freeze dried venom, 6 dilu-	Retail pharma	су
ent 1.8 ml	1 OP	✓ Albay
Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluent		
9 ml, 3 diluent 1.8 ml285.00	1 OP	Albay
WASP VENOM ALLERGY TREATMENT - Special Authority see SA1367 above -	- Retail pharn	nacy
Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze		
dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml	1 OP	Albay
Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze		4
dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml	1 OP	Albay
Antihistamines		
CETIRIZINE HYDROCHLORIDE		
* Tab 10 mg1.59	100	✓ <u>Zetop</u>
*‡ Oral liq 1 mg per ml3.52	200 ml	Cetirizine - AFT
CHLORPHENIRAMINE MALEATE		
*‡ Oral liq 2 mg per 5 ml8.06	500 ml	 Histafen
DEXTROCHLORPHENIRAMINE MALEATE		
* Tab 2 mg1.01	20	
(5.99)		Polaramine
2.02	40	Delevensine
(8.40) *‡ Oral liq 2 mg per 5 ml	100 ml	Polaramine
(10.29)	100 111	Polaramine
FEXOFENADINE HYDROCHLORIDE		
* Tab 60 mg	20	
(11.53)	20	Telfast
* Tab 120 mg	10	
(11.53)		Telfast
14.22	30	
(29.81)		Telfast
LORATADINE		
* Tab 10 mg1.30	100	✓ Lorafix
(2.09)		Loraclear Hayfever Relief
* Oral liq 1 mg per ml	100 ml	Lorapaed
(Loraclear Hayfever Relief Tab 10 mg to be delisted 1 March 2014)		-

	Subsidy (Manufacturer's \$	Price) Subs Per	Fully Brand or sidised Generic ✔ Manufacturer
PROMETHAZINE HYDROCHLORIDE * Tab 10 mg * Tab 25 mg ** Oral liq 5 mg per 5 ml * Inj 25 mg per ml, 2 ml	2.99 2.79	50 50 100 ml 5	 ✓ <u>Allersoothe</u> ✓ <u>Allersoothe</u> ✓ <u>Allersoothe</u> ✓ <u>Hospira</u>
TRIMEPRAZINE TARTRATE ‡ Oral liq 30 mg per 5 ml	2.79 (8.06)	100 ml OP	Vallergan Forte
Inhaled Corticosteroids			
BECLOMETHASONE DIPROPIONATE Aerosol inhaler, 50 mcg per dose CFC-free Aerosol inhaler, 100 mcg per dose CFC-free Aerosol inhaler, 250 mcg per dose CFC-free		200 dose OP 200 dose OP 200 dose OP	 ✓ Beclazone 50 ✓ Beclazone 100 ✓ Beclazone 250
BUDESONIDE Powder for inhalation, 100 mcg per dose	17.00	200 dose OP	 Pulmicort Turbuhaler
Powder for inhalation, 200 mcg per dose	15.20 19.00	200 dose OP	 Budenocort Pulmicort Turbuhaler
Powder for inhalation, 400 mcg per dose	25.60 32.00	200 dose OP	✓ Budenocort ✓ Pulmicort Turbuhaler
(Budenocort Powder for inhalation, 200 mcg per dose to be delisi (Budenocort Powder for inhalation, 400 mcg per dose to be delisi			Turbunaler
FLUTICASONE Aerosol inhaler, 50 mcg per dose CFC-free Powder for inhalation, 50 mcg per dose Powder for inhalation, 100 mcg per dose Aerosol inhaler, 125 mcg per dose CFC-free Aerosol inhaler, 250 mcg per dose CFC-free Powder for inhalation, 250 mcg per dose	7.50 7.50 13.60 27.20	120 dose OP 60 dose OP 60 dose OP 120 dose OP 120 dose OP 60 dose OP	 Flixotide Flixotide Accuhaler Flixotide Accuhaler Flixotide Flixotide Flixotide Flixotide Accuhaler

Inhaled Long-acting Beta-adrenoceptor Agonists

Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor Agonists

The addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended:

- For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).
- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).

Note:

Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).

	Subsidy (Manufacturer's \$	Price) Subs Per	Fully sidised	Brand or Generic Manufacturer
EFORMOTEROL FUMARATE – See prescribing guideline on the	previous page			
Powder for inhalation, 6 mcg per dose, breath activated		60 dose OP	0	xis Turbuhaler
Powder for inhalation, 12 mcg per dose, and monodose de-				
vice	20.64 (35.80)	60 dose	F	oradil
SALMETEROL - See prescribing guideline on the previous page				
Aerosol inhaler CFC-free, 25 mcg per dose		120 dose OP	V S	erevent
Powder for inhalation, 50 mcg per dose, breath activated	26.46	60 dose OP	🗸 S	erevent Accuhaler
Inhaled Corticosteroids with Long-Acting Beta-	Adrenocepto	or Agonists		
SA1170 Special Authority for Subsidy				

►SA1179 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 All of the following:

- 1.1 Patient is a child under the age of 12; and
- 1.2 Has been treated with inhaled corticosteroids of at least 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone; and
- 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- 2 All of the following:
 - 2.1 Patient is over the age of 12; and
 - 2.2 Has been treated with inhaled corticosteroids of at least 800 mcg per day beclomethasone or budesonide, or 500 mcg per day fluticasone; and
 - 2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

BUDESONIDE WITH EFORMOTEROL – Special Authority see SA1179 above Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg26.49 Powder for inhalation 100 mcg with eformoterol fumarate	 Retail pharmacy 120 dose OP 	
6 mcg	120 dose OP	 Symbicort Turbuhaler 100/6
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg31.25 Powder for inhalation 200 mcg with eformoterol fumarate	120 dose OP	🗸 Vannair
6 mcg60.00	120 dose OP	 Symbicort Turbuhaler 200/6
Powder for inhalation 400 mcg with eformoterol fumarate		
12 mcg – No more than 2 dose per day60.00	60 dose OP	 Symbicort Turbuhaler 400/12
FLUTICASONE WITH SALMETEROL - Special Authority see SA1179 above -	Retail pharmacy	
Aerosol inhaler 50 mcg with salmeterol 25 mcg	120 dose OP	 Seretide
Aerosol inhaler 125 mcg with salmeterol 25 mcg	120 dose OP	 Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg – No		
more than 2 dose per day	60 dose OP	 Seretide Accuhaler
Powder for inhalation 250 mcg with salmeterol 50 mcg – No more than 2 dose per day	60 dose OP	✓ Seretide Accuhaler

_		Out state		Fully Duradian
		Subsidy (Manufacturer's		Fully Brand or sidised Generic
		\$	Per	 Manufacturer
Be	ta-Adrenoceptor Agonists			
SALE	BUTAMOL			
-	Oral liq 400 mcg per ml		150 ml	 Salapin
	nfusion 1 mg per ml, 5 ml	2.06 118.38	10	✓ Ventolin
		(130.21)		Ventolin
	nj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO	12.90	5	✓ Ventolin
Inh	aled Beta-Adrenoceptor Agonists			
SALE	BUTAMOL			
1	Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000	0.00		
	dose available on a PSO		200 dose OP	 Respigen Salamol
		(6.00)		Ventolin
I	Nebuliser soln, 1 mg per ml, 2.5 ml – Up to 30 neb available on a PSO	2.05	20	✓ Asthalin
I	Nebuliser soln, 2 mg per ml, 2.5 ml – Up to 30 neb available		20	Astriant
	on a PSO	3.44	20	✓ <u>Asthalin</u>
	BUTALINE SULPHATE	00.00	200 dose OP	
	Powder for inhalation, 250 mcg per dose, breath activated	22.00	200 dose OP	 Bricanyl Turbuhaler
Inn	aled Anticholinergic Agents			
		40.00	000 I 0D	/ • .
	Aerosol inhaler, 20 mcg per dose CFC-free Nebuliser soln, 250 mcg per ml, 1 ml – Up to 40 neb available		200 dose OP	 Atrovent
	on a PSO		20	✓ <u>Univent</u>
I	Nebuliser soln, 250 mcg per ml, 2 ml – Up to 40 neb available	0.07	00	
TIOT	on a PSO		20	✓ <u>Univent</u>
	ROPIUM BROMIDE – Special Authority see SA1193 below - Powder for inhalation, 18 mcg per dose		acy 30 dose	✓ Spiriva
	A1193 Special Authority for Subsidy			
	Il application only from a general practitioner or relevant sp	ecialist. Appro	vals valid for 2 y	ears for applications meeting th
	ving criteria: the following:			
1	To be used for the long-term maintenance treatment of brow			
2	2 In addition to standard treatment, the patient has trialled a sone month; and	short acting bro	onchodilator of at	least 40 mcg ipratropium q.i.d fo
3	B Either:			
	The patient's breathlessness according to the Medic			
	 3.1 Grade 4 (stops for breath after walking about 100 m 3.2 Grade 5 (too breathless to leave the house, or breat 			
	Applicant must state recent measurement of:		0	U
2	 All of the following: 4.1 Actual FEV₁ (litres); and 			
	4.1 Actual EV1 (intes); and 4.2 Predicted FEV_1 (litres); and			
	4.3 Actual FEV ₁ as a % of predicted (must be below 60	%); and		
Ę	5 Either:			continued
				continuou

continued...

- 5.1 Patient is not a smoker (for reporting purposes only); or
- 5.2 Patient is a smoker and has been offered smoking cessation counselling; and

6 The patient has been offered annual influenza immunisation.

Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined); and Applicant must state recent measurement of:
- 3 All of the following:
 - 3.1 Actual FEV_1 (litres); and
 - 3.2 Predicted FEV₁ (litres); and
 - 3.3 Actual FEV_1 as a % of predicted.

Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents

SALBUTAMOL WITH IPRATROPIUM BROMIDE

Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free	200 dose OP	🗸 Duolin HFA
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per		
vial, 2.5 ml – Up to 20 neb available on a PSO	20	✓ <u>Duolin</u>

Leukotriene Receptor Antagonists

MONTELUKAST - Special Authority see SA1409 below - Retail pharmacy

Prescribing Guideline: Clinical evidence indicates that the effectiveness of montelukast is strongest when montelukast is used in short treatment courses.

Tab 4 mg	28	Singulair
Tab 5 mg	28	Singulair
Tab 10 mg	28	 Singulair

➡SA1409 Special Authority for Subsidy

Initial application — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 To be used for the treatment of intermittent severe wheezing (possibly viral); and
- 2 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

Renewal — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (exercise-induced asthma) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been trialled with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
- 2 Patient continues to receive optimal inhaled corticosteroid therapy; and
- 3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

Initial application — (aspirin desensitisation) only from a clinical immunologist or allergist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

Subsidy (Manufacturer's Pric \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer	
---------------------------------------	-----------	---------------------	-------------------------------------	--

- 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and
- 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
- 3 Nasal polyposis, confirmed radiologically or surgically; and
- 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

Mast Cell Stabilisers			
NEDOCROMIL Aerosol inhaler, 2 mg per dose CFC-free		112 dose OP	✔ Tilade
SODIUM CROMOGLYCATE Powder for inhalation, 20 mg per dose Aerosol inhaler, 5 mg per dose CFC-free		50 dose 112 dose OP	✓ Intal Spincaps✓ Intal Forte CFC Free
Methylxanthines			
AMINOPHYLLINE * Inj 25 mg per ml, 10 ml – Up to 5 inj available or THEOPHYLLINE	n a PSO53.75	5	✓ DBL Aminophylline
* Tab long-acting 250 mg *‡ Oral liq 80 mg per 15 ml		100 500 ml	✓ Nuelin-SR✓ Nuelin
Mucolytics			
DORNASE ALFA – Special Authority see SA0611 be Nebuliser soln, 2.5 mg per 2.5 ml ampoule		6	✓ Pulmozyme
► SA0611 Special Authority for Subsidy Special Authority approved by the Cystic Fibrosis Adv Notes: Application details may be obtained from PHA		w.pharmac.govt.ı	nz or:
The Co-ordinator, Cystic Fibrosis Advisory Panel PHARMAC, PO Box 10 254 Wellington	Phone: (04) 460 4990 Facsimile: (04) 916 7571 Email: CFPanel@pharm		_
Prescriptions for patients approved for treatment must and expertise in treating cystic fibrosis.	st be written by respiratory	physicians or pa	ediatricians who have experience
SODIUM CHLORIDE Not funded for use as a nasal drop. Soln 7%	23.50	90 ml OP	✔ Biomed
Nasal Preparations			
Allergy Prophylactics			
BECLOMETHASONE DIPROPIONATE Metered aqueous nasal spray, 50 mcg per dose		200 dose OP	
Metered aqueous nasal spray, 100 mcg per dose		200 dose OP	Alanase
	(5.75)		Alanase

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic Manufacturer
BUDESONIDE			
Metered aqueous nasal spray, 50 mcg per dose	2.35	200 dose OP	
	(4.85)		Butacort Aqueous
Metered aqueous nasal spray, 100 mcg per dose		200 dose OP	.
	(5.75)		Butacort Aqueous
FLUTICASONE PROPIONATE			
Metered aqueous nasal spray, 50 mcg per dose	2.30	120 dose OP	Flixonase Hayfever & Allergy
IPRATROPIUM BROMIDE			
Aqueous nasal spray, 0.03%	4.03	15 ml OP	✓ Univent
Respiratory Devices			
MASK FOR SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under Size 2	2.99	1	✓ <u>EZ-fit Paediatric</u>
PEAK FLOW METER a) Up to 10 dev available on a PSO b) Only on a PSO Low range	11.44	1	<u>Mask</u> ✔ Breath-Alert
Normal range	11.44	1	Breath-Alert
SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO			
230 ml (single patient)	4.72	1	Space Chamber Plus
800 ml	8.50	1	✓ Volumatic
SPACER DEVICE AUTOCLAVABLE a) Up to 5 dev available on a PSO b) Only on a PSO 230 ml (autoclavable) – Subsidy by endorsement Available where the prescriber requires a spacer device endorsed accordingly.		1 e of sterilisation	✓ Space Chamber in an autoclave and the PSO is
Respiratory Stimulants			
CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml)		25 ml OP	✓ Biomed

	Subsidy (Manufacturer's I	Price) Sut	Fully Brand or osidised Generic
	\$	Per	 Manufacturer
Ear Preparations			
CETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BEN	IZETHONIUM		
For Vosol ear drops with hydrocortisone powder refer, page 1			
Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02%		35 ml OP	✔ Vosol
HLORAMPHENICOL	0.07		• • • • • • • • • • • • • • • • • • • •
Ear drops 0.5%	2.20	5 ml OP	 Chloromycetin
Chloromycetin Ear drops 0.5% to be delisted 1 February 2014)			•
LUMETASONE PIVALATE			
Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	 Locacorten-Viaform ED's
			∠Ds ✓ Locorten-Vioform
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCI	N AND NYSTAT	IN	
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate			
2.5 mg and gramicidin 250 mcg per g		7.5 ml OP	 Kenacomb
Ear/Eye Preparations			
EXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and			
gramicidin 50 mcg per ml	4.50	8 ml OP	
	(9.27)		Sofradex
	4 10	8 ml OP	
Ear/Eye drops 0.5%	4.13 (8.65)	8 III OP	Soframycin
Eye Preparations	()		,,,,,,,
ye preparations are only funded for use in the eye, unless explici	tly stated other	WISE.	
Anti-Infective Preparations			
CICLOVIR			
Eye oint 3%	37.53	4.5 g OP	🗸 Zovirax
HLORAMPHENICOL		-	🗸 Zovirax
HLORAMPHENICOL Eye oint 1%	2.76	4 g OP	✓ Chlorsig
Eye drops 0.5%	2.76 1.20	4 g OP 10 ml OP	
HLORAMPHENICOL Eye oint 1% Eye drops 0.5% Funded for use in the ear*. Indications marked with * are U	2.76 1.20	4 g OP 10 ml OP	✓ Chlorsig
HLORAMPHENICOL Eye oint 1% Eye drops 0.5% Funded for use in the ear*. Indications marked with * are U PROFLOXACIN Eye Drops 0.3%	2.76 1.20 Jnapproved India 12.43	4 g OP 10 ml OP cations. 5 ml OP	 ✓ <u>Chlorsig</u> ✓ <u>Chlorafast</u> ✓ Ciloxan
HLORAMPHENICOL Eye oint 1% Eye drops 0.5% Funded for use in the ear*. Indications marked with * are U PROFLOXACIN Eye Drops 0.3% For treatment of bacterial keratitis or severe bacterial conju	2.76 1.20 Jnapproved India 12.43	4 g OP 10 ml OP cations. 5 ml OP	 ✓ <u>Chlorsig</u> ✓ <u>Chlorafast</u> ✓ Ciloxan
HLORAMPHENICOL Eye oint 1% Eye drops 0.5% Funded for use in the ear*. Indications marked with * are U PROFLOXACIN Eye Drops 0.3% For treatment of bacterial keratitis or severe bacterial conju JSIDIC ACID		4 g OP 10 ml OP cations. 5 ml OP nt to chloramph	Chlorsig Chlorafast Chlorafast Ciloxan nenicol.
HLORAMPHENICOL Eye oint 1% Eye drops 0.5% Funded for use in the ear*. Indications marked with * are U PROFLOXACIN Eye Drops 0.3% For treatment of bacterial keratitis or severe bacterial conju JSIDIC ACID Eye drops 1%		4 g OP 10 ml OP cations. 5 ml OP	 ✓ <u>Chlorsig</u> ✓ <u>Chlorafast</u> ✓ Ciloxan
HLORAMPHENICOL Eye oint 1% Eye drops 0.5% Funded for use in the ear*. Indications marked with * are U PROFLOXACIN Eye Drops 0.3% For treatment of bacterial keratitis or severe bacterial conju JSIDIC ACID Eye drops 1%		4 g OP 10 ml OP cations. 5 ml OP nt to chloramph	 <u>Chlorsig</u> <u>Chlorafast</u> <u>Ciloxan</u> <u>Ciloxan</u> <u>Fucithalmic</u>
HLORAMPHENICOL Eye oint 1% Eye drops 0.5% Funded for use in the ear*. Indications marked with * are U PROFLOXACIN Eye Drops 0.3% For treatment of bacterial keratitis or severe bacterial conju JSIDIC ACID Eye drops 1% ENTAMICIN SULPHATE Eye drops 0.3%		4 g OP 10 ml OP cations. 5 ml OP nt to chloramph 5 g OP	Chlorsig Chlorafast Chlorafast Ciloxan nenicol.
HLORAMPHENICOL Eye oint 1% Eye drops 0.5% Funded for use in the ear*. Indications marked with * are U IPROFLOXACIN Eye Drops 0.3% For treatment of bacterial keratitis or severe bacterial conju USIDIC ACID Eye drops 1% ENTAMICIN SULPHATE		4 g OP 10 ml OP cations. 5 ml OP nt to chloramph 5 g OP	 <u>Chlorsig</u> <u>Chlorafast</u> <u>Ciloxan</u> <u>Ciloxan</u> <u>Fucithalmic</u>

	Subsidy		Fully Brand or		
	(Manufacturer's F	,	sidised Generic		
	\$	Per	Manufacturer		
	10.15	0.5 × 0.0			
Eye oint 0.3% Eye drops 0.3%		3.5 g OP 5 ml OP	✓ <u>Tobrex</u> ✓ Tobrex		
Corticosteroids and Other Anti-Inflammatory Pr		5111101			
•	-1				
DEXAMETHASONE * Eye oint 0.1%	5 86	3.5 g OP	✓ Maxidex		
* Eye drops 0.1%		5 ml OP	Maxidex		
DEXAMETHASONE WITH NEOMYCIN AND POLYMYXIN B SU	LPHATE				
✤ Eye oint 0.1% with neomycin sulphate 0.35% and polymyxir	า				
B sulphate 6,000 u per g		3.5 g OP	✓ Maxitrol		
Eye drops 0.1% with neomycin sulphate 0.35% and polymy xin B sulphate 6,000 u per ml		5 ml OP	✓ Maxitrol		
DICLOFENAC SODIUM	4.50	511101			
* Eye drops 1 mg per ml		5 ml OP	Voltaren Ophtha		
FLUOROMETHOLONE			.		
* Eye drops 0.1%		5 ml OP	✓ Flucon		
EVOCABASTINE					
Eye drops 0.5 mg per ml		4 ml OP			
	(10.34)		Livostin		
ODOXAMIDE TROMETAMOL Eye drops 0.1%	8 71	10 ml OP	✓ Lomide		
PREDNISOLONE ACETATE					
Eye drops 0.12%		5 ml OP	✓ Pred Mild		
* Eye drops 1%		5 ml OP	✓ Pred Forte		
SODIUM CROMOGLYCATE					
Eye drops 2%	1.18	5 ml OP	Rexacrom		
Glaucoma Preparations - Beta Blockers					
BETAXOLOL HYDROCHLORIDE					
* Eye drops 0.25%		5 ml OP	Betoptic S		
₭ Eye drops 0.5%		5 ml OP	Betoptic		
.EVOBUNOLOL ₭ Eye drops 0.25%	7.00	5 ml OP	✓ Betagan		
 ► Eye drops 0.5% 	7.00	5 ml OP	✓ Betagan		
TIMOLOL MALEATE					
* Eye drops 0.25%		5 ml OP	Arrow-Timolol		
 ₭ Eye drops 0.25%, gel forming ₭ Eye drops 0.5% 		2.5 ml OP 5 ml OP	 Timoptol XE Arrow-Timolol 		
 Eye drops 0.5%, gel forming 		2.5 ml OP	4		
Glaucoma Preparations - Carbonic Anhydrase I			•		
ACETAZOLAMIDE					
 Tab 250 mg – For acetazolamide oral liquid formulation refer 					
page 194		100	✓ Diamox		
BRINZOLAMIDE					
* Eye Drops 1%	0.77	5 ml OP	✓ Azopt		

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once ▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or sidised Generic ✔ Manufacturer
DORZOLAMIDE HYDROCHLORIDE			
* Eye drops 2%	9.77 (13.95)	5 ml OP	Trusopt
DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE * Eye drops 2% with timolol maleate 0.5%	15.50	5 ml OP	✔ Cosopt
Glaucoma Preparations - Prostaglandin Analogu	les		
BIMATOPROST – Retail pharmacy-Specialist * Eye drops 0.03%		3 ml OP	🗸 Lumigan
LATANOPROST – Retail pharmacy-Specialist * Eye drops 50 mcg per ml, 2.5 ml	1.99	2.5 ml OP	✓ <u>Hysite</u>
TRAVOPROST – Retail pharmacy-Specialist * Eye drops 0.004%		2.5 ml OP	🗸 Travatan
Glaucoma Preparations - Other			
BRIMONIDINE TARTRATE * Eye Drops 0.2%	6.45	5 ml OP	✓ Arrow-Brimonidine
BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE * Eye drops 0.2% with timolol maleate 0.5%		5 ml OP	Combigan
PILOCARPINE			
* Eye drops 1%		15 ml OP	Isopto Carpine
* Eye drops 2%		15 ml OP	✓ Isopto Carpine
* Eye drops 4%		15 ml OP	Isopto Carpine
Subsidised for oral use pursuant to the Standard Formulae # Eye drops 2% single dose – Special Authority see SA0895			
below – Retail pharmacy		20 dose	
	(32.72)	_0 0000	Minims
The CAOSOF Creation Authority for Subaidy	. ,		

➡SA0895 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient has to use an unpreserved solution due to an allergy to the preservative; or

2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be "tools of trade" and are not approved as special authority items. **Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE * Eye drops 1%	15 ml OP	 Atropt
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%	15 ml OP	🗸 Cyclogyl
TROPICAMIDE * Eye drops 0.5%	15 ml OP 15 ml OP	· <u></u>

	Subsidy (Manufacturer's P	rice) Sub	Fully Brand or sidised Generic
	\$	Per	 Manufacturer
Preparations for Tear Deficiency			
For acetylcysteine eye drops refer, page 197			
HYPROMELLOSE			
* Eye drops 0.5%	2.00 (3.92)	15 ml OP	Methopt
HYPROMELLOSE WITH DEXTRAN	(0.52)		Methopt
* Eye drops 0.3% with dextran 0.1%	2.30	15 ml OP	Poly-Tears
POLYVINYL ALCOHOL			
* Eye drops 1.4%		15 ml OP	Vistil
* Eye drops 3%	3./5	15 ml OP	✓ Vistil Forte
Preservative Free Ocular Lubricants			
► SA1388 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Both:	for 12 months for	r applications r	neeting the following criteria:
 Confirmed diagnosis by slit lamp of severe secretory dry et Either: 2.1 Patient is using eye drops more than four times dail 2.2 Patient has had a confirmed allergic reaction to pres 	y on a regular ba	,	
Renewal from any relevant practitioner. Approvals valid for 24 mc and has benefited from treatment. CARBOMER – Special Authority see SA1388 above – Retail pha	onths where the p		es to require lubricating eye drops
Ophthalmic gel 0.3%, 0.5 g		30	✓ Poly-Gel
MACROGOL 400 AND PROPYLENE GLYCOL – Special Authori Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml		bove – Retail p 24	oharmacy <u>Systane Unit Dose</u>
SODIUM HYALURONATE - Special Authority see SA1388 above	e – Retail pharma	су	
Eye drops 1 mg per ml Note: Hylo-Fresh has a 6 month expiry after opening. The	Pharmacy Hand		✓ <u>Hylo-Fresh</u> n allowing one bottle per month is
not relevant and therefore only the prescribed dosage to the	ie nearest OP ma	ay be claimed.	
Other Eye Preparations			
NAPHAZOLINE HYDROCHLORIDE * Eye drops 0.1%	4 15	15 ml OP	Vanhaan Forta
OLOPATADINE	4.13	15 MI OP	✓ <u>Naphcon Forte</u>
Eye drops 0.1%		5 ml OP	✓ Patanol
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN		. .	
* Eye oint with soft white paraffin	3.63	3.5 g OP	 ✓ Lacri-Lube ✓ Refresh Night Time
(Lacri-Lube Eye oint with soft white paraffin to be delisted 1 March	h 2014)		
PARAFFIN LIQUID WITH WOOL FAT LIQUID	0.00		A Daly Vice
* Eye oint 3% with wool fat liq 3%	3.63	3.5 g OP	 Poly-Visc
RETINOL PALMITATE Eye oint 138 mcg per g	3.80	5 g OP	✔ VitA-POS

	Subsidy (Manufacturer's Pri \$	ce) Sub Per	Fully sidised	Brand or Generic Manufacturer
Agents Used in the Treatment of Poisonings				
Antidotes				
ACETYLCYSTEINE – Retail pharmacy-Specialist				
Inj 200 mg per ml, 10 ml	178.00	10	✓ M	lartindale Acetylcysteine
Inj 200 mg per ml, 30 ml	219.00	4	🖌 A	cetadote
NALOXONE HYDROCHLORIDE a) Up to 5 inj available on a PSO b) Only on a PSO				
* Inj 400 mcg per ml, 1 ml		5	🖌 Н	ospira
Removal and Elimination				
CHARCOAL * Oral liq 50 g per 250 ml a) Up to 250 ml available on a PSO b) Only on a PSO	43.50	250 ml OP	✔ C	arbosorb-X
DEFERIPRONE - Special Authority see SA1042 below - Retail	pharmacy			
Tab 500 mg		100		erriprox
Oral liq 100 mg per 1 ml		250 ml OP	V F	erriprox
►SA1042 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals va been diagnosed with chronic transfusional iron overload due to co Note: For the purposes of this Special Authority, a relevant special DESFERRIOXAMINE MESYLATE	ongenital inherited	anaemia.		fied where the patient has
* Inj 500 mg	99.00	10	🖌 Н	ospira
SODIUM CALCIUM EDETATE				
* Inj 200 mg per ml, 5 ml	53.31 (156.71)	6	С	alcium Disodium Versenate

INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The "Standard Formulae".
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
 - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
 - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacy-specialist).
 - c) Menthol crystals only in the following bases: Aqueous cream Urea cream 10% Wool fat with mineral oil lotion Hydrocortisone 1% with wool fat and mineral oil lotion Glycerol, paraffin and cetyl alcohol lotion.

Glossary

Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Hydrocortisone with wool fat and mineral oil lotion
- Oil in water emulsion
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

Dermatological galenical: Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution BP up to 10%
- Hydrocortisone powder up to 5%
- Menthol crystals
- · Salicylic acid powder
- Sulphur precipitated powder

Standard formulae: Standard formulae are a list of fomulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

Explanatory notes

Oral liquid mixtures

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as voghurt should be explored.

The Emixt website www.pharminfotech.co.nz has evidence-based formulations which are intended to standardise compounded oral liquids within New Zealand.

Pharmaceuticals with standardised formula for compounding in Ora products

Acetazolamide 25 mg/ml	Flecainide 20 mg/ml	Rifabutin 20 mg/ml
Allopurinol 20 mg/ml	Gabapentin 100 mg/ml	Sildenafil 2 mg/ml
Amlodipine 1 mg/ml	Gabapentin (Neurontin) 100 mg/ml	Sotalol 5 mg/ml
Azathioprine 50 mg/ml	Hydrocortisone 1 mg/ml	Sulphasalazine 100 mg/ml
Baclofen 10 mg/ml	Labetolol 10 mg/ml	Tacrolimus 1 mg/ml
Carvedilol 1 mg/ml	Levetiracetam 100 mg/ml	Terbinafine 25 mg/ml
Clopidogrel 5 mg/ml	Levodopa with carbidopa (5 mg lev-	Ursodeoxycholic acid 50 mg/ml
Diazoxide 10 mg/ml	odopa + 1.25 mg carbidopa)/ml	Valganciclovir 60 mg/ml*
Diltiazem hydrochloride 12 mg/ml	Metoclopramide 1 mg/ml	Verapamil hydrochloride 50 mg/ml
Dipyridamole 10 mg/ml	Metoprolol tartrate 10 mg/ml	
Domperidone 1 mg/ml	Nitrofurantoin 10 mg/ml	
Enalapril 1 mg/ml	Pyrazinamide 100 mg/ml	

*Note this is a DCS formulation

PHARMAC endorses the recommendations of the Emixt website and encourages New Zealand pharmacists to use these formulations when compounding is appropriate. The Emixt website also provides stability and expiry data for compounded products. For the majority of products compounded with Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet or Ora-Sweet SF a four week expiry is appropriate.

Please note that no oral liquid mixture will be eligible for Subsidy unless all the requirements of Section B and C of the Schedule applicable to that pharmaceutical are met.

Some community pharmacies may not have appropriate equipment to compound all of the listed products, please use appropriate clinical judgement.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

or

Solid dose form

to 100%

as

Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent.

- Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and Ora-Sweet SF when used correctly are an appropriate preservative and suspending agent.
- Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Where a Standard Formula exists in the Pharmaceutical Schedule for a solid dose form, compounding the solid dose form in Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF.
- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

Standard formulae

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.


Dermatological Preparations

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 193) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).

One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on the next page may assist you in deciding whether or not a dermatological ECP is subsidised.



Standard Formulae

•••••••	
ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs
ASPIRIN AND CHLOROFORM APPLICATI Aspirin Soluble tabs 300 mg Chloroform	ON 12 tabs to 100 ml
CODEINE LINCTUS PAEDIATRIC (3 mg pe Codeine phosphate Glycerol Preservative Water	er 5 ml) 60 mg 40 ml qs to 100 ml
CODEINE LINCTUS DIABETIC (15 mg per Codeine phosphate Glycerol Preservative Water	5 ml) 300 mg 40 ml qs to 100 ml
FOLINIC MOUTHWASH Calcium folinate 15 mg tab Preservative Water (Preservative should be used if quantity sup more than 5 days. Maximum 500 ml per pre	
MAGNESIUM HYDROXIDE MIXTURE Magnesium hydroxide paste Methyl hydroxybenzoate Water	275 g 1.5 g 770 ml
METHADONE MIXTURE Methadone powder Glycerol Water	qs qs to 100 ml
METHYL HYDROXYBENZOATE 10% SOL Methyl hydroxybenzoate Propylene glycol (Use 1 ml of the 10% solution per 100 ml of mixture)	10 g to 100 ml

OMEPRAZOLE SUSPENSION

Omeprazole capules or powder Sodium bicarbonate powder BP Water	qs 8.4 g to 100 ml
PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
PHENOBARBITONE SODIUM PAEDIATRIC LIQUID (10 mg per ml) Phenobarbitone Sodium Glycerol BP Water	C ORAL 400 mg 4 ml to 40 ml
PILOCARPINE ORAL LIQUID Pilocarpine 4% eye drops Preservative Water (Preservative should be used if quantity sup more than 5 days.)	qs qs to 500 ml oplied is for
SALIVA SUBSTITUTE FORMULA Methylcellulose Preservative Water (Preservative should be used if quantity sup more than 5 days. Maximum 500 ml per pre	
SODIUM CHLORIDE ORAL LIQUID Sodium chloride inj 23.4%, 20 ml Water (Only funded if prescribed for treatment of h	qs qs ıyponatraemia)
VOSOL EAR DROPS WITH HYDROCORTISONE POWDER 1% Hydrocortisone powder Vosol Ear Drops	1% to 35 ml

	Subsidy (Manufacturer's F	Price) Sul	Fully Brand or bsidised Generic
	(Manulacturer 5 1 \$	Per	Manufacturer
xtemporaneously Compounded Preparations a	and Galenica	s	
NZOIN			
Tincture compound BP	2.44	50 ml	
	(5.10)		PSM
	24.42	500 ml	
	(38.00)		PSM
ILOROFORM – Only in combination			
Only in aspirin and chloroform application.			
Chloroform BP	25.50	500 ml	🖌 PSM
DEINE PHOSPHATE – Safety medicine; prescriber may dete	rmine dispensing	a frequency	
Powder – Only in combination		5 g	
· · · · · · · · · · · · · · · · · · ·	(25.46)	- 3	Douglas
	63.09	25 g	
	(90.09)	-0 g	Douglas
a) Only in extemporaneously compounded codeine linctus	· · ·	ine linctus par	0
b) ‡ Safety cap for extemporaneously compounded oral lic			
DLLODION FLEXIBLE	1		
Collodion flexible	19.30	100 ml	✔ PSM
		100 111	
MPOUND HYDROXYBENZOATE – Only in combination			
Only in extemporaneously compounded oral mixtures.			
Soln	34.18	100 ml	David Craig
YCERIN WITH SODIUM SACCHARIN – Only in combination			
Only in combination with Ora-Plus.			
Suspension		473 ml	Ora-Sweet SF
YCERIN WITH SUCROSE – Only in combination			
Only in combination with Ora-Plus.			
	25 50	473 ml	✓ Ora-Sweet
Suspension		473 mi	V Ora-Sweet
YCEROL			
Liquid – Only in combination		2,000 ml	healthE
Only in extemporaneously compounded oral liquid prepara	ations.		
GNESIUM HYDROXIDE			
Paste	22.61	500 g	🖌 PSM
THADONE HYDROCHLORIDE		0	
a) Only on a controlled drug form			
b) No patient co-payment payable			
, , , , , , , , , , , , , , , , , , , ,			
 c) Safety medicine; prescriber may determine dispensing free d) Extemporaneously compounded methadone will only be re- 		rata of the ob	account form available (mothed
powder, not methadone tablets).	ennouiseu al lite		leapest ionn available (methad
Powder, not methadone tablets). Powder	7 0/	1 g	🖌 AFT
		iy	V AFI
‡ Safety cap for extemporaneously compounded oral liquid The second s	u preparations.		
THYL HYDROXYBENZOATE			4
Powder		25 g	✓ PSM
	8.98		Midwest
THYLCELLULOSE			
Powder		100 g	✓ MidWest
Suspension – Only in combination		473 ml	✓ Ora-Plus

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's P \$	rice) Si Per	Fully ubsidised	Brand or Generic Manufacturer
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHA	ARIN – Only in co	ombination		
Suspension		473 ml	V 0	ra-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE - Only	in combination			
Suspension		473 ml	V 0	ra-Blend
PHENOBARBITONE SODIUM				
Powder – Only in combination		10 g	🖌 M	idWest
,	325.00	100 g	🖌 M	idWest
 a) Only in children up to 12 years b) ‡ Safety cap for extemporaneously compounded oral lic 	uid preparations.			
PROPYLENE GLYCOL				
Only in extemporaneously compounded methyl hydroxybenzo	pate 10% solution	า.		
Liq		500 ml	🖌 P:	• • • •
	11.25		🖌 M	idwest
SODIUM BICARBONATE				
Powder BP – Only in combination	8.95	500 g	🖌 M	idwest
	9.80			
	(29.50)		D	avid Craig
Only in extemporaneously compounded omeprazole and la	ansoprazole susp	pension.		
SYRUP (PHARMACEUTICAL GRADE) – Only in combination				
Only in extemporaneously compounded oral liquid preparatio				
Liq	21.75	2,000 ml	V M	idwest
WATER				
Tap – Only in combination	0.00	1 ml	🖌 Ta	ap water

EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

Who can apply for Special Authority?

Initial Applications:	Only from a dietitian, relevant specialist or a vocationally registered general
	practitioner.
Reapplications:	Only from a dietitian, relevant specialist or a vocationally registered general
	practitioner or general practitioner on the recommendation of a dietitian, rele-
	vant specialist or a vocationally registered general practitioner. Other general
	practitioners must include the name of the dietitian, relevant specialist or voca-
	tionally registered general practitioner and the date contacted.

All applications must be made on an official form available from the PHARMAC website www.pharmac.govt.nz. All applications must include specific details as requested on the form relating to the application. Applications must be forwarded to:

Ministry of Health Sector Services Private Bag 3015 WHANGANUI 4540 Freefax 0800 100 131

Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

Definitions

 Failure to thrive
 An inability to gain or maintain weight resulting in physiological impairment.

 Growth deficiency
 Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

Dietitian Prescribing

Prescriptions from Dietitians will be only valid for subsidy where they are for special foods, as listed in this section, or where they are for the following products:

ASCORBIC ACID Tab 100 mg

CALCIUM CARBONATE

- ✓ Tab eff 1.75 g (1 g elemental)
- ✓ Tab 1.25 g (500 mg elemental)

COMPOUND ELECTROLYTES

✓ Powder for oral soln

DEXTROSE WITH ELECTROLYTES

✓ Soln with electrolytes

FERROUS FUMARATE

✔ Tab 200 mg (65 mg elemental)

FERROUS FUMARATE WITH FOLIC ACID

✓ Tab 310 mg (100 mg elemental) with folic acid 350 mcg

FERROUS SULPHATE

- Tab long-acting 325 mg (105 mg elemental)
- ✓ Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)

FERROUS SULPHATE WITH FOLIC ACID

Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg

FOLIC ACID

🖌 Tab 0.8 mg

MULTIVITAMINS

Powder

PANCREATIC ENZYME

✓ Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease

POTASSIUM BICARBONATE

✓ Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg

POTASSIUM CHLORIDE

- Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)
- ✓ Tab long-acting 600 mg

POTASSIUM IODATE

✓ Tab 256 mcg (150 mcg elemental iodine)

PYRIDOXINE HYDROCHLORIDE

- ✓ Tab 25 mg
- ✓ Tab 50 mg

SODIUM CHLORIDE ✓ Inj 23.4%, 20 ml

✓ IIIJ 23.4%, 20 IIII

SODIUM FLUORIDE

✓ Tab 1.1 mg (0.5 mg elemental)

THIAMINE HYDROCHLORIDE

✔ Tab 50 mg

VITAMIN A WITH VITAMINS D AND C

✓ Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops

VITAMIN B COMPLEX

✓ Tab, strong, BPC

VITAMINS

- Tab (BPC cap strength)
- Cap (fat soluble vitamins A, D, E, K)

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Nutrient Modules

Carbohydrate

►SA1373 Special Authority for Subsidy

Initial application — (Cystic fibrosis or kidney disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Either:

- 1 cvstic fibrosis: or
- 2 chronic kidney disease.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Any of the following:
 - 1 cancer in children; or
 - 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
 - 3 faltering growth in an infant/child; or
 - 4 bronchopulmonary dysplasia; or
 - 5 premature and post premature infant; or
 - 6 inborn errors of metabolism; or
 - 7 for use as a component in a modular formula.

Renewal — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT – Special Authority see SA1373 above – Hospital pharmacy [HP3]

Powder		400 g OP	Polycal
	1.30	368 g OP	•
	(12.00)	0	Moducal
(Madwaal Dowdor to be delicted 1 lune 201)			

(Moducal Powder to be delisted 1 June 2014)

Carbohydrate And Fat

►SA1376 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 Infant or child aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

Soluble Powder

Subsidy	Ful	y Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per	 Manufacturer 	

continued...

- 1 infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children: or
 - 2.2 faltering growth; or
 - 2.3 bronchopulmonary dysplasia: or
 - 2.4 premature and post premature infants.

Renewal - (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment: and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT SUPPLEMENT - Special Authority see SA1376 on the previous page - Hospital pharmacy [HP3] Duocal Super

Powder (neutral)60.31	400 g OP
-----------------------	----------

Fat

SA1374 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application - (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 faltering growth in an infant/child; or
- 2 bronchopulmonary dysplasia; or
- 3 fat malabsorption: or
- 4 lymphangiectasia; or
- 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliary atresia; or
- 8 for use in a ketogenic diet: or
- 9 chyle leak; or
- 10 acites: or
- 11 for use as a component in a modular formula.

Renewal — (Inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

 Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
(Manulastalor 5 1 166) \$	Per 🖌	

continued...

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT - Special Authority see SA1374 on the previous page - Hospital pharmacy [HP3]

	i loopitai pitaittaoj [
Emulsion (neutral)12.30	200 ml OP	 Calogen
30.75	5 500 ml OP	 Calogen
Emulsion (strawberry)12.30	200 ml OP	 Calogen
Oil	0 500 ml OP	MCT oil (Nutricia)
Oil, 250 ml	2 4 OP	 Liquigen

Protein

►SA1375 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT – Special Authority see SA1375 above – Hospital pharmacy [HP3]			
Powder		225 g OP	Protifar
	8.95	227 g OP	 Resource Beneprotein
Powder (vanilla)		275 g OP	Promod

Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

Respiratory Products

SA1094 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CORD ORAL FEED 1.5KCAL/ML - Special Authority see SA1094 above - Hospital pharmacy [HP3]

Liquid1.66	237 ml OP	Pulmocare
------------	-----------	-----------

	Subsidy (Manufacturer's F \$	Price) Sul Per	Fully osidised	Brand or Generic Manufacturer
Diabetic Products				
 SA1095 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or voc: where the patient is a type I or and II diabetic who is suffering we Renewal only from a dietitian, relevant specialist, vocationally registe mendation of a dietitian, relevant specialist or vocationally registe meeting the following criteria: Both: The treatment remains appropriate and the patient is bene 2 General Practitioners must include the name of the dietitian and date contacted. DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see 	ight loss and mal gistered general red general pract efiting from treatm n, relevant specia	nutrition that r practitioner or itioner. Approv nent; and list or vocatior	equires general vals valio nally regi	nutritional support. practitioner on the recom- d for 1 year for applications
Liquid	7.50	1,000 ml OP	• -	iason RTH Iucerna Select RTH
DIABETIC ORAL FEED 1KCAL/ML – Special Authority see SA1 Liquid (strawberry) Liquid (vanilla)	1.50	pital pharmacy 200 ml OP 200 ml OP 250 ml OP 237 ml OP	✓ D ✓ D ✓ G	iasip iasip Iucerna Select esource Diabetic
Fat Modified Products				

►SA1381 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed for adults.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED – Special Authority see SA1381 above – Hospital pharmacy [HP3]

Powder60.48	400 g OP	 Monogen
-------------	----------	-----------------------------

High Protein Products

SA1378 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 decompensating liver disease without encephalopathy; or
- 2 protein losing gastro-enteropathy.

ubsidy	Fully	Brand or
cturer's Price) Subsic	dised	Generic
\$ Per	~	

continued...

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

HIGH PROTEIN ORAL FEED 1KCAL/ML - Special Authority see SA1378 on the previous page - Hospital pharmacy [HP3]

Liqu	d	 1.90	200 ml OP	V	 Fortimel 	Regular

Paediatric Products For Children Awaiting Liver Transplant

➡SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML - Special Authority see SA1098 above - Hospital pharmacy [HP3]

Paediatric Products For Children With Chronic Renal Failure

SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Liquid 54.00 400 g OP 🖌 Kinda					
	' 🖌 Kindergen	400 g OP	54.00	 	Liquid

Paediatric Products

➡SA1379 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
ontinued				
2.3 faltering growth in an infant/child; or				
2.4 increased nutritional requirements; or				
2.5 the child is being transitioned from TPN or tube feature and the child is being transitioned from TPN or tube feature and the child is the child is being transitioned from the child is bein			anaral	practitionar on the racer
nendation of a dietitian, relevant specialist or vocationally registion				
neeting the following criteria:	orea general pract			for i your of application
Both:				
1 The treatment remains appropriate and the patient is ben				
2 General Practitioners must include the name of the dietitia and date contacted.	an, relevant specia	list or vocation	ally regi	stered general practitione
PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority s				
Liquid	2.68	500 ml OP		utrini RTH ediasure RTH
AEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Sp	ecial Authority se	≏ SA1379 on ti		
nacy [HP3]	colui Authonity Set		ic provi	ouo page Troophai pha
Liquid	6.00	500 ml OP		utrini Energy Multi
				Fibre
				utrini Energy RTH
PAEDIATRIC ORAL FEED – Special Authority see SA1379 on t Powder (vanilla)		 Hospital pha 900 g OP 		HP3] ediasure
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see	SA1379 on the p	revious page -	Hospita	al pharmacy [HP3]
Liquid (strawberry)		200 ml OP	🖌 Fo	
Liquid (vanilla)		200 ml OP	🖌 Fo	
PAEDIATRIC ORAL FEED 1KCAL/ML - Special Authority see S				
Liquid (chocolate)		200 ml OP	• • •	ediasure
Liquid (strawberry) Liquid (vanilla)		200 ml OP 200 ml OP		ediasure ediasure
	1.34	250 ml OP		ediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Specia	I Authority see SA	1379 on the pr	evious p	bage – Hospital pharmac
Liquid (chocolate)	1.60	200 ml OP	🖌 Fo	ortini Multi Fibre
Liquid (strawberry)		200 ml OP	🖌 Fo	ortini Multi Fibre
Liquid (vanilla)	1.60	200 ml OP	🖌 Fo	ortini Multi Fibre
Renal Products				
SA1101 Special Authority for Subsidy	- Margally, and share			

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

RENAL ENTERAL	FEED 2 KCAL/ML	- Special	Authority see SA	1101 above -	Hospital pharma	cy [HP3]	
Liquid			-	6.08	500 ml OP	Nepro	RTH

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
RENAL ORAL FEED 2KCAL/ML – Special Authority see SA1101	on the previous	s page – Hospita	al pharı	macy [HP3]
Liquid	2.43	200 ml OP		epro (strawberry) epro (vanilla)
	3.80 2.88	237 ml OP	✔ S	uplena
	(3.31)		Ν	ovaSource Renal
Liquid (apricot)		125 ml OP	🖌 R	enilon 7.5
Liquid (caramel)	2.88	125 ml OP	🖌 R	enilon 7.5
Liquid (apricot) 125 ml		4 OP	🖌 R	enilon 7.5
Liquid (caramel) 125 ml	11.52	4 OP	🗸 R	enilon 7.5

Specialised And Elemental Products

SA1377 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
- 4 eosinophilic oesophagitis; or
- 5 inflammatory bowel disease; or
- 6 patients with multiple food allergies requiring enteral feeding.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML – Special Auth Powder		7 above – Hosp 79 g OP 76 g OP	ital pharmacy [HP3] Vital HN Alitraq
ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see Liquid (grapefruit) Liquid (pineapple & orange) Liquid (summer fruit)	9.50 9.50	Hospital pharn 250 ml OP 250 ml OP 250 ml OP	nacy [HP3] ✓ Elemental 028 Extra ✓ Elemental 028 Extra ✓ Elemental 028 Extra
ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see S/ Powder (unflavoured)		lospital pharma 80.4 g OP	,. ,
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Author Liquid			tal pharmacy [HP3] Peptisorb

Su	ubsidy	Fully	Brand or
(Manufac	cturer's Price) Sub	sidised	Generic
	\$ Per	~	Manufacturer

Paediatric Products For Children With Low Energy Requirements

SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML - Special Authority see SA1196 above - Hospital pharmacy [HP3]

Liquid4.00 500 ml OP 🖌 Nutrini Low Energy

Multi Fibre

Standard Supplements

SA1228 Special Authority for Subsidy

Initial application — (Children) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Adults) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - Patient is Malnourished
 - 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 1.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months; and Apu of the following:
- 2 Any of the following:
 - Patient has not responded to first-line dietary measures over a 4 week period by:
 - 2.1 Increasing their food intake frequency (eg snacks between meals); or
 - 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
 - 2.3 Using over the counter supplements (e.g. Complan); and

()	Subsidy	F	ully	Brand or
	Manufacturer's Price)	Subsidi	sed	Generic
	\$	Per	~	Manufacturer

continued...

3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Aduits) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 A nutrition goal has been set (eg reach a specific weight or BMI); and

2 Any of the following:

- Patient is Malnourished
- 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
- 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
- 2.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Adults transitioning from hospital Discretionary Community Supply) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has had up to a 30 day supply of a 1.0 or a 1.5 kcal/ml Standard Oral Supplement; and
- 2 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 3 Any of the following:

Patient is Malnourished

- 3.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
- 3.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
- 3.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 Is being feed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being meet.

Renewal — (Short-term medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery; or
- 5 Both:
 - 5.1 Pregnant; and

Subsidy		Fully	Brand or	
(Manufacturer's Price		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being meet.

Initial application — (Long-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions; or
- 10 Epidermolysis bullosa; or
- 11 AIDS (CD4 count < 200 cells/mm³); or
- 12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

ENTERAL FEED 1.5KCAL/ML - Special Authority see SA1228	on page 209 – H	lospital pharmac	y [HP3]
Liquid	7.00	1,000 ml	Nutrison Energy
ENTERAL FEED 1KCAL/ML - Special Authority see SA1228 of	n page 209 – Hos	spital pharmacy	[HP3]
Liquid		250 ml OP	 Isosource Standard
			 Osmolite
	5.29	1,000 ml OP	Isosource Standard
			RTH

2.65

5.29

500 ml OP

1,000 ml OP

 Nutrison Standard RTH
 Osmolite RTH

Osmolite RTH

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic ✔ Manufacturer
ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority s Liquid		page 209 – Hosp 237 ml OP 500 ml OP 1,000 ml OP	 bital pharmacy [HP3] Jevity Jevity RTH Jevity RTH Jevity RTH Nutrison Multi Fibre
ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority Liquid		n page 209 – Hos 250 ml OP 1,000 ml OP	spital pharmacy [HP3] Ensure Plus HN Ensure Plus RTH Jevity HiCal RTH Nutrison Energy Multi Fibre
DRAL FEED (POWDER) – Special Authority see SA1228 on pa	ge 209 – Hospit	al pharmacy [HF	23]
Powder (chocolate)	10.22	900 g OP	 Sustagen Hospital Formula
	13.00		 Ensure
Powder (vanilla)	9.50 10.22	900 g OP	 Fortisip Sustagen Hospital Formula
	13.00	850 g OP	 Ensure

	Subsidy (Manufacturer's Pi \$	rice) Subsid Per	Fully Brand or dised Generic Manufacturer
DRAL FEED 1.5KCAL/ML – Special Authority see SA1228 on pa Additional subsidy by endorsement is available for patients be molysis bullosa. The prescription must be endorsed according Liquid (banana) – Higher subsidy of \$1.26 per 200 ml with	ing bolus fed thro		
Endorsement		200 ml OP	
	(1.26)	200 111 01	Ensure Plus
	(1.26)		Fortisip
Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 ml	· · ·		P
with Endorsement		200 ml OP	
	(1.26)		Ensure Plus
	0.85	237 ml OP	
	(1.33)	207 01	Ensure Plus
	0.72	200 ml OP	
	(1.26)	200 0.	Fortisip
Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml	· · ·		i ordolp
with Endorsement		200 ml OP	
	(1.26)	200 111 01	Ensure Plus
Liquid (strawberry) - Higher subsidy of up to \$1.33 per	. ,		Ensure 1 lus
237 ml with Endorsement		200 ml OP	
		200 111 0F	Ensure Plus
	(1.26)		Ensure Flus
	0.85	237 ml OP	
	(1.33)	000	Ensure Plus
	0.72	200 ml OP	E e esté a la
	(1.26)		Fortisip
Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with En-			
dorsement		200 ml OP	
	(1.26)		Fortisip
Liquid (tropical fruit) - Higher subsidy of \$1.26 per 200 ml			
with Endorsement		200 ml OP	
	(1.26)		Fortisip
Liquid (vanilla) - Higher subsidy of up to \$1.33 per 237 ml			
with Endorsement	0.72	200 ml OP	
	(1.26)		Ensure Plus
	0.85	237 ml OP	
	(1.33)		Ensure Plus
	0.72	200 ml OP	
	(1.26)		Fortisip
RAL FEED WITH FIBRE 1.5 KCAL/ML - Special Authority see	SA1228 on nage	209 – Hospital	nharmacy [HP3]
Additional subsidy by endorsement is available for patients be molysis bullosa. The prescription must be endorsed according Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with	ing bolus fed thro		
Endorsement		200 ml OP	
	(1.26)	200 111 01	Fortisip Multi Fibre
Liquid (strouberry) Lligher subsidy of \$1.06 per 000 ml with	(1.20)		
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with	0.70	200 ml OD	
Endorsement		200 ml OP	Fortion Multi Fibre
	(1.26)		Fortisip Multi Fibre
Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with			
Endorsement	0.72	200 ml OP	
	(1.26)		Fortisip Multi Fibre

SPECIAL FOODS

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
---	-----	---------------------	-------------------------------------	--

High Calorie Products

►SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 faltering growth in an infant/child; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
 - 2 other lower calorie products have been tried; and

3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL FEED 2 KCAL/ML	- Special Authority	see SA1195 abov	e – Hospital p	harmacy [HP3]	

ORAL FEED 2 KCAL/ML - Special Authority see SA1195 above - Hospital pharmacy [HP3]

Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.

Liquid (vanilla) - Higher subsidy of \$1.90 per 200 ml with

Endorsement	0.96	200 ml OP	
	(1.90)		Two Cal HN

	Subsidy (Manufacturer's Price) \$	Subsic Per	Fully lised	Brand or Generic Manufacturer
Food Thickeners				
 SA1106 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or voc where the patient has motor neurone disease with swallowing dis Renewal only from a dietitian, relevant specialist, vocationally registe meeting the following criteria: Both: The treatment remains appropriate and the patient is bene 2 General Practitioners must include the name of the dietitian and date contacted. FOOD THICKENER – Special Authority see SA1106 above – Ho Powder 	order. gistered general practitione red general practitione fiting from treatment; a n, relevant specialist or ospital pharmacy [HP3]	tioner or ge r. Approvals and vocationall	neral s valio y regi	practitioner on the recom
Gluten Free Foods				ł
The funding of gluten free foods is no longer being actively mana longer considering the listing of new products, or making subsidy, that the range of funded items will reduce over time. Managemen outcomes. A range of gluten free options are available through re SA1107 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vo further renewal unless notified for applications meeting the follow Either:	or other changes to th nt of Coeliac disease w tail outlets. cationally registered ge	e existing li vith a gluter	stings 1 free	S. As a result we anticipat diet is necessary for goo
 Gluten enteropathy has been diagnosed by biopsy; or Patient suffers from dermatitis herpetiformis. 				
GLUTEN FREE BAKING MIX – Special Authority see SA1107 a Powder		acy [HP3] 00 g OP		
	(5.15)	-	Н	ealtheries Simple

(5.15)	Healtheries Simple Baking Mix
GLUTEN FREE BREAD MIX – Special Authority see SA1107 above – Hospital pl	
Powder	1,000 g OP
(7.32)	NZB Low Gluten Bread Mix
4.77	
(8.71)	Bakels Gluten Free Health Bread Mix
3.51	
(10.87)	Horleys Bread Mix
GLUTEN FREE FLOUR - Special Authority see SA1107 above - Hospital pharm	acy [HP3]
Powder5.62	2,000 g OP
(18.10)	Horleys Flour

	Subsidy (Manufacturer's \$		Fully Brand or dised Generic ✔ Manufacturer
GLUTEN FREE PASTA – Special Authority see SA1107 on the pa	revious page -	- Hospital pharmacy	cy [HP3]
Buckwheat Spirals		250 g OP	
	(3.11)		Orgran
Corn and Vegetable Shells		250 g OP	
	(2.92)		Orgran
Corn and Vegetable Spirals		250 g OP	
	(2.92)		Orgran
Rice and Corn Lasagne Sheets		200 g OP	_
	(3.82)		Orgran
Rice and Corn Macaroni		250 g OP	_
	(2.92)		Orgran
Rice and Corn Penne		250 g OP	-
	(2.92)		Orgran
Rice and Maize Pasta Spirals		250 g OP	-
	(2.92)		Orgran
Rice and Millet Spirals		250 g OP	
	(3.11)		Orgran
Rice and corn spaghetti noodles		375 g OP	
	(2.92)		Orgran
Vegetable and Rice Spirals		250 g OP	0
	(2.92)		Orgran
Italian long style spaghetti		220 g OP	0
	(3.11)		Orgran

Foods And Supplements For Inborn Errors Of Metabolism

SA1108 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Any of the following:
 - 1 Dietary management of homocystinuria; or
 - 2 Dietary management of maple syrup urine disease; or
 - 3 Dietary management of phenylketonuria (PKU); or
 - 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE – Special Authori Powder			ital pharmacy [HP3]
Supplements For MSUD			
AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLE pharmacy [HP3]	EUCINE – S	pecial Authority	v see SA1108 above - Hospital
Powder	300.54 437.22	500 g OP	 MSUD Maxamaid MSUD Maxamum

	Subsidy	Fully	Brand or
(Mai	nufacturer's Price)	Subsidised	Generic
	\$ Per	r 🖌	Manufacturer

Supplements For PKU

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 on the previous page – Hospital pharmacy [HP3]

Tabs		75 OP	Phiexy 10
Powder (unflavoured) 29 g sachets		30	PKU Anamix Junior
Infant formula		400 g OP	🖌 PKU Anamix Infant
Powder (orange)		500 g OP	XP Maxamaid
	320.00	-	XP Maxamum
Powder (unflavoured)		500 g OP	XP Maxamaid
	320.00	Ū	XP Maxamum
Liquid (berry)		125 ml OP	PKU Anamix Junior
			LQ
Liquid (citrus)		62.5 ml OP	PKU Lophlex LQ 10
	31.20	125 ml OP	PKU Lophlex LQ 20
Liquid (forest berries)		250 ml OP	Easiphen Liquid
Liquid (juicy berries)		62.5 ml OP	PKU Lophlex LQ 10
	31.20	125 ml OP	PKU Lophlex LQ 20
Liquid (juicy orange)		62.5 ml OP	PKU Lophlex LQ 10
	31.20	125 ml OP	PKU Lophlex LQ 20
Liquid (orange)		125 ml OP	PKU Anamix Junior
			LQ
Liquid (unflavoured)	13.10	125 ml OP	PKU Anamix Junior LQ

Foods

LOW PROTEIN BAKING MIX - Special Authority see SA1108	on the previous pa		
Powder	8.22	500 g OP	Loprofin Mix
LOW PROTEIN PASTA - Special Authority see SA1108 on the	previous page – H	lospital pharma	acy [HP3]
Animal shapes	11.91	500 g OP	 Loprofin
Lasagne	5.95	250 g OP	Loprofin
Low protein rice pasta	11.91	500 g OP	 Loprofin
Macaroni	5.95	250 g OP	 Loprofin
Penne	11.91	500 g OP	 Loprofin
Spaghetti	11.91	500 g OP	Loprofin
Spirals	11.91	500 g OP	 Loprofin

Infant Formulae

For Premature Infants

PRETERM POST-DISCHARGE INFANT FORMULA - Special Authori	ty see SA11	98 below - Ho	ospital pharmacy [HP3]
Powder	15.25	400 g OP	 S-26 Gold Premgro

SA1198 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth; and
- 2 Either:
 - 2.1 The infant has faltering growth (downward crossing of percentiles); or
 - 2.2 The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

For Williams Syndrome

➡SA1110 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA – Special Authority see SA1110 above – Hospital pharmacy [HP3]

Powder	 	400 g OP	V Locasol

Gastrointestinal and Other Malabsorptive Problems

Powder	6.00	48.5 g OP	Vivonex Pediatric
	53.00	400 g OP	Neocate LCP
Powder (unflavoured)	53.00	400 g OP	Elecare
		Ū	Elecare LCP
			Neocate Advance
			Neocate Gold
Powder (vanilla)	53.00	400 g OP	Elecare
		5 -	✓ Neocate Advance

SA1219 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Sut	bsidy	Fully	Brand or	
(Manufactu	turer's Price) Su	ubsidised	Generic	
	\$ Per	~	Manufacturer	

SA1380 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Step Down from Amino Acid Formula) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The infant is currently receiving funded amino acid formula; and
- 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Ketogenic Diet

SA1197 Special Authority for Subsidy

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA - Special Authority see SA1197	' above – Retail p	bharmacy
Powder (unflavoured)35.50	300 g OP	KetoCal 4:1
	•	Ketocal 3:1
Powder (vanilla)35.50	300 g OP	KetoCal 4:1

Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order

ADRENALINE ✓ Inj 1 in 1,000, 1 ml ampoule5 ✓ Inj 1 in 10,000, 10 ml ampoule5
AMINOPHYLLINE ✔ Inj 25 mg per ml, 10 ml5
AMIODARONE HYDROCHLORIDE Inj 50 mg per ml, 3 ml ampoule6
AMOXYCILLIN ✓ Cap 250 mg
AMOXYCILLIN CLAVULANATE ✓ Tab amoxycillin 500 mg with potassium clavulanate 125 mg
5 ml
✓ Tab dispersible 300 mg
ATROPINE SULPHATE V Inj 600 mcg per ml, 1 ml ampoule5
AZITHROMYCIN V Tab 500 mg – See note on page 918
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE] V Tab 2.5 mg – See note on page 59 150
BENZATHINE BENZYLPENICILLIN V Inj 1.2 mega u per 2.3 ml
BENZTROPINE MESYLATE ✔ Inj 1 mg per ml, 2 ml
BENZYLPENICILLIN SODIUM (PENICILLIN G) ✔ Inj 600 mg
BLOOD GLUCOSE DIAGNOSTIC TEST METER ✓ Meter with 50 lancets, a lancing device and 10 diagnostic test strips – Subsidy by endorsement – See note on page 301
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP ✓ Blood glucose test strips – See note on page 30

BLOOD KETONE DIAGNOSTIC TEST ME Meter – See note on page 29	
 ✓ Inj 500 mg – Subsidy by endorsement – note on page 90 ✓ Inj 1 g – Subsidy by endorsement – See note on page 90 	5 e
CHARCOAL V Oral liq 50 g per 250 ml	250 ml
CHLORPROMAZINE HYDROCHLORIDE V Tab 10 mg V Tab 25 mg V Tab 100 mg V Tab 100 mg V Inj 25 mg per ml, 2 ml	
CIPROFLOXACIN ✓ Tab 250 mg – See note on page 94 ✓ Tab 500 mg – See note on page 94	
 CO-TRIMOXAZOLE ✓ Tab trimethoprim 80 mg and sulphamethoxazole 400 mg ✓ Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml 	
COMPOUND ELECTROLYTES Powder for oral soln	10
CONDOMS	144 144 144 144 144 144 144 144 144 144
CYPROTERONE ACETATE ETHINYLOESTRADIOL Tab 2 mg with ethinyloestradiol 35 mcg 7 inert tabs	
DEXAMETHASONE ✓ Tab 1 mg – Retail pharmacy-Specialist ✓ Tab 4 mg – Retail pharmacy-Specialist	

PRACTITIONER'S SUPPLY ORDERS

(continued)

continued)
DEXAMETHASONE SODIUM PHOSPHATE
 ✓ Inj 4 mg per ml, 1 ml – See note on page 82
✓ INJ 4 mg per mi, 2 mi – See note on page 82
DEXTROSE
✓ lnj 50%, 10 ml
✓ lnj 50%, 90 ml
DIAPHRAGM
✓ 65 mm – See note on page 76
✓ 70 mm – See note on page 76
 ✓ 75 mm – See note on page 761 ✓ 80 mm – See note on page 761
DIAZEPAM
✓ Inj 5 mg per ml, 2 ml – Subsidy by
endorsement – See note on page 1305 ✔ Rectal tubes 5 mg5
 Rectal tubes 10 mg
-
DICLOFENAC SODIUM V Inj 25 mg per ml, 3 ml5
✓ Suppos 50 mg
DIGOXIN
✓ Tab 62.5 mcg
✓ Tab 250 mcg
DOXYCYCLINE HYDROCHLORIDE
Tab 50 mg
✓ Tab 100 mg
ERGOMETRINE MALEATE
✓ Inj 500 mcg per ml, 1 ml
ERYTHROMYCIN ETHYL SUCCINATE
 ✓ Tab 400 mg
✓ Grans for oral liq 400 mg per 5 ml
ERYTHROMYCIN STEARATE Tab 250 mg
•
ETHINYLOESTRADIOL WITH DESOGESTREL
Tab 20 mcg with desogestrel 150 mcg and 7 inert tab84
Tab 30 mcg with desogestrel 150 mcg and 7
inert tab
ETHINYLOESTRADIOL WITH LEVONORGESTREL
✓ Tab 20 mcg with levonorgestrel 100 mcg and
7 inert tab
✓ Tab 50 mcg with levonorgestrel 125 mcg and
7 inert tab
Tab 30 mcg with levonorgestrel 150 mcg63
✓ Tab 30 mcg with levonorgestrel 150 mcg and
7 inert tab84

ETHINYLOESTRADIOL WITH NORETHISTERONE Tab 35 mcg with norethisterone 1 mg63 Tab 35 mcg with norethisterone 1 mg and 7
 Tab 35 mcg with norethisterone 1 mg and 7 inert tab
FLUCLOXACILLIN SODIUM ✓ Cap 250 mg
FLUPENTHIXOL DECANOATE ✓ Inj 20 mg per ml, 1 ml
FLUPHENAZINE DECANOATE ✓ Inj 12.5 mg per 0.5 ml, 0.5 ml5 ✓ Inj 25 mg per ml, 1 ml5 ✓ Inj 100 mg per ml, 1 ml5
FUROSEMIDE [FRUSEMIDE] ✓ Tab 40 mg
GLUCAGON HYDROCHLORIDE ✔ Inj 1 mg syringe kit5
GLYCERYL TRINITRATE ✔ Tab 600 mcg100 ✔ Oral spray, 400 mcg per dose
HALOPERIDOL ✓ Tab 500 mcg
HALOPERIDOL DECANOATE ✔ Inj 50 mg per ml, 1 ml5 ✔ Inj 100 mg per ml, 1 ml5
HYDROCORTISONE ✔ Inj 100 ml vial5
HYDROXOCOBALAMIN ✔ Inj 1 mg per ml, 1 ml6
HYOSCINE N-BUTYLBROMIDE ✔ Inj 20 mg, 1 ml5
INTRA-UTERINE DEVICE ✔ IUD40
continued

(continued)

IPRATROPIUM BROMIDE ✓ Nebuliser soln, 250 mcg per ml, 1 ml
IVERMECTIN V Tab 3 mg – See note on page 71 100
KETONE BLOOD BETA-KETONE ELECTRODES
LEVONORGESTREL Tab 30 mcg
LIDOCAINE [LIGNOCAINE] Gel 2%, 10 ml urethral syringe – Subsidy by endorsement – See note on page 1245
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE ✓ Inj 1%, 5 ml ampoule
LIDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Subsidy by endorsement – See note on page 1245
LOPERAMIDE HYDROCHLORIDE ✓ Tab 2 mg
MASK FOR SPACER DEVICE ✓ Size 2 – See note on page 18720
MEDROXYPROGESTERONE ACETATE ✓ Inj 150 mg per ml, 1 ml syringe
METOCLOPRAMIDE HYDROCHLORIDE ✓ Inj 5 mg per ml, 2 ml
METRONIDAZOLE ✓ Tab 200 mg
 MORPHINE SULPHATE ✓ Inj 5 mg per ml, 1 ml – Only on a controlled drug form
NALOXONE HYDROCHLORIDE V Inj 400 mcg per ml, 1 ml

NICOTINE

 ✓ Patch 7 mg - See note on page 150
NORETHISTERONE ✓ Tab 350 mcg
NORETHISTERONE WITH MESTRANOL Tab 1 mg with mestranol 50 mcg and 7 inert tab
OXYTOCIN ✓ Inj 5 iu per ml, 1 ml ampoule
PARACETAMOL ✓ Tab 500 mg
PEAK FLOW METER ✓ Low range ✓ Normal range 10
PENICILLIN G BENZATHINE [BENZATHINE BENZYLPENICILLIN] ✔ Inj 1.2 mega u per 2 ml
 PETHIDINE HYDROCHLORIDE ✓ Inj 50 mg per ml, 1 ml – Only on a controlled drug form
PHENOXYMETHYLPENICILLIN (PENICILLIN V) ✓ Cap potassium salt 250 mg
PHENYTOIN SODIUM ✓ Inj 50 mg per ml, 2 ml

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

ontinued) PHYTOMENADIONE	SALBUTAMOL WITH IPRATROPIUM BROMIDE
✓ Inj 2 mg per 0.2 ml	 Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml
✓ Inj 10 mg per ml, 1 ml5	SILVER SULPHADIAZINE
PIPOTHIAZINE PALMITATE	✔ Crm 1%250 g
 ✓ Inj 50 mg per ml, 1 ml	SODIUM BICARBONATE ✔ Inj 8.4%, 50 ml
PREDNISOLONE SODIUM PHOSPHATE	✓ Inj 8.4%, 100 ml5
✓ Oral liq 5 mg per ml – See note on page 82	SODIUM CHLORIDE ✓ Inf 0.9% – See note on page 50 2000 m
PREDNISONE ✓ Tab 5 mg	 ✓ Inj 0.9%, 5 ml – See note on page 50 ✓ Inj 0.9%, 10 ml – See note on page 50
 PREGNANCY TESTS - HCG URINE ✓ Cassette	SPACER DEVICE ✓ 230 ml (single patient)20 ✓ 800 ml
PROCAINE PENICILLIN V Inj 1.5 mega u	SPACER DEVICE AUTOCLAVABLE ✓ 230 ml (autoclavable) – Subsidy by endorsement – See note on page 1875
PROCHLORPERAZINE ✓ Tab 5 mg	TRIMETHOPRIM ✓ Tab 300 mg
PROMETHAZINE HYDROCHLORIDE ✓ Inj 25 mg per ml, 2 ml	VERAPAMIL HYDROCHLORIDE ✓ Inj 2.5 mg per ml, 2 ml ampoule5
 ✓ Inj 20 mg per mi, 2 mi SALBUTAMOL ✓ Inj 500 mcg per mi, 1 mi ✓ Aerosol inhaler, 100 mcg per dose CFC 	WATER ✓ Purified for inj, 5 ml – See note on page 50
free	ZUCLOPENTHIXOL DECANOATE ✓ Inj 200 mg per ml, 1 ml5

(continued)

Rural Areas for Practitioner's Supply Orders

NORTH ISLAND

Northland DHB Dargaville Hikurangi Kaeo Kaikohe Kaitaia Kawakawa Kerikeri Mangonui Maungaturoto Moerewa Naunauru Paihia Rawene Ruakaka Russell Tutukaka Waipu Whangaroa

Waitemata DHB

Helensville Huapai Kumeu Snells Beach Waimauku Warkworth Wellsford

Auckland DHB

Great Barrier Island Oneroa Ostend

Counties Manukau DHB Tuakau

Waiuku

Waikato DHB

Coromandel Huntly Kawhia Matamata Morrinsville Ngatea Otorohanga Paeroa Pauanui Beach Putaruru Raglan Tairua Taumarunui Te Aroha Te Kauwhata Te Kuiti Tokoroa Waihi Whangamata Whitianga

Bay of Plenty DHB

Edgecumbe Katikati Kawerau Murupara Opotiki Taneatua Te Kaha Waihi Beach Whakatane

Lakes DHB Mangakino

Turangi

Tairawhiti DHB

Ruatoria Te Araroa Te Karaka Te Puia Springs Tikitiki Tokomaru Bay Tolaga Bay

Taranaki DHB

Eltham Inglewood Manaia Oakura Okato Opunake Patea Stratford Waverley

Hawkes Bay DHB

Chatham Islands Waipawa Waipukurau Wairoa Whanganui DHB Bulls Marton Ohakune Raetihi Taihape Waiouru

MidCentral DHB

Dannevirke Foxton Levin Otaki Pahiatua Shannon Woodville

Wairarapa DHB

Carteron Featherston Greytown Martinborough

SOUTH ISLAND

Nelson/Marlborough DHB

Havelock Mapua Motueka Murchison Picton Takaka Wakefield

West Coast DHB

Dobson Greymouth Hokitika Karamea Reefton South Westland Westport Whataroa

Canterbury DHB

Akaroa Amberley Amuri Cheviot Darfield Diamond Harbour Hanmer Springs Kaikoura Leeston Lincoln Methven Oxford Rakaia Rolleston Rotherham Templeton Waikari

South Canterbury DHB

Fairlie Geraldine Pleasant Point Temuka Twizel Waimate

Southern DHB

Alexandra Balclutha Cromwell Gore Kurow I awrence Lumsden Mataura Milton Oamaru Oban Otautau Outram Owaka Palmerston Queenstown Ranfurly Riverton Roxburah Tapanui Te Anau Tokonui Tuatapere Wanaka Winton

SECTION F: PART I

A Community Pharmaceutical identified with a ***** within the other sections of the Pharmaceutical Schedule:

a) is exempt from any requirement to dispense in Monthly Lots;

b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is under the Dispensing Frequency Rule.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a * within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is is under the Dispensing Frequency Rule.

SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

a) the Community Pharmaceutical is identified with a **A** within the other sections of the Pharmaceutical Schedule and the prescriber/pharmacist has endorsed/annotated the Prescription item(s) on the Prescription to which the exemption applies "certified exemption".

In endorsing/annotating the Prescription items for a certified exemption, the prescriber/pharmacist is certifying that:

- i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
- ii) the patient has been stabilised on the same medicine for a reasonable period of time; and
- iii) the prescriber/pharmacist has reason to believe the patient will continue on the medicine and is compliant.
- b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:
 - i) have limited physical mobility;
 - ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
 - iii) are relocating to another area;
 - iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

SECTION F: PART III: FLEXIBLE AND VARIABLE DISPENSING PERIODS FOR PHARMACY

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in variable dispensing periods under the following conditions:

- a) for stock management where the original pack(s) result in dispensing greater than 30 days supply,
- b) to synchronise a patients medication where multiple medicines result in uneven supply periods, note if dispensing a medicine other than a Pharmaceutical identified with a * please refer to Section F; Part II
- Note the total quantity and dispensing period can not exceed the total quantity and period prescribed on the prescription.



The following Community Pharmaceuticals are identified with a ▲ within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

ALIMENTARY TRACT AND METABOLISM

INSULIN ASPART

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

INSULIN GLARGINE

INSULIN GLULISINE

INSULIN ISOPHANE

INSULIN ISOPHANE WITH INSULIN NEUTRAL

INSULIN LISPRO

INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE

INSULIN NEUTRAL

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

DESMOPRESSIN

Nasal drops 100 mcg Minirin per ml Nasal spray 10 mcg per dose Desmopressin-PH&T

MUSCULOSKELETAL SYSTEM

PYRIDOSTIGMINE BROMIDE

NERVOUS SYSTEM

AMANTADINE HYDROCHLORIDE

APOMORPHINE HYDROCHLORIDE

ENTACAPONE

GABAPENTIN

GABAPENTIN (NEURONTIN)

LACOSAMIDE

LAMOTRIGINE

LISURIDE HYDROGEN MALEATE

PERGOLIDE

PRAMIPEXOLE HYDROCHLORIDE

TOLCAPONE

TOPIRAMATE

VIGABATRIN

CARDIOVASCULAR SYSTEM

AMIODARONE HYDROCHLORIDE				
Tab 100 mg	Cordarone-X			
Tab 200 mg	Cordarone-X			

DISOPYRAMIDE PHOSPHATE

FLECAINIDE ACETATE

Tab 50 mg	Tambocor
Tab 100 mg	Tambocor
Cap long-acting 100 mg	Tambocor CR
Cap long-acting 200 mg	Tambocor CR

MEXILETINE HYDROCHLORIDE

MINOXIDIL

NICORANDIL

PROPAFENONE HYDROCHLORIDE

SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

Reimbursment

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

Safety Caps (NZS 5825:1991)

20 mm	. Clic-Loc, United Closures & Plastics PLC, England
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
24 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
28 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
	PDL Squeezlok
	PDL FG

SAFETY CAP MEDICINES

ALIMENTARY TRACT AND METABOLISM

FERROUS SULPHATE Oral liq 30 mg per 1 ml Ferodan (6 mg elemental per 1 ml)

CARDIOVASCULAR SYSTEM

AMILORIDE HYDROCHLORIDE Oral lig 1 mg per ml Biomed

CAPTOPRIL Oral liq 5 mg per ml Capoten

CHLOROTHIAZIDE Oral liq 50 mg per ml Biomed

DIGOXIN Oral liq 50 mcg per ml Lanoxin

FUROSEMIDE [FRUSEMIDE] Oral liq 10 mg per ml Lasix

SPIRONOLACTONE Oral liq 5 mg per ml

r ml Biomed

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

LEVOTHYROXINE Tab 25 mcg

Tab 50 mcg

Tab 100 mcg

Synthroid Eltroxin Mercury Pharma Synthroid Eltroxin Mercury Pharma Synthroid

(Extemporaneously compounded oral liquid preparations)

INFECTIONS - AGENTS FOR SYSTEMIC USE

QUININE SULPHATE Tab 300 mg Q 300 (Extemporaneously compounded oral liquid preparations)

MUSCULOSKELETAL SYSTEM

IBUPROFEN Oral liq 20 mg per ml Fenpaed

NERVOUS SYSTEM

ALPRAZOLAM	
Tab 250 mcg	Xanax
	Arrow-Alprazolam
Tab 500 mcg	Xanax
-	Arrow-Alprazolam
Tab 1 mg	Xanax
	Arrow-Alprazolam
Extemporaneoucly comp	ounded and liquid proparation

(Extemporaneously compounded oral liquid preparations)

CARBAMAZEPINE Oral liq 100 mg per 5 ml Tegretol

CLOBAZAM Tab 10 mg Frisium (Extemporaneously compounded oral liquid preparations)

CLONAZEPAM Oral drops 2.5 mg per Rivotril ml

DIAZEPAM

Tab 2 mg Arrow-Diazepam Tab 5 mg Arrow-Diazepam (Extemporaneously compounded oral liquid preparations)

ETHOSUXIMIDE Oral lig 250 mg per 5 ml Zarontin

LORAZEPAM Tab 1 mg Tab 2.5 mg

Ativan Ativan

(Extemporaneously compounded oral liquid preparations)

LORMETAZEPAM

Tab 1 mg Noctamid (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE

Oral liq 2 mg per mlBiodoneOral liq 5 mg per mlBiodoneOral liq 10 mg per mlBiodone

Biodone Forte Biodone Extra Forte

MORPHINE HYDROCHLORIDE

	ric morpi
Oral liq 2 mg per ml	RA-Morph
Oral liq 5 mg per ml	RA-Morph
Oral liq 10 mg per ml	RA-Morph

NITRAZEPAM

Tab 5 mg

(Extemporaneously compounded oral liquid preparations)

Nitrados

OXAZEPAM

Tab 10 mg Ox-Pam Tab 15 mg Ox-Pam (Extemporaneously compounded oral liquid preparations)

OXYCODONE HYDROCHLORIDE Oral liq 5 mg per 5 ml OxyNorm

PARACETAMOL

Oral liq 120 mg per 5 ml Ethics Paracetamol Oral liq 250 mg per 5 ml Paracare Double Strength

Ventolin Salapin

PHENYTOIN SODIUM Oral liq 30 mg per 5 ml Dilantin

SODIUM VALPROATE Oral liq 200 mg per 5 ml

Epilim S/F Liquid Epilim Syrup

TEMAZEPAM

Tab 10 mg Normison (Extemporaneously compounded oral liquid preparations)

TRIAZOLAM

 Tab 125 mcg
 Hypam

 Tab 250 mcg
 Hypam

 (Extemporaneously compounded oral liquid preparations)

RESPIRATORY SYSTEM AND ALLERGIES

CETIRIZINE HYDROCHLORIDE Oral liq 1 mg per ml Cetirizine - AFT

CHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Histafen

DEXTROCHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Polaramine

PROMETHAZINE HYDROCHLORIDE Oral liq 5 mg per 5 ml Allersoothe SALBUTAMOL Oral liq 400 mcg per ml

THEOPHYLLINE Oral lig 80 mg per 15 ml Nuelin

TRIMEPRAZINE TARTRATE Oral liq 30 mg per 5 ml Vallergan Forte

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

CODEINE PHOSPHATE Powder Douglas (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE Powder AFT (Extemporaneously compounded oral liquid preparations)

PHENOBARBITONE SODIUM Powder MidWest (Extemporaneously compounded oral liquid preparations)

NATIONAL IMMUNISATION SCHEDULE

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Su Per	Ibsidised	Generic Manufacturer
Vaccinations				
BACILLUS CALMETTE-GUERIN VACCINE – Hospital pharmac				
For infants at increased risk of tuberculosis. Increased risk i 1) living in a house or family with a person with current or pa 2) have one or more household members or carers who with 40 per 100,000 for 6 months or longer or 3) during their first 5 years will be living 3 months or longer i	s defined as: ast history of TB or nin the last 5 years live in a country with a rate	of TB >	or equal	to 40 per 100,000
Note a list of countries with high rates of TB are available at www. Inj multi-dose vial (10 dose) 0.5 ml		sation or 1		jatlas.org/index.php. CG Vaccine
DIPHTHERIA AND TETANUS VACCINE – Hospital pharmacy [For adults aged 45 and 65 years old, and for susceptible ind Inj 0.5 ml	lividuals.	1	🗸 A	DT Booster
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Hospit For children aged 11 years old and pregnant women betwee Inj 0.5 ml	en gestional weeks 28			demics. oostrix
DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE For children aged 4 years old.		Xpharm]		
Inj 0.5 ml	0.00	1	🖌 ir	ifanrix-IPV
DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B A pharmacy [Xpharm] For children aged 6 weeks, 3 months, and 5 months old. Inj 0.5 ml		NFLUEN 1		PE B VACCINE – Hospital
HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Hospital pl For children aged 15 months old, children aged 0-16 years v Inj 0.5 ml	with functional asplenia	a, or for p 1		re- and post-splenectomy. ct-HIB
HEPATITIS B VACCINE – Hospital pharmacy [Xpharm] For household or sexual contacts of known hepatitis B car antigen (HBsAg) postive.				
Inj 0.5 ml	0.00	1	🗸 Н	BvaxPro
HUMAN PAPILOMAVIRUS VACCINE – Hospital pharmacy [Xpt Three doses over a period of six months for young women a		19 vears	old	
Inj 0.5 ml		1		ardasil
INFLUENZA VACCINE – Hospital pharmacy [Xpharm]				
Inj	90.00	10	• •	luarix
(Fluvax Inj to be delisted 1 January 2014)			V F	luvax
 A) is available each year for patients who meet the following a) all people 65 years of age and over; b) people under 65 years of age who: 		ARMAC:		
 i) have any of the following cardiovascular dis 1) ischaemic heart disease, 2) congestive heart disease, 	ease:			
 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; 				
ii) have either of the following chronic respirate 1) asthma, if on a regular preventative t				
2) other chronic respiratory disease wit				

NATIONAL IMMUNISATION SCHEDULE

Subsidy	Fully	Brand or	
(Manufacture's Price)	Subsidised	Generic	
`\$	Per 🖌	Manufacturer	

continued...

- iii) have diabetes;
- iv) have chronic renal disease;

v) have any cancer, excluding basal and squamous skin cancers if not invasive;

vi) have any of the following other conditions:

- a) autoimmune disease,
- b) immune suppression,

c) HIV,

- d) transplant recipients,
- e) neuromuscular and CNS diseases,
- f) haemoglobinopathies, or
- g) are children on long term aspirin, or
- vii) are pregnant
- c) people under 18 years of age living within the boundaries of the Canterbury District Health Board.
- d) children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness;

Unless meeting the criteria set out above, the following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease,
- B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor.
- D) Stock of the seasonal influenza vaccine is typically available from February until late July with suppliers being required to ensure supply until at least 30 June. Exact start and end dates for each season will be notified each year.

MEASLES, MUMPS AND RUBELLA VACCINE - Hospital pharmacy [Xpharm]

For children aged 15 months and 4 years old or for any individ Inj 0.5 ml	ual susceptible to	o measles, i 1	mumps or rubella. ✓ M-M-R II
MENINGOCOCCAL A, C, Y AND W-135 VACCINE - Hospital pha	armacy [Xpharm]		
For patients pre- and post-splenectomy or children aged 0-16 based outbreaks.	years with function	onal asplen	ia. For organisation and community
Inj 0.5 ml	0.00	1	 Menomune
PNEUMOCOCCAL (PCV13) VACCINE - Hospital pharmacy [Xph	arm]		
For high risk children under the age of 5 and those aged less th Inj 0.5 ml		or post-sple 1	enectomy or with functional asplenia.
PNEUMOCOCCAL POLYSACCHARIDE VACCINE – Hospital pha For patients pre- and post-splenectomy or children aged 0-16		onal aspleni	a.
Inj 0.5 ml	0.00	1	Pneumovax 23
PNEUMOCOCCAL VACCINE – Hospital pharmacy [Xpharm] For children aged 6 weeks, 3 months, and 5 months, and 15 m	nonths old.		
Inj 0.5 ml	0.00	1	 Synflorix
POLIOMYELITIS VACCINE – Hospital pharmacy [Xpharm] A primary course of three doses for previously unvaccinated in	ndividuals.		
Inj 0.5 ml		1	🖌 IPOL

- Symbols -
3TC108
50X 3.0 Reservoir36
- A -
A-Lices
A-Scabies72
Abacavir sulphate
Abacavir sulphate with
lamivudine
Abilify
ABM Hydroxocobalamin40
Acarbose
Accarb
Accu-Chek Ketur-Test
Accu-Chek Performa
Accuretic 1053
Accuretic 10
Acetadote
Acetazolamide
Acetec
Acetic acid with 1, 2- propanediol
diacetate and
benzethonium 188
Acetic acid with hydroxyquinoline
and ricinoleic acid79
Acetylcysteine192
Aci-Jel79
Aciclovir
Infection103
Sensory188
Acidex24
Acipimox60
Acitretin73
Aclasta119
Aclin115
Act-HIB230
Actinomycin D155
Actrapid28
Actrapid Penfill
Acupan125
Adalat 1057
Adalat Oros57
Adalimumab171
Adapalene65
Adefin XL57
Adefovir dipivoxil100
ADR Cartridge 1.8
ADR Cartridge 3.0
Adrenaline61
Adriamycin156
ADT Booster
Advantan

Advate	45
AFT-Pyrazinamide	100
Agents Affecting the	
Renin-Angiotensin System	52
Agents for Parkinsonism and	
Related Disorders	122
Agents Used in the Treatment of	
Poisonings	192
Agrylin	
Alanase	
Albay	
Albendazole	.90
Albustix	
Aldara	
Alendronate sodium	117
Alendronate sodium with	
cholecalciferol	117
Alfacalcidol	
Alginic acid	
Alginic aciu	
Alkeran	
Allersoothe	182
Allopurinol Alpha Adrenoceptor Blockers	120
Alpha Adrenoceptor Blockers	52
Alpha-Keri Lotion	70
Alphamox	92
Alprazolam	141
Alu-Tab	
Aluminium hydroxide	24
Amantadine hydrochloride	122
Ambrisentan	63
Amiloride hydrochloride	58
Amiloride hydrochloride with	
furosemide	. 59
Amiloride hydrochloride with	
hydrochlorothiazide	. 59
Aminophylline	186
Amiodarone hydrochloride	54
Amisulpride	
Amitrip	128
Amitriptyline	
Amlodipine	57
Amorolfine	66
Amoxycillin	92
Amoxycillin clavulanate	92
Amphotericin B	
Amsacrine	154
Amsidine	
Amyl nitrite	
Anaesthetics	124
Anagrelide hydrochloride	154
Analgesics	124

Anastrozole	165
Andriol Testocaps	83
Androderm	
Animas Battery Cap	32
Animas Cartridge	36
Animas Vibe	
Antabuse	
Antacids and Antiflatulants	24
Anten	
Anthelmintics	.90
Antiacne Preparations	
Antiallergy Preparations	181
Antianaemics	.44
Antiandrogen Oral	
Contraceptives	79
Antiarrhythmics	
Antibacterials	90
Antibacterials Topical	66
Anticholinesterases	
Antidepressants	128
Antidiarrhoeals	24
Antiepilepsy Drugs	
Antifibrinolytics, Haemostatics	130
and Local Sclorosants	45
and Local Sclerosants Antifungals	45
Antifungals Topical	90
Antihistamines	101
Antihypotensives	101
Antimalarials	
Antimigraine Preparations	
Antinaus	130
Antinausea and Vertigo Agents	105
Agents	135
Antiparasitics	99
Antipruritic Preparations	
Antipsychotics	136
Antiretrovirals	106
Antiretrovirals - Additional	
Therapies	109
Antirheumatoid Agents	115
Antispasmodics and Other	
Agents Altering Gut	
Motility	26
Antithrombotic Agents	46
Antithymocyte globulin	
(equine)	171
Antitrichomonal Agents	99
Antituberculotics and	
Antileprotics	
Antiulcerants	
Antivirals	
Anxiolytics	141

Anzatax157
Apidra28
Apidra SoloStar28
Apo-Allopurinol120
Apo-Amiloride
Apo-Amlodipine57
Apo-Azithromycin91
Apo-Bromocriptine
Apo-Ciclopirox
Apo-Cimetidine
Apo-Clarithromycin
Alimentary
Infection91
Apo-Clomipramine128
Apo-Clopidogrel46
Apo-Diclo114
Apo-Diltiazem CD57
Apo-Doxazosin52
Apo-Folic Acid44
Apo-Gliclazide29
Apo-Megestrol164
Apo-Moclobemide128
Apo-Nadolol56
Apo-Nicotinic Acid60
Ápo-Oxybutynin80
Apo-Perindopril53
Apo-Pindolol
Apo-Prazo
Apo-Prednisone
Apo-Prednisone S2983
Apo-Primidone
Apo-Propranolol
Apo-Pyridoxine
Apo-Risperidone139
Apo-Ropinirole
Apo-Selegiline
Apo-Selegiline S29
Apo-Thiamine
Apo-Timol
Apo-Zopiclone
Apomine
Apomorphine hydrochloride122
Aprepitant135
Apresoline
Aquasun 30+74
Aqueous cream70
Aratac54
Arava115
Aremed165
Arimidex165
Aripiprazole136
Aristocort69
Aromasin165

Arrow - Clopid4	6
Arrow Amitriptyline12	0
	0
Arrow-Alprazolam14	- 1
Arrow-Bendrofluazide5	9
Arrow-Brimonidine19	0
Arrow-Calcium4	2
Arrow-Citalopram12	9
Arrow-Diazepam14	2
Arrow-Doxorubicin15	6
Arrow-Etidronate11	7
Arrow-Gabapentin13	51
Arrow-Lamotrigine13	52
Arrow-Lisinopril5	53
Arrow-Losartan &	
Hvdrochlorothiazide5	64
Arrow-Meloxicam11	5
Arrow-Morphine LA12	26
Arrow-Nifedipine XR5	57
Arrow-Norfloxacin11	3
Arrow-Ornidazole9	99
Arrow-Quinapril 105	3
Arrow-Quinapril 205	3
Arrow-Quinapril 55	3
Arrow-Ranitidine2	70
Arrow-Roxithromycin9	 12
Arrow-Sertraline12	0
Arrow-Simva 10mg6	.ອ :∩
Arrow-Simva 20mg6	
Arrow-Simva 20mg6	
Arrow-Simva 80mg6	
Arrow-Sumatriptan13	0
Arrow-Sumainplan13 Arrow-Timolol	94 00
Arrow-Tolterodine	
Arrow-Topiramate13	3
Arrow-Tramadol12	!/
Arrow-Venlafaxine XR13	
Arsenic trioxide15	
Asacol2	.5
Asamax2	5
Ascorbic acid4	1
Aspec 30012	
Aspen Adrenaline6	51
Aspen Ceftriaxone9	0
Aspirin	
Blood4	
Nervous12	
Asthalin18	
Atazanavir sulphate10	9
Atenolol5	5
Atenolol AFT5	55
ATGAM17	'1
Ativan14	
Atomoxetine14	-5

Atorvastatin	60
Atripla	108
Atropine sulphate	
Cardiovascular	54
Sensory	190
Atropt	190
Atrovent	
Augmentin	92
Auranofin	115
Ava 20 ED	77
Ava 30 ED	77
Avanza	129
Avelox	95
Avomine	136
Avonex	144
Avonex Pen	144
Azathioprine	165
Azithromycin	91
Azol	
Azopt	189
AZT	
- B -	
B-D Micro-Fine	31
B-D Ultra Fine	
B-D Ultra Fine II	

B-D Ultra Fine II	31
B-PlexADE	41
Bacillus Calmette-Guerin (BCG)	
vaccine	171
Bacillus Calmette-Guerin	
vaccine	230
Baclofen	121
Bactroban	66
Bakels Gluten Free Health Bread	
Mix	215
Baraclude	101
Barrier Creams and	
Emollients	70
Batrafen	66
BCG Vaccine	230
Beclazone 100	
Beclazone 250	182
Beclazone 50	182
Beclomethasone	
dipropionate 182,	186
Bee venom allergy	
treatment	181
Bendrofluazide	59
Bendroflumethiazide	
[Bendrofluazide]	59
BeneFIX	
Benhex	
Benzathine benzylpenicillin	93
Benzbromaron AL 100	

Benzbromarone121
Benzoin198
Benztrop123
Benztropine mesylate123
Benzydamine hydrochloride
Benzylpenicillin sodium (penicillin
G)
Beta Adrenoceptor Blockers55
Beta Cream
Beta Ointment
Beta Scalp
Beta-Adrenoceptor Agonists
Betadine
Betadine Skin Prep71
Betaferon144
Betagan
Betahistine dihydrochloride
Betamethasone dipropionate
Betamethasone dipropionate
with calcipotriol73
Betamethasone sodium
phosphate with
betamethasone acetate
Betamethasone valerate
Betamethasone valerate with
clioquinol69
Betamethasone valerate with
fusidic acid69
Betaxolol hydrochloride189
Betnovate
Betnovate-C69
Betoptic189
Betoptic S189
Bezafibrate59
Bezalip59
Bezalip Retard59
Bicalaccord163
Bicalutamide163
Bicillin LA92, 93
BiCNU151
Biltricide90
Bimatoprost190
Biodone
Biodone Extra Forte126
Biodone Forte126
Bisacodyl
Bismuth trioxide27
Bisoprolol
Bisoprolol55 BK Lotion70
BK Lotion70
BK Lotion70
BK Lotion70

meter	30
Blood glucose diagnostic test	
strip	30
Blood glucose test strips (visually	
impaired)	31
Blood ketone diagnostic test	
meter2	29
Boceprevir10)5
Boceprevir10 Bonjela	10
Boostrix23	
Bortezomib15	54
Bosentan6	
Bosvate	
Bplex	
Breath-Alert18	
Brevinor 1/217	78
Brevinor 1/28	78
Brevinor 21	78
Bricanyl Turbuhaler18	
Brilinta4	6
Brimonidine tartrate19	90
Brimonidine tartrate with timolol	
maleate 19	
Brinzolamide18	
Brolene18	
Bromocriptine mesylate12	22
Brufen11	
Brufen SR11	
Buccastem13	
Budenocort18	32
Budesonide	
Alimentary	
Respiratory182, 18	37
Budesonide with eformoterol18	
Bumetanide	80
Buprenorphrine with	
naloxone	18
Bupropion hydrochloride14	
Burinex	
Buscopan	20
Buspirone hydrochloride	12
Busulphan15 Butacort Aqueous)
)/
-0-	
Cabergoline	
Cafergot13	34
Caffeine citrate18	
Cal-d-Forte4	1

Calamine67 Calcipotriol73 Calcitonin82

Calcitriol41

Calcitriol-AFT41
Calcium carbonate24, 42
Calcium Channel Blockers
Calcium Disodium
Versenate
Calcium folinate152
Calcium Folinate Ebewe152
Calcium gluconate
Calcium Homeostasis
Calcium polystyrene
sulphonate
Calcium Resonium
Calogen204
Calsource
Camptosar153
Candesartan cilexetil
Candestar
Canesten
Capecitabine
Capoten
Capsaicin Musculoskeletal System115
Nervous125
Captopril
Carafate27
Carbaccord151
Carbamazepine131
Carbimazole86
Carbomer191
Carboplatin151
Carboplatin Ebewe151
Carbosorb-X192
Cardinol LA56
CareSens
CareSens II30
CareSens N30
CareSens N POP30
Carmustine151
Carvedilol55
Catapres58
Catapres-TTS-158
Catapres-TTS-258
Catapres-TTS-358
CeeNU151
Cefaclor monohydrate90
Cefalexin monohydrate90
Cefalexin Sandoz90
Cefazolin sodium90
Ceftriaxone sodium90
Cefuroxime axetil90
Cefuroxime sodium91
Celestone Chronodose82
Celiprolol55

o
Cellcept166
Celol
Centrally-Acting Agents58
Cephalexin ABM90
Ceptolate
Cerezyme
Cetirizine - AFT
Cetirizine hydrochloride181
Cetomacrogol70
Cetomacrogol with glycerol70
Champix150
Charcoal192
Chemotherapeutic Agents
Chlorafast
Chlorambucil151
Chloramphenicol188
Chlorhexidine gluconate
Alimentary
Dermatological69
Chloroform198
Chloromycetin
Chlorothiazide59
Chlorpheniramine maleate181
Chlorpromazine
hydrochloride137
Chlorsig
Chlortalidone
[Chlorthalidone]
Chlorthalidone
Chlorvescent51
Cholecalciferol41
Cholestyramine60
Choline salicylate with
cetalkonium chloride
Cholvastin60
Ciclopirox olamine
Cilazapril
Cilazapril with
hydrochlorothiazide53
Cilicaine93
Cilicaine VK93
Ciloxan
Cimetidine
Cipflox
Ciprofloxacin
Infection94
Sensory188
Ciprofloxacin Rex94
Cisplatin151
Cisplatin Ebewe151
Citalopram hydrobromide129
Cladribine
Clarithromycin

Alimentary26
Infection91
Clexane47
Climara 10084
Climara 5084
Clindamycin94
Clindamycin ABM94
Clobazam131
Clobetasol propionate68, 74
Clobetasone butyrate
Clofazimine
Clomazol
Dermatological
Genito-Urinary
Clomiphene citrate
Clomipramine hydrochloride
Clonazepam130-131, 142
Clonidine
Clonidine BNM58
Clonidine hydrochloride58
Clopidogrel46
Clopine137
Clopixol140, 141
Clotrimazole
Dermatological
Genito-Urinary79
Clozapine
Clozaril
Co-Renitec
Co-trimoxazole94
Coal tar
Coal tar with allantoin, menthol,
phenol and sulphur
Coal tar with salicylic acid and
sulphur
Coco-Scalp74
Codeine phosphate
Extemporaneous198
Nervous125
Cogentin
Colaspase [L-asparaginase]155
Colchicine121
Colestid60
Colestipol hydrochloride60
Colgout121
Colifoam25
Colistin sulphomethate94
Colistin-Link94
Collodion flexible
Colofac26
Coloxyl
Combigan190
Combivir109

Comfort
Comfort Short34
Compound electrolytes50
Compound
hydroxybenzoate
Concerta
Condoms76
Condyline75
Contact-D
Contraceptives - Hormonal77
Contraceptives -
Non-hormonal76
Copaxone144
Corangin61
Cordarone-X
Corticosteroids and Related
Agents for Systemic Use
Corticosteroids Topical
Cosmegen155
Cosopt190
Coumadin49
Coversyl
Creon 10000
Creon Forte
Crixivan
Crotamiton
Crystaderm
Curam Duo92
Cvite
Cyclizine hydrochloride135
Cyclizine lactate
Cycloblastin151
Cyclogyl190
Cyclopentolate
hydrochloride 190
Cyclophosphamide151
Cycloserine
Cyclosporin
Cyklokapron45
Cyproterone acetate
Cyproterone acetate with
ethinyloestradiol
Cytarabine152
Cytotec
Cytoxan151
- D -
D-Penamine
d4T108
Dabigatran
Dacarbazine
Dactinomycin [Actinomycin
Dacinoniycin [Actinoniycin D]
Daivobet

B 1 · · · ·
Daktarin67
Dalacin C94
Dalteparin sodium47
Danazol89
Danthron with poloxamer39
Dantrium121
Dantrolene121
Daonil29
Dapa-Tabs59
Dapsone99
Daraprim95
Darunavir109
Dasatinib159
Daunorubicin155
DBL Aminophylline186
DBL Bleomycin Sulfate154
DBL Carboplatin151
DBL Doxorubicin156
DBL Doxorubicin S29156
DBL Epirubicin
Hydrochloride
DBL Ergometrine79
DBL Gemcitabine153
DBL Leucovorin Calcium152
DBL Methotrexate154
DBL Morphine Sulphate126
DBL Pethidine
Hydrochloride 127
DBI Tohramvoin 06
DBL Tobramycin96
DDI108
DDI108 De Nol27
DDI
DDI 108 De Nol 27 De-Worm 90 Decozol 40
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Medrol with Lidocaine 82
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Medrol with Lidocaine 82 Depo-Provera 78
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Medrol with Lidocaine 82 Depo-Provera 78 Depo-Testosterone 83
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Medrol with Lidocaine 82 Depo-Provera 78 Depo-Testosterone 83 Deprim 94
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Provera 78 DeporTestosterone 83 Deprim 94 Dermol 68, 74
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Medrol with Lidocaine 82 Depo-Provera 78 Depo-Testosterone 83 Deprim 94 Dermol 68, 74 Desferrioxamine mesylate 192
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Medrol with Lidocaine 82 Depo-Provera 78 Depo-Testosterone 83 Deprim 94 Dermol 68, 74 Desferrioxamine mesylate 192
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Medrol with Lidocaine 82 Depo-Testosterone 83 Deprim 94 Dermol 68, 74 Desferrioxamine mesylate 192 Desmopressin 88 Desmopressin-PH&T 88
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Provera 78 Depor-Testosterone 83 Deprim 94 Dermol 68, 74 Desmopressin 88 Desmopressin 88 Destropressin 88 Detection of Substances in 88
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Provera 78 Depro-Testosterone 83 Deprim 94 Desferrioxamine mesylate 192 Desmopressin 88 Destorproxes 88 Destorportioxamine mesylate 88 Destertion of Substances in 107
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Medrol with Lidocaine 82 Depo-Provera 78 Depro-Testosterone 83 Deprim 94 Dermol 68, 74 Desferrioxamine mesylate 192 Desmopressin 88 Destection of Substances in 192 Desmopressin-PL&T 88 Detection of Substances in 10 Urine 81 Dexamethasone 81
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Provera 78 Depro-Testosterone 83 Deprim 94 Desferrioxamine mesylate 192 Desmopressin 88 Destorproxes 88 Destorproxes in 88 Destorproxes in 88 Detection of Substances in 192 Dexamethasone 81 Hormone 82
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Provera 78 Depor-Testosterone 83 Deprim 94 Dermol 68, 74 Desferrioxamine mesylate 192 Desmopressin 88 Destection of Substances in Urine Urine 81 Dexamethasone Hormone Hormone 82 Sensory 189
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Provera 78 Depor-Testosterone 83 Deprim 94 Dermol 68, 74 Desferrioxamine mesylate 192 Desmopressin 88 Destorprosesin 88 Destorprosesin 88 Destection of Substances in Urine Urine 81 Dexamethasone 82 Hormone 82 Sensory 189
DDI 108 De Nol 27 De-Worm 90 Decozol 40 Deferiprone 192 Deoxycoformycin 157 Depo-Medrol 82 Depo-Provera 78 Depor-Testosterone 83 Deprim 94 Dermol 68, 74 Desferrioxamine mesylate 192 Desmopressin 88 Destection of Substances in Urine Urine 81 Dexamethasone Hormone Hormone 82 Sensory 189

and gramicidin	188
Dexamethasone with neomycin	
and polymyxin b sulphate	189
Dexamphetamine sulphate	145
Dextrochlorpheniramine	
maleate	
Dextrose	49
Dextrose with electrolytes	50
DHC Continus	125
Diabetes	27
Diabetes Management	
Diacomit	
Diamide Relief	
Diamox	
Diaphragm	
Diasip	
Diason RTH	
Diastop	
Diazepam130,	
Diazoxide	
Dibenyline	
Diclax SR	
Diclofenac sodium	. 14
Musculoskeletal System	11/
Sensory	190
Didanosine [DDI]	109
Didanosine [IUU]	
Difflam	
Diflucan	
Diflucortolone valerate	68
Digestives Including Enzymes	07
EIIZYIIIES	.3/
Digoxin	
Dihydrocodeine tartrate	
Dilantin	133
Dilantin Infatab	
Dilatrend	55
Diltiazem hydrochloride	
Dilzem	
Dipentum	25
Diphenoxylate hydrochloride with	
atropine sulphate	. 24
Diphtheria and tetanus	
vaccine	230
Diphtheria, tetanus and pertussis	
vaccine	230
Diphtheria, tetanus, pertussis	
and polio vaccine	230
Diphtheria, tetanus, pertussis,	
polio, hepatitis B and	
haemophilus influenzae type B	
vaccine	230
Diprosone	68

Diprosone OV	68
Dipyridamole	46
Disinfecting and Cleansing	
Agents	69
Disipal	123
Disopyramide phosphate	
Disulfiram	
Diuretics	
Diurin 40	
Docetaxel	
Docetaxel Ebewe	
Docetaxel Sandoz	
Docusate sodium	38
Docusate sodium with	
sennosides	
Domperidone	135
Donepezil hydrochloride	
Donepezil-Rex	148
Dopergin	122
Dopress	
Dornase alfa	186
Dorzolamide hydrochloride	190
Dorzolamide hydrochloride with	
timolol maleate	
Dostinex	
Dothiepin hydrochloride	128
Doxazosin	
Doxepin hydrochloride Doxine	
Doxine	
Doxorubicin Ebewe	
Doxy-50	
Doxycycline hydrochloride	
DP Lotion	
DP Lotn HC	
DP-Anastrozole	
Dr Reddy's Olanzapine	
Dr Reddy's Omeprazole	
Dr Reddy's Ondansetron	136
Dr Reddy's Pantoprazole	
Dr Reddy's Pramipexole	
Dr Reddy's Quetiapine	
Dr Reddy's Risperidone	139
Dr Reddy's Terbinafine	
Drugs Affecting Bone	
Metabolism	116
Dulcolax	
Duocal Super Soluble	
Powder	203
Duolin	
Duolin HFA	185
Durex Confidence	
Durex Extra Safe	

Durex Select Flavours	
Duride	61
Dynacirc-SRO	57
- E -	
E-Mycin	01
Ear Preparations	100
Ear Preparations	188
Ear/Eye Preparations	188
Easiphen Liquid	217
Econazole nitrate	
Efavirenz	108
Efavirenz with emtricitabine and	
tenofovir disoproxil	
fumarate	
Efexor XR	130
Effient	46
Eformoterol fumarate	
Efudix	75
Egopsoryl TA	
Elecare	218
Elecare LCP	218
Electral	
Elemental 028 Extra	
Eligard	
Elocon	
Eloxatin	
Eltroxin	
Emend Tri-Pack	100
EMLA	100
Emtricitabine	100
Emtricitabine with tenofovir	100
	100
disoproxil fumarate	108
Emtriva	108
Emulsifying ointment	
Enalapril maleate	52
Enalapril maleate with	
hydrochlorothiazide	
Enbrel	
Endocrine Therapy	
Endoxan	
Enerlyte	50
Enfuvirtide	109
Enoxaparin sodium	
Ensure	
Ensure Plus	213
Ensure Plus HN	212
Ensure Plus RTH	212
Entacapone	122
Entapone	122
Entecavir	101
Entocort CIR	24
Epilim	
Epilim Crushable	

Epilim IV	
Epilim S/F Liquid	133
Epilim Syrup	133
Epirubicin	156
Epirubicin Ebewe	156
Eprex	100
Eptacog alfa [Recombinant factor	44
	45
VIIa]	
ERA	
Ergometrine maleate	79
Ergotamine tartrate with	
caffeine	134
Erlotinib hydrochloride	159
Erythrocin IV	91
Erythromycin ethyl succinate	91
Erythromycin lactobionate	91
Erythromycin stearate	91
Erythropoietin alpha	44
Erythropoietin beta	44
Escitalopram	129
Eskazole	
Estradot	
Estrofem	
Etanercept	
Ethambutol hydrochloride	
Ethics Aspirin	124
Ethics Aspirin EC	40
Ethics Enalapril	
Ethics Paracetamol	
Ethinyloestradiol	85
Ethinyloestradiol with desogestrel	
desogestrel	77
Ethinyloestradiol with	
levonorgestrel	77
Ethinyloestradiol with	
norethisterone	
Ethosuximide	
Etidronate disodium	
Etopophos	
Etoposide	156
Etoposide phosphate	156
Etravirine	108
Eumovate	68
Evista	117
Exemestane	165
Extemporaneously Compounded	
Preparations and	
Galenicals	198
Eye Preparations	188
EZ-fit Paediatric Mask	
Ezetimibe	
Ezetimibe with simvastatin	
Ezetrol	

- F -
Factor eight inhibitors bypassing
agent 45
Feed Thickener Karicare
Aptamil215
FEIBA45
Felodipine57
Femtran 10084
Femtran 5084
Fenpaed114
Fentanyl125
Ferodan
Ferriprox
Ferro-F-Tabs
Ferro-tab
Ferrograd42
Ferrograd F42
Ferrous fumarate42
Ferrous fumarate with folic
acid
Ferrous sulphate42
Ferrous sulphate with folic
acid
Ferrum H
Fexofenadine hydrochloride
Fibro-vein
Filgrastim
Finasteride80
Flagyl
Flagyl-S99
Flamazine
Flecainide acetate
Fleet Phosphate Enema
Flixonase Hayfever &
Allergy 187
Flixotide182
Flixotide Accuhaler182
Florinef82
Fluanxol140
Fluarix230
Flucloxacillin sodium93
Flucloxin93
Flucon
Fluconazole96
Fludara153
Fludara Oral153
Fludarabine Ebewe153
Fludarabine phosphate153
Fludrocortisone acetate
Fluids and Electrolytes49
Flumetasone pivalate
Fluocortolone caproate with

fluocortolone pivalate and	
cinchocaine	
Fluorometholone1	89
Fluorouracil Ebewe1	
Fluorouracil sodium	
Dermatological	75
Oncology1	53
Fluox	
Fluoxetine hydrochloride1	
Flupenthixol decanoate1	
Fluphenazine decanoate1	40
Flutamide1	
Flutamin1	
Flutamin S291	
Fluticasone1	
Fluticasone propionate1	
Fluticasone propionate1	0/
Fluvax2	
Foban	
Folic acid	
Food Thickeners2	15
Foods And Supplements For	
Inborn Errors Of	
Metabolism2	
Foradil1	
Forteo1	
Fortimel Regular2	06
Fortini2	07
Fortini Multi Fibre2	07
Fortisip212, 2	13
Fortisip Multi Fibre2	13
Fosamax1	
Fosamax Plus1	17
Fragmin	47
Framycetin sulphate1	88
Freestyle Optium 29	30
Freestyle Optium Ketone	29
Frisium1	31
Frumil	
Frusemide	
Frusemide-Claris	
Fucicort	
Fucidin	
Fucithalmic1	
Fungilin	
Furosemide [Frusemide]	
Fusidic acid	50
Dermatological	66
Infection	
Sensory1	
Fuzeon1	09
ŭ	
Gabapentin1	31

Gabapentin (Neurontin)132	
Gamma benzene	
hexachloride71	
Gardasil230	
Gastrosoothe26	
Gaviscon Double Strength24	
Gaviscon Infant24	
Gefitinib160	
Gemcitabine Actavis 1000153	
Gemcitabine Actavis 200153	
Gemcitabine Ebewe153	
Gemcitabine hydrochloride153	
Gemfibrozil59	
Gemzar153	
Genoptic	
Genotropin87	
Genox	
Gentamicin sulphate Infection94	
Sensory	
Ginet 84	
Glatiramer acetate	
Glibenclamide	
Gliclazide	
Glipizide	
Glivec	
Glucagen Hypokit27	
Glucagon hydrochloride27 Glucerna Select205	
Glucerna Select RTH205	
Gluten Free Foods215	
Glycerin with sodium	
saccharin198	
Glycerin with sucrose	
Glycerol	
Alimentary	
Extemporaneous	
Glyceryl trinitrate	
Alimentary	
Cardiovascular61	
Glytrin61	
Gold Knight76	
Gopten	
Goserelin acetate87	
Gutron55	
Gynaecological	
Anti-infectives	
- H -	
- n - Habitrol150	
Haemophilus influenzae type B	
vaccine	
Vaconio	

Haldol140 Haldol Concentrate140

Haloperidol137	7
Haloperidol decanoate140)
Hamilton Sunscreen74	ŀ
HBvaxPro230	
healthE Fatty Cream70	
healthE Urea Cream70)
Healtheries Simple Baking	
Mix	5
Hemastix81	
Heparin sodium48	3
Heparinised saline48	
Heparon Junior206	
Hepatitis B vaccine230)
Hepsera100)
Herceptin178	
Hexamine hippurate112)
Hiprex112)
Histafen181	
Holoxan151	
Horleys Bread Mix215	
Horleys Flour215	5
Hormone Replacement Therapy -	
Systemic83	
Humalog28	3
Humalog Mix 2528	3
Humalog Mix 5028	,
Truinalog Mix 50)
Human papilomavirus	
Human papilomavirus vaccine)
Human papilomavirus vaccine)
Human papilomavirus vaccine)
Human papilomavirus vaccine) 5
Human papilomavirus vaccine230 Humatin95 Humira)
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28) 5 8 8
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin R 28) 5 8 8
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28 Humulin R 28 Hybloc 56	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 26 Humulin NPH 26 Humulin R 28 Hybloc 56 Hydralazine 62	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28 Hublic C 56 Hydralazine 62 Hydralazine 62	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 26 Humulin NPH 26 Humulin R 28 Hybloc 56 Hydralazine 62	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28 Hybloc 56 Hydralazine 62 Hydralazine hydrochloride 62 Hydrae 156 Hydrocortisone 156	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28 Hybloc 56 Hydralazine 62 Hydralazine hydrochloride 62 Hydracortisone 156 Dermatological 68	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28 Hybloc 56 Hydralazine 62 Hydralazine hydrochloride 62 Hydrae 156 Hydrocortisone 156	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28 Hybloc 56 Hydralazine 62 Hydralazine hydrochloride 62 Hydracortisone 56 Dermatological 66 Hydrocortisone acetate 25	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28 Hybloc 56 Hydralazine 62 Hydralazine 62 Hydralazine 56 Hydrocortisone 56 Dermatological 68 Hormone 82	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin 30/70 28 Humulin R 28 Hybloc 56 Hydralazine 62 Hydralazine hydrochloride 62 Hydrocortisone 82 Hydrocortisone acetate 25 Hydrocortisone butyrate 68, 74 Hydrocortisone with 64, 74	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28 Hybloc 56 Hydralazine 62 Hydralazine hydrochloride 62 Hydracortisone 56 Dermatological 68 Hormone 82 Hydrocortisone acetate 25 Hydrocortisone butyrate 68, 74	
Human papilomavirus vaccine 230 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28 Hybloc 56 Hydralazine 62 Hydralazine hydrochloride 62 Hydrocortisone 156 Hydrocortisone acetate 25 Hydrocortisone butyrate 68 Hydrocortisone with 26 Hydrocortisone with 26	
Human papilomavirus vaccine 230 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 28 Humulin NPH 28 Hybloc 56 Hydralazine 62 Hydralazine hydrochloride 62 Hydrocortisone 56 Dermatological 68 Hydrocortisone butyrate 25 Hydrocortisone butyrate 68, 74 Hydrocortisone with 26 Hydrocortisone with 68, 74 Hydrocortisone with 68, 74 Hydrocortisone with 66 Cortisone with 66 Hydrocortisone with 66 Hydrocortisone with 66 Hydrocortisone with 69 Hydrocortisone with 69 Hydrocortisone With 69 Hydrocortisone With 69	
Human papilomavirus vaccine 230 Yaccine 95 Humira 171 HumiraPen 171 Humulin 30/70 26 Humulin 30/70 26 Humulin R 226 Hybloc 56 Hydralazine 62 Hydralazine hydrochloride 62 Hydrocortisone 56 Dermatological 68 Hormone 82 Hydrocortisone acetate 25 Hydrocortisone butyrate 68, 74 Hydrocortisone with 69 Hydrocortisone with	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 26 Humulin NPH 26 Hydroc 56 Hydralazine 62 Hydrazine 62 Hydrocortisone 56 Hydrocortisone acetate 25 Hydrocortisone butyrate 68, 74 Hydrocortisone with 68, 74 Hydrocortisone with 66 Hydrocortisone with 66 Hydrocortisone with 69 Hydrocortisone with natamycin 69 Hydrocortisone with natamycin 69	
Human papilomavirus vaccine 230 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 26 Humulin 30/70 26 Humulin NPH 26 Hydroc 56 Hydralazine 62 Hydrazine 62 Hydrocortisone 56 Dermatological 68 Hydrocortisone acetate 25 Hydrocortisone butyrate 68, 74 Hydrocortisone with 66 Hydrocortisone with 66 Hydrocortisone with 69 Hydrocortisone with natamycin 64 Hydrocortisone with wool fat and 65	
Human papilomavirus 230 vaccine 231 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 26 Humulin 30/70 26 Humulin NPH 26 Hydroloc 56 Hydralazine 62 Hydrazine 62 Hydrocortisone 62 Hydrocortisone acetate 25 Hydrocortisone butyrate 68, 74 Hydrocortisone with 68, 74 Hydrocortisone with 66 Hydrocortisone with 66 Hydrocortisone with 69 Hydrocortisone with natamycin 64 Hydrocortisone with natamycin 64 Hydrocortisone with natamycin 64 Hydrocortisone with wool fat and 64	
Human papilomavirus vaccine 230 Humatin 95 Humira 171 HumiraPen 171 Humulin 30/70 26 Humulin 30/70 26 Humulin NPH 26 Hydroc 56 Hydralazine 62 Hydrazine 62 Hydrocortisone 56 Dermatological 68 Hydrocortisone acetate 25 Hydrocortisone butyrate 68, 74 Hydrocortisone with 66 Hydrocortisone with 66 Hydrocortisone with 69 Hydrocortisone with natamycin 64 Hydrocortisone with wool fat and 65	

Alimentary40
Dermatological66
Hydroxocobalamin40
Hydroxychloroquine115
Hydroxyurea156
Thydroxyurea
Hygroton59
Hylo-Fresh191
Hyoscine hydrobromide135
Hyoscine N-butylbromide26
Hypam145
Hyperuricaemia and
Antigout120
Aniigout
Hypnovel144
Hypromellose191
Hypromellose with Dextran191
Hysite190
-1-
Ibiamox92
Ibuprofen114
Idarubicin hydrochloride157
Ifosfamide151
Igroton59
Ikorel62
lloprost64
Imatinib mesilate
Imiglucerase
Imigramine hydrochloride128
Imiquimod75
Immune Modulators110
Immunosuppressants165
Imuprine165
Imuran165
Indapamide59
Indinavir109
Infanrix-hexa230
Infanrix-IPV230
Infant Formulae217
Influenza vaccine230
Inhaled Anticholinergic
Agents184
Inhaled Corticosteroids182
Inhaled Long-acting
Beta-adrenoceptor
Agonists 182
Inhibace Plus53
Innovacon hCG One Step
Pregnancy Test
Inset 30
Inset II
Insulin aspart
Insulin aspart with insulin aspart
protamine28

Insulin glargine28
Insulin glulisine28
Insulin isophane28
Insulin isophane with insulin
neutral
Insulin lispro28
Insulin lispro with insulin lispro
protamine
Insulin neutral28
Insulin pen needles31
Insulin pump
Insulin pump accessories
Insulin pump infusion set (steel
cannula)
Insulin pump infusion set (teflon
cannula, angle insertion with
insertion device)
Insulin pump infusion set (teflon
cannula, angle insertion)
Insulin pump infusion set (teflon
cannula, straight insertion with
insertion device)
Insulin pump infusion set (teflon
cannula, straight insertion)
Insulin pump reservoir
Insulin syringes, disposable with
attached needle
Intal Forte CFC Free
Intal Spincaps
Intelence
Interferon alfa-2a111
Interferon alfa-2b
Interferon beta-1-alpha144
Interferon beta-1-beta144
Intra-uterine device76
Intron-A111
IPOL
Ipratropium bromide184, 187
Iressa160
Irinotecan153
Irinotecan Actavis 100153
Irinotecan Actavis 40153
Irinotecan-Rex153
Iron polymaltose42
Isentress109
Ismo 2061
Isoniazid100
Isoprenaline62
Isoptin58
Isopto Carpine190
Isosorbide mononitrate61
Isosource Standard211
Isosource Standard RTH211

Isotretinoin	
Ispaghula (psyllium) husk Isradipine	
Isuprel	
Itch-Soothe	
Itraconazole	
Itrazole	97
Ivermectin	71
- J -	
Jadelle	78
Jevity	
Jevity HiCal RTH	212
Jevity RTH	212

- K -

Kaletra109
Kemadrin123
Kenacomb188
Kenacort-A83
Kenacort-A4083
Ketocal 3:1219
KetoCal 4:1219
Ketoconazole
Dermatological74
Infection
Ketogenic Diet219
Ketone blood beta-ketone
electrodes29
Ketoprofen114
Ketostix29
Kindergen206
Kivexa108
Klacid91
Kliogest85
Kliovance85
Kogenate FS45
Konakion MM46
Konsyl-D

-L-

L-asparaginase	155
Labetalol	56
Lacosamide	132
Lacri-Lube	191
Lactulose	
Laevolac	38
Lamictal	132
Lamivudine	102, 108
Lamivudine Alphapharm	108
Lamotrigine	132
Lamprene	99
Lanoxin	54
Lanoxin PG	54
Lansoprazole	27

Lantus28 Lantus SoloStar28
Lantuc SoloStar 28
Lanus 501051ai20
Lanvis154
Lapatinib Ditosylate161
Largactil137
Lasix
Latanoprost
Lax-Sachets
Lax-Tab
Laxatives
Laxofast 120
Laxofast 50
Laxsol
Leflunomide115
Letraccord165
Letrozole165
Leukeran FC151
Leukotriene Receptor
Antagonists 185
Leunase155
Leuprorelin
•
Leustatin152
Levetiracetam133
Levetiracetam-Rex133
Levobunolol189
Levocabastine189
Levodopa with benserazide
Levodopa with carbidopa
Levomepromazine maleate
Levonorgestrel
Genito-Urinary78–79
Hormone
Hormone 85 Levothyroxine 86 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] 124 hydrochloride 124 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] with 124 chlorhexidine 124 Lidocaine [Lignocaine] with 124 Lidocaine [Lignocaine] with 124 Lidocaine [Lignocaine] with 124 Lidocaine-Claris 124 Lifestyles Flared 76
Hormone 85 Levothyroxine 86 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] with 124 chlorhexidine 124 Lidocaine [Lignocaine] with 124 Lidocaine [Lignocaine] with 124 Lidocaine [Lignocaine] with 124 Lidocaine [Lignocaine] with 124 Lidocaine - 124 124 Lidocaine-Claris 124 Lifestyles Flared 76 Lignocaine 82, 124
Hormone 85 Levothyroxine 86 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] with 124 chlorhexidine 124 Lidocaine [Lignocaine] with 124 chlorhexidine 124 Lidocaine [Lignocaine] with 124 Lidocaine 82 Lignocaine 82
Hormone
Hormone
Hormone
Hormone 85 Levothyroxine 86 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] with 124 Lidocaine [Lignocaine] with 124 Lidocaine [Lignocaine] 124 Lidocaine-Claris 124 Lifestyles Flared 76 Lignocaine 82 Nervous 124 Lincocin 95 Lincomycin 95 Lipazil 59
Hormone 85 Levothyroxine 86 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] 124 hydrochloride 124 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] with 124 chlorhexidine 124 Lidocaine [Lignocaine] with 124 Lidocaine-Claris 124 Lifestyles Flared 76 Lignocaine 82 Nervous 124 Lincocin 95 Linozin 95 Lipazil 59 Lipid-Modifying Agents 59
Hormone 85 Levothyroxine 86 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] 124 hydrochloride 124 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] with 124 chlorhexidine 124 Lidocaine [Lignocaine] with 124 Lidocaine-Claris 124 Lifestyles Flared 76 Lignocaine 82 Nervous 124 Lincocin 95 Linozin 95 Lipazil 59 Lipid-Modifying Agents 59
Hormone85Levothyroxine86Lidocaine [Lignocaine]124Lidocaine [Lignocaine]124Lidocaine [Lignocaine]124Lidocaine [Lignocaine] with124chlorhexidine124Lidocaine [Lignocaine] with124Lidocaine-Claris124Lignocaine124Lignocaine124Lignocaine124Lignocaine82, 124Hormone82Nervous124Lincocin95Lipazil59Lipid-Modifying Agents59Liquigen204
Hormone 85 Levothyroxine 86 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] 124 Lidocaine [Lignocaine] with 124 chlorhexidine 124 Lidocaine [Lignocaine] with 124 prilocaine 124 Lidocaine-Claris 124 Lifestyles Flared 76 Lignocaine 82 Nervous 124 Lincocin 95 Lincocin 95 Lipid-Modifying Agents 59 Liquigen 204 Lisinopril 53
Hormone85Levothyroxine86Lidocaine [Lignocaine]124Lidocaine [Lignocaine]124Lidocaine [Lignocaine]124Lidocaine [Lignocaine] with124chlorhexidine124Lidocaine [Lignocaine] with124Lidocaine-Claris124Lignocaine124Lignocaine124Lignocaine124Lignocaine82, 124Hormone82Nervous124Lincocin95Lipazil59Lipid-Modifying Agents59Liquigen204

Lithium carbonate	137
Livostin	
Locacorten-Viaform ED's	188
Local preparations for Anal and	
Rectal Disorders	26
Locasol	
Loceryl	66
Locoid	
Locoid Crelo	
Locoid Lipocream	
Locorten-Vioform	188
Lodoxamide trometamol	
Logem	
Lomide	
Lomustine	
Loniten	
Loperamide hydrochloride	24
Lopinavir with ritonavir	109
Lopresor	56
Loprofin	
Loprofin Mix	
Loraclear Hayfever Relief	181
Lorafix	181
Lorapaed	181
Loratadine	181
Lorazepam	142
Lormetazepam	
Losartan potassium	
Losartan potassium with	
hydrochlorothiazide	54
Lostaar	
Lovir	
Loxalate	
Loxamine	
Lucrin Depot	
Lucrin Depot PDS	07 87
Ludiomil	
Lumigan	
Lycinate	
Lyderm	
- M -	
m-Captopril	50
m-Cefuroxime	
m-Enalapril	
m-Eslon M-M-R II	120
m-Mometasone	

Mabthera	.177
Macrogol 3350	38
Macrogol 400 and propylene	
glycol	191
Madopar 125	.122

Madopar 250122
Madopar 62.5122
Madopar HBS
Madopar Rapid
Madopar Rapid
Magnesium hydroxide198
Magnesium sulphate
Alimentary42
Dermatological75
Malathion72
Malathion with permethrin and
ninerend butevide 70
piperonyl butoxide
Marevan49
Marine Blue Lotion SPF 30+74
Marquis Black76
Marquis Conforma76
Marquis Protecta
Marquis Selecta
Marquis Sensolite76
Marquis Supalite76
Marquis Titillata76
MarguisTantiliza76
Martindale Acetylcysteine
Marvelon 2877
Mask for spacer device
Mask for spacer device
Mast Cell Stabilisers186
Maxidex189
Maxitrol189
MCT oil (Nutricia)204
Measles, mumps and rubella
vaccine
Mebendazole90
Mebeverine hydrochloride
Medrol82
Medroxyprogesterone acetate
Genito-Urinary78
Hormone85-86
Mefenamic acid114
Megestrol acetate164
Meloxicam115
Melphalan151
Meningococcal A, C, Y and
W-135 vaccine
Menomune231
Menthol67
Mercaptopurine153
Mercilon 2877
Mesalazine25
Mesna157
Mestinon114
Mestinon114 Metabolic Disorder Agents
Mestinon114

Methadone hydrochloride	
Extemporaneous	198
Nervous	126
Methatabs	126
Methoblastin	154
Methopt	191
Methotrexate	154
Methotrexate Ebewe	154
Methotrexate Sandoz	
Methyl hydroxybenzoate	
Methylcellulose	198
Methylcellulose with glycerin and	
sodium saccharin	199
Methylcellulose with glycerin and	
sucrose	199
Methyldopa	
Methylphenidate	
hydrochloride	146
Methylphenidate hydrochloride	
extended-release	147
Methylprednisolone	82
Methylprednisolone	
aceponate	. 68
Methylprednisolone acetate	
Methylprednisolone acetate with	
lidocaine [Lignocaine]	82
Methylprednisolone sodium	
succinate	. 82
Methylxanthines	186
Metoclopramide	
hydrochloride	135
Metoclopramide hydrochloride	
with paracetamol	134
Metolazone	
Metopirone	
Metoprolol - AFT CR	56
Metoprolol succinate	56
Metoprolol tartrate	
Metronidazole	
Metyrapone	
Mexiletine hydrochloride	55
Mexiletine Hydrochloride	
USP	55
Miacalcic	
Mianserin hydrochloride	128
Micolette	
Miconazole	40
Miconazole nitrate	
Dermatological	67
Genito-Urinary	
Micreme	
Micreme H	
Microgynon 30	

Microgynon 50 ED	77
Microlut	
Midazolam	
Midodrine	
Minerals	
Minidiab	
Minirin	
Mino-tabs	93
Minocycline hydrochloride	93
Minomycin Minor Skin Infections	93
Minoxidil	
Mirena	
Mirtazapine	129
Misoprostol Mitomycin C	26
Mitomycin C	157
Mitozantrone	157
Mitozantrone Ebewe	157
Mixtard 30	28
Moclobemide	128
Modafinil	148
Modavigil	148
Modecate	140
Moducal	
Moduretic	
Mogine	132
Mometasone furoate	201
	03
	205
Monogen	205
Montelukast	205 185
Montelukast Moroctocog alfa [Recombinant	185
Montelukast Moroctocog alfa [Recombinant factor VIII]	185 45
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride	185 45 126
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate	185 45 126 126
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate	185 45 126 126 126
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis	45 45 126 126 126 124
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat	45 126 126 126 126 124 39
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Moxifloxacin	185 126 126 126 126 124 39 95
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Moxifloxacin MSUD Maxamaid	185 126 126 126 126 124 39 95 216
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Moxifloxacin MSUD Maxamaid MSUD Maxamum	185 126 126 126 126 124 39 95 216
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Moxifloxacin MSUD Maxamaid MSUD Maxamum Mucilaginous laxatives with	185 126 126 126 124 39 95 216 216
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Moxifloxacin MSUD Maxamaid MSUD Maxamum Mucilaginous laxatives with	185 126 126 126 124 39 95 216 216
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Moxifloxacin MSUD Maxamaid MSUD Maxamum Mucilaginous laxatives with stimulants	185 126 126 126 124 39 95 216 216 38
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Moxifloxacin MSUD Maxamum MSUD Maxamum Mucilaginous laxatives with stimulants Mucolytics	185 126 126 126 124 39 95 216 216 38 38 186
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motth and Throat Moxifloxacin MSUD Maxamaid MSUD Maxamum Mucilaginous laxatives with stimulants Mucolytics MultiADE	185 126 126 126 126 124 39 95 216 216 216 38 38 38 41
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motth and Throat Mouth and Throat Moxifloxacin MSUD Maxamaid MSUD Maxamum Mucilaginous laxatives with stimulants Mucolytics MultiADE Multiload Cu 375	185 45 126 126 126 124 39 95 216 38 186 41 76
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Mottis Mouth and Throat Mouth and Throat Multiabe Multiabe Multiabe Multiabe Sciencess	185 126 126 126 126 216 216 216 38 186 41 76
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Mottis Mouth and Throat Mouth and Throat Multiabe Multiabe Multiabe Multiabe Sciencess	185 126 126 126 126 216 216 216 38 186 41 76
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motth and Throat Moxifloxacin MSUD Maxamaid MSUD Maxamum Mucilaginous laxatives with stimulants Mucolytics MultiADE MultiADE MultiOad Cu 375 Multiload Cu 375 SL Multiple Sclerosis Treatments	185 126 126 126 126 126 216 216 216 38 38 38 416 76 76 76
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Mottis Mouth and Throat Mouth and Throat MultiAbe Multiload Cu 375 Multiload Cu 375 SL Multiload Cu 375 SL Multiple Sclerosis Treatments Multivitamins	185 126 126 126 124 39 95 216 38 38 3186 41 76 76 76
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Mouth and Throat Mouth and Throat MSUD Maxamum Mucilaginous laxatives with stimulants Mucolytics MultiADE Multiload Cu 375 Multiload Cu 375 SL Multiload Cu 375 SL Multiple Sclerosis Treatments Multivitamins Mupirocin	185 126 126 126 124 395 216 38 38 38 38 3186 41 76 76 76
Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Moxifloxacin MSUD Maxamum Mucilaginous laxatives with stimulants Mucolytics MultiADE Multiload Cu 375 Multiload Cu 375 SL Multiload Cu 375 SL Multiple Sclerosis Treatments Multivitamins Mupirocin Muscle Relaxants	185 126 126 126 126 124 39 95 216 216 38 38 38 38 3186 41 76 76 41
Montelukast	185 126 126 126 126 126 216 216 38 38 38 38 318 36 41 76 76 41 66 41 41
Montelukast	185 126 126 126 126 126 39 95 216 38 95 216 38 41 76 41 41 66 41 41 61
Montelukast	185 126 126 126 126 126 39 95 216 38 95 216 38 41 76 41 41 66 41 41 61

Mycobutin	66 67 90 55 25 24 51 15
- N -	
Nadolol	
Nalcrom	25
Naloxone hydrochloride1	
Naltraccord1	
Naltrexone hydrochloride1	
Naphazoline hydrochloride1	91
Naphcon Forte1	91
Naprosyn SR 10001	14
Naprosyn SR 7501	14
Naproxen1	
Nardil1	
Nasal Preparations1	
Natulan1	
Nausicalm1 Navelbine1	
Navoban1	
Nedocromil1	
Nefopam hydrochloride1	25
Neo-Mercazole	
Neocate Advance2	
Neocate Gold2	
Neocate LCP2	
Neoral1	
NeoRecormon	44
Neostigmine metilsulfate1	14
Neotigason	73
Nepro (strawberry)2	80
Nepro (vanilla)2	80
Nepro RTH2	
Nerisone	
Neulactil1	
Neulastim	
NeuroKare	
Neurontin1	
Nevirapine1	
Nevirapine Alphapharm1	60
Nicorandil Nicotine1	
Nicotine1	
Nifedipine	
Nifuran1	
InituraliI	10

Nilstat
Alimentary
Genito-Urinary79
Infection
Nipent
Nitrados144
Nitrates61
Nitrazepam144
Nitroderm TTS61
Nitrofurantoin113
Nizoral97
Noctamid144
Nodia24
Noflam 250114
Noflam 500114
Non-Steroidal Anti-Inflammatory
Drugs 114
Nonacog alfa [Recombinant
factor IX]
Norethisterone
Genito-Urinary78
Hormone
Norethisterone with
mestranol78
Norflex121
Norfloxacin113
Noriday 28
Norimin
Norinyl-1/28
Normacol Plus
Normison144
Norpress
Nortriptyline hydrochloride
Norvir109
NovaSource Renal
Novatretin
NovoFine
NovoMix 30 FlexPen
NovoRapid
NovoRapid Penfill
NovoSeven RT45
Novoseven RT45
Noxafil
Nozinan
Nuelin
Nuelin-SR186
Nupentin131
Nutraplus70
Nutrient Modules202
Nutrini Energy Multi Fibre207
Nutrini Energy RTH207
Nutrini Low Energy Multi
Fibre

Nutrini RTH 207 Nutrison Concentrated 214 Nutrison Energy 211 Nutrison Energy Multi Fibre 212 Nutrison Standard RTH 211 Nystatin Alimentary Alimentary 40 Dermatological 67 Genito-Urinary 79 Infection 97 NZB Low Gluten Bread Mix 215 - O - Octocog alfa [Recombinant factor VIII] 45 Octreotide (somatostatin analogue) 164 Octreotide MaxRx 164 Octreotide MaxRx 164 Octreotide NaxRx 164 Ocstradiol valerate 84 Oestradiol 84 Oestradiol valerate 85 Oestroil 70 Ganito-Urinary 79 Hormone 85 Oestroil 70 Genito-Urinary 79 Hormone 85 Olanzapine 138 Olanzapine
Nutrison Energy 211 Nutrison Energy Multi Fibre 212 Nutrison Standard RTH 211 Nystatin 212 Nutrison Standard RTH 211 Nystatin 40 Dermatological 67 Genito-Urinary 79 Infection 97 NZB Low Gluten Bread Mix 215 -0- 0 Octreotide (somatostatin analogue) 164 Octreotide LAR (somatostatin analogue) 164 Octreotide MaRx 164 Oestradiol valerate 84 Oestradiol valerate 84 Oestradiol valerate 85 Oestrogens 84 Oestrogens with medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olanzine-D 138 Olapatadine 191 Olsalazine 25 Omerzapine 136 Olanzine-D 138 Olanzine-D 138 Olanzine <td< td=""></td<>
Nutrison Energy Multi Fibre 212 Nutrison Multi Fibre 212 Nutrison Standard RTH 211 Nyefax Retard 57 Nystatin 40 Dermatological 67 Genito-Urinary 79 Infection 97 NZB Low Gluten Bread Mix 215 - 0 - Octocog alfa [Recombinant factor VIII] 45 Octreotide (somatostatin analogue) 164 Octreotide LAR (somatostatin analogue) 164 Octreotide MaxRx 164 Octreotide MaxRx 164 Oestradiol with norethisterone 85 Oestriol Genito-Urinary Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olanzapine 138 Olanzapine 138 Olanzapine 138 Olanzapine 27
Nutrison Standard RTH
Nutrison Standard RTH
Nyefax Retard 57 Nystatin Alimentary 40 Dermatological 67 Genito-Urinary 79 Infection 97 NZB Low Gluten Bread Mix 215 -0- 0 Octocog alfa [Recombinant factor VIII] VIII] 45 Octreotide (somatostatin analogue) analogue) 164 Octreotide LAR (somatostatin analogue) analogue) 164 Octreotide MaxRx 164 Oestradiol with norethisterone norethisterone 85 Oestroil 84 Oestrogens with medroxyprogesterone medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olapatadine 191 Onsapar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 One-Alpha 41
Nystatin 40 Alimentary 40 Dermatological 67 Genito-Urinary 79 Infection 97 NZB Low Gluten Bread Mix 215 -0- 0 Octocog alfa [Recombinant factor VIII] VIII] 45 Octreotide (somatostatin analogue) analogue) 164 Octreotide LAR (somatostatin analogue) analogue) 164 Octreotide MaxRx 164 Oestradiol with norethisterone Ast 0estradiol valerate Øestriol 6 Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with medroxyprogesterone medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olapatadine 19 OncoTICE 171 Ondansetron 136 Onezaple 27
Nystatin 40 Alimentary 40 Dermatological 67 Genito-Urinary 79 Infection 97 NZB Low Gluten Bread Mix 215 -0- 0 Octocog alfa [Recombinant factor VIII] VIII] 45 Octreotide (somatostatin analogue) analogue) 164 Octreotide LAR (somatostatin analogue) analogue) 164 Octreotide MaxRx 164 Oestradiol with norethisterone Ast 0estradiol valerate Øestriol 6 Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with medroxyprogesterone medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olapatadine 19 OncoTICE 171 Ondansetron 136 Onezaple 27
Alimentary 40 Dermatological 67 Genito-Urinary 79 Infection 97 NZB Low Gluten Bread Mix 215 -0- 0 Octocog alfa [Recombinant factor 45 Octreotide (somatostatin 45 analogue) 164 Octreotide LAR (somatostatin 164 analogue) 164 Octreotide MaxRx 164 Oestradiol 84 Oestradiol valerate 84 Oestradiol valerate 84 Oestrologens 84 Oestrologens 84 Oestrogens 84 Oestrogens 84 Oestrogens 84 Oestrogens with medroxyprogesterone medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olapataline 138 Olopatadine 191 Onkatore 157 OncoTICE 171 Ondansetron 136 One-Alpha 41
Dermatological 67 Genito-Urinary 79 Infection 97 NZB Low Gluten Bread Mix 215 - O - O Octocog alfa [Recombinant factor VIII] 45 Octreotide (somatostatin analogue) 164 Octreotide LAR (somatostatin 164 Octreotide MaxRx 164 Octreotide MaxRx 164 Oestradiol 84 Oestradiol valerate 84 Oestradiol with norethisterone norethisterone 85 Oestrogens 84 Oestrogens with 70 medroxyprogesterone 85 Olanzapine 138 Olanz
Genito-Urinary 79 Infection 97 NZB Low Gluten Bread Mix 215 - O - Octocog alfa [Recombinant factor VIII] 45 Octreotide (somatostatin analogue) analogue) 164 Octreotide LAR (somatostatin analogue) analogue) 164 Octreotide MaxRx 164 Oestradiol waRax 164 Oestradiol valerate 84 Oestradiol with norethisterone norethisterone 85 Oestrogens 84 Oestrogens with 79 Hormone 85 Oestrogens with 70 Olanzapine 138 Olanzine-D 138 Olanzine-D 138 Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Oncaspar 157 OncoTICE 171 Ondansetron 136 One-Alpha<
Infection
NZB Low Gluten Bread Mix 215 - O - Octocog alfa [Recombinant factor VIII] 45 Octreotide (somatostatin 164 analogue) 164 Octreotide LAR (somatostatin 164 analogue) 164 Octreotide MaRx 164 Octreotide MaRx 164 Oestradiol 84 Oestradiol valerate 84 Oestradiol with norethisterone norethisterone 85 Oestrogens 84 Oestrogens with 79 Hormone 85 Oestrogens with 70 Olanzapine 138 Olanzine-D 138 Olanzine-D 138 Olopatadine 191 Olsalzine 25 Omeprazole 27 OmcoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 OncotICE 17
- 0 - Octocog alfa [Recombinant factor VIII]
Octocog alfa [Recombinant factor VIII]
VIII] 45 Octreotide (somatostatin analogue) 164 Octreotide LAR (somatostatin analogue) 164 Octreotide MaxRx 164 Octreotide MaxRx 164 Oestradiol 84 Oestradiol valerate 84 Oestradiol valerate 85 Oestriol 6 Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olanzine-D 138 Olopatadine 191 Olsalazine 25 Omeprazole 27 OmcoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 OnceTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157
Octreotide (somatostatin analogue) 164 Octreotide LAR (somatostatin analogue) 164 Octreotide MaxRx 164 Oestradiol 84 Oestradiol valerate 84 Oestradiol with norethisterone 85 Oestrol 79 Hormone 85 Oestrogens 84 Oestrogens with medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olanzine-D 138 Oladataline 191 Olsalazine 25 Omeprazole 27 OmcoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone <td< td=""></td<>
Octreotide (somatostatin analogue) 164 Octreotide LAR (somatostatin analogue) 164 Octreotide MaxRx 164 Oestradiol 84 Oestradiol valerate 84 Oestradiol with norethisterone 85 Oestrol 79 Hormone 85 Oestrogens 84 Oestrogens with medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olanzine-D 138 Oladataline 191 Olsalazine 25 Omeprazole 27 OmcoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone <td< td=""></td<>
Octreotide LAR (somatostatin analogue) 164 Octreotide MaxRx 164 Oestradiol 84 Oestradiol valerate 84 Oestradiol valerate 84 Oestradiol with norethisterone 85 Oestroid 6 Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olanzine 138 Olapatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 Oncaspar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Oncaspar 157 Oncaspar 157 One-Alpha 41 Onelink 62 Onkotrone 157
Octreotide LAR (somatostatin analogue) 164 Octreotide MaxRx 164 Oestradiol 84 Oestradiol valerate 84 Oestradiol valerate 84 Oestradiol with norethisterone 85 Oestroid 6 Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olanzine 138 Olapatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 Oncaspar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Oncaspar 157 Oncaspar 157 One-Alpha 41 Onelink 62 Onkotrone 157
analogue) 164 Octreotide MaxRx 164 Oestradiol 84 Oestradiol valerate 84 Oestradiol with norethisterone norethisterone 85 Oestriol Genito-Urinary Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens 84 Oestrogens 84 Oestrogens with medroxyprogesterone medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olanzine-D 138 Olapatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onra-Blend 199 Ora-Blend SF 199 Ora-Plend SF 199
Octreotide MaxRx 164 Oestradiol 84 Oestradiol valerate 84 Oestradiol with norethisterone norethisterone 85 Oestriol 6enito-Urinary Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens 85 Oil in water emulsion 70 Olanzine 138 Olanzine 138 Olapataline 191 Olsalazine 27 Omezol Relief 27 Oncospar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink
Oestradiol 84 Oestradiol valerate 84 Oestradiol with 85 norethisterone 85 Oestriol Genito-Urinary Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with medroxyprogesterone medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138, 140 Olanzine 138 Olanzine 138 Olaziapine 138 Olazapine 138 Olazine 139 Orazine 157 Oncori ICE 17
Oestradiol valerate
Oestradiol with norethisterone 85 Oestriol Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138 Olanzine-D 138 Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Oncospar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend 199 Ora-Plend SF 199 Ora-Plend SF 198
norethisterone 85 Oestriol Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with 70 medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138, 140 Olanzine 138 Olanzine 138 Olanzine 138 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omcospar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onra-Blend 199 Ora-Blend 199 Ora-Blend 199 Ora-Plus 198
Oestriol Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with 70 medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138, 140 Olanzapine 138, 140 Olanzine 138 Olanzine 138 Olanzine 138 Olanzine 138 Olanzapine 138 Olanzine 138 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 Oncaspar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone <t< td=""></t<>
Genito-Urinary 79 Hormone 85 Oestrogens 84 Oestrogens with 84 medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138, 140 Olanzapine 138 Olanzine 138 Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 Oncospar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend 199 Ora-Plend SF 199 Ora-Plend SF 198
Hormone 85 Oestrogens 84 Oestrogens with 85 Oil in water emulsion 70 Olanzapine 138, 140 Olanzine 138 Olanzine 138 Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omcospar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onra-Blend 199 Ora-Blend 199 Ora-Plus 198
Oestrogens
Oestrogens with medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138, 140 Olanzine 138 Olanzine 138 Olatzapine 138 Olazine 138 Olazine 138 Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
Oestrogens with medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138, 140 Olanzine 138 Olanzine 138 Olatzapine 138 Olazine 138 Olazine 138 Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
medroxyprogesterone 85 Oil in water emulsion 70 Olanzapine 138, 140 Olanzine 138 Olanzine 138 Olazine-D 138 Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
Oil in water emulsion 70 Olanzapine 138, 140 Olanzine 138 Olanzine 138 Olanzine 138 Olanzine 138 Olatzine 138 Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkortone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
Olanzapine
Olanzine 138 Olanzine-D 138 Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 Oncaspar 157 Oncaspar 157 Ondansetron 136 One-Alpha 41 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
Olanzine-D 138 Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 Oncaspar 157 OnconTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
Olbetam 60 Olopatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 Oncaspar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
Olopatadine 191 Olsalazine 25 Omeprazole 27 Omezol Relief 27 Oncaspar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
Olsalazine 25 Omeprazole 27 Omezol Relief 27 Oncaspar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Pleus 198
Omeprazole 27 Omezol Relief 27 Oncaspar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Pleus 198
Omezol Relief 27 Oncaspar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Pleus 198
Oncaspar 157 OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
OncoTICE 171 Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
Ondansetron 136 One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
One-Alpha 41 Onelink 62 Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
Onelink
Onkotrone 157 Onrex 136 Ora-Blend 199 Ora-Blend SF 199 Ora-Plus 198
Onrex
Ora-Blend199 Ora-Blend SF199 Ora-Plus
Ora-Blend SF199 Ora-Plus
Ora-Plus198
01a-FIUS
108
Ora-Sweet198 Ora-Sweet SF198
Orabase40

Oracort	40
Oral Supplements/Complete Diet	
(Nasogastric/Gastrostomy	
Tube Feed)	204
Oratane	65
Orgran	
Ornidazole	99
Orphenadrine citrate	101
Orphenadrine hydrochloride	102
Ortho All-flex	.120
Ortho taliding	/0
Ortho-tolidine	
Oruvail SR	.114
Osmolite	.211
Osmolite RTH	
Ospamox	
Ospamox Paediatric Drops	92
Other Endocrine Agents	88
Other Oestrogen	
Preparations	85
Other Progestogen Preparations	
Preparations	85
Other Skin Preparations	75
Ovestin	
Genito-Urinary	79
Hormone	
Ox-Pam	
Oxaliplatin	
Oxaliplatin Actavis 100	152
Ovalipiatin Actavis 100	.152
Oxaliplatin Actavis 50	.152
Oxaliplatin Ebewe	
Oxazepam	.142
Oxis Turbuhaler	
Oxpentifylline	
Oxybutynin	80
Oxycodone hydrochloride	
Oxycodone Orion	
OxyContin	.127
Oxydone BNM	.127
OxyNorm	.127
Oxytocin	79
Oxytocin BNM	79
Ozole	
- P -	
Pacifen	101
Pacific Buspirone	
Paclitaxel	.157
Paclitaxel Actavis	.157
Paclitaxel Ebewe	.157
Paediatric Seravit Pamidronate BNM	41
Pamidronate BNM	.117
Pamidronate disodium	
Pamisol	.117
Panadol	.125

Pancreatic enzyme37
Pantoprazole
Panzytrat
Papaverine hydrochloride62
Para Plus72
Para-amino salicylic acid100
Paracare125
Paracare Double Strength125
Paracetamol125
Paracotamol L Codoino
(Relieve)
Paracetamol with codeine
Paradigm 1.8 Reservoir
Paradigm 3.0 Reservoir
Paradigm 522
Paradigm 72232
Paradigm Mio MMT-92135
Paradigm Mio MMT-92335
Paradigm Mio MMT-92535
Paradigm Mio MMT-94135
Paradigm Mio MMT-94335
Paradigm Mio MMT-94535
Paradigm Mio MMT-96535
Paradigm Mio MMT-97535
Paradigm Quick-Set
MMT-386
Paradigm Quick-Set
MMT-387
Paradigm Quick-Set
MMT-396
Paradigm Quick-Set
MMT-397
Paradium Quick-Set
MMT-398
Paradigm Quick-Set
MMT-399
Paradigm Silhouette
MMT-368
Nini 1-500
Paradigm Silhouette MMT-377
Paradigm Silhouette
MMT-378
Paradigm Silhouette MMT-381
MMT-381
Paradigm Silhouette
MMT-382 34
Paradigm Silhouette
MMT-383
Paradigm Silhouette
MMT-384
Paradigm Sure-T MMT-864
Paradigm Sure-T MMT-866
Falauly III SULE-1 IVIVI 1-000
Paradigm Sure-T MMT-87433

Paradigm Sure-T MMT-87633
Paradigm Sure-T MMT-88433
Paradigm Sure-T MMT-88633
Parafast125
Paraffin70
Paraffin liquid with soft white
paraffin 191
Paraffin liquid with wool fat
liquid
Paraldehyde130
Paramax
Parasiticidal Preparations71
Parnate128
Paromomycin95
Paroxetine hydrochloride
Paser
Patanol191
Paxam142
Pazopanib161
Peak flow meter
Pedialyte - Bubblegum50
Pediasure
Pediasure RTH207
Pegaspargase157
Pegasys111
Pegasys RBV Combination
Pack 111
Pegfilgrastim
Pegylated interferon alfa-2a111
Penicillamine
Penicillin G benzathine
[Benzathine
benzylpenicillin]93
PenMix 30
PenMix 40
PenMix 5028
Pentasa
Pentostatin
[Deoxycoformycin]
Pentoxifylline [Oxpentifylline]62
Pepti Junior Gold Karicare
Aptamil
Peptisoothe27
Peptisorb208
Pergolide122
Perhexiline maleate
Pericyazine138
Perindopril53
Permax
Permethrin72
Persantin
Peteha100
Pethidine hydrochloride127

Pevaryl	.67
Pexsig	.57
Phenelzine sulphate1	28
Phenobarbitone1	
Phenobarbitone sodium	
Extemporaneous1	199
Nervous1	
Phenoxybenzamine	
hydrochloride	52
Phenoxymethylpenicillin	
(Penicillin V)	93
Phenytoin sodium130, 1	133
Phlexy 10	
Phosphate-Sandoz	
Phytomenadione	
Pilocarpine1	
Pimafucort	
Pindolol	
Pinetarsol	
Pinorax	
Pinorax Forte	
Pioglitazone	
Piportil1	
Pipothiazine palmitate1	141
Pizaccord	
Pizotifen	
PKU Anamix Infant	
PKU Anamix Junior	
PKU Anamix Junior LQ	217
PKU Lophlex LQ 10	
PKU Lophlex LQ 20	217
Plaquenil1	
Plendil ER	57
pms-Bosentan	
Pneumococcal (PCV13)	.05
vaccine	221
Pneumococcal polysaccharide	-01
vaccine	221
Pneumococcal vaccine	
Pneumovax 23	
Podophyllotoxin	
Polaramine1	
Poliomyelitis vaccine	
Poloxamer	
Poly-Gel1	191
Poly-Tears1	
Poly-Visc1	
Polycal	
Polyvinyl alcohol1	191
Ponstan1	
Posaconazole	07
Postinor-1	
Potassium bicarbonate	.50

Potassium chloride50-51
Potassium citrate80
Potassium iodate42
Povidone iodine71
Pradaxa48
Pramipexole hydrochloride122
Prasugrel
Pravastatin60
Praziquantel90
Prazosin
Pred Forte
Pred Mild189
Prednisolone acetate
Prednisolone sodium
phosphate
Prednisone
Pregnancy Tests - hCG Urine80
Premarin
Premia 2.5 Continuous85
Premia 5 Continuous85
Prevenar 13231
Prezista
Priadel
Primacin
Primaquine phosphate
Primidone
Primolut N
Probenecid
Probenecid-AFT121
Procaine penicillin93
Procarbazine hydrochloride
Prochlorperazine136
Proctosedyl26
Procyclidine hydrochloride123
Procytox151
Prodopa58
Progesterone86
Proglicem27
Prograf180
Progynova84
Prokinex135
Promethazine hydrochloride182
Promethazine theoclate136
Promod204
Propafenone hydrochloride55
Propamidine isethionate188
Propranolol
Propylene glycol199
Propylthiouracil87
Protamine sulphate48
Protaphane
Protaphane Penfill28
Protifar204

Protionamide	100
Provera	85, 86
PSO	220–223
Psoriasis and Eczema	
Preparations	73
PTU	87
Pulmicort Turbuhaler	182
Pulmocare	204
Pulmozyme	186
Puri-nethol	
Pyrazinamide	100
Pyridostigmine bromide	
PyridoxADE	40
Pyridoxine hydrochloride	40
Pyrimethamine	95
ytazen SR	
•	

- Q -

Q 300	99
Questran-Lite	60
Quetapel	.138
Quetiapine	.138
Quick-Set MMT-390	36
Quick-Set MMT-391	36
Quick-Set MMT-392	36
Quick-Set MMT-393	36
Quinapril	53
Quinapril with	
hydrochlorothiazide	53
Quinine sulphate	99

- R -

RA-Morph	126
Raloxifene hydrochloride	117
Raltegravir potassium	
Ramipex	
Ranbaxy-Cefaclor	
Ranitidine hydrochloride	27
Rapamune	
Reandron 1000	
Recombinant factor IX	45
Recombinant factor VIIa	45
Recombinant factor VIII	45
Rectogesic	26
Redipred	82
Refresh Night Time	
Renilon 7.5	
Resonium-A	51
Resource Beneprotein	204
Resource Diabetic	
Respigen	184
Respiratory Devices	187
Respiratory Stimulants	
Retinol palmitate	

ReTrieve65
Retrovir109
Rexacrom189
Reyataz109
Ridal139
Ridaura s29115
Rifabutin100
Rifadin100
Rifampicin100
Rifinah100
Rilutek123
Riluzole123
Riodine71
Risedronate Sandoz118
Risedronate sodium
Risperdal139
Risperdal Consta141
Risperdal Quicklet
Risperidone139, 141
Risperon
Ritalin146
Ritalin LA147
Ritalin SR146
Ritonavir109
Rituximab177
Rivaroxaban
Rivotril
Rizamelt
Rizatriptan134
Rocaltrol solution41
Roferon-A111
Ropin123 Ropinirole hydrochloride123
Roxane
Roxane
Alimentary24
Cardiovascular
Roxithromycin
Rubifen
Rubifen SR146
Rythmodan54
Rytmonorm55
- S -
S-26 Gold Premgro217
Sabril
Salamol184
Salapin184
Salazopyrin25
Salazopyrin EN25
Salbutamol184
Salbutamol with ipratropium
bromide 185

Salicylic acid74 Salmeterol183

Sandomigran135
Sandostatin LAR164
Scalp Preparations74
Scopoderm TTS135
Sebizole74
Sedatives and Hypnotics144
Selegiline hydrochloride
Senna
Senokot
SensoCard
Serenace
Seretide
Seretide Accuhaler
Serevent
Serevent Accuhaler183
Serophene88
Seroquel138
Sertraline129
Sevredol126
Sex Hormones Non
Contraceptive83
Shield 49
Shield Blue76
Shield XL76
Silagra63
Sildenafil63
Silhouette MMT-37134
Silhouette MMT-373
Silver sulphadiazine
Simethicone
Simvastatin60
Sindopa122
Sinemet122
Sinemet CR122
Singulair
Sirolimus180
Siterone
Slow-Lopresor
Sodibic
Sodium acid phosphate
Sodium alginate24
Sodium aurothiomalate115
Sodium bicarbonate
Blood50-51
Extemporaneous199
Sodium calcium edetate192
Sodium
carboxymethylcellulose40
Sodium chloride
Blood50
Respiratory186
Sodium citrate with sodium lauryl
sulphoacetate

Sodium citro-tartrate81
Sodium cromoglycate
Alimentary25
Respiratory
Sensory
Sodium fluoride
Sodium hyaluronate191
Sodium nitroprusside29
Sodium polystyrene
sulphonate51
Sodium tetradecyl sulphate45
Sodium valproate133
Sofradex
Soframycin188
Solian
Solifenacin succinate81
Solox
Solu-Cortef
Solu-Medrol82
Somatropin87
Sotacor57
Sotalol57
Space Chamber187
Space Chamber Plus187
Spacer device
Spacer device autoclavable
Span-K51
Spiractin
Spiriva184
Spironolactone
Spirotone
Sporanox97
Sprycel159
Staphlex93
Stavudine [d4T]109
Stelazine140
Stemetil136
Stesolid130
Stimulants/ADHD
Treatments 145
Stiripentol
Stocrin
Stomahesive
Strattera
Stromectol
Suboxone148
Sucralfate27
Sulfadiazine sodium96
Sulindac115
Sulphasalazine25
Sulphur74
Sumatriptan134
Sunitinib
102

Sunscreens74
Sunscreens, proprietary74
Suplena208
Sure-T MMT-863
Sure-T MMT-865
Sure-T MMT-873
Sure-T MMT-875
Sure-T MMT-883
Sure-T MMT-885
Surgam115
Sustagen Hospital Formula212
Sustanon Ampoules
Sutent
Symbicort Turbuhaler 100/6
Symbicort Turbuhaler 200/6
Symbicort Turbuhaler
400/12
400/12
Sympathomimetics
Synacthen83
Synacthen Depot83
Synflorix231
Synthroid
Syntocinon
Current em estrin e
Syntometrine
Syntometrine
Syntometrine79 Syrup (pharmaceutical grade)199
Syntometrine

Terbutaline sulphate184
Teriparatide118
Testosterone83
Testosterone cypionate83
Testosterone esters83
Testosterone undecanoate83
Tetrabenazine124
Tetrabromophenol81
Tetracosactrin83
Tetracyclin Wolff93
Tetracycline93
Teva154
Thalidomide158
Thalomid158
Theophylline
Thiamine hydrochloride41
THIO-TEPA152
Thioguanine
Thiotepa152
Thymol glycerin40
Thyroid and Antithyroid
Agents
Tiaprofenic acid115
Ticagrelor46
Tilade
Tilcotil115
TIICOUI
Timolol maleate
Timolol maleate Cardiovascular57
Timolol maleate Cardiovascular57 Sensory189
Timolol maleate Cardiovascular
Timolol maleate Cardiovascular
Timolol maleate Cardiovascular
Timolol maleate Cardiovascular
Timolol maleate Cardiovascular
Timolol maleate Cardiovascular
Timolol maleate Cardiovascular
Timolol maleate Cardiovascular
Timolol maleate 57 Cardiovascular 57 Sensory 189 Timoptol XE 189 Tiotropium bromide 184 TMP 96 Tobramycin 1 Infection 96 Sensory 189 Tobramycin 16 Jobrex 189 Tofranil 128 Tofranil 128
Timolol maleate 57 Cardiovascular 57 Sensory 189 Timoptol XE 189 Tiotropium bromide 184 TMP 96 Tobramycin 1 Infection 96 Sensory 189 Tobramycin 1 Infection 96 Sensory 189 Tobrex 189 Tofranil 128 Tolcapone 123 Tolterodine 81
Timolol maleate 57 Cardiovascular 57 Sensory 189 Timoptol XE 189 Tiotropium bromide 184 TMP 96 Tobramycin 1 Infection 96 Sensory 189 Tobramycin 16 Infection 96 Sensory 189 Tobrex 189 Tobrex 189 Tobrang 189 Tobrex 189 Tobrex 189 Tobrex 189 Tolcapone 128 Tolcapone 123 Tolterodine 81 Tolvon 128
Timolol maleate 57 Cardiovascular 57 Sensory 189 Timoptol XE 189 Tiotropium bromide 184 TMP 96 Tobramycin 1 Infection 96 Sensory 189 Tobramycin 16 Infection 96 Sensory 189 Tobrex 189 Tofranil 128 Tolcapone 123 Tolterodine 81 Tolvon 128 Topamax 133
Timolol maleate Cardiovascular
Timolol maleate Cardiovascular
Timolol maleate Cardiovascular
Timolol maleate 57 Cardiovascular 57 Sensory 189 Timoptol XE 189 Tiotropium bromide 184 TMP 96 Tobramycin 1 Infection 96 Sensory 189 Tobrex 189 Tobrex 189 Tobranil 128 Tolcapone 123 Tolterodine 81 Tolvon 128 Topamax 133 Topical Products for Joint and 115 Muscular Pain 115 Topiramate 133
Timolol maleate Cardiovascular
Timolol maleate Cardiovascular
Timolol maleate 57 Cardiovascular 57 Sensory 189 Timoptol XE 189 Tiotropium bromide 184 TMP 96 Tobramycin 1 Infection 96 Sensory 189 Tobramycin 16 Infection 96 Sensory 189 Tobrax 189 Tobrax 189 Tobray 189 Tobray 189 Tobrax 189 Tobrax 189 Tobrax 189 Tobrax 189 Tobrax 189 Tolcapone 123 Tolcapone 123 Tolyon 128 Topamax 133 Topical Products for Joint and Muscular Pain Muscular Pain 115 Topiramate 133 Total parenteral nutrition (TPN) Top 50 Tracleer 63
Timolol maleate 57 Cardiovascular 57 Sensory 189 Timoptol XE 189 Tiotropium bromide 184 TMP 96 Tobramycin 1 Infection 96 Sensory 189 Tobrax 189 Tobramycin 1 Infection 96 Sensory 189 Tobrex 189 Tobrax 189 Tobramil 128 Tolcapone 123 Tolterodine 81 Tolvon 128 Topamax 133 Topical Products for Joint and Muscular Pain Muscular Pain 115 Toparmate 133 Total parenteral nutrition 50 TPN 50 TPN 50 Tracleer 63 Tramadol hydrochloride 127
Timolol maleate 57 Cardiovascular 57 Sensory 189 Timoptol XE 189 Tiotropium bromide 184 TMP 96 Tobramycin 1 Infection 96 Sensory 189 Tobrax 189 Tobramycin 1 Infection 96 Sensory 189 Tobrex 189 Tobrax 189 Tobrax 189 Tobrex 189 Tobrex 189 Tobrex 189 Tolcapone 123 Tolcapone 123 Tolexon 128 Topamax 133 Topical Products for Joint and Muscular Pain Muscular Pain 115 Topiramate 133 Total parenteral nutrition 50 TPN 50 TPN 50 Tracleer 63 Tramadol hydrochloride 127 Tramal SR 100 127
Timolol maleate Cardiovascular
Timolol maleate 57 Cardiovascular 57 Sensory 189 Timoptol XE 189 Tiotropium bromide 184 TMP 96 Tobramycin 1 Infection 96 Sensory 189 Tobrax 189 Tobramycin 1 Infection 96 Sensory 189 Tobrex 189 Tobrax 189 Tobrax 189 Tobrex 189 Tobrex 189 Tobrex 189 Tolcapone 123 Tolcapone 123 Tolexon 128 Topamax 133 Topical Products for Joint and Muscular Pain Muscular Pain 115 Topiramate 133 Total parenteral nutrition 50 TPN 50 TPN 50 Tracleer 63 Tramadol hydrochloride 127 Tramal SR 100 127

Trandolapril	53
Tranexamic acid	
Tranylcypromine sulphate	
Trastuzumab	
Travatan	
Travoprost	
Treatments for Dementia	.148
Treatments for Substance	
Dependence	148
Trental 400	
Tretinoin	
Dermatological	
Oncology	
Triamcinolone acetonide	
Alimentary	40
Dermatological	
Hormone	
Triamcinolone acetonide with	00
gramicidin, neomycin and nysta	atin
Dermatological	69
Sensory	188
Triazolam	
Trichozole	
Triclosan	
Trifluoperazine	03
hydrochloride	140
Trimeprazine tartrate	100
Trimethoprim	- 102
Trisequens	
Trisul	
Trophic Hormones	
Tropicamide	
Tropisetron	
Trusopt	
Truvada	
Two Cal HN	
Two Cal HN RTH	01/
Tykerb	161
,	. 101
- U -	
Ultraproct	
Univent184,	
Ural	
Urea	
Urex Forte	
Urinary Agents	80
Urinary Tract Infections	
Uromitexan	.157

Valaciclovir	103
Valcvte	103
Valganciclovir	103
Vallergan Forte	182
Valtrex	103
Vancomycin hydrochloride	96
Vannair	183
Varenicline tartrate	150
Vasodilators	
Vasopressin Agonists	
Velcade	154
Venlafaxine	130
Ventavis	
Ventolin	
Vepesid	
Veracol	
Verapamil hydrochloride	
Vergo 16	
Vermox	
Vernox Verpamil SR	90
Vesanoid	
Vesicare	
Vfend	
Viaderm KC	69
Victrelis	
Videx EC	
Vigabatrin	
Vimpat	132
Vinblastine sulphate	158
Vincristine sulphate	
Vinorelbine	159
Vinorelbine Ebewe	159
Viramune Suspension	
Viread	
Vistil	
Vistil Forte	
VitA-POS	
Vitabdeck	
Vitadol C	40
Vital HN	
Vitala-C	41
Vitamin A with vitamins D and	
С	
Vitamin B complex	41
Vitamins	.40–41
Vivonex Pediatric	218
Vivonex TEN	
Volibris	
Voltaren	
Voltaren D	114
Voltaren Ophtha	189
Volumatic	
Voriconazole	

Vosol	.188			
Votrient	.161			
Vytorin	61			
- W -				
Warfarin sodium	49			
Wart Preparations	75			
Wasp venom allergy				
treatment	. 181			
Water				
Blood	50			
Extemporaneous	.199			
Wool fat with mineral oil	70			
- X -				
Xanax	.141			
Xarelto	48			
Xeloda	.152			
XMET Maxamum	.216			
XP Maxamaid	.217			
XP Maxamum				
Xylocaine	.124			
Xylocaine Viscous	.124			

Xyntha	45
-Z-	07
Zantac	
Zapril	52
Zarator	60
Zarontin	131
Zaroxolyn	59
Zarzio	49
Zavedos	157
Zeffix	102
Zeldox	140
Zerit	109
Zetlam	102
Zetop	181
Ziagen	
Zidovudine [AZT]	109
Zidovudine [AZT] with	
lamivudine	109
Zinc and castor oil	
Zinc sulphate	
Zincaps	
21100000	40

Zinnat	90
Ziprasidone	140
Zithromax	91
Zofran Zydis	136
Zoladex	
Zoledronic acid	
Zopiclone	
Zostrix	
Zostrix HP	
Zovirax	
Zuclopenthixol decanoate	
Zuclopenthixol	
hydrochloride	140
Zyban	149
Zypine	138
Zypine ODT	
Zyprexa	
Zyprexa Relprevv	
Zyprexa Zydis	
Zypicka Zyulo	







